
<html lang="en"     class="pb-page"  data-request-id="6cc619f5-84a1-401e-bdfe-edf842531d01"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-23;article:article:10.1021/acs.jmedchem.9b01405"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells" /></meta><meta name="dc.Creator" content="Shuai  Han" /></meta><meta name="dc.Creator" content="Xin  Li" /></meta><meta name="dc.Creator" content="Yun  Xia" /></meta><meta name="dc.Creator" content="Zhengsen  Yu" /></meta><meta name="dc.Creator" content="Ningning  Cai" /></meta><meta name="dc.Creator" content="Satish R.  Malwal" /></meta><meta name="dc.Creator" content="Xu  Han" /></meta><meta name="dc.Creator" content="Eric  Oldfield" /></meta><meta name="dc.Creator" content="Yonghui  Zhang" /></meta><meta name="dc.Description" content="Human farnesyl pyrophosphate synthase (Homo sapiens FPPS, HsFPPS) is a target for treating bone resorption diseases and some cancers. HsFPPS is potently inhibited by bisphosphonates, but due to poo..." /></meta><meta name="Description" content="Human farnesyl pyrophosphate synthase (Homo sapiens FPPS, HsFPPS) is a target for treating bone resorption diseases and some cancers. HsFPPS is potently inhibited by bisphosphonates, but due to poo..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 14, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01405" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01405" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01405" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01405" /></link>
        
    
    

<title>Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01405" /></meta><meta property="og:title" content="Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0024.jpeg" /></meta><meta property="og:description" content="Human farnesyl pyrophosphate synthase (Homo sapiens FPPS, HsFPPS) is a target for treating bone resorption diseases and some cancers. HsFPPS is potently inhibited by bisphosphonates, but due to poor cell penetration and distribution in soft tissue, there is currently interest in the development of non-bisphosphonate inhibitors as cancer therapeutics. Here, we report the discovery and development of HsFPPS inhibitors based on the phenolic diterpene carnosic acid (CA), an antimicrobial found in rosemary and sage, which showed better cellular anticancer activities than the bisphosphonate drug zoledronate in pancreatic cancer cell lines, as well as an HsFPPS-dependent mechanism of action. Hit-to-lead optimization of CA improved HsFPPS inhibition by &gt;100-fold. A slow dissociation inhibition pattern and a noncompetitive allosteric binding mode were found, and cellular mechanism-of-action studies showed that these inhibitors inhibit tumor cell growth primarily by inhibiting HsFPPS, leading to downregulation of Ras prenylation and cell apoptosis. The discovery of this series of compounds together with proof-of-mechanism in pancreatic cancer cells may pave the way for targeting HsFPPS in soft tissue cancers using natural-product-derived inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01405"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01405">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01405&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01405&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01405&amp;href=/doi/10.1021/acs.jmedchem.9b01405" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 10867-10896</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01462" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01528" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Shuai Han</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuai Han</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua University, 100084 Beijing, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuai++Han">Shuai Han</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Xin Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua University, 100084 Beijing, China</div><div class="loa-info-affiliations-info">Joint Graduate Program of Peking-Tsinghua-NIBS, School of Life Sciences, Tsinghua University, 100084 Beijing, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Li">Xin Li</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yun Xia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yun Xia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua University, 100084 Beijing, China</div><div class="loa-info-affiliations-info">Joint Graduate Program of Peking-Tsinghua-NIBS, School of Life Sciences, Tsinghua University, 100084 Beijing, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yun++Xia">Yun Xia</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Zhengsen Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhengsen Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua University, 100084 Beijing, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhengsen++Yu">Zhengsen Yu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ningning Cai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ningning Cai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua University, 100084 Beijing, China</div><div class="loa-info-affiliations-info">Collaborative Innovation Center for Biotherapy, Sichuan University, 610041 Chengdu, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ningning++Cai">Ningning Cai</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Satish R. Malwal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Satish R. Malwal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, University of Illinois at UrbanaâChampaign, Urbana, Illinois 61801, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Satish+R.++Malwal">Satish R. Malwal</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7606-1932" title="Orcid link">http://orcid.org/0000-0001-7606-1932</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Xu Han</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xu Han</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Industrial Enzymes National Engineering Laboratory, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, 300308 Tianjin, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xu++Han">Xu Han</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Eric Oldfield</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric Oldfield</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, University of Illinois at UrbanaâChampaign, Urbana, Illinois 61801, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E.O.: e-mail, <a href="/cdn-cgi/l/email-protection#2d484241494b4448416d444141444342445e03484958"><span class="__cf_email__" data-cfemail="d5b0bab9b1b3bcb0b995bcb9b9bcbbbabca6fbb0b1a0">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric++Oldfield">Eric Oldfield</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0996-7352" title="Orcid link">http://orcid.org/0000-0002-0996-7352</a></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Yonghui Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yonghui Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua University, 100084 Beijing, China</div><div class="loa-info-affiliations-info">Joint Graduate Program of Peking-Tsinghua-NIBS, School of Life Sciences, Tsinghua University, 100084 Beijing, China</div><div class="loa-info-affiliations-info">Collaborative Innovation Center for Biotherapy, Sichuan University, 610041 Chengdu, Sichuan, China</div></div><span class="conrtib-corresp"><strong>*</strong>Y.Z.: e-mail, <a href="/cdn-cgi/l/email-protection#29534148474e5046474e415c40695d5a40474e415c48074c4d5c074a47"><span class="__cf_email__" data-cfemail="c8b2a0a9a6afb1a7a6afa0bda188bcbba1a6afa0bda9e6adacbde6aba6">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yonghui++Zhang">Yonghui Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9842-3049" title="Orcid link">http://orcid.org/0000-0002-9842-3049</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01405&amp;href=/doi/10.1021%2Facs.jmedchem.9b01405" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 10867â10896</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 14, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 September 2019</li><li><span class="item_label"><b>Published</b> online</span>14 November 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 December 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01405" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01405</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10867%26pageCount%3D30%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DShuai%2BHan%252C%2BXin%2BLi%252C%2BYun%2BXia%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D23%26contentID%3Dacs.jmedchem.9b01405%26title%3DFarnesyl%2BPyrophosphate%2BSynthase%2Bas%2Ba%2BTarget%2Bfor%2BDrug%2BDevelopment%253A%2BDiscovery%2Bof%2BNatural-Product-Derived%2BInhibitors%2Band%2BTheir%2BActivity%2Bin%2BPancreatic%2BCancer%2BCells%26numPages%3D30%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10896%26publicationDate%3DDecember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01405"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1218</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01405" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Shuai&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yun&quot;,&quot;last_name&quot;:&quot;Xia&quot;},{&quot;first_name&quot;:&quot;Zhengsen&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Ningning&quot;,&quot;last_name&quot;:&quot;Cai&quot;},{&quot;first_name&quot;:&quot;Satish&quot;,&quot;last_name&quot;:&quot;R. Malwal&quot;},{&quot;first_name&quot;:&quot;Xu&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;Oldfield&quot;},{&quot;first_name&quot;:&quot;Yonghui&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;10867-10896&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01405&quot;},&quot;abstract&quot;:&quot;Human farnesyl pyrophosphate synthase (Homo sapiens FPPS, HsFPPS) is a target for treating bone resorption diseases and some cancers. HsFPPS is potently inhibited by bisphosphonates, but due to poor cell penetration and distribution in soft tissue, there is currently interest in the development of non-bisphosphonate inhibitors as cancer therapeutics. Here, we report the discovery and development of HsFPPS inhibitors based on the phenolic diterpene carnosic acid (CA), an antimicrobial found in rosemary and sage, which showed better cellular anticancer activities than the bisphosphonate drug zoledronate in pancreatic cancer cell lines, as well as an HsFPPS-dependent mechanism of action. Hit-to-lead optimization of CA improved HsFPPS inhibition by &gt;100-fold. A slow dissociation inhibition pattern and a noncompetitive allosteric binding mode were found, and cellular mechanism-of-action studies showed that these inhibitors inhibit tumor cell growth primarily by inhibiting HsFPPS, leading to downregulation of Ras p&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01405&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01405" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01405&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01405" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01405&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01405" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01405&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01405&amp;href=/doi/10.1021/acs.jmedchem.9b01405" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01405" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01405" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (12 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01405%26sid%3Dliteratum%253Aachs%26pmid%3D31725297%26genre%3Darticle%26aulast%3DHan%26date%3D2019%26atitle%3DFarnesyl%2BPyrophosphate%2BSynthase%2Bas%2Ba%2BTarget%2Bfor%2BDrug%2BDevelopment%253A%2BDiscovery%2Bof%2BNatural-Product-Derived%2BInhibitors%2Band%2BTheir%2BActivity%2Bin%2BPancreatic%2BCancer%2BCells%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D23%26spage%3D10867%26epage%3D10896%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291456" title="Hydrocarbons">Hydrocarbons</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291091" title="Oxidation">Oxidation</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/jmcmar.2019.62.issue-23/20191212/jmcmar.2019.62.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Human farnesyl pyrophosphate synthase (<i>Homo sapiens</i> FPPS, <i>Hs</i>FPPS) is a target for treating bone resorption diseases and some cancers. <i>Hs</i>FPPS is potently inhibited by bisphosphonates, but due to poor cell penetration and distribution in soft tissue, there is currently interest in the development of non-bisphosphonate inhibitors as cancer therapeutics. Here, we report the discovery and development of <i>Hs</i>FPPS inhibitors based on the phenolic diterpene carnosic acid (<b>CA</b>), an antimicrobial found in rosemary and sage, which showed better cellular anticancer activities than the bisphosphonate drug zoledronate in pancreatic cancer cell lines, as well as an <i>Hs</i>FPPS-dependent mechanism of action. Hit-to-lead optimization of <b>CA</b> improved <i>Hs</i>FPPS inhibition by >100-fold. A slow dissociation inhibition pattern and a noncompetitive allosteric binding mode were found, and cellular mechanism-of-action studies showed that these inhibitors inhibit tumor cell growth primarily by inhibiting <i>Hs</i>FPPS, leading to downregulation of Ras prenylation and cell apoptosis. The discovery of this series of compounds together with proof-of-mechanism in pancreatic cancer cells may pave the way for targeting <i>Hs</i>FPPS in soft tissue cancers using natural-product-derived inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10808" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10808" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Terpenoids, also known as isoprenoids, constitute the largest class of natural products.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Isoprenoids are produced by all organisms, and many isoprenoid biosynthesis enzymes are drug targets or potential drug targets. For example, in humans, the cholesterol-lowering drug Lipitor targets an âupstreamâ enzyme, hydroxymethylglutaryl coenzyme A reductase; the antiosteoporosis drug zoledronate targets farnesyl pyrophosphate synthase, inhibiting protein prenylation and cell signaling; while the antifungal drug terbinafine targets squalene epoxidase, even further downstream in isoprenoid biosynthesis, inhibiting ergosterol biosynthesis in fungi. In addition to these well-known targets and mechanisms of action, we recently showed that isoprenoid biosynthesis is a target for vaccine adjuvant discovery,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> expanding the potential of this ancient pathway as a drug target.</div><div class="NLM_p">Farnesyl pyrophosphate synthase is the âgatekeeper enzyme<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a>â for mammalian isoprenoid biosynthesis and catalyzes the condensation of dimethylallyl pyrophosphate (<b>1</b>, DMAPP) and isopentenyl pyrophosphate (<b>2</b>, IPP), forming geranyl pyrophosphate (<b>3</b>, GPP) and then farnesyl pyrophosphate (<b>4</b>, FPP) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Further condensation of FPP with IPP is catalyzed by geranylgeranyl pyrophosphate synthase (GGPPS) and yields geranylgeranyl pyrophosphate (<b>5</b>, GGPP), <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. Both FPP and GGPP are used in protein prenylation, and FPP can be converted into many downstream products including cholesterol, CoQ<sub>10</sub>, and the dolichols.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of isoprenoid biosynthesis pathway and its associated biological processes in human cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Protein prenylation involves the post-translational modification of proteins such as Ras, Rac, Rab, and Rho and these prenylated proteins are essential for protein localization to cell membranes,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> required for cell signaling and proliferation.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Inhibition of human FPPS (<i>Homo sapiens</i> FPPS, <i>Hs</i>FPPS) can, therefore, downregulate the activity of mutated Ras, one of the most frequent oncogenic mutations (â¼33% of human cancers).<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7â9)</a> In addition, inhibition of <i>Hs</i>FPPS causes accumulation of the substrates IPP and DMAPP. These molecules are known as phosphoantigens and they have the interesting property that they can induce activation of Î³Î´ T cells.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10â12)</a> Thus, <i>Hs</i>FPPS inhibition has also been shown to lead to immune killing of some cancer cells.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> It has also been shown that elevated <i>Hs</i>FPPS expression is found in Alzheimerâs disease brain samples<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and is believed to contribute to neuronal dysfunction,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> so <i>Hs</i>FPPS inhibitors may additionally have potential in treating neurodegenerative diseases.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Since bisphosphonates such as zoledronate (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a, <b>6</b>) inhibit <i>Hs</i>FPPS and have been reported to have utility in treating breast cancer and multiple myeloma,<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24">(17â24)</a> efforts have been made to make improved inhibitors since the bisphosphonates in current use have poor membrane permeability, poor soft tissue distribution, and potent bone affinity, removing them from the circulatory system. One approach to alleviate these drawbacks has been to produce lipophilic bisphosphonates such as <b>7</b>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> since lipophilic bisphosphonates are expected to have much better cell penetration, as well as weak bone affinity. A second approach has been to develop completely different <i>Hs</i>FPPS inhibitors, compounds lacking the polar bisphosphonate moiety. This approach was first developed by Jahnke and co-workers at Novartis<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (e.g., with <b>8</b>) and since this work, numerous non-bisphosphonate<i>Hs</i>FPPS inhibitors have been reported.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30 ref31 ref32">(27â32)</a> For example, the (C<sub>20</sub>) diterpenoid arenarone (<b>9</b>)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> inhibits <i>Hs</i>FPPS as does the bisamidine BPH-1358 (<b>10</b>),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> as well as the monophosphonate <b>11</b>.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Some of these compounds showed potent <i>in vitro</i> activities against <i>Hs</i>FPPS, but few had good cellular (or animal) <i>Hs</i>FPPS-dependent anticancer activities,<a onclick="showRef(event, 'ref26 ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29 ref30">(26â30)</a> so there is still a need for new scaffold, non-bisphosphonate <i>Hs</i>FPPS inhibitors.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative <i>Hs</i>FPPS inhibitors together with X-ray crystallographic structures illustrating ligand binding to sites S1, S2, S3, and S4. (a) Inhibitor structures. (b) Superimposition of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4N1Z">4N1Z</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N6K">3N6K</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RXA">4RXA</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0W">4P0W</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JA0">5JA0</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV2">5JV2</a> showing sites S1, S2, S3, and S4. (c) <b>7</b> (red, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4N1Z">4N1Z</a>). (d) <b>8</b> (magenta, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N6K">3N6K</a>). (e) <b>6</b> + <b>9</b> (slate, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0W">4P0W</a>). (f) <b>10</b> (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RXA">4RXA</a>). (g) <b>4</b> (wheat, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JA0">5JA0</a>). (h) <b>11</b> (yellow, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV2">5JV2</a>). Asp residues in the first aspartate-rich domain (DDXXD) are shown in blue; Asp residues in the second aspartate-rich domain are shown in orange.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">What is of interest about <b>1</b>â<b>4</b> and <b>6</b>â<b>11</b> is that they display a very broad variety of binding modes to <i>Hs</i>FPPS, a highly Î±-helical protein (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">Figure S1a</a>), as shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>bâh and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">S1aâc</a>. Ligand binding for <b>2</b>, <b>4</b>, and <b>6</b>â<b>11</b> is illustrated in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">S1b,c</a> using a cartoon representation for the protein to facilitate a good comparison between the different binding sites, while the protein is shown as a surface in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>câh in order to show ligand exposure. <a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">Figure S1c</a> is the stereoview of <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b. The two main catalytic sites in <i>Hs</i>FPPS are the S1 site, which binds the allylic substrates DMAPP (<b>1</b>) or GPP (<b>3</b>) and 3 Mg<sup>2+</sup>, and the S2 site, which binds the homoallylic substrate IPP (<b>2</b>). The bisphosphonate zoledronate (<b>6</b>) also binds to the S1 site with 3 Mg<sup>2+</sup> with IPP binding to S2, <a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">Figure S1b</a> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2F8Z">2F8Z</a>). Likewise, the lipophilic bisphosphonate <b>7</b> binds to the S1 site with 3 Mg<sup>2+</sup>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b (in red, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4N1Z">4N1Z</a>), but the dicarboxylate <b>8</b> binds to an allosteric site S3 (magenta, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N6K">3N6K</a>) and has a partial overlap with the S2 site, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b. Arenarone binds to another hydrophobic site, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b (slate, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0W">4P0W</a>) that is close to S2. The large bisamidine <b>10</b> has three rings that are located close to the S2 and S3 sites (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b, green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RXA">4RXA</a>), while the other half of the molecule is located in another pocket called the S4 site.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> FPP itself is also known to act as an <i>Hs</i>FPPS allosteric inhibitor<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> in which one phosphate group overlays an IPP phosphate position while the farnesyl side chain occupies a hydrophobic pocket (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>g, wheat, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JA0">5JA0</a>), the distal part of the farnesyl side chain occupying the same S4 site as seen with the bisamidine <b>10</b>. In structures that contain 3 Mg<sup>2+</sup>, the ligands are buried in the interior of the protein (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c,e), but in the absence of Mg<sup>2+</sup>, the structures are more open and ligands are more visible (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>d,f,g,h). In more recent work,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> novel phosphate-containing allosteric inhibitors have been reported with <b>11</b> being found to bind close to sites 2 and 3 (yellow, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV2">5JV2</a>), <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b, but surprisingly, the phosphate group is not buried in the interior of the protein, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>h. What is common, then, about most <i>Hs</i>FPPS-inhibitor structures is that the known allosteric inhibitors occupy relatively exposed surface sites in the S2, S3 and S4 regions, while bisphosphonates bind to S1 and lead (especially in the presence of IPP) to pocket closure.</div><div class="NLM_p">Here, we report the identification and development of novel scaffold, carnosic acid (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) and carnosol-based <i>Hs</i>FPPS inhibitors with nanomolar potency, as well as a structureâactivity relationship (SAR) exploration of the series. We investigated their binding to <i>Hs</i>FPPS by NMR (water-ligand observed via gradient spectroscopy, WaterLOGSY; saturation-difference NMR, STD NMR) and surface plasmon resonance (SPR), cell growth inhibition activity utilizing PANC-1 and MIA PaCa-2 cell lines, and geranylgeraniol and farnesol cell growth inhibitionârescue experiments. This work expands the toolbox of non-bisphosphonate<i>Hs</i>FPPS inhibitors to lipophilic, natural-product-derived compounds and is a systematic proof-of-mechanism study in pancreatic cancer cells suggesting that targeting <i>Hs</i>FPPS by carnosic acid-derived inhibitors may be a potential route to treating certain soft tissue cancers.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of carnosic acid and carnosol, abietane-skeleton diterpenes from rosemary and sage, together with known <i>Hs</i>FPPS inhibitors, taxodone (<b>12</b>) and taxodione (<b>13</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12757" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12757" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Hit Compound Discovery</h3><div class="NLM_p last">In earlier work we found that the diterpenoids taxodone (<b>12</b>), taxodione (<b>13</b>), and arenarone (<b>9</b>) were <i>Hs</i>FPPS inhibitors<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and that taxodione and arenarone bound to a hydrophobic pocket in <i>Hs</i>FPPS with one ring occupying the position of the IPP, S2 site. These results were of interest since these diterpenoids are structurally similar to carnosic acid and carnosol (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), compounds that are abundant in rosemary and sage extracts, plants that form part of the Mediterranean diet that has been associated with decreased cardiovascular and diabetes risk.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Rosemary and sage extracts abundant in carnosic acid and carnosol have also been reported to have anticancer,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> antimicrobial,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and cholesterol-lowing effects,<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37â39)</a> but little is known about their molecular targets, in cells.<a onclick="showRef(event, 'ref34 ref40'); return false;" href="javascript:void(0);" class="ref ref34 ref40">(34,40)</a> Given the structural similarities between carnosic acid, carnosol, taxodione, and arenarone, we hypothesized that carnosic acid and carnosol might function, at least in part, by inhibiting <i>Hs</i>FPPS. We thus tested their activities in a PPi (inorganic pyrophosphate) release assay<a onclick="showRef(event, 'ref27 ref29 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref27 ref29 ref41 ref42">(27,29,41,42)</a> finding that both carnosic acid and carnosol inhibited <i>Hs</i>FPPS with IC<sub>50</sub> values of 20.0 Î¼M and 13.3 Î¼M, respectively. Considering its commercial availability, we chose carnosic acid as our hit compound to develop novel non-bisphosphonate <i>Hs</i>FPPS inhibitors.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Inhibitor Design and Synthesis Strategy</h3><div class="NLM_p">Having confirmed carnosic acidâs (hereinafter referred to as <b>CA</b>) activity toward <i>Hs</i>FPPS, we synthesized three major types of inhibitor (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) based on the <b>CA</b>âs structure: (1) derivatives exploring the carboxyl group space (C4a); (2) derivatives with modification at the benzyl position (C9); (3) the oxidation state of the series 1 compounds. The carboxyl group of <b>CA</b> is readily modified with various amines to produce amides or heterocyclic compounds, based on condensation reactions, while esterification seemed less desirable since esters might hydrolyze in cells. The benzyl position of <b>CA</b> (C9) can be easily oxidized, after which various substituents can be introduced via Michael addition.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Then, Michael adducts can be further oxidized leading to quinones. The benzyl position and the para-phenol group together give <b>CA</b> relatively high reactivity, leading to series 3. We designed these three types of derivatives mainly because they can be easily obtained through routine reactions, thus enabling us to quickly extend our SAR exploration despite their different modification sites (e.g., C4a and C9) compared with the previously reported taxod(i)one (C10). We also found that, due to <b>CA</b>âs spatial structure and high reactivity of the benzyl position and phenol groups, many other derivatives including bridged compounds could be obtained, as discussed in detail below.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Three major routes for compound synthesis. Note that the numbering here is that of <b>CA</b> and is based on the IUPAC nomenclature of octahydrophenanthrene and varies in some analogs, depending on the actual substituents, and is also not the popular non-IUPAC form used for abietane diterpenes that have the same ring structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Chemistry</h3><div class="NLM_p">A series of <b>CA</b> derivatives were synthesized according to the routes depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>â<a class="ref internalNav" href="#sch4" aria-label="4">4</a>. Because of the reactivity of <b>CA</b>, we first used methylation with trimethylsilyldiazomethane (TMSCHN<sub>2</sub>) leading to compound <b>CA1</b> in good yield (79%). Further oxidation using 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) or Ag<sub>2</sub>O provided <b>CA2</b> in 67% yield, which served as a Michael addition receptor for the next modifications at position C9. Acetylation of the catechol hydroxyls of <b>CA</b> provided <b>CA3</b> in a high yield (97%). We introduced various substituents at C4a of <b>CA3</b> via amide condensation, leading to <b>CA4a-l</b>. The condensation reactions involved two steps: oxalyl chloride treatment of <b>CA3</b> in the presence of a catalytic amount DMF yielded the corresponding acyl chloride which was then reacted with various of amines in the next step. Yields ranged from about 30% to 80%. Deprotections of <b>CA4a-l</b> were carried out using <i>p-</i>toluenesulfonic acid (<i>p-</i>TSA) or LiAlH<sub>4</sub>, as appropriate, leading to <b>CA5a-l</b>. Oxidation at the C9 position of <b>CA4d-l</b> was only achieved with <b>CA4d</b>. Reactions of <b>CA4e-l</b> with CrO<sub>3</sub> were unsuccessful, due presumably to the instability of these compounds under drastic oxidation conditions. Compound <b>CA7</b> was prepared from <b>CA6</b> via LiAlH<sub>4</sub> reduction in nearly quantitative yield. Compound <b>CA4l</b> was synthesized from <b>CA4h</b> and <i>N</i>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-alanine using hexafluorophosphate azabenzotriazole tetramethyluronium (HATU) condensation, in 68% yield.</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>CA1</b>,<b>2</b>, <b>CA5a</b>â<b>l</b>, and <b>CA7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ac<sub>2</sub>O, DMAP, DCM, rt, 12 h; (b) (i) (COCl)<sub>2</sub>, dry DMF (catalytic amount), dry DCM, rt, 8â12 h; (ii). R<sub>1</sub>NH<sub>2</sub>, DMAP, dry DCM, 0 Â°C to rt, 0.5â2 h; (c<sub>1</sub>) <i>p-</i>toluenesulfonic acid, toluene, Ar, 80 Â°C,12 h; (c<sub>2</sub>) LiAlH<sub>4</sub>, dry THF, 0 Â°C to rt, 0.5â4 h; (d) TMSCHN<sub>2</sub>, toluene/MeOH = 5:1, 0 Â°C; (e) CrO<sub>3</sub>, AcOH, rt, 12 h; (f<sub>1</sub>) DDQ, 1,4-dioxane, 0.5 h; (f<sub>2</sub>) Ag<sub>2</sub>O, DCM, N<sub>2</sub>, 0.5 h.</p><p class="last"><span class="fn-label"><sup>b</sup></span><b>CA4l</b> was synthesized from <b>CA4h</b> under the following conditions: <i>N</i>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-alanine, HATU, <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA), DCM, rt, 12 h.</p></p></figure><div class="NLM_p">Various modifications of the phenolic hydroxyl (C9 and C10) positions of <b>CA1</b> were carried out leading to <b>CA8a</b>â<b>c</b>, <b>CA10</b>, <b>CA11a</b>,<b>b</b>, and <b>CA12</b>â<b>14</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Different protecting groups including <i>tert</i>-butyldimethylsilyl (TBS), benzyl (Bn), and acetyl (Ac) on the phenolic hydroxyls of <b>CA1</b> were used providing <b>CA8a</b>â<b>c</b>. Compounds <b>CA8a</b>,<b>b</b> were all monosubstitution products because of TBS or Bnâs steric hindrance. To avoid side reactions of the phenolic hydroxyls in the following steps, we chose the dual-acetyl protection product <b>CA8c</b> as our starting point. <b>CA9</b> was prepared by CrO<sub>3</sub> oxidation in a 70% yield. <b>CA14</b> was obtained in high yield (â¼80%) by the deprotection of <b>CA9</b>, followed by DDQ oxidation of <b>CA10</b>. Carbonyl Î±-halogenation of <b>CA9</b> gave the target compounds <b>CA11a</b>,<b>b</b>. Further deprotection of <b>CA11a</b> afforded an unexpected product, <b>CA12</b>, presumably because the intramolecular nucleophilic substitution of chloride can occur after methyl ester hydrolysis, under acid conditions. Following DDQ oxidation of <b>CA12</b>, the corresponding quinone <b>CA13</b> was obtained in quantitative yield.</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>CA8a</b>â<b>c</b>, <b>CA10</b>, <b>CA11a</b>,<b>b</b>, and <b>CA12</b>â<b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a<sub>1</sub>) TBSCl, imidazole, DCM, rt, 12 h; (a<sub>2</sub>) BnBr, K<sub>2</sub>CO<sub>3</sub>, acetone, rt, 4.5 h; (a<sub>3</sub>) Ac<sub>2</sub>O, DMAP, DCM, rt, 12 h; (b) CrO<sub>3</sub>, AcOH, rt, 12 h; (c) <i>p-</i>toluenesulfonic acid, toluene, Ar, 80 Â°C,12 h; (d) DDQ, 1,4-dioxane, 0.5 h; (e<sub>1</sub>) SO<sub>2</sub>Cl<sub>2</sub>, CCl<sub>4</sub>, 60 Â°C, 40 h; (e<sub>2</sub>) Br<sub>2</sub>, Et<sub>2</sub>O, 0 Â°C, 0.5 h.</p></p></figure><div class="NLM_p">Next, on the basis of the strong intramolecular nucleophilicity mentioned above, we constructed several additional bridged compounds: <b>CA19</b>â<b>22</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). <b>CA22</b> was obtained by a two-step DDQ oxidation procedure or a single step oxidation using 2 equiv of DDQ. <b>CA20</b> was obtained in a similar manner except that there was an additional (LiAlH<sub>4</sub>) reduction of the methyl ester before DDQ oxidation. On the basis of the observations that DDQ oxidation of <b>CA1</b> yielded <b>CA2</b>, it appears that formation of <b>CA19</b> and <b>CA21</b> involves dehydrogenation of the phenolic hydroxyl at C6 and the methylene at C9, <a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">Figure S2</a>, leading to a highly reactive intermediate. This intermediate would be a typical Michael addition receptor which could then react with its own Michael addition donor (carbonyl or hydroxyl) to form the corresponding bridged compounds. In addition, <b>CA17</b> was readily prepared via an intramolecular DCC condensation. To further explore substituent effects at the C9 position, we utilized <b>CA2</b> as a Michael addition receptor to install various substituents at C9, leading to <b>CA15a</b>â<b>f</b>. Subsequent oxidation of <b>CA15c</b>, <b>CA15e</b>, and <b>CA15f</b> by DDQ yielded <b>CA16a</b>â<b>c</b>, respectively.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>CA15a</b>â<b>f</b>, <b>CA16a</b>â<b>c</b>, and <b>CA17</b>â<b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DCC, DMAP, DCM, rt, 2.5 h; (b) (1) TMSCHN<sub>2</sub>, toluene/MeOH = 5:1, 0 Â°C; (2) LiAlH<sub>4</sub>, dry THF, Ar, reflux; (c<sub>1</sub>) DDQ (1 equiv), 1,4-dioxane, 0.5â1 h; (c<sub>2</sub>) Ag<sub>2</sub>O, DCM, Ar; (d) R<sub>4</sub>-X<sub>2</sub>H, MeOH, Ar, 0 Â°C, 4â5 h (when X<sub>2</sub> = S); R<sub>4</sub>-X<sub>2</sub>H, Ar, rt, 2â12 h (when X<sub>2</sub> = O).</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> shows the syntheses of <b>CA25a</b>â<b>g</b>, <b>CA27a</b>â<b>e</b>, and <b>CA28a</b>â<b>d</b>. <b>CA4i</b>â<b>k</b> were obtained as described above and as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> (here, for condition a<sub>1</sub>). Compounds <b>CA23a</b>â<b>c</b> were prepared by reaction of <b>CA4h</b> with the corresponding carboxyl (R<sub>5</sub>COOH) by using HATU. <b>CA4i</b>â<b>j</b> were treated directly with POCl<sub>3</sub>, and intramolecular ring closing and deprotection were accomplished in one step, leading to <b>CA25a</b>,<b>b</b>. Since the workup of the POCl<sub>3</sub> reaction was not particularly convenient, we finally chose another more moderate ring-closing strategy, utilizing <i>p</i>-toluenesulfonyl chloride (<i>p</i>-TsCl). <b>CA24c</b>â<b>f</b> were formed readily from <b>CA23a</b>,<b>b</b>, <b>CA4k</b>, and <b>CA23c</b> using this approach. Subsequent acetyl deprotection by <i>p</i>-TSA or LiAlH4 gave the corresponding <b>CA25c</b>,<b>d</b> and <b>CA25f</b>,<b>g</b>. Interestingly, lengthy (12 h) LiAlH<sub>4</sub> reduction of <b>CA24d</b> yielded another side-product, <b>CA25e</b>. Oxidation of <b>CA24a</b> and <b>CA24d</b>â<b>e</b> gave <b>CA26a</b>â<b>d</b> smoothly. <b>CA26c</b> was also the side product of CrO<sub>3</sub> oxidation when <b>CA24d</b> was reacted for 12 h. It appears that <b>CA24d</b> may first undergo benzyl oxidation, followed by oxidation of the CâN bond to yield an imine intermediate which is readily hydrolyzed to the corresponding ketone (<b>CA26c</b>) under acid conditions. <b>CA28a</b>â<b>d</b> were afforded by acetyl deprotection of <b>CA26a</b>â<b>d</b> and subsequent DDQ oxidation of <b>CA27a</b>â<b>d</b>.</div><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>CA25a</b>â<b>g</b>, <b>CA27a</b>â<b>e</b>, and <b>CA28a</b>â<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a<sub>1</sub>) (i) (COCl)<sub>2</sub>, dry DMF (catalytic amount), dry DCM, Ar, rt, 8â12 h; (ii) R<sub>5</sub>CONHNH<sub>2</sub>, DMAP, dry DCM, 0 Â°C to rt, 0.5â2 h; (a<sub>2</sub>) (i) (COCl)<sub>2</sub>, dry DMF (catalytic amount), dry DCM, Ar, rt, 8â12 h; (ii) NH<sub>2</sub>NH<sub>2</sub>Â·H<sub>2</sub>O, DMAP, DCM, 0 Â°C to rt, 0.5â2 h; (iii). R<sub>5</sub>COOH, HATU, DIEA, DCM, rt, 6â12 h; (b<sub>1</sub>) <i>p</i>-TsCl, DIEA, DCM/CH<sub>3</sub>CN, rt/65 Â°C, 12 h; (b<sub>2</sub>) POCl<sub>3</sub>, 80 Â°C, 1â5 h; (c<sub>1</sub>) <i>p-</i>toluenesulfonic acid, toluene, Ar, 80 Â°C,12 h; (c<sub>2</sub>) LiAlH<sub>4</sub>, dry THF, 0 Â°C to rt, 0.5â12 h; (d) CrO<sub>3</sub>, AcOH, rt, 4â12 h; (e) NaHCO<sub>3</sub>, MeOH/H<sub>2</sub>O = 4:1, 65 Â°C, 10 h; (f) DDQ, 1,4-dioxane, 0.5 h; (g) TFA, DCM, rt, 1â2 h.</p><p><span class="fn-label"><sup>b</sup></span><b>CA25a</b>/<b>CA25b</b> were synthesized from <b>CA4i</b>/<b>CA4j</b> under condition b<sub>2</sub>, <b>CA24a/CA24b</b> were the intermediates. For the synthesis of <b>CA26a</b>, procedure b<sub>1</sub> was chosen for <b>CA4i</b>âs ring closure.</p><p class="last"><span class="fn-label"><sup>c</sup></span>Note that the <i>S</i> configuration shown is the overall moleculeâs stereochemistry not the fragmentâs.</p></p></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> StructureâActivity Relationships for <i>Hs</i>FPPS Inhibition</h3><div class="NLM_p">As noted above, there are three major, readily modifiable sites in <b>CA</b>, so we next discuss how modifications at these sites affect <i>Hs</i>FPPS inhibition. We first investigated carboxyl group modifications, obtaining <b>CA1</b> from <b>CA</b> by methylation. Perhaps surprisingly, <b>CA1</b> showed greatly enhanced (>20-fold) inhibition activity as compared to <b>CA</b> itself (IC<sub>50</sub> = 20 Î¼M) with an IC<sub>50</sub> = 865 nM, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Because <b>CA1</b> possesses a catechol group, which is an alerting PAINS (pan-assay interference compounds) substructure,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> we confirmed its physical binding to <i>Hs</i>FPPS by SPR and PAINS exclusion experiments, as will be discussed below. Also of interest, the activity of <b>CA2</b> (IC<sub>50</sub> = 833 nM) was very similar to that of <b>CA1</b>. These results were encouraging and suggested that removing a likely carboxylate charge might facilitate binding to the hydrophobic channel seen in <i>Hs</i>FPPS structures and that both reduced and oxidized species can bind, but of course, esters may be undesirable because they often hydrolyze in cells. We thus next explored amides rather than esters, despite the potent activity of <b>CA1</b> and <b>CA2.</b></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> of Compounds on <i>Hs</i>FPPS and <i>Hs</i>GGPPS Activity<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0019.gif" alt="" id="GRAPHIC-d7e1798-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0020.gif" alt="" id="gr19" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">ND, not determined.</p></div></div><div></div></div><div class="NLM_p">We next synthesized the series of amides <b>CA5a</b>â<b>l</b> to further explore whether the carboxyl group might be masked as well as extended, to improve hydrophobic interactions (and cell penetration) but without steric clashes with <i>Hs</i>FPPS. As can be seen in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, methyl (<b>CA5a</b>) and benzyl (<b>CA5c</b>) substitutions increased the IC<sub>50</sub> values from those seen with <b>CA1</b> (and <b>CA2</b>) by 7.4-fold and 3.3-fold, respectively, but addition of a cycloheptyl group (compound <b>CA5b)</b> decreased activity far more dramatically (by >50-fold). Since the cycloheptyl and benzyl groups have the same number of carbons and similar sizes, aromatic groups are clearly preferred, and since the results described above indicated that neutral (methyl ester) groups were preferred over (likely anionic) carboxylates, we next investigated other neutral (as well as basic) species, including several with aromatic groups.</div><div class="NLM_p">We first produced compound <b>CA5d</b>, which contains a dimethylaminoethyl terminal group. Its activity was improved by 16.7-fold versus <b>CA1</b> to 1.2 Î¼M. However, <b>CA5e</b>, which instead of a dimethylaminoethyl group contains a hydroxyethyl side-chain, had slightly increased activity compared to <b>CA5d</b>, similar to that of <b>CA1</b>. The imidazole (<b>CA5f</b>) and pyridine (<b>CA5g</b>) species had improved activity over <b>CA</b> but less so than with <b>CA1</b> or <b>CA 5d</b>/<b>e</b>, possibly due to the length of their carbon linker groups. However, the short chain hydrazide species <b>CA5h</b> had very poor activity (IC<sub>50</sub> = 35 Î¼M). Masking the hydrazide amino group with small (acetyl, formyl) substituents (<b>CA5i</b> and <b>CA5j</b>) resulted in good activity with <b>CA5i</b> having IC<sub>50</sub> = 1.5 Î¼M. Moreover, with more hydrophobic substituents (<b>CA5k</b> and <b>CA5l</b>), there was even better activity (in the 500â800 nM range, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Taken together, these results indicate that the presence of the carboxyl/carboxylate group in <b>CA</b> is undesirable for <i>Hs</i>FPPS inhibition, but conversion to amide and substituted amides can result in large increases in activity, the best inhibitors having relatively large, neutral, hydrophobic groups (<b>CA5k</b>, clogP and clogD<sub>7.4</sub> = 6.37, 6.36; <b>CA5l</b>, clogP and clogD<sub>7.4</sub> = 4.96, 1.62). The IC<sub>50</sub> values for these compounds in these <i>Hs</i>FPPS assays were in the 500â800 nM range, to be compared with â¼100â200 nM for <b>6</b> (zoledronate, clogP and clogD<sub>7.4</sub> = â3.85, â7.39).</div><div class="NLM_p">Next, we explored the effects of modifications of the phenol groups in <b>CA</b>. Monoprotection or dual-protection as in <b>CA8a</b>â<b>c</b> and <b>CA11a</b>,<b>b</b> all greatly decreased activity or eliminated it, in most cases independent of the protecting group used. Halogenation at position C10 of <b>CA9</b> did not contribute to any activity increase in compounds <b>CA11a</b>,<b>b</b>. These results indicate that the phenol groups are essential for activity against <i>Hs</i>FPPS. Oxidation at position C9 of <b>CA1</b> led to compounds <b>CA10</b> and <b>CA12</b>, which both retain the catechol moiety but have greatly reduced activity (<b>CA10</b> IC<sub>50</sub> = 41.2 Î¼M, <b>CA12</b> IC<sub>50</sub> > 100 Î¼M). However, the catechol oxidation products <b>CA13</b> and <b>CA14</b> in which the C9 carbonyl is also present both showed potent <i>Hs</i>FPPS inhibition. The IC<sub>50</sub> values were 0.389 Î¼M for <b>CA13</b> and 0.523 Î¼M for <b>CA14</b>, approaching that of <b>6</b>, due perhaps to covalent inhibition, as discussed below. We also performed selectivity studies for <i>Hs</i>FPPS versus <i>Hs</i>GGPPS inhibition, and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> shows that all compounds with <1 Î¼M IC<sub>50</sub> toward <i>Hs</i>FPPS were selective <i>Hs</i>FPPS inhibitors. The selectivity index ranged from â¼20 to >200.</div><div class="NLM_p">Next, we investigated a series of <b>CA</b> analogs, <b>CA15a</b>â<b>f</b>, modified at the C9 position using S or O linker atoms. Large substituents had little effect or reduced activity, but methyl (<b>CA15e</b>) and hydroxyethyl (<b>CA15c</b>) substituents had good activity with IC<sub>50</sub> of â¼1 Î¼M, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. We then turned to an exploration of the effects of oxidation of three of these compounds, <b>CA15c</b>, <b>CA15e</b>, and <b>CA15f</b>, to determine if utilizing quinone groups enhanced activity. DDQ oxidation led to compounds <b>CA16a</b>â<b>c</b> with <b>CA16b</b> (from <b>CA15e</b>, the methoxy analog) having potent activity with IC<sub>50</sub> â¼ 200 nM, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, almost 100-fold more active than <b>CA</b> and comparable to <b>6</b>. Interestingly, the presence of the quinone structures in <b>CA16a</b> and <b>CA16c</b> did not greatly improve their activities, unlike the situation with <b>CA13</b> and <b>CA14</b>. The reason for this is not known.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. IC<sub>50</sub> of Compounds on <i>Hs</i>FPPS and <i>Hs</i>GGPPS Activity<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0021.gif" alt="" id="GRAPHIC-d7e2121-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0022.gif" alt="" id="gr20" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">ND, not determined.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Note that the <i>R</i>/<i>S</i> configuration shown is the overall moleculeâs stereochemistry, not the fragmentâs.</p></div></div><div></div></div><div class="NLM_p">As noted above in the synthesis section, we discovered several bridged or polycyclic compounds during our initial work so we next synthesized and tested a series of such analogs of <b>CA</b>, compounds <b>CA17</b>, <b>19</b>â<b>22</b>. <b>CA17</b> has the carboxyl group esterified with a phenol OH-group to make a cyclic ester and had an IC<sub>50</sub> of 10.6 Î¼M, in accord with our previous finding that no phenol group substitution improved activity. A 2.6-fold activity increase was achieved with <b>CA18</b> in which the carbonyl group is reduced. This seems a surprisingly small effect since the charge would be masked, but both <b>CA19</b> and <b>CA21</b> also showed only minor activity improvements compared with <b>CA</b> so it appears that charge-masking by a hydrophobic species is preferable in the phenol series. However, oxidation of <b>CA19</b> and <b>CA21</b> to <b>CA20</b> and <b>CA22</b> resulted in large (â¼30-fold) increases in activity with IC<sub>50</sub> values of 0.596 Î¼M and 0.473 Î¼M, respectively, basically as seen with <b>CA13</b> and <b>CA14</b>.</div><div class="NLM_p">The results described above indicate that hydrophobic groups can be well tolerated at the C4a position of <b>CA</b>, while substitutions at C9 or phenol group modifications (other than oxidations) are undesirable. We thus next synthesized and tested compounds <b>CA25a</b>â<b>g</b> and some of their corresponding oxidation products, <b>CA28a</b>â<b>d</b>. Since we found that <b>CA5i</b>â<b>l</b> all showed excellent activities toward <i>Hs</i>FPPS, we chose this hydrazide-based series to develop derivatives. Ring closure of <b>CA23</b> led to the oxadiazole <b>CA24</b>, and as can be seen in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, modifications of the 1,3,4-oxadiazole side chains in some cases increased their activity. <b>CA25a</b>, with a 2-methyl-1,3,4-oxadiazole substituent, inhibited <i>Hs</i>FPPS with an IC<sub>50</sub> of 2.20 Î¼M, but <b>CA25b</b>, with a 2-amino-1,3,4-oxadiazole substituent, resulted in an IC<sub>50</sub> of 0.859 Î¼M. <b>CA25c</b>, with a terminal <i>N</i>,<i>N</i>-dimethylmethyleneamine substituent, did not show any potency improvement, having IC<sub>50</sub> = 1.00 Î¼M, similar to that of <b>CA25d</b> (IC<sub>50</sub> = 0.644 Î¼M), while <b>CA25e</b> had more potent (IC<sub>50</sub> = 0.194 Î¼M) activity, the same as the control compound zoledronate (<b>6</b>, IC<sub>50</sub> = 0.1â0.2 Î¼M). Compared to compounds <b>CA25a</b> and <b>CA25b</b>, the substituents in <b>CA25d</b> and <b>CA25e</b> were quite large but they could still be tolerated and the compounds exhibited potent activity. The addition of phenyl substituents with compounds <b>CA25f</b> and <b>CA25g</b> resulted in greatly decreased activity, perhaps due to steric clashes with the protein. Oxidation at position C9 yielded <b>CA27a</b>â<b>e</b> and with the exception of <b>CA27b</b>, each compound lost its inhibition activity toward <i>Hs</i>FPPS. On the other hand, <b>CA28a</b>â<b>c</b>, the (quinone) oxidation products of <b>CA27a</b>â<b>c</b> all had IC<sub>50</sub> values of â¼300 nM. The bromophenyl was again only moderately active, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Finally, we tested most compounds against <i>Hs</i>GGPPS, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Compounds with IC<sub>50</sub> < 1 Î¼M were all selective <i>Hs</i>FPPS inhibitors with selectivity indexes in the â¼30â200 range.</div><div class="NLM_p">Finally, we briefly summarize these SAR results, as shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. The catechol series (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a) encompass a wide range of structures with the R group being an ester, an amide (from methylamine, benzylamine, hydroxyethylamine, an amine of a terminal basic aryl group, a hydrazide), or a 1,3,4-oxadiazole and its derivatives. In general, larger hydrophobic groups that mask the carboxyl charge increased activity. Typical examples are <b>CA5k</b> and <b>CA5l</b>. 1,3,4-Oxadiazoles were generally better than amides, although large oxadiazole substituents decreased activity, as with <b>CA25f</b> and <b>CA25g</b>. As for the phenolic hydroxyl moiety, OH modifications blocked activity. Modifications at C9 (shown as a red X) reduced activity, although the methoxy substitution was an exception. As for quinone series, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b, they generally had good activity with 8 of the 11 compounds having IC<sub>50</sub> values of â¼500 nM. Activity was only moderate when X was an ethoxy group or a mercaptoethyl group (8.60 Î¼M and 22.7 Î¼M). Incorporation of a large aromatic group (such as <i>p</i>-bromophenyl) to the oxadiazole again reduced activity (<b>CA28d</b>, 13.7 Î¼M). The questions then arise as to whether the compounds synthesized are PAINS compounds: Is there independent evidence that they bind to <i>Hs</i>FPPS? Are any active in cells, and if they are, is there evidence that <i>Hs</i>FPPS and prenylation are being targeted?</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. SAR summary of (a) catechol series and (b) quinone series <b>CA</b>-derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> PAINS Property Evaluation</h3><div class="NLM_p">As noted above, the compounds in this study possess alerting PAINS substructures:<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> catechols and quinones. Such compounds might interfere with assays in a variety of ways including via redox reactions/colorimetric interference effects, aggregation, binding to coupling enzymes, and metal chelation. We thus carried out a series of experiments aimed at studying ligand binding and protein inhibition in more detail. First, we directly measured product formation/inhibition using a [<sup>14</sup>C]-IPP radioactive assay. Second, we investigated the effects of Triton X-100 on activity/inhibition. Third, we used NMR (water-ligand observed via gradient spectroscopy, WaterLOGSY) to observe ligand binding. Fourth, we used surface plasmon resonance (SPR) to directly measure ligand binding. Plus, as discussed in the next section, we carried out conventional enzyme inhibition kinetics experiments to help determine inhibition mechanisms, as well as LCâMS to probe potential covalent adduct formation.</div><div class="NLM_p">We first used a [<sup>14</sup>C]-IPP radioactivity assay<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> to measure the inhibition of product formation. By using isotopically labeled IPP as the substrate, we directly detect the amount of product formed after inhibition, avoiding possible interference in a coupling assay. We chose two representative compounds, <b>CA20</b> and <b>CA28a</b>, as our test compounds with zoledronate (<b>6</b>) as the positive control. As can be seen in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, <b>CA20</b> and <b>CA28a</b> both showed inhibition of <i>Hs</i>FPPS in this [<sup>14</sup>C]-IPP radioactivity assay. The amounts of enzyme and substrate differ in the PPi and radioactive assays, as do the methods (kinetics versus end-point), so there is a systematic difference between the IC<sub>50</sub> values obtained (in the 1.7â4.5Ã range), but this is not unexpected and is seen in other related work.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibition Data of Some Compounds on <i>Hs</i>FPPS Activity with Different Assays</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">PPi release assay (Î¼M) IC<sub>50</sub>Â Â±Â SD, <i>n</i>Â =Â 4</th><th class="colsep0 rowsep0" align="center">[<sup>14</sup>C]-IPP assay (Î¼M) IC<sub>50</sub>Â Â±Â SD, <i>n</i>Â =Â 3</th><th class="colsep0 rowsep0" align="center">([<sup>14</sup>C]-IPPÂ IC<sub>50</sub>)/(PPiÂ IC<sub>50</sub>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">0.1Â Â±Â 0.0034</td><td class="colsep0 rowsep0" align="left">0.17Â Â±Â ND<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA20</b></td><td class="colsep0 rowsep0" align="left">0.596Â Â±Â 0.079</td><td class="colsep0 rowsep0" align="left">2.7Â Â±Â 0.040</td><td class="colsep0 rowsep0" align="left">4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA28a</b></td><td class="colsep0 rowsep0" align="left">0.335Â Â±Â 0.011</td><td class="colsep0 rowsep0" align="left">1.3Â Â±Â 0.080</td><td class="colsep0 rowsep0" align="left">3.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">ND, not determined.</p></div></div></div><div class="NLM_p">Next, since catechols and quinones can produce H<sub>2</sub>O<sub>2</sub> during their redox cycling,<a onclick="showRef(event, 'ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50">(48â50)</a> we added catalase in our assay in order to avoid possible reducing factors<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> that might interfere with the results. <b>CA28a</b> and <b>CA28b</b> had nearly the same inhibition potency with or without catalase (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">Table S1</a>). However, this <i>in vitro</i> experiment cannot exclude the possible influence of reactive oxygen species (ROS) which may be generated intracellularly by these compounds. Catechols can also chelate Mg<sup>2+</sup> (which is essential for <i>Hs</i>FPPS catalysis), so we added 2 mM Mg<sup>2+</sup>, and since the highest concentration of our compounds was no more than 100 Î¼M, there would be no significant effect of catechol-metal binding.</div><div class="NLM_p">Aggregation is another possible effect of PAINS compounds, but aggregation can be disrupted by adding nonionic detergents such as Triton X-100 or Tween-80.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Online tools such as Aggregator Advisor<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> (<a href="http://advisor.bkslab.org/search/" class="extLink">http://advisor.bkslab.org/search/</a>) can also help identify such molecules, so we first screened most compounds <i>in silico</i> on this site but found no alerting structures. We then assayed most compounds with IC<sub>50</sub> < 1 Î¼M again but this time in the presence of 0.01% Triton X-100, and as can be seen in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, they all had very similar activity to that obtained in the absence of Triton X-100, making aggregation unlikely.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. IC<sub>50</sub> of Some Compounds on <i>Hs</i>FPPS Activity with 0.01% Triton X-100 in Assay</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> in assay without 0.01% Triton X-100 (Î¼M), IC<sub>50</sub>Â Â±Â SD, <i>n</i>Â =Â 4</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> in assay with 0.01% Triton X-100 (Î¼M), IC<sub>50</sub>Â Â±Â SD, <i>n</i>Â =Â 4</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">0.10â0.20</td><td class="colsep0 rowsep0" align="left">0.14â0.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA1</b></td><td class="colsep0 rowsep0" align="left">0.87Â Â±Â 0.045</td><td class="colsep0 rowsep0" align="left">0.47Â Â±Â 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA2</b></td><td class="colsep0 rowsep0" align="left">0.83Â Â±Â 0.065</td><td class="colsep0 rowsep0" align="left">0.81Â Â±Â 0.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA5e</b></td><td class="colsep0 rowsep0" align="left">0.91Â Â±Â 0.044</td><td class="colsep0 rowsep0" align="left">0.65Â Â±Â 0.058</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA5k</b></td><td class="colsep0 rowsep0" align="left">0.80Â Â±Â 0.11</td><td class="colsep0 rowsep0" align="left">1.52Â Â±Â 0.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA13</b></td><td class="colsep0 rowsep0" align="left">0.39Â Â±Â 0.014</td><td class="colsep0 rowsep0" align="left">0.40Â Â±Â 0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA14</b></td><td class="colsep0 rowsep0" align="left">0.52Â Â±Â 0.053</td><td class="colsep0 rowsep0" align="left">0.43Â Â±Â 0.026</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA20</b></td><td class="colsep0 rowsep0" align="left">0.60Â Â±Â 0.079</td><td class="colsep0 rowsep0" align="left">0.23Â Â±Â 0.033</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA25b</b></td><td class="colsep0 rowsep0" align="left">0.86Â Â±Â 0.22</td><td class="colsep0 rowsep0" align="left">0.39Â Â±Â 0.0063</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA25c</b></td><td class="colsep0 rowsep0" align="left">1.00Â Â±Â 0.14</td><td class="colsep0 rowsep0" align="left">0.70Â Â±Â 0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA25e</b></td><td class="colsep0 rowsep0" align="left">0.19Â Â±Â 0.0066</td><td class="colsep0 rowsep0" align="left">0.62Â Â±Â 0.032</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA28a</b></td><td class="colsep0 rowsep0" align="left">0.34Â Â±Â 0.011</td><td class="colsep0 rowsep0" align="left">0.73Â Â±Â 0.072</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA28b</b></td><td class="colsep0 rowsep0" align="left">0.25Â Â±Â 0.017</td><td class="colsep0 rowsep0" align="left">0.23Â Â±Â 0.0086</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CA28c</b></td><td class="colsep0 rowsep0" align="left">0.29Â Â±Â 0.027</td><td class="colsep0 rowsep0" align="left">0.31Â Â±Â 0.0070</td></tr></tbody></table></div></div><div class="NLM_p">Next, we investigated ligand binding to <i>Hs</i>FPPS using WaterLOGSY experiments (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) and SPR (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). First, we used WaterLOGSY<a onclick="showRef(event, 'ref26 ref52'); return false;" href="javascript:void(0);" class="ref ref26 ref52">(26,52)</a> to verify binding of <b>CA28a</b> to <i>Hs</i>FPPS. In the absence of <i>Hs</i>FPPS, the WaterLOGSY NMR spectrum of <b>CA28a</b> (200 Î¼M) in Tris buffer alone shows only very weak signals (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a, in red). However, in the presence of <i>Hs</i>FPPS (10 Î¼M) and again in Tris buffer (and in the absence of Mg<sup>2+</sup>), there are now five sharp peaks (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a, in blue). These resonances arise from <b>CA28a</b> and exhibit a negative nuclear Overhauser enhancement (by convention, shown as upright peaks in this experiment) due to protein binding and can be assigned as follows (see numbering system used in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b): Î´ = 7.51 ppm, H14; Î´ = 2.31 ppm, Me on the oxadiazole ring; Î´ â¼ 1.04 ppm, isopropyl methyl groups H16 and H17; Î´ = 0.85 ppm, H18; and Î´ = 0.33 ppm, H19. The shifts are essentially the same as seen in CDCl<sub>3</sub> except for the oxadiazole methyl which is shifted by â¼0.2 ppm due to a solvent effect. An interesting observation is that there is a large (â¼0.5 ppm) shielding of one of the methyl groups attached to C4 in <b>CA28a</b> (in this experiment and in organic solvent), but this is not unexpected since as shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>c, the protons on C19 are expected to undergo a significant upfield ring current shift (a shielding) due to their interaction with the oxadiazole ring, if it adopts the conformation deduced in the computational experiments discussed below. The shift is not seen in compounds that lack the ring. The WaterLOGSY experiments thus confirm that <b>CA28a</b> binds to <i>Hs</i>FPPS. Similar experiments were also performed on <b>CA5d</b>, and at least 2â3 peaks reversals were observed upon adding <i>Hs</i>FPPS (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">Figure S3</a>). Since <b>CA28a</b> and <b>CA5d</b> represent typical quinone and catechol series inhibitors, their qualitative results supporting physical bindings promoted us to further explore some representative derivativesâ quantitative binding affinities by SPR.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. WaterLOGSY results for <b>CA28a</b> (200 Î¼M) without and with <i>Hs</i>FPPS (10 Î¼M). (a) WaterLOGSY spectra. The spectrum shown in red is that of <b>CA28a</b> alone in Tris buffer (pH 7.5). The spectrum shown in blue is that of <b>CA28a</b> + <i>Hs</i>FPPS in Tris buffer (pH 7.5). Peaks due to Tris, DMSO, and HOD are not shown, for clarity. Shift assignments are shown above each peak. (b) Numbering system used for <b>CA28a</b>, based on general terpene numbering system since IUPAC nomenclatures vary with the substituents. (c) Proposed <b>CA28a</b> geometry that leads to shielding of H19 due to a ring current interaction with the oxadiazole ring. The distances shown are in Ã.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Binding kinetics of some compounds. (a) Binding kinetics profiles of <b>CA1</b>, <b>CA5l</b>, <b>CA13</b>, and <b>CA28a</b>: <i>K</i><sub>D</sub> = <i>k</i><sub>off</sub>/<i>k</i><sub>on</sub>, Ï = 1/<i>k</i><sub>off</sub>. (b) Single cycle kinetic analysis graphs of the above compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The SPR results with <b>CA1</b>, <b>CA5l</b>, <b>CA13</b>, and <b>CA28a</b> showed that all compounds except <b>CA5l</b> displayed slow dissociation behavior (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). We employed a single-cycle kinetic analysis for all compounds because of the difficult regeneration steps during normal titration.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> All four compounds associated with <i>Hs</i>FPPS with a similar association rate constant (<i>k</i><sub>on</sub>) of about (2â5) Ã 10<sup>2</sup> M<sup>â1</sup> s<sup>â1</sup>. Since these association rate constants are of the same order of magnitude, the binding constants mainly depend on the dissociation rate constant (<i>k</i><sub>off</sub>). For example, the high binding affinities of <b>CA13</b> (<i>K</i><sub>D</sub> = 448 nM) and <b>CA28a</b> (<i>K</i><sub>D</sub> = 61.6 nM) correlate with their slow dissociation rates of 1.23 Ã 10<sup>â4</sup> s<sup>â1</sup> (<b>CA13</b>) and 3.18 Ã 1 0<sup>â5</sup> s<sup>â1</sup> (<b>CA28a</b>). These results show that most of these compounds will reside on the protein for a long time after binding, with the residence time Ï = 1/ <i>k</i><sub>off</sub> for <b>CA28a</b> meaning that it could remain bound for â¼9 h. Long Ï-values are a favorable factor for long-term <i>in vivo</i> efficacy.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Binding Mode Studies</h3><div class="NLM_p">Next, we sought to investigate the inhibition mode of <b>CA28a</b> with <i>Hs</i>FPPS. We first investigated <b>6</b> (zoledronate), which is a validated DMAPP/GPP site competitive inhibitor (IC<sub>50</sub> = 220 nM, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a). When <b>6</b> was preincubated with GPP + Mg<sup>2+</sup> and <i>Hs</i>FPPS for 30 min before the assay began, its IC<sub>50</sub> increased considerably (to IC<sub>50</sub> = 2.0 Î¼M); since <b>6</b> is a competitive inhibitor at this site, GPP + Mg<sup>2+</sup> binding decreases its efficacy. However, when co-incubated with IPP, the IC<sub>50</sub> of <b>6</b> was observed to be about the same or slightly smaller (173 nM vs 220 nM), since <b>6</b> does not bind to the IPP site.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> With <b>CA28a</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>b), we find an IC<sub>50</sub> of 370 nM when preincubated with only <i>Hs</i>FPPS for 30 min. However, preincubation of <b>CA28a</b> with GPP + Mg<sup>2+</sup> essentially completely abolished all inhibition activity of <b>CA28a</b> (red curve in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b, IC<sub>50</sub> â« 50 Î¼M) due, we propose, to GPP + Mg<sup>2+</sup> resulting in a partial closure of the protein structure which prevents <b>CA28a</b> binding. Preincubation with <b>CA28a</b> + GPP alone had essentially no effect, consistent with the fact that there are no GPP (or DMAPP) structures of FPPS in the absence of Mg<sup>2+</sup>, while preincubation of <b>CA28a</b> with IPP and <i>Hs</i>FPPS did result in an increase in IC<sub>50</sub> (to 6.3 Î¼M), suggesting that <b>CA28a</b> might bind near the IPP site.</div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Preincubation assay and enzyme kinetics studies. (a) Preincubation assay of positive control <b>6</b> with GPP + Mg<sup>2+</sup> or IPP. <i>V</i><sub>0</sub> represents the initial velocity of the reaction. (b) Preincubation assay of <b>CA28a</b> with GPP + Mg<sup>2+</sup>, GPP, or IPP. <i>V</i><sub>0</sub> represents the initial velocity of the reaction. (c) MichaelisâMenten kinetics of <i>Hs</i>FPPS with IPP set at 35 Î¼M and GPP varying. (d) MichaelisâMenten kinetics of <i>Hs</i>FPPS with GPP set at 70 Î¼M and IPP varying. Data are presented as the mean Â± SD, <i>n</i> = 4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To help further clarify the inhibition mechanism, we measured MichaelisâMenten inhibition kinetics with <b>CA28a</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>c,d. Compound <b>CA28a</b> was found to be a noncompetitive inhibitor with respect to both GPP and IPP, and the <i>K</i><sub>m</sub> values of GPP and IPP remained at 2.2 Î¼M and 4.4 Î¼M, respectively (overall fitting <i>R</i><sup>2</sup> values were 0.94 and 0.92). The striking affinity difference between preincubation with GPP + Mg<sup>2+</sup> versus GPP indicates the importance of Mg<sup>2+</sup> in blocking <b>CA28a</b>âs activity, and since Mg<sup>2+</sup> is required for the conformational transition from the open to the partly closed state,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> this suggests that the partly closed conformation prevents <b>CA28a</b> binding to <i>Hs</i>FPPS. Taken together, the above results indicate that <b>CA28a</b> functions primarily by binding to the open state of <i>Hs</i>FPPS, preventing substrate binding and pocket closure required for catalytic activity. We should also note here that since our compounds in many cases contain a nucleophilic receptor which can react with an electrophilic donor such as cysteine, they might also act as covalent inhibitors. We therefore performed time-dependent preincubation assays but found that IC<sub>50</sub> values were not dependent on the length of preincubation (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">Table S2</a>). Plus, preincubation of excess <b>CA28a</b> with <i>Hs</i>FPPS overnight did not result in any adduct formation, as determined by LCâMS (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">Figure S4</a>).</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Computational Docking, Mutagenesis and STD NMR</h3><div class="NLM_p">In order to determine how our inhibitors might bind to <i>Hs</i>FPPS, we used a combination of computational docking using Glide<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> together with site-directed mutagenesis and saturation transfer difference (STD) NMR. Since our kinetics studies indicated that <b>CA28a</b> bound to an open conformation, we used two open structures for docking: <i>Hs</i>FPPS + two taxodiones (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0X">4P0X</a>) and <i>Hs</i>FPPS with the allosteric inhibitor <b>14</b><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV1">5JV1</a>).</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0025.gif" alt="" id="GRAPHIC-d7e3370-autogenerated" /></img><div class="NLM_p">As for <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0V">4P0V</a> (taxodione + zoledronate + 3 Mg<sup>2+</sup>) and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0W">4P0W</a> (arenarone + zoledronate + 3 Mg<sup>2+</sup>), it is difficult to dock <b>CA28a</b> into these two cocrystals since the structures are closed, so we did not attempt docking. We used structures with and without water molecules and, where appropriate, with or without sulfate ions. Four top ranked poses are shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>.</div><figure id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Four candidate docking poses. ÏâÏ stacking and H-bonds are represented by yellow dashes with numbers showing the distances between heavy atoms in angstrom. (a) <b>CA28a</b> docked into <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0X">4P0X</a>. ÏâÏ stacking with Phe-239, H-bonding with protein backbone and water1127. (b) <b>CA28a</b> docked into <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV1">5JV1</a> (without sulfate and crystal waters, pose 1). H-bonding with Asn-59, Arg-60, and backbone of Lys-57. (c) <b>CA28a</b> docked into <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV1">5JV1</a> (without sulfate and crystal waters, pose 2). H-bonding with Asn-59 and Arg-60. (d) <b>CA28a</b> docked into <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV1">5JV1</a> (with sulfate and crystal waters). H-bonding is with Asn-59.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Features found in many but not all poses include a T-shaped ÏâÏ interaction between Phe-239 and the oxadiazole ring, and H-bond interactions between Asn-59 and the oxadiazole or ligand carbonyl groups. However, the orientations of <b>CA28a</b> were in many cases flipped, resulting in different ligandâprotein interactions as well as differences in solvent exposure. To try and clarify which interactions might be most important, we used site-directed mutagenesis. We made two mutants, N59A and F239A, in order to determine whether the H-bond or ÏâÏ stacking interactions were more important. As shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>a,b, <b>CA28a</b> exhibited essentially the same IC<sub>50</sub> against the N59A mutant <i>Hs</i>FPPS as against wild type protein, but the IC<sub>50</sub> against the F239A mutant <i>Hs</i>FPPS was â¼500% larger than against wild type protein, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>a,c. So the mutagenesis experiments indicate that an interaction between Phe-239 and <b>CA28a</b> is important for inhibition/binding while Asn-59 is not essential for binding. This result supported the docking pose in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0X">4P0X</a> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a).</div><figure id="fig10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Mutagenesis results, overlay of four candidate poses, and STD results. Doseâresponse curves of <b>CA28a</b> against (a) <i>Hs</i>FPPS WT, (b) <i>Hs</i>FPPS N59A, and (c) <i>Hs</i>FPPS F239A. Data are shown as the mean Â± SD, <i>n</i> = 4. (d) Overlay of four candidate poses. Poses of <b>CA28a</b> in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>aâd are shown in green, cyan, magenta, and yellow, respectively. (e) STD spectrum of <b>CA28a</b> (400 Î¼M) + <i>Hs</i>FPPS (10 Î¼M) in Hepes buffer (pH 7.4). (f) <b>CA28a</b> structure and numbering system.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Overlay of four poses shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> indicates that the pose in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0X">4P0X</a> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>d, green) is more buried than the other three poses, which are more exposed to water. We thus next carried out saturation difference (STD) NMR experiments in which (in brief) protein resonances are saturated, leading to decreased intensity of nearby bound ligand protons or, in a difference spectrum, large signals for ligand groups that are more buried/less solvent exposed, to further validate this pose. As can be seen in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>e, there are six STD peaks, five of which are the methyl groups C16, C17, C18, C19, and C23. This result indicated the isopropyl group (C16,17), C18,19, and oxadiazole ring are more buried like the pose in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0X">4P0X</a> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>d, green), unlike poses such as that shown in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV1">5JV1</a> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>d, cyan, magenta, and yellow), consistent with the pose shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a.</div><div class="NLM_p">Therefore, on the basis of the totality of the docking, mutagenesis, and STD results, we conclude that the docking pose shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a is a reasonable one. As shown for clarity in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">Figure S5</a>, <b>CA28a</b> occupies the S2âS3 sites with its oxadiazole ring inserting deeply into the allosteric site, the benzoquinone partially occupying the IPP site S2 and the A ring colocating to the S3 site, the allosteric FPP site, although of course X-ray structures are needed to confirm this. Nevertheless, when taking all of the activity, kinetics, NMR, SPR, docking, and mutagenesis results together, we conclude that <b>CA28a</b> (and by inference, its analogs) inserts into the allosteric site of unliganded <i>Hs</i>FPPS, preventing the binding of DMAPP/GPP and the subsequent conformational changes needed for catalysis.</div><div class="NLM_p">The catalytic mechanism of <i>Hs</i>FPPS as well as its inhibition by <b>6</b> and <b>CA28a</b> is summarized in cartoon form in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>. <i>Hs</i>FPPS is initially expected to be ligand free, then DMAPP and (probably) 2 Mg<sup>2+</sup> bind, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>a,b. There are no X-ray structures of FPPS with DMAPP or GPP with 3 Mg<sup>2+</sup> bound, but structures of an avian FPPS reveal binding of 2 Mg<sup>2+</sup> and the structure is partially closed. Then, IPP and a third Mg<sup>2+</sup> bind, forming the catalytically competent structure, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>c. In the presence of <b>CA28a</b>, the surface pocket is occupied, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>d, and the entrance for DMAPP and IPP is blocked. These open structures are very different from those found with bisphosphonate inhibitors such as zoledronate (<b>6</b>) where there are large numbers of X-ray structures that all contain the bisphosphonate with 3 Mg<sup>2+</sup> and the structures are all largely closed, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>e, with IPP binding then finally closing the structure, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>f.</div><figure id="fig11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Schematic illustration of the inhibition of <i>Hs</i>FPPS by <b>CA28a</b> and its analogs, and zoledronic acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Cell Growth Inhibition</h3><div class="NLM_p">To investigate whether the compounds discussed above are active at the cellular level, we tested their ability to inhibit the growth of pancreatic cancer cells. As noted above, the activities of mutated Ras can be downregulated by <i>Hs</i>FPPS inhibitors through prenylation blockade. PANC-1 and MIA PaCa-2 are typical pancreatic ductal adenocarcinoma cell lines with elevated expression of a mutated Ras, KRAS, which plays as a major role in pancreatic cancer.<a onclick="showRef(event, 'ref8 ref60'); return false;" href="javascript:void(0);" class="ref ref8 ref60">(8,60)</a> Statins have been reported to have anticancer effects in pancreatic cancer cell lines <i>in vitro</i> and <i>in vivo</i>,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> and current evidence shows that statins act mainly by blockade of downstream small GTPase prenylation.<a onclick="showRef(event, 'ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref62 ref63 ref64">(62â64)</a> Direct inhibition of <i>Hs</i>FPPS to block the prenylation of small GTPase is thus expected to inhibit pancreatic cancer cell growth. We chose to investigate two cell lines, PANC-1 and MIA PaCa-2, to evaluate the potency of our inhibitors. By way of a control, we used the <i>Hs</i>FPPS inhibitor zoledronate (<b>6</b>) which showed an EC<sub>50</sub> of 16.1â24.2 Î¼M in PANC-1 cells, consistent with reported values.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> It was slightly more potent in MIA PaCa-2 cells with an EC<sub>50</sub> of 13.4 Î¼M, a dramatic decrease in its activity in cells when contrasted with its potency in <i>Hs</i>FPPS inhibition (IC<sub>50</sub> = 0.1â0.2 Î¼M), presumably due to poor cell permeability.</div><div class="NLM_p">As can be seen in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, although most of the compounds tested are not as potent as <b>6</b> in <i>Hs</i>FPPS enzyme inhibition, 21 out of 31 compounds displayed better activity than did <b>6</b> against PANC-1 cells, due most likely to improved cell penetration since clogP and clogD<sub>7.4</sub> values are improved, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. The most potent inhibitor in PANC-1 cells was <b>CA15a</b> (EC<sub>50</sub> = 2.7 Î¼M), with an IC<sub>50</sub> of 28.0 Î¼M toward <i>Hs</i>FPPS. However, <b>CA15a</b> was also the most potent <i>Hs</i>GGPPS inhibitor (IC<sub>50</sub> = 5.5 Î¼M) and <i>Hs</i>GGPPS inhibition can block pancreatic cancer cell growth through disruption of Rab-mediated activity.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> We also see that most of the quinone-containing compounds (<b>CA13</b>, <b>CA14</b>, <b>CA22</b>, <b>CA28a</b>, and <b>CA28c</b>) have an EC<sub>50</sub> of >40.0 Î¼M. Most had an IC<sub>50</sub> below 1 Î¼M toward <i>Hs</i>FPPS, so this efficacy loss may imply that most quinone derivatives react with compounds such as glutathione in the cellular environment before they bind to <i>Hs</i>FPPS, thereby losing their activity.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Cellular Activities of Compounds toward Cancer Cell Lines<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0023.gif" alt="" id="GRAPHIC-d7e3769-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">ND, not determined.</p></div></div><div></div></div><div class="NLM_p">Given the very diverse range of compounds investigated (e.g., catechols, quinones, amines, carboxylates), it is unclear whether or not one would expect a good correlation between <i>Hs</i>FPPS inhibition and cell activity since there could be compound metabolism as well as large differences in cellular uptake. We thus next investigated whether there were in fact correlations between enzyme inhibition and cell activity by simply plotting the corresponding IC<sub>50</sub> and EC<sub>50</sub> values, using for clarity a semilog scale since the enzyme inhibition results covered a larger range of values. We deleted inactives (defined as compounds with EC<sub>50</sub> > 40 Î¼M, in cells) as well as that for <b>CA15a</b>, the <i>Hs</i>GGPPS inhibitor.</div><div class="NLM_p">Results for PANC-1 cells are shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>a from which it can be seen that there is a âVâ shaped overall curve. For the eight compounds on the right of the graph there is a very good correlation between <i>Hs</i>FPPS inhibition and PANC-1 cell growth inhibition with a Pearson correlation coefficient <i>R</i> = 0.9. This supports the idea that these compounds target <i>Hs</i>FPPS. The same trend is seen with the MIA PaCa-2 cell line although there are fewer points: both data sets are shown superimposed in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>b from which it can be seen that in both cell lines there is a correlation between cell growth inhibition and <i>Hs</i>FPPS inhibition for the less active <i>Hs</i>FPPS inhibitors, indicating that <i>Hs</i>FPPS is a likely target in both cell lines. For the more potent <i>Hs</i>FPPS inhibitors (the compounds on the left in both graphs in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), there appears to be an inverse correlation with the PANC-1 cell line, but this is less obvious when data from both cell lines are considered, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>b. We found no correlations between EC<sub>50</sub> with clogP or clogD<sub>7.4</sub>, <a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">Figure S6</a>. So the results shown above support an <i>Hs</i>FPPS target for the nine compounds that are, paradoxically, the less active <i>Hs</i>FPPS inhibitors. This raises the question as to the targets of the more potent <i>Hs</i>FPPS inhibitors that have good activity in cells, so we next investigated compound <b>CA5d</b> which is one of the most active species in the cluster of compounds on the left of <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>a,b, as well as being a potent <i>Hs</i>FPPS inhibitor. We did not choose <b>CA18</b> and <b>CA15a</b> which displayed more potent activities toward PANC-1 cells compared with <b>CA5d</b> as our tool compounds for verifying their mechanisms of action since they both got weak potencies toward <i>Hs</i>FPPS (7.80 Î¼M and 28.0 Î¼M, respectively) and <b>CA15a</b> is also the most potent <i>Hs</i>GGPPS inhibitor among these derivatives, raising concerns about off-targets effect.</div><figure id="fig12" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Correlation between <i>Hs</i>FPPS inhibition and cellular activity. (a) PANC-1 results. The blue curve is the fitted linear regression trend (<i>R</i><sup>2</sup> = 0.81) for the eight compounds indicated. The dotted lines are the 95% confidence intervals. (b) As in (a) but MIA PaCa-2 results shown in orange, superimposed with the PANC-1 data (in blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Mechanism of Action of <b>CA5d</b>: Induction of Apoptosis and Downregulation of Ras Prenylation</h3><div class="NLM_p">To pinpoint the target of <b>CA5d</b> in cells, we investigated whether it blocked protein prenylation and induced apoptosis that could be blocked by adding ârescue agentsâ, farnesol (FOH) and/or geranylgeraniol (GGOH), since these can be converted in cells by kinases to FPP or GGPP.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> PANC-1 cells were treated with PBS (phosphate buffered saline, control), <b>6</b> (positive control, 10 Î¼M), or <b>CA5d</b> (10, 20, 40 Î¼M) for 48 h. Apoptosis was detected by staining of annexin V and propidium iodide (PI) and showed a dose-dependent correlation between apoptosis rate and <b>CA5d</b> exposure, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>. <b>CA5d</b> had a statistically significant effect on apoptosis as compared to the control when its concentration was >10 Î¼M. Both <b>6</b> and <b>CA5d</b> induced primarily early but not late stage apoptosis when the concentration was low (10 Î¼M), and <b>CA5d</b> induced both early and late stage apoptosis when its concentration was high (20, 40 Î¼M, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>c,d).</div><figure id="fig13" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. <b>CA5d</b> induces apoptosis in pancreatic cancer cells. (a) Flow cytometry analysis of apoptosis rates of PANC-1 cell upon <b>6</b> and <b>CA5d</b> 48 h treatment using annexin V and PI staining. (b) Apoptosis rates in different groups (early stage plus late stage apoptosis, Q3 + Q2). (c) Statistical results for late stage apoptosis (Q2) in different groups. (d) Statistical results for early stage apoptosis (Q3) in different groups. Data are presented as the mean Â± SD, <i>n</i> = 3: *<i>P</i> < 0.05 vs Ctrl; **<i>P</i> < 0.01 vs Ctrl; ***<i>P</i> < 0.001 vs Ctrl; ****<i>P</i> < 0.0001 vs Ctrl. Unpaired Studentâs <i>t</i> test was used for significance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To determine whether apoptosis was induced by <i>Hs</i>FPPS inhibition, we performed cell growth inhibition rescue experiments (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) since <i>Hs</i>FPPS inhibition will cause both FPP and GGPP starvation in cells, leading to prenylation blockade of downstream proteins including Ras, Rab, Rho, and Rac. <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>a shows that the effects of <b>6</b> and <b>CA5d</b> on apoptosis can be largely rescued by addition of GGOH and FOH (10 Î¼M), indicating that <b>CA5d</b> acts in the same manner as does <b>6</b>, by inhibiting <i>Hs</i>FPPS. GGOH and FOH alone did not show any effects on cell apoptosis. We also note that the effect of <b>CA5d</b> (at 20 Î¼M) on apoptosis is not fully rescued by GGOH + FOH since there was still a 2.8% higher apoptosis rate as compared to the <b>6</b> control group. So although most of the apoptosis effects were rescued, it does appear that <b>CA5d</b> has additional off-target (non-<i>Hs</i>FPPS) activity or nonspecific cytotoxicity (e.g., ROS) in PANC-1 cells (as do the cluster of compounds to the left of the graphs).</div><figure id="fig14" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. PANC-1 apoptosis rescues by GGOH + FOH, Ras prenylation results, and mechanism summary. (a) Statistical graph of apoptosis rate in different groups. Concentrations of GGOH and FOH were 10 Î¼M in different groups; inhibitors were at 20 Î¼M. Data are presented as the mean Â± SD, <i>n</i> = 3: ****<i>P</i> < 0.0001 vs corresponding groups. Unpaired Studentâs <i>t</i> test was used for significance. (b) Downregulation of Ras prenylation upon <b>CA5d</b>âs treatment on PANC-1 cells. Western blot shows the membrane Ras and total Ras level upon a 24 h treatment with <b>CA25d</b>. Na<sup>+</sup>/K<sup>+</sup> ATPase and Î²-tubulin are internal references. (c) Schematic representation of <b>CA5d</b> mechanism of action in PANC-1 cells. Ras proteins in green represent the increase parts of membrane Ras after rescue of GGOH and FOH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Next, we determined the effects of <b>CA5d</b> on protein prenylation by measuring the amount of membrane Ras by Western blot after a 24 h treatment with <b>CA5d</b>. As briefly noted above, Ras can be regulated by <i>Hs</i>FPPS activity via its prenylation with FPP, so <i>Hs</i>FPPS inhibition in cells should lead to a decrease in membrane Ras. <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>b shows a dose-dependent decrease of membrane Ras when cells are treated with increasing concentrations of <b>CA5d</b>, while the amount of total Ras (membrane Ras plus cytoplasmic Ras) remained unchanged. These results indicate that <b>CA5d</b> affects the relocalization of cytoplasmic Ras via <i>Hs</i>FPPS inhibition, leading to the accumulation of cytoplasm Ras and a decrease of membrane Ras. Membrane Ras is indispensable for Ras signaling and it is well-known that Ras blockade can result in later apoptosis in cancer cells.<a onclick="showRef(event, 'ref7 ref60 ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref7 ref60 ref68 ref69">(7,60,68,69)</a> Taking all these results into consideration, we propose the mechanism of action of <b>CA5d</b> illustrated in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>c: <i>Hs</i>FPPS inhibition of <b>CA5d</b> leads to a decrease in FPP and GGPP, which results in the decline of membrane Ras. Reduction of membrane Ras finally causes PANC-1 cell apoptosis.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02214" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02214" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Nitrogen-containing bisphosphonates, N-BPs, have clear antiosteoporosis benefits, and promising bone-related anticancer effects have been reported in several clinical results.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21 ref22 ref23">(17â23)</a> However, whether they have anticancer activity in soft tissues is controversial,<a onclick="showRef(event, 'ref70 ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref70 ref71 ref72">(70â72)</a> and it is generally thought that the development of <i>Hs</i>FPPS inhibitors with better cell permeability is desirable. Here, we report the discovery and development of a series of non-bisphosphonate <i>Hs</i>FPPS inhibitors based on a natural product hit, carnosic acid (<b>CA</b>). <b>CA</b> had an IC<sub>50</sub> of 20 Î¼M toward <i>Hs</i>FPPS, a good start for further optimization, leading to derivatives such as <b>CA16b</b>, <b>CA25e</b>, and <b>CA28b</b> which had nearly equal potency to that of zoledronate (<b>6</b>). <i>Hs</i>FPPS inhibitors with IC<sub>50</sub> below 1 Î¼M showed weak or no activity toward <i>Hs</i>GGPPS. Results from [<sup>14</sup>C]-IPP radioactivity assays, catalase-addition assays, and Triton X-100 assays excluded the possibility of PAINS-interference, and WaterLOGSY NMR and SPR experiments confirmed the physical binding of our compounds to <i>Hs</i>FPPS. The SPR results also indicated slow dissociation kinetics of <b>CA1</b>, <b>CA13</b>, and <b>CA28a</b>, suggesting potential long-lasting effects <i>in vivo</i>.</div><div class="NLM_p">Binding modes were evaluated via enzyme kinetics and preincubation assays with GPP/GPP+Mg<sup>2+</sup>/IPP with <b>CA28a</b> exhibiting noncompetitive inhibition with respect to GPP and IPP. When combined with the results of docking studies, we propose that <b>CA28a</b> is an allosteric inhibitor that binds to <i>Hs</i>FPPS in its open conformation, as found with known <i>Hs</i>FPPS allosteric site inhibitors. Since this series of inhibitors form stable complexes with similar on rates but slow and variable off-rates, this may indicate that further optimization should focus on reducing the dissociation rate. The cellular activities of our compounds toward PANC-1 and MIA PaCa-2 cells were also evaluated. As expected, most inhibitors were more potent than <b>6</b> in cells even though they had weaker enzyme inhibition activities. Also notable was the observation that <b>CA15a</b> inhibited both <i>Hs</i>FPPS and <i>Hs</i>GGPPS and had potent activity against two pancreatic cancer cell lines, so the development of such dual inhibitors appears to be of interest. We also found evidence, using rescue experiments for <i>Hs</i>FPPS inhibition in cells, leading to decreased Ras prenylation and subsequent apoptosis. It is also noteworthy that such compounds carrying quinone or catechol moieties must be carefully evaluated because of their likely PANIS properties and potential nonspecific cytotoxicities.</div><div class="NLM_p last">In summary, the natural-product-derived <i>Hs</i>FPPS inhibitors discussed here were based on previous observations that related diterpenoids were <i>Hs</i>FPPS inhibitors, as well as the observation that <b>CA</b> and carnosol, components of rosemary and sage, have diverse biological activities. The compounds we synthesized eliminated the highly charged bisphosphonate or carboxylic acid fragments of traditional <i>Hs</i>FPPS inhibitors and were found to be active in pancreatic cancer cell killing where they acted by targeting <i>Hs</i>FPPS. However, there are still many topics to explore including the exact binding mode of our compounds with <i>Hs</i>FPPS, more optimization to enhance cellular activities, and evaluation of effects in animal models; work in all three areas is currently underway.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81264" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81264" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Chemistry Synthesis and Characterization</h3><div class="NLM_p last">All chemicals (except for carnosic acid) and solvents were of reagent grade. Carnosic acid was technical grade and was purified via silica gel column chromatography (200â300 mesh, Qingdao Haiyang Chemical Co. Ltd.). Reactions were monitored by thin-layer chromatography (TLC). <sup>1</sup>H and <sup>13</sup>C spectra were recorded on a Bruker ADVANCE III 400 MHz spectrometer. Solvent residues or tetramethylsilane (TMS) was used as internal references. <sup>1</sup>H spectra are reported as chemical shifts (Î´ ppm), peak multiplicity (s, d, t, q, b, m), and coupling constants (<i>J,</i> Hz). <sup>13</sup>C spectra are reported as chemical shifts (Î´, ppm). High-resolution mass spectrometric (HRMS) analyses were conducted on a Waters mass spectrometer using positive ion or negative ion mode. The purities of the key final compounds were determined to be â¥95% by NMR and HPLC.</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Synthesis of Final Compounds. Procedure a<sub>1</sub></h3><div class="NLM_p last">Reactant catechol (1.0 equiv) and 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ, 1.1 equiv) were dissolved in 1,4-dioxane and stirred at room temperature for 30 min. The mixture was then filtered with diatomite, concentrated in vacuo, and purified by silica gel column chromatography using PE/EA.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Procedure a<sub>2</sub></h3><div class="NLM_p last">Reactant catechol (1.0 equiv) and Ag<sub>2</sub>O (1.1 equiv) were dissolved in 1,4-dioxane and stirred at room temperature for 30 min. The mixture was then filtered with diatomite, concentrated in vacuo, and purified by silica gel column chromatography using PE/EA.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Procedure b</h3><div class="NLM_p last"><b>CA3</b> (1.0 equiv) was dissolved in dry DCM and (CO)<sub>2</sub>Cl<sub>2</sub> (excessive amount), and a catalytic amount of dry DMF was then slowly added to the mixture which was then allowed to react at room temperature overnight under an Ar atmosphere. The mixture was then concentrated in vacuo, and the corresponding acyl chlorides residues were used in the next step without further purification. The acyl chlorides were dissolved in dry DCM at 0 Â°C, then the corresponding amines R<sub>1</sub>NH<sub>2</sub> (1.5â2.0 equiv, except for <b>CA4l</b>) and DMAP (1.5â2.0 equiv) were added. The mixtures were then slowly warmed to room temperature or 35 Â°C, stirred for 2 h, washed with 2 N HCl and saturated brine, extracted with DCM, and concentrated in vacuo to give the residues to be purified by silica gel column chromatography using PE/EA to yield <b>CA4a</b>â<b>k</b>.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Procedure c<sub>1</sub></h3><div class="NLM_p last">Acetyl-protected catechol <b>CA4a</b>â<b>l</b> (1.0 equiv) was dissolved in toluene. To this solution, <i>p</i>-TSAÂ·H<sub>2</sub>O (4.0â6.0 equiv) was added under an Ar atmosphere. The mixtures were then heated to 80 Â°C until reaction completion. They were then washed with saturated NaHCO<sub>3</sub>, extracted with EA, concentrated in vacuo, and purified by silica gel column chromatography to obtain the corresponding compounds.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Procedure c<sub>2</sub></h3><div class="NLM_p last">Acetyl-protected catechol <b>CA4a</b>â<b>l</b> (1.0 equiv) was dissolved in dry THF. To this solution, LiAlH<sub>4</sub> (5.0 equiv) was slowly added at 0 Â°C. The stirred mixture was then allowed to slowly warm to room temperature. On reaction completion, excess LiAlH<sub>4</sub> was quenched with saturated NH<sub>4</sub>Cl, the mixture was washed twice with brine, extracted with EA, concentrated in vacuo, and purified by silica gel column chromatography to obtain the corresponding compounds.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Procedure c<sub>3</sub></h3><div class="NLM_p last">Acetyl-protected catechol (1.0 equiv) and NaHCO<sub>3</sub> (13.7 equiv) were added to MeOH/H<sub>2</sub>O (4:1) and stirred at 65 Â°C overnight. The mixture was then washed with 2 N HCl, extracted with EA, dried with anhydrous MgSO<sub>4</sub>, concentrated in vacuo, and purified by silica gel column chromatography.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Procedure d</h3><div class="NLM_p last">Acetyl-protected catechol (1.0 equiv) and CrO<sub>3</sub> (2.0 equiv) were dissolved in AcOH at room temperature and stirred for 12 h, after which the mixture was concentrated in vacuo, redissolved in EA/DCM, washed with saturated NaHCO<sub>3</sub>, extracted with EA, and purified by silica gel column chromatography.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Procedure e</h3><div class="NLM_p last"><b>CA2</b> (1.0 equiv) and corresponding nucleophilic reagent R<sub>4</sub>X<sub>2</sub>H (1.1 equiv) were dissolved in MeOH or EtOH at 0 Â°C (when X<sub>2</sub> = S) or room temperature (when X<sub>2</sub> = O) and were stirred until reaction completion. Then, the mixture was concentrated in vacuo and the product purified by silica gel column chromatography.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Procedure f<sub>1</sub></h3><div class="NLM_p last"><b>CA4i</b>,<b>j</b> (1.0 equiv) was added into an excess amount of POCl<sub>3</sub> which served as both reactant and solvent. The mixture was then stirred at 80 Â°C for 1â5 h until reaction completion. Then, the mixture was washed with saturated NaHCO<sub>3</sub> and brine, dried with anhydrous MgSO<sub>4</sub>, and purified by silica gel column chromatography. <b>CA25a</b>,<b>b</b> were obtained in 31â41% yield.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Procedure f<sub>2</sub></h3><div class="NLM_p last"><b>CA4k</b> (1.0 equiv) was dissolved in DCM/CH<sub>3</sub>CN (1:1). 4-Toluenesulfonyl chloride (<i>p</i>-TsCl, 3.0 equiv) and diisopropylethylamine (DIEA, 5.0 equiv) were then added, and the mixture was allowed to react at 65 Â°C until the reaction completed. Then, the mixture was washed with saturated NH<sub>4</sub>Cl and brine, dried with anhydrous MgSO<sub>4</sub>, and purified by silica gel column chromatography.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Procedure g</h3><div class="NLM_p last">Carboxylic acid R<sub>5</sub>COOH (1.5 equiv), hexafluorophosphate azabenzotriazole tetramethyluronium (HATU, 1.5 equiv), and <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA, 2.0 equiv) were dissolved and stirred in DCM at room temperature for 30 min. After the solution became clear, <b>CA4h</b> (1.0 equiv) was added into the mixture which was then stirred overnight until the reaction completed. Then, the mixture was washed with brine, extracted with EA, concentrated in vacuo, and purified by silica gel column chromatography to form compounds <b>CA23a</b>â<b>c</b>.</div></div><div id="sec4_2_11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Methyl (4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA1</b>)</h3><div class="NLM_p last">Carnosic acid (<b>CA</b>, 3.32 g, 10 mmol) was dissolved in 90 mL of toluene/MeOH (5:1) at 0 Â°C. Trimethylsilyldiazomethane (TMSCHN<sub>2</sub>, 10 mL, 20 mmol) was then slowly added to the mixture. After reaction completion indicated by TLC, solvent was removed in vacuo and the product washed with brine, extracted with EA, dried with anhydrous MgSO<sub>4</sub>, and purified by silica gel column chromatography using PE/EA. <b>CA1</b> was obtained in 90% yield (3.1 g). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.48 (s, 1H), 6.55 (s, 1H), 5.79 (s, 1H), 3.68 (s, 3H), 3.33â3.29 (m, 1H), 3.21 (hept, 1H), 2.83â2.80 (m, 2H), 2.35â2.24 (m, 1H), 1.89â1.85 (m, 1H), 1.71â1.55 (m, 3H), 1.48â1.45 (m, 1H), 1.35â1.27 (m, 2H), 1.25 (d, <i>J</i> = 4.9 Hz, 3H), 1.23 (d, <i>J</i> = 4.4 Hz, 3H), 1.00 (s, 3H), 0.80 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 179.0, 142.2, 141.8, 133.5, 128.6, 122.1, 119.3, 54.1, 52.3, 49.2, 42.2, 35.1, 34.5, 32.8, 31.8, 27.3, 22.6, 22.3, 21.9, 20.5, 19.4. HRMS <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>29</sub>O<sub>4</sub> (M â H)<sup>â</sup>, 345.2066; found, 345.2056.</div></div><div id="sec4_2_11_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Methyl (4a<i>R</i>,10a<i>S</i>)-5-Hydroxy-7-isopropyl-1,1-dimethyl-6-oxo-1,3,4,6,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA2</b>)</h3><div class="NLM_p last">Procedure a<sub>1</sub>/a<sub>2</sub> was used for the synthesis of <b>CA2</b>, using <b>CA1</b> (3.16 g, 9.1 mmol) and DDQ (2.2 g, 9.7 mmol) or Ag<sub>2</sub>O (2.2 g, 9.7 mmol). <b>CA2</b> was provided in 66% yield (2.05 g, procedure a<sub>1</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.62 (s, 1H), 6.93 (dd, <i>J</i> = 6.8, 3.1 Hz, 1H), 6.85 (s, 1H), 3.72 (dt, <i>J</i> = 13.5, 4.0 Hz, 1H), 3.62 (s, 3H), 3.07 (h, <i>J</i> = 6.7 Hz, 1H), 2.95 (ddd, <i>J</i> = 20.7, 12.3, 3.1 Hz, 1H), 2.63 (ddd, <i>J</i> = 20.6, 6.8, 4.4 Hz, 1H), 1.98 (qt, <i>J</i> = 13.9, 4.5 Hz, 1H), 1.79 (dd, <i>J</i> = 12.3, 4.4 Hz, 1H), 1.62 (dt, <i>J</i> = 14.4, 3.6 Hz, 1H), 1.51â1.43 (m, 1H), 1.38â1.19 (m, 2H), 1.14 (dd, <i>J</i> = 6.9, 5.0 Hz, 6H), 0.95 (s, 3H), 0.80 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 181.0, 173.6, 150.8, 146.3, 140.6, 137.2, 130.9, 118.6, 51.8, 51.0, 47.2, 41.9, 34.1, 33.3, 32.1, 26.9, 26.8, 21.9, 21.5, 20.1, 20.0. HRMS <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>29</sub>O<sub>4</sub> (M + H)<sup>+</sup>, 345.2066; found, 345.2051.</div></div><div id="sec4_2_11_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (4a<i>R</i>,10a<i>S</i>)-5,6-Diacetoxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxylic Acid (<b>CA3</b>)</h3><div class="NLM_p last">Compound <b>CA</b> (8 g, 24.1 mmol) was dissolved in dichloromethane (DCM, 100 mL). Acetic anhydride (11.4 mL, 120.6 mmol) and 4-dimethylaminopyridine (DMAP, 3.5 g, 28.6 mmol) were added to the solution at room temperature. The resulting mixture was stirred at room temperature for 12 h, washed with 2 N HCl and then saturated brine, extracted with DCM, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered. The remaining filtrate was then concentrated in vacuo. The crude product was purified by silica gel column chromatography using petroleum ether (PE)/ethyl acetate (EA) to give <b>CA3</b> (9.9 g, 23.9 mmol, 99%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.45 (br, 1H), 6.95 (s, 1H), 3.22 (d, <i>J</i> = 13.3 Hz, 1H), 2.98â2.79 (m, 3H), 2.40â2.27 (m, 1H), 2.26 (s, 3H), 2.24 (s, 3H), 2.16â2.09 (m, 1H), 1.88â1.79 (m, 1H), 1.57â1.41 (m, 3H), 1.33â1.22 (m, 2H), 1.21 (d, <i>J</i> = 6.9 Hz, 3H), 1.14 (d, <i>J</i> = 6.9 Hz, 3H), 0.96 (s, 3H), 0.86 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 180.7, 168.8, 168.2, 141.5, 140.0, 138.8, 136.9, 132.2, 125.3, 54.0, 47.7, 41.2, 34.6, 34.1, 32.6, 32.1, 27.5, 23.1, 22.8, 20.6, 20.5, 20.2, 19.9, 18.2.</div></div><div id="sec4_2_11_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (4b<i>R</i>,8a<i>S</i>)-4b-(2-Acetylhydrazine-1-carbonyl)-2-isopropyl-8,8-dimethyl-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diyl Diacetate (<b>CA4i</b>)</h3><div class="NLM_p last">Compound <b>CA3</b> (6.06 g, 14.5 mmol) was dissolved in dry DCM (100 mL). Oxalyl chloride (48.5 mL) was slowly added into the solution, then dry dimethylformamide (DMF, 0.66 mL) was added dropwise. The final mixture was allowed to react at room temperature overnight under an Ar atmosphere. After completion, the mixture was concentrated in vacuo and the acyl chloride product was directly used in the next step without further purification. The acyl chloride was dissolved in dry DCM (100 mL), and acethydrazide (2.1 g, 28.4 mmol) and DMAP (3.5 g, 28.6 mmol) were added at 0 Â°C. The reaction mixture was stirred at 35 Â°C for 2 h, washed with 2 N HCl and brine, extracted with DCM, and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and then concentrated in vacuo to give the crude product. The crude product was purified by silica gel column chromatography using PE/EA to give <b>CA4i</b> (5.06 g, 12.1 mmol, 83.5%) in two steps. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.40 (br, 1H), 7.65 (s, 1H), 6.94 (s, 1H), 3.16â3.13 (m, 1H), 2.98â2.85 (m, 2H), 2.82 (hepta, 1H), 2.22 (s, 3H), 2.18 (s, 3H), 2.22â2.18 (m, 1H), 2.00â1.90 (m, 1H), 1.84 (s, 3H), 1.54 (m, 3H), 1.23â1.20 (m, 2H), 1.17 (d, 3H), 1.11 (d, 3H), 0.93 (s, 3H), 0.80 (s, 3H), 0.85â0.70 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 171.7, 168.3, 168.2, 166.8, 141.2, 140.4, 138.8, 135.9, 132.7, 125.3, 52.4, 47.2, 39.9, 34.0, 33.5, 32.1, 31.2, 27.2, 22.7, 22.6, 20.4, 20.3, 20.3, 20.2, 19.7, 18.6.</div></div><div id="sec4_2_11_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7-isopropyl-<i>N</i>,1,1-trimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxamide (<b>CA5a</b>)</h3><div class="NLM_p last"><b>CA5a</b> was synthesized by using procedures b and c<sub>2</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.30 (s, 1H), 6.49 (s, 1H), 5.99â5.93 (m, 1H), 3.46 (dd, <i>J</i> = 13.6, 4.0 Hz, 1H), 3.20 (hept, <i>J</i> = 7.0 Hz, 1H), 2.89 (dd, <i>J</i> = 8.4, 4.1 Hz, 2H), 2.78 (d, <i>J</i> = 4.8 Hz, 3H), 2.21â2.11 (m, 1H), 1.79â1.54 (m, 4H), 1.52 (ddt, <i>J</i> = 13.4, 4.6, 2.2 Hz, 1H), 1.47â1.40 (m, 1H), 1.39â1.30 (m, 1H), 1.22 (d, <i>J</i> = 2.8 Hz, 3H), 1.20 (d, <i>J</i> = 2.8 Hz, 3H), 1.03 (s, 3H), 0.93 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 178.1, 143.1, 142.0, 133.3, 126.8, 124.0, 118.4, 53.2, 49.5, 42.1, 35.7, 34.6, 33.2, 31.7, 27.2, 26.8, 23.0, 22.7, 22.3, 21.1, 20.5.</div></div><div id="sec4_2_11_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (4a<i>R</i>,10a<i>S</i>)-<i>N</i>-Cycloheptyl-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxamide (<b>CA5b</b>)</h3><div class="NLM_p last"><b>CA5b</b> was synthesized by using procedures b and c<sub>2</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.55â9.50 (m, 1H), 6.48 (s, 1H), 5.95 (s, 1H), 5.91 (d, <i>J</i> = 7.6 Hz, 1H), 3.97â3.85 (m, 1H), 3.46 (dd, <i>J</i> = 13.8, 3.8 Hz, 1H), 3.20 (hept, <i>J</i> = 6.9 Hz, 1H), 2.88 (dd, <i>J</i> = 8.2, 4.1 Hz, 2H), 2.19â2.08 (m, 1H), 1.96 (dq, <i>J</i> = 14.0, 5.4, 4.8 Hz, 2H), 1.75â1.44 (m, 14H), 1.40 (dt, <i>J</i> = 9.3, 3.5 Hz, 1H), 1.39â1.22 (m, 2H), 1.22 (d, <i>J</i> = 1.1 Hz, 3H), 1.20 (d, <i>J</i> = 1.1 Hz, 3H), 1.03 (s, 3H), 1.00 (s, 3H). HRMS <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>40</sub>NO<sub>3</sub> (M â H)<sup>â</sup>, 426.3008; found, 426.3000.</div></div><div id="sec4_2_11_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-<i>N</i>-phenyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxamide (<b>CA5c</b>)</h3><div class="NLM_p last"><b>CA5c</b> was synthesized by using procedures b and c<sub>2</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.45 (s, 1H), 7.14 (dt, <i>J</i> = 4.9, 2.3 Hz, 3H), 6.98â6.89 (m, 2H), 6.42 (s, 1H), 6.08 (t, <i>J</i> = 5.4 Hz, 1H), 5.92 (s, 1H), 4.36 (dd, <i>J</i> = 14.8, 5.8 Hz, 1H), 4.25 (dd, <i>J</i> = 14.8, 5.0 Hz, 1H), 3.40 (dt, <i>J</i> = 13.8, 3.9 Hz, 1H), 3.14 (hept, <i>J</i> = 6.9 Hz, 1H), 2.82â2.74 (m, 2H), 2.00 (dt, <i>J</i> = 12.1, 3.9 Hz, 1H), 1.81â1.38 (m, 4H), 1.23 (td, <i>J</i> = 11.8, 10.4, 2.9 Hz, 1H), 1.17 (d, <i>J</i> = 5.0 Hz, 2H), 1.14 (d, <i>J</i> = 2.2 Hz, 3H), 1.13 (d, <i>J</i> = 2.3 Hz, 3H), 0.91 (s, 3H), 0.78 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 177.4, 143.0, 141.8, 137.4, 133.5, 128.8, 127.7, 127.6, 127.0, 124.3, 118.6, 53.3, 49.5, 44.3, 42.0, 35.4, 34.5, 33.0, 31.5, 27.2, 22.9, 22.6, 22.5, 21.0, 20.4.</div></div><div id="sec4_2_11_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (4a<i>R</i>,10a<i>S</i>)-<i>N</i>-(2-(Dimethylamino)ethyl)-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxamide (<b>CA5d</b>)</h3><div class="NLM_p last"><b>CA5d</b> was synthesized by using procedures b and c<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.58 (s, 1H), 6.10 (t, <i>J</i> = 5.9 Hz, 1H), 3.51 (tt, <i>J</i> = 11.0, 5.4 Hz, 2H), 3.34 (dq, <i>J</i> = 15.0, 5.7 Hz, 1H), 3.16 (h, <i>J</i> = 6.9 Hz, 1H), 2.89â2.75 (m, 2H), 2.41 (t, <i>J</i> = 5.6 Hz, 2H), 2.38â2.25 (m, 1H), 2.19 (s, 6H), 2.06â1.95 (m, 1H), 1.91â1.82 (m, 1H), 1.58 (ddd, <i>J</i> = 21.7, 12.8, 9.0 Hz, 3H), 1.32 (tt, <i>J</i> = 11.9, 6.4 Hz, 2H), 1.20 (t, <i>J</i> = 6.4 Hz, 6H), 0.97 (s, 3H), 0.89 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 176.6, 144.7, 141.6, 132.4, 131.2, 128.0, 120.4, 57.2, 54.2, 48.8, 44.5, 41.5, 36.4, 34.7, 34.1, 32.7, 32.0, 27.5, 22.5, 22.4, 21.6, 20.4, 19.6. HRMS <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>39</sub>N<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup>, 403.2961; found, 403.2980. HPLC purity: 95.1%. <i>t</i><sub>R</sub> = 2.96 min.</div></div><div id="sec4_2_11_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-<i>N</i>-(2-hydroxyethyl)-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxamide (<b>CA5e</b>)</h3><div class="NLM_p last"><b>CA5e</b> was synthesized by using procedures b and c<sub>2</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.33 (s, 1H), 6.50 (s, 1H), 6.38 (t, <i>J</i> = 5.6 Hz, 1H), 6.18 (s, 1H), 3.58 (t, <i>J</i> = 5.2 Hz, 2H), 3.45 (dd, <i>J</i> = 13.9, 4.0 Hz, 1H), 3.32 (dddd, <i>J</i> = 19.6, 14.3, 9.3, 5.1 Hz, 2H), 3.17 (hept, <i>J</i> = 6.6 Hz, 1H), 2.86 (dd, <i>J</i> = 8.8, 4.1 Hz, 2H), 2.08â1.98 (m, 1H), 1.86 (tq, <i>J</i> = 15.5, 7.1, 6.3 Hz, 2H), 1.65 (d, <i>J</i> = 12.8 Hz, 1H), 1.57 (td, <i>J</i> = 10.2, 9.5, 4.3 Hz, 2H), 1.37â1.29 (m, 1H), 1.25 (t, <i>J</i> = 7.0 Hz, 2H), 1.19 (d, <i>J</i> = 6.9 Hz, 6H), 1.00 (s, 3H), 0.93 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 178.3, 143.0, 141.6, 133.9, 128.0, 126.0, 118.8, 61.3, 53.5, 49.2, 42.4, 41.6, 35.2, 34.3, 33.0, 31.8, 27.2, 22.8, 22.3, 22.3, 20.4, 20.3.</div></div><div id="sec4_2_11_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (4a<i>R</i>,10a<i>S</i>)-<i>N</i>-(3-(1<i>H</i>-Imidazol-1-yl)propyl)-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxamide (<b>CA5f</b>)</h3><div class="NLM_p last"><b>CA5f</b> was synthesized by using procedures b and c<sub>2</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.31 (s, 1H), 6.88â6.85 (m, 1H), 6.71 (d, <i>J</i> = 1.3 Hz, 1H), 6.51 (s, 1H), 6.00 (dd, <i>J</i> = 7.9, 4.4 Hz, 1H), 3.75 (s, 0H), 3.77â3.57 (m, 2H), 3.57â3.42 (m, 1H), 3.26 (ttd, <i>J</i> = 9.6, 7.0, 6.1, 2.5 Hz, 2H), 3.06 (ddt, <i>J</i> = 13.4, 7.3, 5.6 Hz, 1H), 2.96â2.82 (m, 2H), 2.12â1.97 (m, 2H), 1.98â1.85 (m, 1H), 1.84â1.69 (m, 1H), 1.68â1.47 (m, 3H), 1.43â1.18 (m, 3H), 1.21â1.10 (m, 6H), 0.97 (s, 3H), 0.87 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 177.3, 144.2, 140.3, 137.0, 135.1, 128.9, 128.5, 126.2, 119.0, 118.2, 53.3, 48.8, 44.5, 41.2, 36.5, 34.8, 34.1, 32.8, 31.7, 31.2, 27.1, 23.1, 22.7, 21.7, 20.3, 20.0. HRMS <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>38</sub>N<sub>3</sub>O<sub>3</sub> (M + H)<sup>+</sup>, 440.2913; found, 440.2907.</div></div><div id="sec4_2_11_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-<i>N</i>-(pyridin-3-ylmethyl)-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxamide (<b>CA5g</b>)</h3><div class="NLM_p last"><b>CA5g</b> was synthesized by using procedures b and c<sub>2</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.39â8.30 (m, 2H), 7.37 (dt, <i>J</i> = 7.9, 2.0 Hz, 1H), 7.13 (ddd, <i>J</i> = 7.8, 4.8, 0.9 Hz, 1H), 6.49 (s, 1H), 6.27 (t, <i>J</i> = 6.0 Hz, 1H), 4.47 (dd, <i>J</i> = 15.3, 6.2 Hz, 1H), 4.29 (dd, <i>J</i> = 15.3, 5.5 Hz, 1H), 3.54â3.44 (m, 1H), 3.22 (hept, <i>J</i> = 6.8 Hz, 1H), 2.90â2.82 (m, 2H), 2.16 (s, 1H), 2.06â1.80 (m, 2H), 1.67 (dd, <i>J</i> = 12.9, 2.3 Hz, 1H), 1.62â1.46 (m, 2H), 1.36â1.25 (m, 2H), 1.18 (d, <i>J</i> = 6.9 Hz, 6H), 0.98 (s, 3H), 0.84 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 177.3, 148.6, 148.1, 143.8, 140.8, 135.8, 134.6, 134.2, 128.3, 125.3, 123.6, 118.4, 60.5, 53.3, 49.1, 41.5, 35.1, 34.3, 32.8, 31.6, 27.1, 22.9, 22.6, 22.2, 20.4, 20.3. HRMS <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>35</sub>N<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup>, 423.2648; found, 423.2658.</div></div><div id="sec4_2_11_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carbohydrazide (<b>CA5h</b>)</h3><div class="NLM_p last"><b>CA5h</b> was synthesized by using procedures b and c<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.00 (s, 1H), 6.57 (s, 1H), 5.76 (s, 1H), 3.31 (d, <i>J</i> = 14.0 Hz, 1H), 3.18 (hept, <i>J</i> = 6.9 Hz, 1H), 2.84 (p, <i>J</i> = 7.5, 6.3 Hz, 2H), 2.37 (m, 1H), 1.92â1.84 (m, 1H), 1.76 (t, <i>J</i> = 13.8 Hz, 1H), 1.60 (t, <i>J</i> = 13.2 Hz, 2H), 1.50 (d, <i>J</i> = 13.4 Hz, 1H), 1.30 (dt, <i>J</i> = 20.3, 12.0 Hz, 2H), 1.25â1.18 (m, 6H), 1.02 (s, 3H), 0.91 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 183.3, 142.3, 141.5, 134.0, 129.2, 122.2, 119.5, 54.1, 48.8, 42.0, 34.5, 32.7, 31.6, 29.9, 27.3, 22.7, 22.3, 21.8, 20.5, 19.0.</div></div><div id="sec4_2_11_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (4a<i>R</i>,10a<i>S</i>)-<i>N</i>â²-Acetyl-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carbohydrazide (<b>CA5i</b>)</h3><div class="NLM_p last"><b>CA5i</b> was synthesized by using procedures b and c<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.56 (s, 1H), 5.91 (br, 1H), 3.73 (dd, <i>J</i> = 10.7, 7.2 Hz, 1H), 3.19 (hept, <i>J</i> = 6.9 Hz, 1H), 2.87 (dt, <i>J</i> = 14.1, 7.1 Hz, 2H), 2.46 (s, 3H), 2.21 (ddd, <i>J</i> = 21.6, 12.9, 8.6 Hz, 1H), 2.06â1.96 (m, 1H), 1.85 (ddd, <i>J</i> = 17.5, 10.6, 7.0 Hz, 1H), 1.74 (d, <i>J</i> = 12.5 Hz, 1H), 1.66 (dt, <i>J</i> = 14.7, 3.8 Hz, 1H), 1.65â1.32 (m, 2H), 1.43 (m, 1H), 1.27 (m, 2H), 1.20 (d, <i>J</i> = 6.9 Hz, 6H), 1.03 (s, 3H), 0.53 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 171.8, 163.9, 142.3, 142.0, 133.9, 127.8, 123.0, 119.2, 54.8, 42.2, 41.9, 35.3, 34.1, 32.5, 31.8, 29.8, 27.3, 22.6, 22.2, 21.4, 19.9, 19.6.</div></div><div id="sec4_2_11_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 2-((4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7- isopropyl-1,1-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-4a-carbonyl)hydrazine-1-carboxamide (<b>CA5j</b>)</h3><div class="NLM_p last"><b>CA5j</b> was synthesized by using procedures b and c<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) Î´ 10.91 (br, 1H), 7.02 (br, 1H), 6.51 (s, 1H), 3.92â3.82 (m, 1H), 3.23 (hept, <i>J</i> = 6.9 Hz, 1H), 2.91â2.74 (m, 2H), 2.38â2.21 (m, 1H), 2.17â2.04 (m, 1H), 1.98â1.80 (m, 1H), 1.65 (dd, <i>J</i> = 12.5, 1.8 Hz, 1H), 1.63â1.48 (m, 2H), 1.45â1.31 (m, 2H), 1.17 (dd, <i>J</i> = 6.9, 3.9 Hz, 6H), 1.00 (s, 3H), 0.70 (s, 3H). <sup>13</sup>C NMR (100 MHz, acetone) Î´ 161.0, 155.0, 145.2, 139.9, 135.2, 130.1, 125.5, 117.6, 54.5, 42.2, 41.3, 33.9, 33.8, 32.3, 31.9, 26.8, 22.7, 22.4, 20.0, 19.7, 19.0.</div></div><div id="sec4_2_11_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (4a<i>R</i>,10a<i>S</i>)-<i>N</i>â²-(4-Bromobenzoyl)-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carbohydrazide (<b>CA5k</b>)</h3><div class="NLM_p last"><b>CA5k</b> was synthesized by using procedures b and c<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) Î´ 10.08 (br, 1H), 8.93 (br, 1H), 7.84 (d, <i>J</i> = 8.3 Hz, 2H), 7.68 (d, <i>J</i> = 8.3 Hz, 2H), 7.18 (br, 1H), 6.59 (s, 1H), 3.79â3.68 (m, 1H), 3.19 (hept, <i>J</i> = 7.1 Hz, 1H), 2.88â2.76 (m, 2H), 2.54â2.41 (m, 1H), 2.34â2.24 (m, 1H), 1.82 (d, <i>J</i> = 13.1 Hz, 1H), 1.60 (d, <i>J</i> = 8.6 Hz, 2H), 1.53 (d, <i>J</i> = 12.7 Hz, 1H), 1.35 (dd, <i>J</i> = 11.9, 4.3 Hz, 1H), 1.28â1.23 (m, 1H), 1.19 (t, <i>J</i> = 6.9 Hz, 6H), 0.99 (s, 3H), 0.90 (s, 3H). <sup>13</sup>C NMR (100 MHz, acetone) Î´ 174.5, 167.1, 144.7, 141.5, 132.8, 131.8, 131.4, 131.0, 129.5, 128.1, 126.4, 120.4, 54.7, 47.7, 41.1, 34.1, 33.7, 32.1, 31.6, 27.1, 22.2, 21.7, 20.5, 20.3, 18.8.</div></div><div id="sec4_2_11_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>tert</i>-Butyl ((<i>S</i>)-1-(2-((4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-4a-carbonyl)hydrazinyl)-1-oxopropan-2-yl)carbamate (<b>CA5l</b>)</h3><div class="NLM_p last"><b>CA5l</b> was synthesized from <b>CA4l</b> by using procedure c<sub>2.</sub><b>CA4l</b> was the condensation product of <b>CA4h</b> and <i>N</i>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-alanine. <i>N</i>-(<i>tert</i>-Butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-alanine (1.1 g, 5.76 mmol), hexafluorophosphate azabenzotriazole tetramethyluranium (HATU, 2.1 g, 5.76 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA, 1.3 mL, 7.68 mmol) were dissolved in DCM (20 mL) and stirred at room temperature for 30 min. After the solution became clear, <b>CA4h</b> (1.66 g, 3.84 mmol) was added and the mixture stirred overnight until the reaction completed. Then, the mixture was washed with brine, extracted with EA, concentrated in vacuo, and purified by silica gel column chromatography. <b>CA4l</b> (1.59 g) was obtained in 69% yield. <b>CA4l</b> (0.1 g, 0.17 mmol) was then deprotected by using procedure c<sub>2</sub> and <b>CA5l</b> was obtained in 68% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.95 (s, 1H), 7.88 (br, 1H), 7.53 (br, 1H), 6.60 (s, 1H), 6.27 (s, 1H), 5.53 (d, <i>J</i> = 7.2 Hz, 1H), 4.23â4.13 (m, 1H), 3.51 (d, <i>J</i> = 14.8 Hz, 1H), 3.16 (hept, <i>J</i> = 6.9 Hz, 1H), 2.82 (m, 2H), 2.22 (t, <i>J</i> = 9.6 Hz, 1H), 2.12â2.01 (m, 1H), 1.85 (d, <i>J</i> = 12.9 Hz, 1H), 1.65â1.50 (m, 4H), 1.41 (s, 9H), 1.38â1.26 (m, 2H), 1.21â1.19 (m, 2H), 1.19â1.13 (m, 6H), 0.97 (s, 3H), 0.84 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 175.5, 173.6, 156.0, 144.3, 141.2, 133.9, 130.0, 128.4, 121.0, 80.9, 54.5, 48.1, 41.2, 34.4, 34.0, 32.7, 31.7, 29.8, 28.5, 28.4, 27.3, 27.0, 22.8, 22.3, 21.1, 20.3, 19.3, 17.6.</div></div><div id="sec4_2_11_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (4a<i>R</i>,10a<i>S</i>)-<i>N</i>-(2-(Dimethylamino)ethyl)-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-9-oxo-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxamide (<b>CA7</b>)</h3><div class="NLM_p last"><b>CA7</b> was synthesized from <b>CA4d</b> by using procedures d and c<sub>2</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.76 (s, 1H), 6.48â6.41 (m, 1H), 3.98 (dtd, <i>J</i> = 15.8, 8.1, 4.3 Hz, 1H), 3.79 (dd, <i>J</i> = 16.7, 15.0 Hz, 1H), 3.69â3.61 (m, 1H), 3.21 (hept, <i>J</i> = 6.9 Hz, 1H), 3.11 (ddt, <i>J</i> = 14.5, 7.1, 3.6 Hz, 1H), 2.67â2.56 (m, 2H), 2.49 (ddd, <i>J</i> = 12.3, 7.2, 3.9 Hz, 1H), 2.21 (s, 6H), 2.12 (dd, <i>J</i> = 15.0, 3.3 Hz, 1H), 1.98â1.87 (m, 1H), 1.72â1.64 (m, 1H), 1.55 (d, <i>J</i> = 13.2 Hz, 1H), 1.44â1.36 (m, 2H), 1.23 (d, <i>J</i> = 6.9 Hz, 6H), 0.97 (s, 3H), 0.95 (s, 3H). HRMS <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>37</sub>N<sub>2</sub>O<sub>4</sub> (M + H)<sup>+</sup>, 417.2753; found, 417.2755.</div></div><div id="sec4_2_11_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Methyl (4a<i>R</i>,10a<i>S</i>)-5-((<i>tert</i>-Butyldimethylsilyl)oxy)-6-hydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA8a</b>)</h3><div class="NLM_p last"><b>CA1</b> (0.1 g, 0.29 mmol) was dissolved in DCM (5 mL). To this solution, <i>tert</i>-butyldimethylsilyl chloride (TBSCl, 109.3 mg, 0.73 mmol) and imidazole (49.4 mg, 0.73 mmol) were added, and the mixture was allowed to react at room temperature for 12 h. After reaction completion, the mixture was quenched by 1% HCl, extracted with DCM, dried with anhydrous MgSO<sub>4</sub>, and purified by silica gel column chromatography. <b>CA8a</b> (55.6 mg) was obtained in 42% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.50 (s, 1H), 5.98 (s, 1H), 3.62 (s, 3H), 3.49â3.43 (m, 1H), 3.20 (hept, <i>J</i> = 6.9, 1H), 2.84â2.81 (m, 2H), 2.32â2.21 (m, 1H), 3.14â2.02 (m, 1H), 1.85â1.81 (m, 1H), 1.60â1.48 (m, 3H), 1.34â1.26 (m, 2H), 1.15 (d, <i>J</i> = 6.9, 3H), 1.12 (d, <i>J</i> = 6.9, 3H), 1.00 (s, 9H), 0.98 (s, 3H), 0.79 (s, 3H), 0.19 (s, 3H), 0.17 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 177.2, 146.2, 138.4, 137.8, 131.3, 124.7, 117.9, 54.3, 51.7, 48.2, 41.8, 34.5, 34.2, 32.8, 32.0, 26.4, 26.1, 23.4, 23.0, 20.6, 20.2, 18.9, 18.8, â3.7, â3.9.</div></div><div id="sec4_2_11_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Methyl (4a<i>R</i>,10a<i>S</i>)-5-(Benzyloxy)-6-hydroxy-7-isopropyl-1,1-dimethyl-1,3,4,10a-tetrahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA8b</b>)</h3><div class="NLM_p last"><b>CA2</b> (0.1 g, 0.3 mmol) was dissolved in acetone (5 mL). To this solution, benzyl bromide (154 mg, 0.9 mmol) and potassium carbonate (83 mg, 0.6 mmol) were added, and the mixture was allowed to react at room temperature until completion. Then, the mixture was quenched by 1% HCl, extracted with EA, dried with anhydrous MgSO<sub>4</sub>, and purified by silica gel column chromatography. <b>CA8b</b> was obtained. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.45â7.37 (m, 5H), 6.54 (s, 1H), 6.36 (dd, <i>J</i> = 9.6 Hz, 3.2 Hz, 1H), 6.15 (s, 1H), 6.07 (dd, <i>J</i> = 9.6 Hz, 2.8 Hz, 1H), 4.85 (dd, <i>J</i> = 14.2 Hz, 11.2 Hz, 2H), 3.74â3.70 (m, 1H), 3.53 (s, 3H), 3.27 (hept, <i>J</i> = 6.9 Hz, 1H), 2.59 (t, <i>J</i> = 3.0 Hz, 2H), 1.80â1.70 (m, 1H), 1.66â1.61 (m, 1H), 1.55â1.51 (m,1H), 1.49â1.43 (m, 1H), 1.27 (d, <i>J</i> = 6.9 Hz, 3H), 1.21 (d, <i>J</i> = 6.9 Hz, 3H), 1.04 (s, 3H), 0.85 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 174.3, 148.1, 143.2, 140.2, 136.7, 132.7, 128.7, 128.5, 128.1, 127.9, 127.0, 122.0, 116.8, 51.5, 51.2, 49.2, 41.1, 33.8, 33.7, 32.0, 29.7, 26.7, 23.6, 23.3, 21.7, 20.4. HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>33</sub>O<sub>4</sub> (M â H)<sup>â</sup>, 433.2379; found, 433.2369.</div></div><div id="sec4_2_11_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (4b<i>R</i>,8a<i>S</i>)-2-Isopropyl-4b-(methoxycarbonyl)-8,8-dimethyl-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diyl Diacetate (<b>CA8c</b>)</h3><div class="NLM_p last"><b>CA1</b> (0.1 g, 0.29 mmol) was dissolved in DCM (5 mL). To this solution, acetic anhydride (148 mg, 1.45 mmol) and DMAP (43 mg, 0.35 mmol) were added, and the mixture was stirred at room temperature until reaction completion. Then, the mixture was washed with 2 N HCl and brine, extracted with DCM, dried with anhydrous MgSO<sub>4</sub>, concentrated in vacuo, and purified by silica gel column chromatography. 50 mg of <b>CA8c</b> was obtained (40%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.95 (s, 1H), 3.51 (s, 3H), 3.28 (d, <i>J</i> = 12 Hz, 1H), 2.91â2.87 (m, 3H), 2.25 (s, 6H), 2.11â2.04 (m, 1H), 1.86â1.84 (m, 1H), 1.54â1.45 (m, 3H), 1.26â1.23 (m, 3H), 1.21 (d, <i>J</i> = 6.6 Hz, 3H), 1.14 (d, <i>J</i> = 6.7 Hz, 3H), 0.96 (s, 3H), 0.74 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 175.3, 168.7, 168.4, 141.4, 139.8, 138.8, 136.9, 131.8, 125.3, 53.7, 51.9, 47.8, 41.2, 34.8, 34.0, 32.6, 32.0, 27.5, 23.1, 22.7, 20.8, 20.5, 20.0, 19.9, 18.4. HRMS <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>34</sub>O<sub>6</sub>Na (M + Na)<sup>+</sup>, 453.2253; found, 453.2252.</div></div><div id="sec4_2_11_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Methyl (4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-9-oxo-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA10</b>)</h3><div class="NLM_p last"><b>CA10</b> (42 mg, 52%) was synthesized from <b>CA9</b> (0.1 g, 0.23 mmol) by using procedure c<sub>3</sub>. <b>CA9</b> was synthesized from <b>CA8c</b> by using procedure d. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.74 (s, 1H), 7.45 (s, 1H), 6.47 (s, 1H), 3.72 (s, 3H), 3.43 (dt, <i>J</i> = 14.0, 3.8 Hz, 1H), 3.31â3.17 (m, 2H), 2.68 (dd, <i>J</i> = 17.0, 3.4 Hz, 1H), 2.16 (dd, <i>J</i> = 15.3, 3.4 Hz, 1H), 1.76â1.62 (m, 2H), 1.52 (dt, <i>J</i> = 13.2, 3.8 Hz, 1H), 1.44â1.26 (m, 2H), 1.27â1.20 (m, 6H), 1.00 (s, 3H), 0.86 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 197.7, 177.8, 149.5, 141.1, 134.4, 127.4, 124.4, 120.1, 52.7, 50.5, 49.7, 41.7, 35.8, 34.5, 34.1, 32.1, 27.4, 22.4, 22.1, 21.5, 20.3. HRMS <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>27</sub>O<sub>5</sub> (M â H)<sup>â</sup>, 359.1858; found, 359.1863.</div></div><div id="sec4_2_11_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (4b<i>R</i>,8a<i>S</i>)-9-Chloro-2-isopropyl-4b-(methoxycarbonyl)-8,8-dimethyl-10-oxo-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diyl Diacetate (<b>CA11a</b>)</h3><div class="NLM_p last"><b>CA9</b> (40 mg, 0.09 mmol) was dissolved in 2 mL of CCl<sub>4</sub>, and SO<sub>2</sub>Cl<sub>2</sub> (46 L, 0.57 mmol) was added dropwise into the solution. The mixture was slowly warmed to 60 Â°C until reaction completion. Then, the mixture was concentrated in vacuo and the product purified by silica gel column chromatography. <b>CA11a</b> (31.4 mg) was obtained in 73% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.78 (s, 1H), 4.75 (d, <i>J</i> = 8.1 Hz, 1H), 3.55 (s, 3H), 3.26 (m, 1H), 2.94 (hept, <i>J</i> = 6.9 Hz, 1H), 2.39 (d, <i>J</i> = 7.9 Hz, 1H), 2.31 (s, 6H), 1.80â1.68 (m, 2H), 1.47 (d, <i>J</i> = 13.2 Hz, 1H), 1.47â1.38 (m, 2H), 1.39â1.17 (m, 9H), 0.87 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 191.1, 173.1, 167.8, 145.5, 143.0, 140.7, 132.6, 125.7, 57.9, 52.7, 50.1, 41.1, 35.7, 33.4, 29.8, 28.0, 22.9, 22.5, 21.4, 20.9, 20.5, 19.9. HRMS <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>31</sub>O<sub>7</sub>ClNa (M + Na)<sup>+</sup>, 501.1656; found, 501.1657.</div></div><div id="sec4_2_11_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (4b<i>R</i>,8a<i>S</i>)-9-Bromo-2-isopropyl-4b-(methoxycarbonyl)-8,8-dimethyl-10-oxo-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diyl Diacetate (<b>CA11b</b>)</h3><div class="NLM_p last"><b>CA9</b> (100 mg, 0.22 mmol) was dissolved in 4 mL of Et<sub>2</sub>O, and Br<sub>2</sub> (38 mg, 0.24 mmol) in Et<sub>2</sub>O was added dropwise into the solution at 0 Â°C. The final mixture was then allowed to react for 25 min. After that, the mixture was washed with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, extracted with EA, dried with anhydrous MgSO<sub>4,</sub> concentrated in vacuo, and purified by silica gel column chromatography. <b>CA11b</b> (68 mg) was obtained in 59% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.76 (s, 1H), 4.82 (d, <i>J</i> = 7.5 Hz, 1H), 3.54 (s, 3H), 3.24 (s, 1H), 2.93 (hept, <i>J</i> = 6.9 Hz, 1H), 2.57 (d, <i>J</i> = 7.4 Hz, 1H), 2.30 (s, 3H), 2.29 (s, 3H), 1.79â1.59 (m, 3H), 1.41 (dq, <i>J</i> = 15.1, 12.4, 11.4 Hz, 2H), 1.28â1.18 (m, 9H), 0.86 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 191.3, 173.1, 167.8, 145.3, 143.0, 140.6, 133.1, 125.6, 58.0, 52.6, 50.4, 49.1, 41.2, 36.0, 33.7, 28.0, 22.9, 22.5, 21.2, 20.9, 20.5, 19.9.</div></div><div id="sec4_2_11_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (4b<i>R</i>,8a<i>S</i>)-3,4-Dihydroxy-2-isopropyl-8,8-dimethyl-5,6,7,8,8a,9-hexahydro-10<i>H</i>-9,4b-(epoxymethano)phenanthrene-10,12-dione (<b>CA12</b>)</h3><div class="NLM_p last"><b>CA12</b> was synthesized from <b>CA11a</b> by using procedure c<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.61 (s, 1H), 6.78 (s, 2H), 4.70 (s, 1H), 3.28 (dt, <i>J</i> = 14.4, 3.5 Hz, 1H), 3.08 (h, <i>J</i> = 6.9 Hz, 1H), 2.43 (s, 1H), 2.05 (td, <i>J</i> = 14.1, 5.4 Hz, 1H), 1.74â1.42 (m, 4H), 1.17 (ddd, <i>J</i> = 7.0, 2.7, 1.1 Hz, 6H), 1.00 (s, 3H), 0.94 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 190.1, 178.1, 149.1, 141.7, 135.1, 128.4, 122.1, 120.7, 81.4, 60.6, 49.8, 37.8, 32.6, 31.7, 27.4, 27.2, 27.0, 22.5, 22.1, 18.9. HRMS <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>23</sub>O<sub>5</sub> (M â H)<sup>â</sup>, 343.1545; found, 343.1547.</div></div><div id="sec4_2_11_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (4b<i>R</i>,8a<i>S</i>)-2-Isopropyl-8,8-dimethyl-5,6,7,8,8a,9-hexahydro-3<i>H</i>-9,4b-(epoxymethano)phenanthrene-3,4,10,12-tetraone (<b>CA13</b>)</h3><div class="NLM_p last"><b>CA13</b> was synthesized from <b>CA12</b> by using procedure a<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.26 (s, 1H), 4.75 (s, 1H), 3.28â3.18 (m, 1H), 2.94 (pd, <i>J</i> = 6.8, 1.3 Hz, 1H), 2.49 (s, 1H), 1.69â1.42 (m, 4H), 1.29â1.16 (m, 1H), 1.12 (t, <i>J</i> = 7.1 Hz, 6H), 1.02 (s, 3H), 0.94 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 190.0, 181.9, 179.0, 173.4, 151.2, 145.6, 136.5, 128.1, 80.0, 60.7, 49.4, 37.7, 32.5, 31.4, 27.9, 25.1, 21.8, 21.3, 21.3, 18.1. HRMS <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>26</sub>O<sub>5</sub>N (M + NH<sub>4</sub>)<sup>+</sup>, 360.1811; found, 360.1804.</div></div><div id="sec4_2_11_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Methyl (4a<i>R</i>,10a<i>S</i>)-7-Isopropyl-1,1-dimethyl-5,6,9-trioxo-1,3,4,5,6,9,10,10a-octahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA14</b>)</h3><div class="NLM_p last"><b>CA14</b> was synthesized from <b>CA10</b> by using procedure a<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.46 (s, 1H), 3.70 (s, 3H), 3.15â3.02 (m, 2H), 2.92 (dq, <i>J</i> = 14.5, 7.3 Hz, 1H), 2.67 (dd, <i>J</i> = 17.7, 3.8 Hz, 1H), 2.28â2.12 (m, 1H), 2.05 (dd, <i>J</i> = 14.7, 3.4 Hz, 1H), 1.66â1.48 (m, 2H), 1.34â1.22 (m, 2H), 1.12 (dd, <i>J</i> = 6.9, 4.0 Hz, 6H), 0.93 (s, 3H), 0.79 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 198.3, 185.1, 180.0, 172.3, 148.8, 147.6, 137.5, 130.4, 52.8, 50.4, 47.8, 40.7, 34.8, 33.4, 32.8, 31.7, 27.7, 21.5, 21.4, 19.6, 19.0. HRMS <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>26</sub>O<sub>5</sub>Na (M + Na)<sup>+</sup>, 381.1678; found, 381.1681.</div></div><div id="sec4_2_11_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Methyl (4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-9-(phenylthio)-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA15a</b>)</h3><div class="NLM_p last"><b>CA15a</b> was prepared from <b>CA2</b> and thiophenol (obtained by acidification of sodium thiophenolate with HCl) by using procedure e. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) Î´ 7.56â7.49 (m, 2H), 7.36 (dd, <i>J</i> = 8.4, 6.9 Hz, 2H), 7.35â7.21 (m, 2H), 7.24 (s, 1H), 6.90 (s, 1H), 4.82 (dd, <i>J</i> = 4.4, 1.7 Hz, 1H), 3.57 (s, 3H), 3.24 (hept, <i>J</i> = 6.9 Hz, 1H), 2.65 (ddd, <i>J</i> = 13.9, 12.5, 4.4 Hz, 1H), 2.35 (dd, <i>J</i> = 12.5, 1.7 Hz, 1H), 2.19â2.05 (m, 1H), 1.89 (dt, <i>J</i> = 13.9, 1.8 Hz, 1H), 1.63â1.25 (m, 4H), 1.24â1.11 (m, 7H), 0.82 (s, 3H), 0.73 (s, 3H). <sup>13</sup>C NMR (100 MHz, acetone) Î´ 176.9, 144.8, 142.4, 137.7, 135.0, 132.1, 129.9, 128.3, 127.6, 127.3, 121.3, 51.9, 50.6, 48.9, 48.2, 42.1, 35.0, 34.2, 32.7, 27.6, 24.4, 23.1, 22.8, 21.1, 20.9.</div></div><div id="sec4_2_11_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Methyl (4a<i>R</i>,10a<i>S</i>)-9-(Butylthio)-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA15b</b>)</h3><div class="NLM_p last"><b>CA15b</b> was prepared from <b>CA2</b> and <i>n</i>-butyl alcohol by using procedure e. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.43 (s, 1H), 6.82 (s, 1H), 5.90 (s, 1H), 4.26â4.17 (m, 1H), 3.67 (s, 3H), 3.37â3.23 (m, 1H), 3.19 (hept, <i>J</i> = 6.9 Hz, 1H), 2.66 (dddd, <i>J</i> = 11.1, 9.0, 7.5, 3.6 Hz, 2H), 2.53 (ddd, <i>J</i> = 12.3, 8.2, 7.0 Hz, 1H), 2.36 (dd, <i>J</i> = 12.6, 1.7 Hz, 1H), 1.97 (dt, <i>J</i> = 14.0, 1.9 Hz, 1H), 1.77â1.56 (m, 3H), 1.56â1.40 (m, 4H), 1.38â1.14 (m, 2H), 1.23 (d, <i>J</i> = 7.0 Hz, 6H), 1.03 (s, 3H), 0.95 (t, <i>J</i> = 7.3 Hz, 3H), 0.81 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 178.6, 142.9, 141.8, 133.5, 128.1, 122.5, 122.0, 52.3, 49.2, 46.8, 46.0, 41.8, 34.7, 34.0, 32.3, 32.1, 31.8, 27.5, 24.1, 22.5, 22.4, 22.3, 22.2, 20.5, 13.9.</div></div><div id="sec4_2_11_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Methyl (4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-9-((2-hydroxyethyl)thio)-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA15c</b>)</h3><div class="NLM_p last"><b>CA15c</b> was prepared from <b>CA2</b> and mercaptoethanol by using procedure e. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.42 (s, 1H), 6.80 (s, 1H), 5.93 (s, 1H), 4.25 (dd, <i>J</i> = 4.4, 1.8 Hz, 1H), 3.83 (q, <i>J</i> = 6.3, 5.2 Hz, 2H), 3.67 (s, 3H), 3.29 (dt, <i>J</i> = 13.8, 3.6 Hz, 1H), 3.19 (hept, <i>J</i> = 6.9 Hz, 1H), 2.89 (dt, <i>J</i> = 13.5, 5.6 Hz, 1H), 2.82â2.65 (m, 2H), 2.33 (dd, <i>J</i> = 12.7, 1.7 Hz, 1H), 2.24 (s, 1H), 1.96 (dt, <i>J</i> = 14.2, 1.9 Hz, 1H), 1.73â1.60 (m, 2H), 1.54â1.36 (m, 2H), 1.28 (s, 1H), 1.23 (s, 3H), 1.22 (s, 3H), 1.03 (s, 3H), 0.81 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 178.4, 143.1, 141.8, 133.6, 127.3, 122.7, 122.1, 60.7, 52.4, 49.1, 46.8, 46.1, 41.8, 35.5, 34.7, 34.0, 32.3, 27.5, 24.4, 22.4, 22.3, 22.2, 20.4.</div></div><div id="sec4_2_11_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>N</i>-Acetyl-<i>S</i>-((4a<i>R</i>,10a<i>S</i>)-5,6-dihydroxy-7-isopropyl-4a-(methoxycarbonyl)-1,1-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-9-yl)-<span class="smallcaps smallerCapital">l</span>-cysteine (<b>CA15d</b>)</h3><div class="NLM_p last"><b>CA15d</b> was prepared from <b>CA2</b> and <i>N</i>-acetyl-<span class="smallcaps smallerCapital">l</span>-cysteine by using procedure e. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.93 (br, 1H), 7.32 (br, 1H), 6.77 (s, 1H), 6.70 (t, <i>J</i> = 6.7 Hz, 1H), 6.07 (br, 1H), 4.87 (td, <i>J</i> = 7.2, 4.4 Hz, 1H), 4.24 (dd, <i>J</i> = 4.0, 1.7 Hz, 1H), 3.63 (s, 3H), 3.31â3.24 (m, 1H), 3.16 (dtd, <i>J</i> = 20.8, 13.8, 5.7 Hz, 2H), 2.89 (dd, <i>J</i> = 13.7, 7.0 Hz, 1H), 2.74â2.61 (m, 1H), 2.29â2.21 (m, 1H), 2.11 (s, 3H), 1.96â1.86 (m, 1H), 1.74â1.63 (m, 1H), 1.63â1.52 (m, 1H), 1.50â1.41 (m, 1H), 1.44â1.31 (m, 1H), 1.18 (dd, <i>J</i> = 6.9, 3.2 Hz, 7H), 0.98 (s, 3H), 0.77 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 178.2, 173.4, 171.6, 142.9, 141.9, 133.7, 126.9, 123.0, 122.0, 52.3, 52.0, 48.9, 46.8, 46.5, 41.7, 34.5, 33.8, 33.6, 32.2, 27.3, 23.7, 22.9, 22.4, 22.2, 22.0, 20.3. HRMS <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>37</sub>NO<sub>7</sub>NaS (M + Na)<sup>+</sup>, 530.2188; found, 530.2179.</div></div><div id="sec4_2_11_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Methyl (4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7-isopropyl-9-methoxy-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA15e</b>)</h3><div class="NLM_p last"><b>CA15e</b> was prepared from <b>CA2</b> and MeOH by using procedure e. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) Î´ 7.18 (br, 2H), 6.73 (s, 1H), 4.21 (t, <i>J</i> = 2.7 Hz, 1H), 3.58 (s, 3H), 3.57â3.47 (m, 1H), 3.39 (s, 3H), 3.33â3.19 (m, 1H), 2.37 (ddd, <i>J</i> = 14.4, 13.2, 3.6 Hz, 1H), 2.17â2.05 (m, 3H), 1.60â1.46 (m, 2H), 1.40â1.27 (m, 1H), 1.20 (dd, <i>J</i> = 10.7, 6.9 Hz, 6H), 1.19â1.07 (m, 1H), 0.99 (s, 3H), 0.80 (s, 3H). <sup>13</sup>C NMR (100 MHz, acetone) Î´ 177.3, 144.5, 143.0, 134.7, 130.1, 126.7, 121.7, 79.0, 56.5, 52.0, 49.4, 47.3, 42.3, 35.0, 34.2, 33.0, 27.7, 23.4, 23.3, 22.9, 21.1, 21.0.</div></div><div id="sec4_2_11_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Methyl (4a<i>R</i>,10a<i>S</i>)-9-Ethoxy-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA15f</b>)</h3><div class="NLM_p last"><b>CA15f</b> was prepared from <b>CA2</b> and EtOH by using procedure e. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.54 (br, 1H), 6.78 (s, 1H), 5.94 (br, 1H), 4.33 (d, <i>J</i> = 2.7 Hz, 1H), 3.72 (dt, <i>J</i> = 9.2, 6.9 Hz, 1H), 3.67 (s, 3H), 3.65â3.51 (m, 1H), 3.32â3.14 (m, 2H), 2.39 (td, <i>J</i> = 13.7, 3.4 Hz, 1H), 2.18â2.09 (m, 2H), 1.73â1.59 (m, 2H), 1.47 (dt, <i>J</i> = 13.3, 3.6 Hz, 1H), 1.42â1.31 (m, 1H), 1.29 (m, 4H), 1.28â1.20 (m, 6H), 1.01 (s, 3H), 0.82 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 178.8, 143.6, 141.7, 133.8, 128.2, 122.6, 121.9, 76.2, 64.2, 52.3, 49.4, 46.2, 41.8, 34.5, 33.9, 32.4, 27.4, 23.2, 22.5, 22.1, 22.1, 20.5, 15.9.</div></div><div id="sec4_2_11_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Methyl (4a<i>R</i>,10a<i>S</i>)-9-((2-Hydroxyethyl)thio)-7-isopropyl-1,1-dimethyl-5,6-dioxo-1,3,4,5,6,9,10,10a-octahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA16a</b>)</h3><div class="NLM_p last"><b>CA16a</b> was prepared from <b>CA15c</b> by using procedure a<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.75 (s, 1H), 4.56 (dd, <i>J</i> = 9.5, 5.9 Hz, 1H), 4.01 (td, <i>J</i> = 10.2, 4.3 Hz, 1H), 3.67 (s, 3H), 3.31 (dd, <i>J</i> = 10.7, 4.4 Hz, 1H), 3.17 (td, <i>J</i> = 11.0, 5.8 Hz, 1H), 2.98â2.85 (m, 2H), 2.55 (t, <i>J</i> = 14.2 Hz, 1H), 2.33â2.16 (m, 2H), 1.69 (d, <i>J</i> = 13.6 Hz, 1H), 1.49 (d, <i>J</i> = 14.9 Hz, 2H), 1.30â1.19 (m, 4H), 1.12 (t, <i>J</i> = 6.2 Hz, 6H), 0.94 (s, 3H), 0.74 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 181.5, 180.4, 173.8, 146.8, 146.4, 141.3, 135.7, 92.8, 70.8, 52.4, 49.8, 46.9, 41.0, 36.1, 34.9, 33.6, 33.0, 32.0, 27.5, 21.5, 21.4, 19.8, 19.3.</div></div><div id="sec4_2_11_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Methyl (4a<i>R</i>,10a<i>S</i>)-7-Isopropyl-9-methoxy-1,1-dimethyl-5,6-dioxo-1,3,4,5,6,9,10,10a-octahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA16b</b>)</h3><div class="NLM_p last"><b>CA16b</b> was prepared from <b>CA15e</b> by using procedure a<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.67 (d, <i>J</i> = 1.3 Hz, 1H), 3.91 (dd, <i>J</i> = 4.2, 1.5 Hz, 1H), 3.65 (s, 3H), 3.49 (s, 3H), 2.90 (tdd, <i>J</i> = 12.4, 6.1, 4.6 Hz, 2H), 2.29â2.18 (m, 1H), 2.22â2.13 (m, 1H), 2.09 (dt, <i>J</i> = 14.4, 2.0 Hz, 1H), 1.68â1.59 (m, 1H), 1.51 (dddd, <i>J</i> = 17.2, 13.0, 5.6, 2.5 Hz, 2H), 1.32â1.19 (m, 1H), 1.12 (d, <i>J</i> = 3.4 Hz, 3H), 1.10 (d, <i>J</i> = 3.5 Hz, 3H), 1.00 (td, <i>J</i> = 13.1, 4.4 Hz, 1H), 0.95 (s, 3H), 0.74 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 181.3, 180.8, 174.1, 147.8, 146.3, 141.4, 136.9, 76.6, 57.6, 52.2, 47.0, 46.8, 41.2, 33.5, 33.1, 32.1, 27.4, 21.5, 21.4, 21.4, 19.9, 19.4.</div></div><div id="sec4_2_11_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Methyl (4a<i>R</i>,10a<i>S</i>)-9-Ethoxy-7-isopropyl-1,1-dimethyl-5,6-dioxo-1,3,4,5,6,9,10,10a-octahydrophenanthrene-4a(2<i>H</i>)-carboxylate (<b>CA16c</b>)</h3><div class="NLM_p last"><b>CA16c</b> was prepared from <b>CA15f</b> by using procedure a<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.67 (s, 1H), 4.04â3.99 (m, 1H), 3.79 (dtd, <i>J</i> = 13.9, 7.0, 3.5 Hz, 1H), 3.65 (s, 3H), 3.57 (dtt, <i>J</i> = 11.6, 7.1, 3.4 Hz, 1H), 2.90 (qt, <i>J</i> = 8.3, 6.2, 4.6 Hz, 2H), 2.30â2.13 (m, 2H), 2.09â2.00 (m, 1H), 1.68 (dt, <i>J</i> = 13.4, 2.3 Hz, 1H), 1.51 (td, <i>J</i> = 15.4, 14.7, 3.4 Hz, 2H), 1.34â1.20 (m, 4H), 1.16â1.05 (m, 6H), 1.09â0.97 (m, 1H), 0.94 (s, 3H), 0.73 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 181.3, 180.8, 174.2, 147.8, 146.4, 141.4, 136.8, 74.9, 65.7, 52.2, 47.0, 46.9, 41.2, 33.4, 33.2, 32.1, 27.4, 22.4, 21.5, 19.9, 19.4, 15.8.</div></div><div id="sec4_2_11_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> (4a<i>R</i>,11a<i>S</i>)-7-Hydroxy-8-isopropyl-1,1-dimethyl-1,3,4,10,11,11a-hexahydro-2<i>H</i>,5<i>H</i>-phenanthro[4,4<i>b</i>-<i>bc</i>]furan-5-one (<b>CA17</b>)</h3><div class="NLM_p last"><b>CA</b> (5 g, 15 mmol) and dicyclohexylcarbodiimide (DCC, 4 g, 15.5 mmol) were stirred in 100 mL of DCM at room temperature. DMAP (0.2 g, 1.5 mmol) was then added into the mixture and allowed to react until completion. After that, the mixture was filtered and concentrated in vacuo and purified by silica gel column chromatography. <b>CA17</b> (2.5 g) was afforded in 53% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.65(s, 1H), 4.78 (br, 1H), 3.26 (hept, <i>J</i> = 6.9 Hz, 1H), 2.59â2.57 (m, 2H), 2.36â2.20 (m, 1H), 2.15â2.06 (m, 1H), 2.04â1.93 (m, 1H), 1.93â1.76 (m, 3H), 1.75â1.66 (m, 1H), 1.45â1.28 (m, 2H), 1.30â1.20 (m, 6H), 1.15 (s, 3H), 1.07 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 178.3, 139.9, 136.4, 135.4, 131.6, 130.0, 120.3, 56.6, 50.1, 41.8, 38.6, 32.9, 32.6, 31.9, 29.8, 27.4, 24.4, 23.2, 22.5, 18.3. HRMS <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>25</sub>O<sub>3</sub> (M â H)<sup>â</sup>, 313.1804; found, 313.1794.</div></div><div id="sec4_2_11_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (4b<i>R</i>,8a<i>S</i>)-4b-(Hydroxymethyl)-2-isopropyl-8,8-dimethyl-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol (<b>CA18</b>)</h3><div class="NLM_p last"><b>CA18</b> was synthesized from <b>CA</b> in two steps: <b>CA</b> was first subjected to methylation leading to <b>CA1</b>, which was then reduced by LiAlH<sub>4</sub> to afford <b>CA18</b>. LiAlH<sub>4</sub> (32.4 mg) was dissolved in dry THF, and <b>CA1</b> (0.1 g, 0.29 mmol) dissolved in dry THF (3 mL) was then slowly added to the mixture at 0 Â°C. After reaction completion (as indicated by TLC), the pH of the mixture was adjusted to 1.0â3.0 using 2 N HCl. Then, the mixture was washed with brine, dried with MgSO<sub>4</sub>, concentrated, and purified by silica gel column chromatography. <b>CA18</b> (40.1 g) was afforded in 43% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.70 (s, 1H), 6.54 (s, 1H), 5.97 (s, 1H), 4.48 (d, <i>J</i> = 9.7 Hz, 1H), 3.94 (d, <i>J</i> = 9.7 Hz, 1H), 3.29â3.14 (m, 2H), 2.95â2.80 (m, 2H), 2.33 (s, 1H), 1.83â1.71 (m, 1H), 1.75â1.57 (m, 2H), 1.61â1.47 (m, 1H), 1.44 (dd, <i>J</i> = 7.4, 5.7 Hz, 2H), 1.35â1.26 (m, 2H), 1.23 (dd, <i>J</i> = 7.0, 5.6 Hz, 6H), 0.98 (s, 3H), 0.89 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 142.3, 142.2, 132.6, 130.2, 127.7, 119.0, 67.4, 52.8, 44.1, 41.2, 34.0, 33.7, 32.1, 31.4, 27.3, 22.9, 22.7, 22.4, 19.1, 19.0. HRMS <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>29</sub>O<sub>3</sub> (M â H)<sup>â</sup>,317.2117; found, 317.2123.</div></div><div id="sec4_2_11_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (4a<i>R</i>,10a<i>S</i>)-7-Isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydro-2<i>H</i>-9,4a-(epoxymethano)phenanthrene-5,6-diol (<b>CA19</b>)</h3><div class="NLM_p last"><b>CA19</b> was prepared from <b>CA18</b> by using procedure a<sub>1</sub>/a<sub>2</sub>, employing 1.0 equiv of oxidizing agent (DDQ or Ag<sub>2</sub>O). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.62 (s, 1H), 5.58 (s, 1H), 5.13 (s, 1H), 4.71 (dd, <i>J</i> = 3.8, 1.7 Hz, 1H), 4.32 (d, <i>J</i> = 8.5 Hz, 1H), 3.16â3.02 (m, 2H), 2.58 (ddd, <i>J</i> = 13.3, 10.5, 7.4 Hz, 1H), 2.12 (dq, <i>J</i> = 13.4, 2.7 Hz, 1H), 2.04 (ddd, <i>J</i> = 13.0, 5.7, 3.8 Hz, 1H), 1.74â1.52 (m, 3H), 1.46 (ddd, <i>J</i> = 11.6, 5.6, 1.8 Hz, 1H), 1.34â1.27 (m, 2H), 1.25 (dd, <i>J</i> = 6.9, 2.7 Hz, 6H), 1.15 (s, 3H), 0.86 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 141.1, 139.6, 133.3, 132.6, 127.9, 112.4, 71.2, 68.7, 43.2, 41.4, 40.0, 34.0, 33.0, 31.0, 30.2, 27.1, 22.9, 22.8, 21.3, 19.2. HRMS <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>27</sub>O<sub>3</sub> (M â H)<sup>â</sup>,315.1960; found, 315.1966.</div></div><div id="sec4_2_11_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (4a<i>R</i>,10a<i>S</i>)-7-Isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydro-2<i>H</i>-9,4a-(epoxymethano)phenanthrene-5,6-dione (<b>CA20</b>)</h3><div class="NLM_p last"><b>CA20</b> was prepared from <b>CA18</b> by using procedure a<sub>1</sub> with 2.0 equiv of oxidizing agent (DDQ). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.61 (d, <i>J</i> = 1.4 Hz, 1H), 4.47 (dd, <i>J</i> = 3.7, 1.8 Hz, 1H), 4.28 (d, <i>J</i> = 8.5 Hz, 1H), 3.02 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 2.94 (pd, <i>J</i> = 6.8, 1.4 Hz, 1H), 2.42 (td, <i>J</i> = 14.2, 4.5 Hz, 1H), 2.07â1.97 (m, 1H), 1.92 (dq, <i>J</i> = 14.7, 2.8 Hz, 1H), 1.77â1.37 (m, 4H), 1.37â1.21 (m, 2H), 1.18â1.05 (m, 9H), 0.87 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 180.4, 177.6, 152.3, 149.8, 140.1, 132.5, 70.3, 67.9, 42.4, 40.8, 40.5, 33.9, 33.3, 29.0, 28.2, 27.6, 21.6, 21.6, 21.2, 18.7.</div></div><div id="sec4_2_11_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> (4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydro-2<i>H</i>-9,4a-(epoxymethano)phenanthren-12-one (<b>CA21</b>)</h3><div class="NLM_p last"><b>CA21</b> was prepared from <b>CA</b> by using procedure a<sub>1</sub>/a<sub>2</sub> with 1.0 equiv of oxidizing agent (DDQ or Ag<sub>2</sub>O). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) Î´ 7.44 (br, 2H), 6.77 (s, 1H), 5.43 (dd, <i>J</i> = 4.0, 1.6 Hz, 1H), 3.30 (hept, <i>J</i> = 6.8 Hz, 1H), 2.82â2.77 (m, 1H), 2.54 (td, <i>J</i> = 13.8, 4.4 Hz, 1H), 2.20 (ddd, <i>J</i> = 13.8, 5.8, 4.0 Hz, 1H), 2.02â1.79 (m, 2H), 1.69 (dd, <i>J</i> = 10.7, 5.7 Hz, 1H), 1.63â1.46 (m, 2H), 1.31 (td, <i>J</i> = 13.4, 3.6 Hz, 1H), 1.19 (dd, <i>J</i> = 6.9, 2.5 Hz, 6H), 0.88 (d, <i>J</i> = 2.2 Hz, 6H). <sup>13</sup>C NMR (100 MHz, acetone) Î´ 176.0, 144.1, 143.4, 135.2, 133.7, 123.2, 112.5, 78.3, 49.3, 46.4, 42.0, 35.3, 32.1, 30.7, 30.1, 27.6, 23.3, 23.2, 20.1, 19.8.</div></div><div id="sec4_2_11_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> (4a<i>R</i>,10aS)-7-Isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydro-2<i>H</i>-9,4a-(epoxymethano)phenanthrene-5,6,12-trione (<b>CA22</b>)</h3><div class="NLM_p last"><b>CA22</b> was prepared from <b>CA</b> by using procedure a<sub>1</sub> with 2.0 equiv of oxidizing agent (DDQ) or from <b>CA21</b> via procedure a<sub>1</sub> with 1.0 equiv of oxidizing agent (DDQ). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.68 (s, 1H), 5.20 (dd, <i>J</i> = 4.1, 1.6 Hz, 1H), 3.02â2.89 (m, 1H), 2.72â2.63 (m, 1H), 2.37â2.24 (m, 1H), 2.28â2.18 (m, 1H), 2.06â1.80 (m, 2H), 1.65 (dd, <i>J</i> = 10.6, 6.1 Hz, 1H), 1.65â1.44 (m, 2H), 1.21 (dd, <i>J</i> = 13.6, 3.6 Hz, 1H), 1.12 (d, <i>J</i> = 6.8 Hz, 6H), 0.89 (s, 3H), 0.86 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 179.4, 176.5, 173.5, 152.8, 151.3, 135.8, 129.8, 76.2, 48.9, 45.1, 40.7, 34.6, 32.2, 28.0, 28.0, 27.1, 21.6, 21.5, 19.5, 18.4.</div></div><div id="sec4_2_11_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> (4b<i>R</i>,8a<i>S</i>)-2-Isopropyl-8,8-dimethyl-4b-(5-methyl-1,3,4-oxadiazol-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diyl Diacetate (<b>CA24a</b>)</h3><div class="NLM_p last">To a solution of <b>CA4i</b> (5 g, 10.6 mmol) and 4-toluenesulfonyl chloride (<i>p-</i>TsCl, 6.2 g, 31.8 mmol) in 100 mL of DCM was added <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA, 8.7 mL, 53 mmol) dropwise at room temperature. After reaction completion (monitored by TLC), concentration in vacuo and purification by silica gel column chromatography using PE/EA gave <b>CA24a</b> (2.5 g, 5.5 mmol, 52%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.98 (s, 1H), 3.70â3.62 (m, 1H), 2.97 (tt, <i>J</i> = 11.3, 7.7 Hz, 2H), 2.87 (hept, 1H), 2.53â2.37 (m, 1H), 2.39 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H), 2.17â2.01 (m, 1H), 2.00â1.90 (m, 1H), 1.71â1.46 (m, 4H), 1.33 (td, <i>J</i> = 13.1, 4.2 Hz, 1H), 1.20 (d, <i>J</i> = 6.8 Hz, 3H), 1.13 (d, <i>J</i> = 6.8 Hz, 3H), 0.96 (s, 3H), 0.33 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 169.5, 168.7, 168.6, 163.9, 142.0, 140.5, 139.1, 136.5, 131.1, 125.2, 54.2, 41.8, 41.0, 35.2, 33.9, 32.6, 32.1, 27.5, 23.1, 22.7, 20.8, 20.5, 19.8, 19.7, 18.7, 11.2.</div></div><div id="sec4_2_11_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> (4b<i>R</i>,8a<i>S</i>)-2-Isopropyl-8,8-dimethyl-4b-(5-methyl-1,3,4-oxadiazol-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol (<b>CA25a</b>)</h3><div class="NLM_p last"><b>CA25a</b> was synthesized from <b>CA4i</b> by using procedure f<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.66 (br, 1H), 6.56 (s, 1H), 5.91 (br, 1H), 3.73 (dt, <i>J</i> = 14.0, 3.8 Hz, 1H), 3.19 (hept, <i>J</i> = 6.9 Hz, 1H), 2.91â2.83 (m, 2H), 2.46 (s, 3H), 2.29â2.14 (m, 1H), 2.06â1.96 (m, 1H), 1.93â1.77 (m, 1H), 1.74 (dd, <i>J</i> = 12.6, 1.9 Hz, 1H), 1.72â1.58 (m, 1H), 1.58â1.43 (m, 2H), 1.43â1.29 (m, 1H), 1.20 (d, <i>J</i> = 6.9 Hz, 6H), 1.03 (s, 3H), 0.53 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 171.8, 163.9, 142.3, 141.9, 133.8, 127.7, 123.0, 119.2, 54.8, 42.2, 41.9, 35.3, 34.1, 32.5, 31.8, 27.3, 27.0, 22.6, 22.2, 21.5, 19.9, 19.6.</div></div><div id="sec4_2_11_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> (4b<i>R</i>,8a<i>S</i>)-4b-(5-Amino-1,3,4-oxadiazol-2-yl)-2-isopropyl-8,8-dimethyl-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol (<b>CA25b</b>)</h3><div class="NLM_p last"><b>CA25b</b> was synthesized from <b>CA4j</b> by using procedure f<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.45 (br, 2H), 6.51 (s, 1H), 5.31 (br, 2H), 3.89 (d, <i>J</i> = 13.9 Hz, 1H), 3.26 (p, <i>J</i> = 7.0 Hz, 1H), 2.82 (dtd, <i>J</i> = 30.6, 17.2, 7.7 Hz, 2H), 2.22â1.97 (m, 2H), 1.93 (dd, <i>J</i> = 13.2, 5.7 Hz, 1H), 1.68 (d, <i>J</i> = 12.4 Hz, 2H), 1.53â1.46 (m, 2H), 1.43â1.28 (m, 1H), 1.17 (d, <i>J</i> = 6.8 Hz, 3H), 1.09 (d, <i>J</i> = 6.9 Hz, 3H), 1.02 (s, 3H), 0.51 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 163.6, 163.3, 144.2, 141.3, 135.9, 129.0, 123.5, 118.2, 54.5, 41.8, 41.7, 34.0, 32.6, 31.7, 27.0, 26.9, 23.2, 22.0, 20.2, 19.7, 19.2.</div></div><div id="sec4_2_11_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (4b<i>R</i>,8a<i>S</i>)-4b-(5-((Dimethylamino)methyl)-1,3,4-oxadiazol-2-yl)-2-isopropyl-8,8-dimethyl-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol (<b>CA25c</b>)</h3><div class="NLM_p last"><b>CA25c</b> was synthesized from <b>CA24c</b> through by using procedure c<sub>2</sub>. <b>CA24c</b> was synthesized from <b>CA4h</b> and dimethylglycine by using procedures g and f<sub>2</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 6.54 (s, 1H), 3.75 (dt, <i>J</i> = 13.5, 3.6 Hz, 1H), 3.68 (d, <i>J</i> = 2.4 Hz, 2H), 3.17 (hept, <i>J</i> = 6.9 Hz, 1H), 2.92â2.83 (m, 2H), 2.28 (s, 6H), 2.27â2.14 (m, 1H), 2.06â1.95 (m, 1H), 1.95â1.83 (m, 1H), 1.75 (dd, <i>J</i> = 12.7, 1.8 Hz, 1H), 1.73â1.63 (m, 1H), 1.60â1.31 (m, 3H), 1.20 (d, <i>J</i> = 1.4 Hz, 3H), 1.18 (d, <i>J</i> = 1.4 Hz, 3H), 1.02 (s, 3H), 0.53 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 172.3, 164.1, 142.1, 142.1, 134.0, 127.9, 123.2, 119.2, 54.9, 52.9, 45.0, 42.4, 41.9, 35.3, 34.1, 32.4, 31.8, 27.3, 22.6, 22.3, 21.6, 19.9, 19.6.</div></div><div id="sec4_2_11_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> <i>tert</i>-Butyl ((<i>S</i>)-1-(5-((4a<i>R</i>,10a<i>S</i>)-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthren-4a(2<i>H</i>)-yl)-1,3,4-oxadiazol-2-yl)ethyl)carbamate (<b>CA25d</b>)</h3><div class="NLM_p last"><b>CA25d</b> was synthesized from <b>CA24d</b> by using procedure c<sub>2</sub>. <b>CA24d</b> was synthesized from <b>CA4h</b> and <i>N</i>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-alanine by using procedures g and f<sub>2</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.58 (s, 1H), 6.55 (s, 1H), 5.85 (s, 1H), 5.09 (d, <i>J</i> = 8.2 Hz, 1H), 5.05â4.96 (m, 1H), 3.73 (dd, <i>J</i> = 14.1, 3.6 Hz, 1H), 3.18 (hept, <i>J</i> = 7.0 Hz, 1H), 2.92â2.82 (m, 2H), 2.25â2.12 (m, 1H), 2.00 (d, <i>J</i> = 13.6 Hz, 1H), 1.85â1.70 (m, 2H), 1.70â1.62 (m, 1H), 1.66â1.55 (m, 1H), 1.53 (d, <i>J</i> = 6.6 Hz, 3H), 1.42 (s, 9H), 1.37â1.32 (m, 2H), 1.20 (d, <i>J</i> = 6.9 Hz, 6H), 1.03 (s, 3H), 0.52 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 172.1, 167.6, 154.8, 142.3, 141.9, 133.9, 127.8, 122.9, 119.4, 80.5, 54.8, 42.3, 41.9, 35.4, 34.1, 32.5, 31.8, 29.8, 28.4, 27.3, 27.1, 22.6, 22.3, 21.5, 19.9, 19.6. HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>42</sub>N<sub>3</sub>O<sub>5</sub> (M + H)<sup>+</sup>, 500.3124; found, 500.3119.</div></div><div id="sec4_2_11_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> (4b<i>R</i>,8a<i>S</i>)-4b-(5-((<i>S</i>)-1-((Hydroxymethyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)-2-isopropyl-8,8-dimethyl-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol (<b>CA25e</b>)</h3><div class="NLM_p last"><b>CA25e</b> was the side-product of <b>CA24d</b> reduction using LiAlH<sub>4</sub> (procedure c<sub>2</sub>, long time reduction, and excess LiAlH<sub>4</sub>). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) Î´ 8.42 (s, 1H), 7.82 (br, 1H), 7.00 (s, 1H), 6.57 (s, 1H), 6.43 (s, 1H), 3.82â3.70 (m, 1H), 3.65 (t, <i>J</i> = 7.7 Hz, 1H), 3.56 (dt, <i>J</i> = 14.0, 4.5 Hz, 1H), 3.23 (t, <i>J</i> = 7.5 Hz, 1H), 3.22â3.10 (m, 1H), 2.82â2.74 (m, 2H), 2.46â2.30 (m, 1H), 2.28â2.12 (m, 1H), 1.84 (td, <i>J</i> = 4.9, 2.7 Hz, 1H), 1.64 (dt, <i>J</i> = 12.7, 4.2 Hz, 1H), 1.59â1.46 (m, 2H), 1.39â1.28 (m, 1H), 1.32â1.25 (m, 1H), 1.23 (d, <i>J</i> = 6.1 Hz, 3H), 1.18 (dd, <i>J</i> = 11.7, 6.9 Hz, 6H), 0.99 (s, 3H), 0.92 (s, 3H). <sup>13</sup>C NMR (100 MHz, acetone) Î´ 176.7, 163.1, 146.3, 142.0, 133.8, 133.2, 128.3, 121.3, 54.8, 54.5, 48.6, 45.8, 41.5, 35.4, 34.4, 32.9, 32.5, 27.9, 23.0, 22.5, 21.0, 20.9, 20.8, 19.7. HRMS <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>36</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup>, 430.2706; found, 430.2706.</div></div><div id="sec4_2_11_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> (4b<i>R</i>,8a<i>S</i>)-4b-(5-(4-Bromophenyl)-1,3,4-oxadiazol-2-yl)-2-isopropyl-8,8-dimethyl-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol (<b>CA25f</b>)</h3><div class="NLM_p last"><b>CA25f</b> was synthesized from <b>CA4k</b> by using procedures f<sub>2</sub> and c<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.79 (d, <i>J</i> = 8.2 Hz, 2H), 7.60 (d, <i>J</i> = 8.3 Hz, 2H), 6.58 (s, 1H), 3.82 (d, <i>J</i> = 14.0 Hz, 1H), 3.18 (p, <i>J</i> = 7.0 Hz, 1H), 2.93 (q, <i>J</i> = 4.9, 4.3 Hz, 2H), 2.53â2.40 (m, 1H), 2.36â2.20 (m, 1H), 2.12 (d, <i>J</i> = 13.3 Hz, 1H), 1.84 (dd, <i>J</i> = 26.1, 12.7 Hz, 2H), 1.72 (s, 1H), 1.58 (dd, <i>J</i> = 15.2, 11.7 Hz, 1H), 1.49 (d, <i>J</i> = 13.6 Hz, 1H), 1.34â1.27 (m, 2H), 1.19 (t, <i>J</i> = 7.3 Hz, 6H), 1.07 (s, 3H), 0.58 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 171.8, 164.1, 142.4, 141.9, 134.0, 132.6, 128.4, 127.7, 126.8, 123.0, 122.5, 119.4, 54.9, 42.4, 41.8, 35.4, 34.2, 32.6, 31.8, 29.8, 27.3, 27.0, 22.6, 22.2, 21.8, 20.0, 19.9.</div></div><div id="sec4_2_11_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> 4-(5-((4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-1,3,4,9,10,10a-hexahydrophenanthren-4a(2<i>H</i>)-yl)-1,3,4-oxadiazol-2-yl)benzonitrile (<b>CA25g</b>)</h3><div class="NLM_p last"><b>CA25g</b> was synthesized from <b>CA24f</b> by using procedure c<sub>1</sub>. <b>CA24f</b> was synthesized from <b>CA4h</b> and 4-cyanobenzoic acid by using procedures g and f<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.13â8.03 (m, 2H), 7.84â7.74 (m, 2H), 7.51 (s, 1H), 6.58 (s, 1H), 5.80 (s, 1H), 3.81 (dt, <i>J</i> = 14.1, 3.5 Hz, 1H), 3.17 (dq, <i>J</i> = 13.8, 7.0, 6.3 Hz, 1H), 3.08â2.89 (m, 2H), 2.40â2.22 (m, 1H), 2.19â2.00 (m, 1H), 1.96â1.78 (m, 2H), 1.72 (dt, <i>J</i> = 14.5, 3.6 Hz, 1H), 1.66â1.55 (m, 1H), 1.54â1.39 (m, 2H), 1.22â1.15 (m, 6H), 1.07 (s, 3H), 0.56 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 172.5, 163.3, 142.3, 141.9, 134.1, 133.1, 133.0, 127.8, 127.6, 127.5, 122.8, 119.5, 117.9, 54.9, 42.5, 41.8, 35.4, 34.2, 32.5, 31.8, 29.9, 27.3, 22.6, 22.2, 21.8, 20.0.</div></div><div id="sec4_2_11_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> (4b<i>R</i>,8a<i>S</i>)-2-Isopropyl-8,8-dimethyl-4b-(5-methyl-1,3,4-oxadiazol-2-yl)-10-oxo-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diyl Diacetate (<b>CA26a</b>)</h3><div class="NLM_p last">Compound <b>CA24a</b> (2.5 g, 5.5 mmol) and chromium trioxide (1.1 g, 11 mmol) were added into acetic acid (30 mL) at room temperature. After reaction completion (TLC), the mixture was concentrated in vacuo, the product dissolved in EA, washed with brine, extracted with EA, and then purified by silica gel column chromatography using PE/EA to give the target compound (2.11 g, 4.5 mmol, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.04 (s, 1H), 3.77â3.74 (m, 1H), 3.15â3.07 (m, 1H), 2.91 (hept, 1H), 2.79â2.74 (m, 1H), 2.36 (s, 3H), 2.42â2.07 (m, 2H), 2.23 (s, 3H), 2.20 (s, 3H), 1.70â1.30 (m, 4H), 1.22 (d, <i>J</i> = 6.8 Hz 3H), 1.17 (d, <i>J</i> = 6.8 Hz 3H), 0.91 (s, 3H), 0.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 196.6, 168.2, 167.7, 167.4, 164.1, 145.8, 142.2, 141.6, 136.3, 130.8, 124.3, 51.0, 42.4, 40.8, 35.2, 34.5, 33.6, 31.9, 27.7, 26.9, 22.8, 22.5, 20.3, 19.5, 19.1, 11.0.</div></div><div id="sec4_2_11_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> (4a<i>R</i>)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-4a-(5-methyl-1,3,4-oxadiazol-2-yl)-2,3,4,4a,10,10a-hexahydrophenanthren-9(1<i>H</i>)-one (<b>CA27a</b>)</h3><div class="NLM_p last">Compound <b>CA26a</b> (2.11 g, 4.5 mmol) was dissolved in 100 mL of MeOH/H<sub>2</sub>O (4:1). Sodium bicarbonate (5.3 g, 62.6 mmol) was added into the mixture which was then heated to 65 Â°C. After reaction completion (TLC), the product was washed with 2 N HCl and brine, extracted with EA, and purified by silica gel column chromatography using PE/EA. Compound <b>CA27a</b> was obtained in high yield (1.7 g, 4.4 mmol, 98%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.81 (s, 1H), 7.73 (s, 1H), 6.55 (s, 1H), 3.94â3.76 (m, 1H), 3.31â3.12 (m, 2H), 2.81 (dd, <i>J</i> = 17.0, 3.1 Hz, 1H), 2.48 (s, 3H), 2.32 (dd, <i>J</i> = 15.2, 3.1 Hz, 1H), 1.83 (m, 1H), 1.73 (m, 1H), 1.66â1.45 (m, 2H), 1.43 (m, 1H), 1.23 (s, 3H), 1.22 (s, 3H), 1.03 (s, 3H), 0.63 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 196.8, 170.7, 164.2, 150.2, 140.8, 134.7, 128.3, 123.6, 120.0, 51.0, 42.6, 41.4, 35.6, 34.9, 33.8, 32.0, 27.4, 22.3, 22.1, 21.2, 19.6, 11.3. HRMS <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub> (M â H)<sup>â</sup>, 383.1971; found, 383.1973.</div></div><div id="sec4_2_11_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> <i>tert</i>-Butyl ((<i>S</i>)-1-(5-((4a<i>R</i>,10a<i>S</i>)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-9-oxo-1,3,4,9,10,10a-hexahydrophenanthren-4a(2<i>H</i>)-yl)-1,3,4-oxadiazol-2-yl)ethyl)carbamate (<b>CA27b</b>)</h3><div class="NLM_p last"><b>CA27b</b> was synthesized from <b>CA24d</b> and <b>CA26b</b> by using procedures d and c<sub>3</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.67 (s, 1H), 7.02 (br, 1H), 5.27 (d, <i>J</i> = 8.4 Hz, 1H), 4.97â4.93 (m, 1H), 3.88 (dd, <i>J</i> = 13.6, 3.4 Hz, 1H), 3.27â3.08 (m, 2H), 2.75 (dd, <i>J</i> = 17.0, 3.0 Hz, 1H), 2.28 (dd, <i>J</i> = 15.2, 3.0 Hz, 1H), 1.93â1.78 (m, 1H), 1.73â1.64 (m, 1H), 1.62â1.54 (m, 1H), 1.48 (d, <i>J</i> = 7.2 Hz, 3H), 1.44â1.38 (m, 2H), 1.36 (s, 9H), 1.19â1.13 (m, 6H), 0.98 (s, 3H), 0.55 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 196.9, 170.4, 167.8, 154.8, 149.9, 141.1, 134.8, 128.6, 123.8, 119.8, 80.6, 51.1, 42.5, 41.2, 35.5, 34.7, 33.7, 31.9, 29.7, 28.3, 27.2, 26.9, 22.3, 22.0, 20.8, 19.6, 14.2. HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>40</sub>N<sub>3</sub>O<sub>6</sub> (M + H)<sup>+</sup>, 514.2917; found, 514.2913.</div></div><div id="sec4_2_11_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> (4a<i>R</i>,10a<i>S</i>)-4a-(5-Acetyl-1,3,4-oxadiazol-2-yl)-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-2,3,4,4a,10,10a-hexahydrophenanthren-9(1<i>H</i>)-one (<b>CA27c</b>)</h3><div class="NLM_p last"><b>CA27c</b> was synthesized from <b>CA26c</b> by using procedure c<sub>3</sub>. <b>CA26c</b> was the side-product of <b>CA24d</b> oxidation using procedure d. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.74 (s, 1H), 3.93 (dt, <i>J</i> = 14.3, 3.3 Hz, 1H), 3.30 (dd, <i>J</i> = 17.1, 15.3 Hz, 1H), 3.19 (hept, <i>J</i> = 6.9 Hz, 1H), 2.84 (dd, <i>J</i> = 17.1, 3.0 Hz, 1H), 2.70 (s, 3H), 2.36 (dd, <i>J</i> = 15.2, 3.0 Hz, 1H), 1.90â1.73 (m, 2H), 1.76â1.65 (m, 1H), 1.65â1.46 (m, 1H), 1.49â1.34 (m, 1H), 1.23 (d, <i>J</i> = 1.7 Hz, 3H), 1.21 (d, <i>J</i> = 1.7 Hz, 3H), 1.03 (s, 3H), 0.57 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 196.5, 183.6, 172.6, 161.1, 149.6, 140.9, 135.0, 127.8, 124.0, 120.2, 51.4, 43.0, 41.2, 35.5, 34.8, 33.9, 31.9, 27.4, 27.3, 22.3, 22.1, 21.0, 19.7. HRMS <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>29</sub>N<sub>2</sub>O<sub>5</sub> (M + H)<sup>+</sup>, 413.2076; found, 413.2062.</div></div><div id="sec4_2_11_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> (4a<i>R</i>,10a<i>S</i>)-4a-(5-(4-Bromophenyl)-1,3,4-oxadiazol-2-yl)-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-2,3,4,4a,10,10a-hexahydrophenanthren-9(1<i>H</i>)-one (<b>CA27d</b>)</h3><div class="NLM_p last"><b>CA27d</b> was synthesized from <b>CA24e</b> by using procedures d and c<sub>3</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.76 (s, 2H), 7.63 (d, <i>J</i> = 8.4 Hz, 2H), 7.54 (d, <i>J</i> = 8.2 Hz, 2H), 6.90 (s, 1H), 4.00 (d, <i>J</i> = 14.1 Hz, 1H), 3.25 (d, <i>J</i> = 15.5 Hz, 1H), 3.24â3.17 (m, 1H), 2.89 (dd, <i>J</i> = 17.1, 2.9 Hz, 1H), 2.39 (dd, <i>J</i> = 15.1, 3.0 Hz, 1H), 2.06â1.87 (m, 1H), 1.81â1.73 (m, 1H), 1.73â1.59 (m, 1H), 1.58â1.41 (m, 2H), 1.25â1.12 (m, 6H), 1.04 (s, 3H), 0.62 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 196.8, 170.2, 164.2, 150.6, 140.9, 134.9, 132.6, 129.0, 128.2, 127.2, 123.7, 121.8, 120.3, 51.2, 42.7, 41.3, 35.7, 34.8, 33.9, 31.9, 27.4, 27.0, 22.1, 21.1, 19.7. HRMS <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub>Br (M â H)<sup>â</sup>, 523.1232; found, 523.1226.</div></div><div id="sec4_2_11_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> (4a<i>R</i>,10a<i>S</i>)-4a-(5-((<i>S</i>)-1-aminoethyl)-1,3,4-oxadiazol-2-yl)-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-2,3,4,4a,10,10a-hexahydrophenanthren-9(1<i>H</i>)-one (<b>CA27e</b>)</h3><div class="NLM_p last"><b>CA27e</b> was synthesized from <b>CA26e</b> by using procedure c<sub>3</sub>. <b>CA26e</b> was synthesized by deprotection of <b>CA26b</b>: <b>CA26b</b> (0.44 g, 0.74 mmol) was dissolved in DCM and excess trifluoroacetic acid (TFA) was added. The mixture was allowed to stir at room temperature for 2â4 h. Then, the mixture was washed with saturated NaHCO<sub>3</sub> and brine, extracted with EA, dried with anhydrous MgSO<sub>4</sub>, and purified by silica gel column chromatography. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.70 (s, 1H), 4.34 (s, 2H), 4.21â4.05 (m, 1H), 3.90 (dt, <i>J</i> = 14.1, 3.5 Hz, 1H), 3.26â3.08 (m, 2H), 2.80 (dd, <i>J</i> = 17.0, 3.1 Hz, 1H), 2.32 (dd, <i>J</i> = 15.2, 3.1 Hz, 1H), 1.95â1.79 (m, 1H), 1.72 (dt, <i>J</i> = 14.6, 3.7 Hz, 1H), 1.66â1.55 (m, 1H), 1.55â1.48 (m, 1H), 1.45 (d, <i>J</i> = 6.9 Hz, 3H), 1.20 (d, <i>J</i> = 6.9 Hz, 6H), 1.02 (s, 4H), 0.57 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 196.8, 170.7, 170.5, 150.3, 141.0, 134.9, 128.8, 123.8, 120.0, 51.1, 44.1, 42.6, 41.3, 35.6, 34.8, 33.8, 31.9, 27.4, 22.3, 22.0, 21.6, 20.9, 19.6. HRMS <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>32</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup>, 414.2393; found, 414.2383.</div></div><div id="sec4_2_11_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> (4b<i>R</i>)-2-Isopropyl-8,8-dimethyl-4b-(5-methyl-1,3,4-oxadiazol-2-yl)-5,6,7,8,8a,9-hexahydrophenanthrene-3,4,10(4b<i>H</i>)-trione (<b>CA28a</b>)</h3><div class="NLM_p last">Compound <b>CA27a</b> (1.7 g, 4.4 mmol) and 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ, 1.13 g, 4.92 mmol) were dissolved in 1,4-dioxane (50 mL) and stirred at room temperature for 30 min. The mixture was then filtered with diatomite, concentrated in vacuo, and purified by silica gel column chromatography using PE/EA to give <b>CA28a</b> (1.2 g, 3.1 mmol, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.48 (s, 1H), 3.43 (dd, J = 17.2, 15.0 Hz, 1H), 3.33 (dd, J = 13.8, 3.8 Hz, 1H), 2.97â2.89 (m, 1H), 2.77 (dd, J = 17.2, 3.0 Hz, 1H), 2.57 (s, 3H), 2.29â2.12 (m, 2H), 1.82â1.70 (m, 1H), 1.60â1.50 (m, 1H), 1.47â1.30 (m, 2H), 1.12 (m, 6H), 0.95 (s, 3H), 0.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 198.0, 184.4, 179.3, 166.4, 163.6, 149.2, 146.6, 136.6, 130.2, 50.5, 41.0, 40.5, 34.8, 33.2, 33.2, 31.6, 27.8, 21.5, 21.4, 19.7, 19.2, 11.2. HRMS <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub> (M + H)<sup>+</sup>, 383.1971; found, 383.1957. HPLC purity: 95.3%. <i>t</i><sub>R</sub> = 5.13 min.</div></div><div id="sec4_2_11_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> <i>tert</i>-Butyl ((<i>S</i>)-1-(5-((4a<i>R</i>,10a<i>S</i>)-7-Isopropyl-1,1-dimethyl-5,6,9-trioxo-1,3,4,5,6,9,10,10a-octahydrophenanthren-4a(2<i>H</i>)-yl)-1,3,4-oxadiazol-2-yl)ethyl)carbamate (<b>CA28b</b>)</h3><div class="NLM_p last"><b>CA28b</b> was synthesized from <b>CA27b</b> by using procedure a<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.44 (s, 1H), 5.16 (d, <i>J</i> = 8.6 Hz, 1H), 5.09â5.00 (m, 1H), 3.37 (dd, <i>J</i> = 17.2, 15.0 Hz, 1H), 3.28 (dd, <i>J</i> = 13.7, 3.5 Hz, 1H), 2.89 (pd, <i>J</i> = 6.9, 1.3 Hz, 1H), 2.73 (dd, <i>J</i> = 17.2, 3.0 Hz, 1H), 2.18 (dd, <i>J</i> = 15.0, 3.0 Hz, 1H), 2.17 (s, 1H), 1.72 (dt, <i>J</i> = 15.5, 3.5 Hz, 1H), 1.57 (d, <i>J</i> = 7.0 Hz, 3H), 1.54â1.47 (m, 1H), 1.40 (s, 9H), 1.45â1.23 (m, 2H), 1.09 (t, <i>J</i> = 6.9 Hz, 6H), 0.92 (s, 3H), 0.33 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 197.8, 184.3, 179.3, 167.6, 166.5, 154.8, 149.2, 146.4, 136.6, 130.1, 72.8, 50.4, 40.9, 40.4, 34.7, 33.1, 33.0, 31.6, 29.7, 28.3, 27.7, 27.0, 21.4, 21.4, 19.5, 19.0. HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>38</sub>N<sub>3</sub>O<sub>6</sub> (M + H)<sup>+</sup>, 512.2761; found, 512.2750.</div></div><div id="sec4_2_11_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> (4b<i>R</i>,8a<i>S</i>)-4b-(5-Acetyl-1,3,4-oxadiazol-2-yl)-2-isopropyl-8,8-dimethyl-5,6,7,8,8a,9-hexahydrophenanthrene-3,4,10(4b<i>H</i>)-trione (<b>CA28c</b>)</h3><div class="NLM_p last"><b>CA28c</b> was synthesized from <b>CA27c</b> by using procedure a<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.49 (s, 1H), 3.42â3.26 (m, 2H), 2.93 (hept, <i>J</i> = 8.8, 7.9 Hz, 1H), 2.81 (dd, <i>J</i> = 17.2, 2.9 Hz, 1H), 2.74 (s, 3H), 2.37â2.26 (m, 1H), 2.30â2.22 (m, 1H), 1.80 (dt, <i>J</i> = 14.9, 3.7 Hz, 1H), 1.57 (dt, <i>J</i> = 13.9, 3.9 Hz, 1H), 1.53â1.32 (m, 2H), 1.12 (d, <i>J</i> = 7.1 Hz, 6H), 0.96 (s, 3H), 0.34 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 197.4, 184.3, 184.2, 179.2, 169.1, 161.0, 149.7, 145.9, 137.2, 129.9, 50.7, 41.4, 40.3, 34.7, 33.2, 31.6, 29.8, 27.9, 27.4, 21.5, 21.4, 19.5, 19.1.</div></div><div id="sec4_2_11_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> (4b<i>R</i>,8a<i>S</i>)-4b-(5-(4-Bromophenyl)-1,3,4-oxadiazol-2-yl)-2-isopropyl-8,8-dimethyl-5,6,7,8,8a,9-hexahydrophenanthrene-3,4,10(4b<i>H</i>)-trione (<b>CA28d</b>)</h3><div class="NLM_p last"><b>CA28d</b> was synthesized from <b>CA27d</b> by using procedure a<sub>1</sub>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.88 (dd, <i>J</i> = 8.5, 3.1 Hz, 2H), 7.64 (dd, <i>J</i> = 8.6, 3.2 Hz, 2H), 7.49 (d, <i>J</i> = 3.0 Hz, 1H), 3.55â3.40 (m, 2H), 2.98â2.85 (m, 1H), 2.81 (dt, <i>J</i> = 17.3, 3.2 Hz, 1H), 2.33â2.16 (m, 2H), 1.83 (dq, <i>J</i> = 14.8, 3.6 Hz, 1H), 1.55 (td, <i>J</i> = 11.6, 9.4, 3.7 Hz, 1H), 1.48â1.33 (m, 2H), 1.16â1.06 (m, 6H), 0.95 (s, 3H), 0.41 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 197.9, 184.3, 179.2, 166.4, 163.9, 149.4, 146.2, 136.8, 132.6, 130.1, 128.4, 126.8, 122.5, 50.5, 41.2, 40.5, 34.9, 33.3, 33.2, 31.6, 27.8, 27.0, 21.4, 19.8, 19.3. HRMS <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub>Br (M + H)<sup>+</sup>, 523.1232; found, 523.1225.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> Enzymatic Activity Assays</h3><div class="NLM_p last"><i>Hs</i>FPPS and <i>Hs</i>GGPPS activities were determined via PPi release using a continuous spectrophotometric assay for phosphate releasing enzymes,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> as described previously.<a onclick="showRef(event, 'ref27 ref73'); return false;" href="javascript:void(0);" class="ref ref27 ref73">(27,73)</a><i>Hs</i>FPPS WT, <i>Hs</i>FPPS N59A, or <i>Hs</i>FPPS F239A was preincubated with compounds at room temperature for 30 min before the addition of GPP and IPP. The final reaction system contained 200 Î¼L of reaction mixture. The reaction buffer contained 50 mM Tris-HCl (pH 7.5) and 2 mM MgCl<sub>2</sub>. In some cases, 50 Î¼g/mL catalase or 0.01% Triton X-100 was added, as discussed above. Kinetics assays were carried out in a similar manner except that the GPP and IPP concentrations were varied. IC<sub>50</sub> values were calculated by fitting the inhibition data to the doseâresponse curves in Prism 7. For the [<sup>14</sup>C]-IPP radioactivity assay, the protocol was as described in the literature.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> WaterLOGSY</h3><div class="NLM_p last">This experiment was performed according to the method reported in literature.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a><i>Hs</i>FPPS concentration was 10 Î¼M, and <b>CA28a/CA5d</b> was 200/400 Î¼M. Tris buffer (25 mM Tris, pH 7.5) without DTT was used for this experiment.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Saturation Transfer Difference (STD) NMR</h3><div class="NLM_p last">STD was performed according to the method reported in literature.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Sample for STD was prepared with 400 Î¼M <b>CA28a</b> in 5% DMSO-<i>d</i><sub>6</sub>, 10 Î¼M <i>Hs</i>FPPS in Hepes buffer (1.5%), and 10% D2O in PBS (pH 7.4).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> Surface Plasmon Resonance (SPR)</h3><div class="NLM_p last">SPR was performed at 25 Â°C on a Reichert 4SPR using a carboxymethyl dextran sensor chip. Phosphate buffered saline containing 0.05% Tween-20 (PBST) and 5% DMSO were used as running buffer. The amount of <i>Hs</i>FPPS captured was about 5000 Î¼RIU (refractive index unit). Flow rate was 25 Î¼L/min. <b>CA1</b> and <b>CA28a</b> were assayed at 40â2.5 Î¼M with 2-fold dilution. <b>CA5l</b> and <b>CA13</b> were assayed at 50, 37.5, 25, 18.75, and 12.5 Î¼M.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> Computational Methods</h3><div class="NLM_p">Protein structures were prepared by using the Protein Preparation Wizard<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> in Schrodinger software by adding hydrogens, while waters beyond 5 Ã from inhibitor ligands groups were deleted. PROPKA was used to assign H-bonds present at pH 7.0. Then, restrained minimization was performed and the prepared proteins were used for subsequent protein alignments, grid generation, and docking.</div><div class="NLM_p last">Grids of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0X">4P0X</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV1">5JV1</a> (with/without sulfate ions and waters) were generated using default settings. Compound <b>CA28a</b> was prepared for docking by using LigPrep. Ionization states of <b>CA28a</b> were generated between pH 5.0 and pH 9.0 by Epik.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Finally, the prepared <b>CA28a</b> and protein structures were docked by using the standard precision method in Glide and docking poses were visualized, analyzed using Maestro 11.9 and Pymol 2.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> Cellular Activity Evaluation</h3><div class="NLM_p last">Cell growth inhibition was determined by using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. PANC-1 and MIA PaCa-2 cells were seeded at 4 Ã 10<sup>3</sup> cells per well in a 96-well flat bottomed plate and allowed to adhere at 37 Â°C in a 5% CO<sub>2</sub> atmosphere overnight before addition of drugs. 200 Î¼L of DMEM (Dulbeccoâs modified Eagle medium) was used in each well. The next day, inhibitor-free medium was replaced by inhibitor-containing DMEM. There were three duplicates for each inhibitor concentration. Plates were then incubated at 37 Â°C and 5% CO<sub>2</sub> atmosphere for 72 h. After incubation, 20 Î¼L of MTT (5 mg/mL, dissolved in PBS) was added to each well and the plates were incubated for a further 4 h period. Finally, the medium was removed and the formed formazan was dissolved in 150 Î¼L of DMSO per well. Cell densities were measured at 490 nm. Doseâresponse curves and EC<sub>50</sub> values were fitted by using Prism 7.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> Apoptosis Assay</h3><div class="NLM_p last">The apoptosis rates of PANC-1 cells were measured by using an annexin V-FITC/PI apoptosis detection kit (CWBIO). Briefly, 5 Ã 10<sup>4</sup> PANC-1 cells per well were incubated in a 12-well plate and allowed to grow in 1 mL of DMEM per well at 37 Â°C and 5% CO<sub>2</sub> atmosphere overnight before compound treatment. After incubation, an additional 1 mL of DMEM containing the inhibitor was added to each well. Each concentration contained three duplicates. The following cell sample treatments were carried out according to the kit protocol. Briefly, after a 48 h incubation, cells were collected, resuspended twice in cold PBS, and then resuspended by using the binding buffer in the kit. Annexin V/FITC and PI were then added and incubated in the dark at room temperature for 15 min. Finally, flow cytometry was utilized to analyze the apoptosis rate of PANC-1 cells using FlowJo (FLOWJO LLC) for data processing.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> Rescue Experiments</h3><div class="NLM_p last">Rescue experiments were carried out by measuring the effects of various treatments (FOH and/or GGOH) on apoptosis rates, basically as described above. Briefly, after incubation overnight in a 12-well plate, cells were treated with rescue compounds for 48 h, followed by flow cytometry analysis. All experiments were performed using three duplicates.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> Western Blot Analysis of Membrane Ras</h3><div class="NLM_p">Subcellular extractions of PANC-1 cell proteins and subsequent Western blots were used to measure the amount of membrane Ras and total Ras. PANC-1 cells were seeded into a 150 mm dish and were allowed to proliferate to about (2.0â5.0) Ã 10<sup>7</sup> cells/dish. After treatment with compounds for 24 h, cells were gently collected using a cell scraper and washed three times with cold PBS. Subsequent membrane protein extractions were conducted basically according to the protocol provided with the membrane and cytosol protein extraction kit (Beyotime). Cells were collected by centrifugation and suspended in 1 mL of extraction reagent A (containing freshly added phenylmethylsulfonyl fluoride, PMSF) in the kit. After cooling in an ice bath for 10â15 min, cells were subjected to three freeze/thaw cycles (between liquid nitrogen and room temperature), followed by centrifugation at 700<i>g</i> for 10 min at 4 Â°C. The supernatants were then collected and centrifuged at 14â¯000<i>g</i> for 30 min (again at 4 Â°C) to remove membrane fragments, and the supernatants were collected for cytosolic protein analysis. The cell membrane fragments were then treated with 200 Î¼L of extraction reagent B in the kit and vortexed for 5 s, then cooled in an ice bath for 5â10 min. The vortexing and ice-bath treatment was repeated two more times. After centrifugation at 14â¯000<i>g</i> for 15 min at 4 Â°C, the supernatant was collected as the membrane protein fraction. The cytosolic and membrane protein fractions were combined as the whole protein sample for Western blot analysis. Protein concentrations were determined by using a BCA (bicinchoninic acid assay) protein assay kit (CWBIO).</div><div class="NLM_p last">42 Î¼g of membrane proteins and 80 Î¼g of whole proteins were used as Western blot samples. Membrane and whole proteins were separated by electrophoresis at 90 V, 25 min and then 130 V, 60 min. After that, protein transfer to a PVDF (polyvinylidene difluoride) membrane was conducted in an ice bath at 300 mA for 70 min. Subsequent blocking was performed in 5% nonfat dried milk (in PBS) at 4 Â°C, overnight. Rabbit anti-Ras antibody (abcam, EP1125Y), rabbit anti-sodium potassium ATPase antibody (abcam, EP1845Y), and mouse anti-Î² tubulin antibody (Byotime) were used at room temperature for 2 h in primary antibody incubation. After washing with PBST (0.05% Tween 20) five times for 5 min each, membranes were incubated with the corresponding secondary antibody conjugated with horseradish peroxidase (mouse IgG for Î² tubulin, rabbit IgG was for the others; Byotime) at room temperature for 2 h. The same washing protocol was performed after secondary antibody incubation. The immunoblot bands were detected by using ECL (enhanced chemiluminescence) substrate (BeyoECL Plus) and then visualized in a Tanon gel imaging system.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Protein Expression and Purification</h3><div class="NLM_p last">Clones encoding <i>Hs</i>FPPS WT, <i>Hs</i>FPPS N59A, <i>Hs</i>FPPS F239A, or <i>Hs</i>GGPPS residues as N-terminally His6-tagged fusion proteins with a TEV protease cleavage site were expressed in <i>E. coli</i> BL21(DE3). Cells were lysed by using an ultrasonic cell disruptor, and the proteins were purified by nickel affinity column chromatography (GE). The histidine tag was removed by incubation with TEV protease, and gel filtration chromatography was performed with a Superdex 200 column (GE). The purified enzymes were dialyzed against 10 mM HEPES/Tris buffer (pH 7.5) containing 500 mM NaCl and stored at â80 Â°C before use.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i105"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01405" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17263" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17263" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01405?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01405</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Binding mode of various inhibitors to <i>Hs</i>FPPS, mechanism involved in the formation of bridged compounds, catalase-addition experiment results, IC<sub>50</sub> values of zoledronate (<b>6</b>) and <b>CA28a</b> after different incubation times, WaterLOGSY result of <b>CA5d</b>, LCâMS detection results of <b>CA28a</b> plus <i>Hs</i>FPPS, <b>CA28a</b>âs docking pose in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0X">4P0X</a> with the location of S1âS4 sites, correlation analysis between clogP and clogD<sub>7.4</sub> with EC<sub>50</sub>, HPLC analysis of key compounds, and NMR spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and associated biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Docking files (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_003.zip" class="ext-link">ZIP</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf">jm9b01405_si_001.pdf (5.87 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_002.csv">jm9b01405_si_002.csv (12.7 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_003.zip">jm9b01405_si_003.zip (585.34 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01405" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41512" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41512" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric Oldfield</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Illinois at
UrbanaâChampaign, Urbana, Illinois 61801, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0996-7352" title="Orcid link">http://orcid.org/0000-0002-0996-7352</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#34515b5850525d5158745d58585d5a5b5d471a515041"><span class="__cf_email__" data-cfemail="e4818b8880828d8188a48d88888d8a8b8d97ca818091">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yonghui Zhang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus
Chemistry and Chemical Biology, Tsinghua
University, 100084 Beijing, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Joint
Graduate Program of Peking-Tsinghua-NIBS, School of Life Sciences, Tsinghua University, 100084 Beijing, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Collaborative
Innovation Center for Biotherapy, Sichuan
University, 610041 Chengdu, Sichuan, China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9842-3049" title="Orcid link">http://orcid.org/0000-0002-9842-3049</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3b41535a555c4254555c534e527b4f4852555c534e5a155e5f4e155855"><span class="__cf_email__" data-cfemail="c3b9aba2ada4baacada4abb6aa83b7b0aaada4abb6a2eda6a7b6eda0ad">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuai Han</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus
Chemistry and Chemical Biology, Tsinghua
University, 100084 Beijing, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Li</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus
Chemistry and Chemical Biology, Tsinghua
University, 100084 Beijing, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Joint
Graduate Program of Peking-Tsinghua-NIBS, School of Life Sciences, Tsinghua University, 100084 Beijing, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yun Xia</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus
Chemistry and Chemical Biology, Tsinghua
University, 100084 Beijing, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Joint
Graduate Program of Peking-Tsinghua-NIBS, School of Life Sciences, Tsinghua University, 100084 Beijing, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhengsen Yu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus
Chemistry and Chemical Biology, Tsinghua
University, 100084 Beijing, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ningning Cai</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus
Chemistry and Chemical Biology, Tsinghua
University, 100084 Beijing, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Collaborative
Innovation Center for Biotherapy, Sichuan
University, 610041 Chengdu, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Satish R. Malwal</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Illinois at
UrbanaâChampaign, Urbana, Illinois 61801, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7606-1932" title="Orcid link">http://orcid.org/0000-0001-7606-1932</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xu Han</span> - <span class="hlFld-Affiliation affiliation">Industrial
Enzymes National Engineering Laboratory, Tianjin Institute of Industrial Biotechnology, Chinese Academy of
Sciences, 300308 Tianjin, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.Z. and S.H. designed this project. S.H. and Z.Y. designed and synthesized compounds. X.L. and N.C. provided HsFPPS and HsGGPPS proteins. S.H. and Y.X. performed the apoptosis and Western blotting assays. S.R.M. performed data analysis. X.L., N.C., and X.H. helped with the binding mode analysis. All other experiments were done by S.H. S.H. and E.O. wrote the paper.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i107">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55211" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55211" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was funded in part by grants from the National Key R&D Program of China (Grants 2015BAI08B03, 2017YFA1014000, 2017YFA1014001), National Natural Science Foundation of China (Grant 81573270), Beijing Natural Science Foundation (Grant Z190015), the Beijing Municipal Science and Technology Commission (Grant Z161100000216154), the 1000 Young Talents Program, the Tsinghua Peking Center for Life Science, the Beijing Advanced Innovation Centre for Structural Biology, and in part by the United States Public Health Service (NIH Grant GM065307). We thank Wolfgang Jahnke for his WaterLOGSY pulse sequence and Yi Xue for his assistance with WaterLOGSY experiment. We thank Rey-ting Guo and Chun-Chi Chen for their help and suggestions on binding mode investigations. We thank colleagues of Center of Pharmaceutical Technology, Tsinghua University, for their help on this project.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term"><i>Hs</i>FPPS</td><td class="NLM_def"><p class="first last"><i>Homo sapiens</i> farnesyl pyrophosphate synthase</p></td></tr><tr><td class="NLM_term"><i>Hs</i>GGPPS</td><td class="NLM_def"><p class="first last"><i>Homo sapiens</i> geranylgeranyl pyrophosphate synthase</p></td></tr><tr><td class="NLM_term">CA</td><td class="NLM_def"><p class="first last">carnosic acid</p></td></tr><tr><td class="NLM_term">IPP</td><td class="NLM_def"><p class="first last">isopentenyl diphosphate</p></td></tr><tr><td class="NLM_term">DMAPP</td><td class="NLM_def"><p class="first last">dimethylallyl diphosphate</p></td></tr><tr><td class="NLM_term">GPP</td><td class="NLM_def"><p class="first last">geranyl diphosphate</p></td></tr><tr><td class="NLM_term">FPP</td><td class="NLM_def"><p class="first last">farnesyl diphosphate</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">WaterLOGSY</td><td class="NLM_def"><p class="first last">water-ligand observed via gradient spectroscopy</p></td></tr><tr><td class="NLM_term">STD</td><td class="NLM_def"><p class="first last">saturation transfer difference</p></td></tr><tr><td class="NLM_term">DDQ</td><td class="NLM_def"><p class="first last">2,3-dichloro-5,6-dicyanobenzoquinone</p></td></tr><tr><td class="NLM_term"><i>p-</i>TSA</td><td class="NLM_def"><p class="first last"><i>p-</i>toluenesulfonic acid</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriazole tetramethyluranium</p></td></tr><tr><td class="NLM_term">TBS</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl</p></td></tr><tr><td class="NLM_term">Bn</td><td class="NLM_def"><p class="first last">benzyl</p></td></tr><tr><td class="NLM_term">Ac</td><td class="NLM_def"><p class="first last">acetyl</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last">dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term"><i>p</i>-TsCl</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonyl chloride</p></td></tr><tr><td class="NLM_term">PAINS</td><td class="NLM_def"><p class="first last">pan-assay interference compounds</p></td></tr><tr><td class="NLM_term">PPi</td><td class="NLM_def"><p class="first last">inorganic pyrophosphate</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffered saline</p></td></tr><tr><td class="NLM_term">FOH</td><td class="NLM_def"><p class="first last">farnesol</p></td></tr><tr><td class="NLM_term">GGOH</td><td class="NLM_def"><p class="first last">geranylgeraniol</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">PE</td><td class="NLM_def"><p class="first last">petroleum ether</p></td></tr><tr><td class="NLM_term">EA</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">RIU</td><td class="NLM_def"><p class="first last">refractive index unit</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbeccoâs modified Eagle medium</p></td></tr><tr><td class="NLM_term">PMSF</td><td class="NLM_def"><p class="first last">phenylmethylsulfonyl fluoride</p></td></tr><tr><td class="NLM_term">BCA</td><td class="NLM_def"><p class="first last">bicinchoninic acid assay</p></td></tr><tr><td class="NLM_term">PVDF</td><td class="NLM_def"><p class="first last">polyvinylidene difluoride</p></td></tr><tr><td class="NLM_term">ECL</td><td class="NLM_def"><p class="first last">enhanced chemiluminescence</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i109">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 77 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Firn, R.</span></span> <i>Natureâs Chemicals. The Natural Products That Shaped Our World</i>; <span class="NLM_publisher-name">Oxford University Press</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=R.+Firn&title=Nature%E2%80%99s+Chemicals.+The+Natural+Products+That+Shaped+Our+World"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DFirn%26aufirst%3DR.%26btitle%3DNature%25E2%2580%2599s%2520Chemicals.%2520The%2520Natural%2520Products%2520That%2520Shaped%2520Our%2520World%26pub%3DOxford%2520University%2520Press%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">The mevalonate pathway is a druggable target for vaccine adjuvant discovery</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">1059</span>â <span class="NLM_lpage">1073</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2018.08.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.cell.2018.08.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=30270039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVahsb7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=1059-1073&author=Y.+Xiaauthor=Y.+Xieauthor=Z.+Yuauthor=H.+Xiaoauthor=G.+Jiangauthor=X.+Zhouauthor=Y.+Yangauthor=X.+Liauthor=M.+Zhaoauthor=L.+Liauthor=M.+Zhengauthor=S.+Hanauthor=Z.+Zongauthor=X.+Mengauthor=H.+Dengauthor=H.+Yeauthor=Y.+Faauthor=H.+Wuauthor=E.+Oldfieldauthor=X.+Huauthor=W.+Liuauthor=Y.+Shiauthor=Y.+Zhang&title=The+mevalonate+pathway+is+a+druggable+target+for+vaccine+adjuvant+discovery&doi=10.1016%2Fj.cell.2018.08.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery</span></div><div class="casAuthors">Xia, Yun; Xie, Yonghua; Yu, Zhengsen; Xiao, Hongying; Jiang, Guimei; Zhou, Xiaoying; Yang, Yunyun; Li, Xin; Zhao, Meng; Li, Liping; Zheng, Mingke; Han, Shuai; Zong, Zhaoyun; Meng, Xianbin; Deng, Haiteng; Ye, Huahu; Fa, Yunzhi; Wu, Haitao; Oldfield, Eric; Hu, Xiaoyu; Liu, Wanli; Shi, Yan; Zhang, Yonghui</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1059-1073.e21</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Motivated by the clin. observation that interruption of the mevalonate pathway stimulates immune responses, the authors hypothesized that this pathway may function as a druggable target for vaccine adjuvant discovery.  The authors found that lipophilic statin drugs and rationally designed bisphosphonates that target three distinct enzymes in the mevalonate pathway have potent adjuvant activities in mice and cynomolgus monkeys.  These inhibitors function independently of conventional "danger sensing.".  Instead, they inhibit the geranylgeranylation of small GTPases, including Rab5 in antigen-presenting cells, resulting in arrested endosomal maturation, prolonged antigen retention, enhanced antigen presentation, and T cell activation.  Addnl., inhibiting the mevalonate pathway enhances antigen-specific anti-tumor immunity, inducing both Th1 and cytolytic T cell responses.  As demonstrated in multiple mouse cancer models, the mevalonate pathway inhibitors are robust for cancer vaccinations and synergize with anti-PD-1 antibodies.  The authors' research thus defines the mevalonate pathway as a druggable target for vaccine adjuvants and cancer immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpbTJq8U36HLVg90H21EOLACvtfcHk0ljNb0K5KyhmYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVahsb7K&md5=64063b0872662a46e146e183f47067d6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.08.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.08.070%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DZong%26aufirst%3DZ.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DFa%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DOldfield%26aufirst%3DE.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DThe%2520mevalonate%2520pathway%2520is%2520a%2520druggable%2520target%2520for%2520vaccine%2520adjuvant%2520discovery%26jtitle%3DCell%26date%3D2018%26volume%3D175%26spage%3D1059%26epage%3D1073%26doi%3D10.1016%2Fj.cell.2018.08.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Schutter, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5764</span>â <span class="NLM_lpage">5776</span>, <span class="refDoi">Â DOI: 10.1021/jm500629e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500629e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVegtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5764-5776&author=J.+W.+De%0ASchutterauthor=J.+Parkauthor=C.+Y.+Leungauthor=P.+Gormleyauthor=Y.+S.+Linauthor=Z.+Huauthor=A.+M.+Berghuisauthor=J.+Poirierauthor=Y.+S.+Tsantrizos&title=Multistage+screening+reveals+chameleon+ligands+of+the+human+farnesyl+pyrophosphate+synthase%3A+implications+to+drug+discovery+for+neurodegenerative+diseases&doi=10.1021%2Fjm500629e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multistage Screening Reveals Chameleon Ligands of the Human Farnesyl Pyrophosphate Synthase: Implications to Drug Discovery for Neurodegenerative Diseases</span></div><div class="casAuthors">De Schutter, Joris W.; Park, Jaeok; Leung, Chun Yuen; Gormley, Patrick; Lin, Yih-Shyan; Hu, Zheping; Berghuis, Albert M.; Poirier, Judes; Tsantrizos, Youla S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5764-5776</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human farnesyl pyrophosphate synthase (hFPPS) is the gate-keeper of mammalian isoprenoids and the key target of bisphosphonate drugs.  Bisphosphonates suffer from poor "drug-like" properties and are mainly effective in treating skeletal diseases.  Recent investigations have implicated hFPPS in various nonskeletal diseases, including Alzheimer's disease (AD).  Anal. of single nucleotide polymorphisms in the hFPPS gene and mRNA levels in autopsy-confirmed AD subjects was undertaken, and a genetic link between hFPPS and phosphorylated tau (P-Tau) levels in the human brain was identified.  Elevated P-Tau levels are strongly implicated in AD progression.  The development of nonbisphosphonate inhibitors can provide mol. tools for validating hFPPS as a therapeutic target for tauopathy-assocd. neurodegeneration.  A multistage screening protocol led to the identification of a new monophosphonate chemotype that bind in an allosteric pocket of hFPPS.  Optimization of these compds. could lead to human therapeutics that block tau metab. and arrest the progression of neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrenHVATZq2I7Vg90H21EOLACvtfcHk0ljNb0K5KyhmYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVegtLo%253D&md5=b54b5f0f17e867c4c8707e3d58f26eab</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm500629e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500629e%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSchutter%26aufirst%3DJ.%2BW.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DC.%2BY.%26aulast%3DGormley%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DY.%2BS.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26aulast%3DPoirier%26aufirst%3DJ.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DMultistage%2520screening%2520reveals%2520chameleon%2520ligands%2520of%2520the%2520human%2520farnesyl%2520pyrophosphate%2520synthase%253A%2520implications%2520to%2520drug%2520discovery%2520for%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5764%26epage%3D5776%26doi%3D10.1021%2Fjm500629e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukkamala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houlihan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Lipophilic pyridinium bisphosphonates: potent gammadelta T cell stimulators</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1136</span>â <span class="NLM_lpage">1138</span>, <span class="refDoi">Â DOI: 10.1002/anie.200905933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1002%2Fanie.200905933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGktbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=1136-1138&author=Y.+Zhangauthor=R.+Caoauthor=F.+Yinauthor=F.+Y.+Linauthor=H.+Wangauthor=K.+Krysiakauthor=J.+H.+Noauthor=D.+Mukkamalaauthor=K.+Houlihanauthor=J.+Liauthor=C.+T.+Moritaauthor=E.+Oldfield&title=Lipophilic+pyridinium+bisphosphonates%3A+potent+gammadelta+T+cell+stimulators&doi=10.1002%2Fanie.200905933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Pyridinium Bisphosphonates: Potent Î³Î´ T Cell Stimulators</span></div><div class="casAuthors">Zhang, Yonghui; Cao, Rong; Yin, Fenglin; Lin, Fu-Yang; Wang, Hong; Krysiak, Kilannin; No, Joo-Hwan; Mukkamala, Dushyant; Houlihan, Kevin; Li, Jikun; Morita, Craig T.; Oldfield, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1136-1138, S1136/1-S1136/10</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Novel lipophilic Pyridinium bisphosphonates are shown to be approx. 250 times more effective than any other bisphosphonate drugs in Î³Î´ T Cell activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFABM7NZO2NLVg90H21EOLACvtfcHk0liDkLLCGd_dGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGktbs%253D&md5=cfa33355fbd51f711ea1d6165cc400cb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fanie.200905933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200905933%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DYin%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DF.%2BY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DKrysiak%26aufirst%3DK.%26aulast%3DNo%26aufirst%3DJ.%2BH.%26aulast%3DMukkamala%26aufirst%3DD.%26aulast%3DHoulihan%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMorita%26aufirst%3DC.%2BT.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DLipophilic%2520pyridinium%2520bisphosphonates%253A%2520potent%2520gammadelta%2520T%2520cell%2520stimulators%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D1136%26epage%3D1138%26doi%3D10.1002%2Fanie.200905933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, P. J.</span></span> <span> </span><span class="NLM_article-title">Protein prenylation: unique fats make their mark on biology</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">110</span>â <span class="NLM_lpage">122</span>, <span class="refDoi">Â DOI: 10.1038/nrm.2015.11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fnrm.2015.11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=26790532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOrsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=110-122&author=M.+Wangauthor=P.+J.+Casey&title=Protein+prenylation%3A+unique+fats+make+their+mark+on+biology&doi=10.1038%2Fnrm.2015.11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Protein prenylation: unique fats make their mark on biology</span></div><div class="casAuthors">Wang, Mei; Casey, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">110-122</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The modification of eukaryotic proteins by isoprenoid lipids, which is known as prenylation, controls the localization and activity of a range of proteins that have crucial functions in biol. regulation.  The roles of prenylated proteins in cells are well conserved across species, underscoring the biol. and evolutionary importance of this lipid modification pathway.  Genetic suppression and pharmacol. inhibition of the protein prenylation machinery have provided insights into several cellular processes and into the etiol. of diseases in which prenylation is involved.  The functional dependence of prenylation substrates, such as RAS proteins, on this modification and the therapeutic potential of targeting the prenylation process in pathol. conditions accentuate the need to fully understand this form of post-translational modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr08TXPqy6XorVg90H21EOLACvtfcHk0liDkLLCGd_dGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOrsrk%253D&md5=b6694153ce758f85c4e01c499d8de74a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2015.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2015.11%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DCasey%26aufirst%3DP.%2BJ.%26atitle%3DProtein%2520prenylation%253A%2520unique%2520fats%2520make%2520their%2520mark%2520on%2520biology%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2016%26volume%3D17%26spage%3D110%26epage%3D122%26doi%3D10.1038%2Fnrm.2015.11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">ten
Klooster, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hordijk, P. L.</span></span> <span> </span><span class="NLM_article-title">Targeting and localized signalling by small GTPases</span>. <i>Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">12</span>, <span class="refDoi">Â DOI: 10.1042/BC20060071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1042%2FBC20060071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=17155934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlWnurvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2007&pages=1-12&author=J.+P.+ten%0AKloosterauthor=P.+L.+Hordijk&title=Targeting+and+localized+signalling+by+small+GTPases&doi=10.1042%2FBC20060071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting and localized signalling by small GTPases</span></div><div class="casAuthors">ten Klooster, Jean Paul; Hordijk, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Biology of the Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">BCELDF</span>;
        ISSN:<span class="NLM_cas:issn">0248-4900</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Polarized cellular responses, for example, cell migration, require the coordinated assembly of signalling complexes at a particular subcellular location, such as the leading edge of cells.  Small GTPases of the Ras superfamily play central roles in many (polarized) responses to growth factors, chemokines or integrin ligands.  These small GTPases are functionally distinct, yet remarkably homologous in their primary sequence and esp. in their effector domains.  Therefore it has long been unclear how GTPase signalling specificity is regulated.  Small GTPases carry a lipid anchor, in the context of a hypervariable region, which mediates membrane assocn.  However, whereas the lipid has long been proposed to be the crit. regulator of subcellular GTPase targeting, there is now increasing evidence that specific protein-protein interactions are important as well.  This review discusses recent findings on GTPase targeting and proposes a revised model for GTPase signalling.  In this model, the hypervariable domain acts in conjunction with the lipid tail to target the GTPase to specific membrane-assocd. protein complexes.  Here, local GTPase activation occurs, leading to subsequent exposure of the effector domain, binding to effector proteins and the initiation of downstream signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0_6O2lhvmT7Vg90H21EOLACvtfcHk0liQPqqrZPV8EQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlWnurvO&md5=283d8f42fee85bc98c094dbb8709589b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1042%2FBC20060071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBC20060071%26sid%3Dliteratum%253Aachs%26aulast%3Dten%2BKlooster%26aufirst%3DJ.%2BP.%26aulast%3DHordijk%26aufirst%3DP.%2BL.%26atitle%3DTargeting%2520and%2520localized%2520signalling%2520by%2520small%2520GTPases%26jtitle%3DBiol.%2520Cell%26date%3D2007%26volume%3D99%26spage%3D1%26epage%3D12%26doi%3D10.1042%2FBC20060071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baines, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Ras for cancer treatment: the search continues</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1787</span>â <span class="NLM_lpage">1808</span>, <span class="refDoi">Â DOI: 10.4155/fmc.11.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.4155%2Ffmc.11.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=22004085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlertbjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1787-1808&author=A.+T.+Bainesauthor=D.+Xuauthor=C.+J.+Der&title=Inhibition+of+Ras+for+cancer+treatment%3A+the+search+continues&doi=10.4155%2Ffmc.11.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Ras for cancer treatment: the search continues</span></div><div class="casAuthors">Baines, Antonio T.; Xu, Dapeng; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1787-1808</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in human cancers (33%), thus stimulating intensive effort in developing anti-Ras inhibitors for cancer treatment.  Despite intensive effort, to date, no effective anti-Ras strategies have successfully made it to the clinic.  We present an overview of past and ongoing strategies to inhibit oncogenic Ras in cancer.  Since approaches to directly target mutant Ras have not been successful, most efforts have focused on indirect approaches to block Ras membrane assocn. or downstream effector signaling.  While inhibitors of effector signaling are currently under clin. evaluation, genome-wide unbiased genetic screens have identified novel directions for future anti-Ras drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSljlfnR2TbVg90H21EOLACvtfcHk0liQPqqrZPV8EQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlertbjJ&md5=bb810b0cf2b8dc975d5a476907f5c2ec</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.121%26sid%3Dliteratum%253Aachs%26aulast%3DBaines%26aufirst%3DA.%2BT.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DInhibition%2520of%2520Ras%2520for%2520cancer%2520treatment%253A%2520the%2520search%2520continues%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1787%26epage%3D1808%26doi%3D10.4155%2Ffmc.11.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prior, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattos, C.</span></span> <span> </span><span class="NLM_article-title">A comprehensive survey of Ras mutations in cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2457</span>â <span class="NLM_lpage">2467</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-11-2612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1158%2F0008-5472.CAN-11-2612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=22589270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvF2ntL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2457-2467&author=I.+A.+Priorauthor=P.+D.+Lewisauthor=C.+Mattos&title=A+comprehensive+survey+of+Ras+mutations+in+cancer&doi=10.1158%2F0008-5472.CAN-11-2612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Survey of Ras Mutations in Cancer</span></div><div class="casAuthors">Prior, Ian A.; Lewis, Paul D.; Mattos, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2457-2467</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  All mammalian cells express 3 closely related Ras proteins, termed H-Ras, K-Ras, and N-Ras, that promote oncogenesis when they are mutationally activated at codon 12, 13, or 61.  Although there is a high degree of similarity among the isoforms, K-Ras mutations are far more frequently obsd. in cancer, and each isoform displays preferential coupling to particular cancer types.  We examd. the mutational spectra of Ras isoforms curated from large-scale tumor profiling and found that each isoform exhibits surprisingly distinctive codon mutation and amino-acid substitution biases.  These findings were unexpected given that these mutations occur in regions that share 100% amino-acid sequence identity among the 3 isoforms.  Of importance, many of these mutational biases were not due to differences in exposure to mutagens, because the patterns were still evident when compared within specific cancer types.  We discuss potential genetic and epigenetic mechanisms, as well as isoform-specific differences in protein structure and signaling, that may promote these distinct mutation patterns and differential coupling to specific cancers.  Cancer Res; 72(10); 2457-67.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg2lqiicosOLVg90H21EOLACvtfcHk0liQPqqrZPV8EQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvF2ntL4%253D&md5=6d1894847015468f77c8b08b57c6d62a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-2612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-2612%26sid%3Dliteratum%253Aachs%26aulast%3DPrior%26aufirst%3DI.%2BA.%26aulast%3DLewis%26aufirst%3DP.%2BD.%26aulast%3DMattos%26aufirst%3DC.%26atitle%3DA%2520comprehensive%2520survey%2520of%2520Ras%2520mutations%2520in%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2457%26epage%3D2467%26doi%3D10.1158%2F0008-5472.CAN-11-2612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karnoub, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Ras oncogenes: split personalities</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">517</span>â <span class="NLM_lpage">531</span>, <span class="refDoi">Â DOI: 10.1038/nrm2438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fnrm2438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=18568040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFGnsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=517-531&author=A.+E.+Karnoubauthor=R.+A.+Weinberg&title=Ras+oncogenes%3A+split+personalities&doi=10.1038%2Fnrm2438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Ras oncogenes: split personalities</span></div><div class="casAuthors">Karnoub, Antoine E.; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">517-531</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Extensive research over the past 30 years has revealed the involvement of Ras not only in tumorigenesis but also in many developmental disorders.  The complexity of the mol. and cell biol. mechanisms of action of Ras proteins indicates that much remains to be learns.  Extensive research on the Ras proteins and their functions in cell physiol. over the past 30 years has led to numerous insights that have revealed the involvement of Ras not only in tumorigenesis but also in many developmental disorders.  Despite great strides in our understanding of the mol. and cellular mechanisms of action of the Ras proteins, the expanding roster of their downstream effectors and the complexity of the signaling cascades that they regulate indicate that much remains to be learns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocptUdlhqaM7Vg90H21EOLACvtfcHk0ljw3v_YXaxelA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFGnsr0%253D&md5=9de78b17b953b2560238d7a98f3bea6a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrm2438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2438%26sid%3Dliteratum%253Aachs%26aulast%3DKarnoub%26aufirst%3DA.%2BE.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DRas%2520oncogenes%253A%2520split%2520personalities%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D517%26epage%3D531%26doi%3D10.1038%2Fnrm2438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieves, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, B. R.</span></span> <span> </span><span class="NLM_article-title">Natural and synthetic non-peptide antigens recognized by human gamma delta T cells</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">155</span>â <span class="NLM_lpage">158</span>, <span class="refDoi">Â DOI: 10.1038/375155a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2F375155a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=7753173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADyaK2MXls1Wisrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=1995&pages=155-158&author=Y.+Tanakaauthor=C.+T.+Moritaauthor=Y.+Tanakaauthor=E.+Nievesauthor=M.+B.+Brennerauthor=B.+R.+Bloom&title=Natural+and+synthetic+non-peptide+antigens+recognized+by+human+gamma+delta+T+cells&doi=10.1038%2F375155a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Natural and synthetic non-peptide antigens recognized by human Î³Î´ T cells</span></div><div class="casAuthors">Tanaka, Yoshimasa; Morita, Craig T.; Tanaka, Yoko; Nieves, Edward; Brenner, Michael B.; Bloom, Barry R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">6527</span>),
    <span class="NLM_cas:pages">155-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A major human Î³Î´ T-cell subset expressing VÎ³2 and VÎ´2 germline genes, but having diverse junctional sequences, is found in human mycobacterial lesions and responds in vitro to antigens of bacteria and parasites.  VÎ³2VÎ´2-bearing T cells were shown to recognize mycobacterial antigens that are protease-resistant and phosphatase-sensitive.  Because of the difficulty in isolating natural antigens from mycobacterial culture filtrates or exts., the authors synthesized a series of monoalkyl phosphates, and found that some, particularly monoethyl phosphate, could mimic the activity of mycobacterial antigens in simulating these Î³Î´ T cells.  Here, natural antigens produced by mycobacteria recognized by human VÎ³2VÎ´2-bearing T cells were identified as isopentenyl pyrophosphate and related prenyl pyrophosphate derivs., compds. involved in the synthesis of complex polyisoprenoid compds. in microbial and mammalian cells.  Substitution of phosphate for the pyrophosphate moiety, or elimination of the double bond, greatly reduced antigenic activity of these compds.  These results provide formal evidence that, in contrast to recognition of major histocompatibility complex-bound peptide antigens by Î±Î² T cells, human Î³Î´ T cells can recognize naturally occurring small non-peptidic antigens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH74R45PP7ULVg90H21EOLACvtfcHk0ljw3v_YXaxelA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXls1Wisrk%253D&md5=a0e1c8698010db1d164f066556fa7080</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2F375155a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F375155a0%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DMorita%26aufirst%3DC.%2BT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DNieves%26aufirst%3DE.%26aulast%3DBrenner%26aufirst%3DM.%2BB.%26aulast%3DBloom%26aufirst%3DB.%2BR.%26atitle%3DNatural%2520and%2520synthetic%2520non-peptide%2520antigens%2520recognized%2520by%2520human%2520gamma%2520delta%2520T%2520cells%26jtitle%3DNature%26date%3D1995%26volume%3D375%26spage%3D155%26epage%3D158%26doi%3D10.1038%2F375155a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gober, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kistowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeno, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Libero, G.</span></span> <span> </span><span class="NLM_article-title">Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">163</span>â <span class="NLM_lpage">168</span>, <span class="refDoi">Â DOI: 10.1084/jem.20021500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1084%2Fjem.20021500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=12538656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1Sjtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2003&pages=163-168&author=H.+J.+Goberauthor=M.+Kistowskaauthor=L.+Angmanauthor=P.+Jenoauthor=L.+Moriauthor=G.+De+Libero&title=Human+T+cell+receptor+gammadelta+cells+recognize+endogenous+mevalonate+metabolites+in+tumor+cells&doi=10.1084%2Fjem.20021500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Human T cell receptor Î³Î´ cells recognize endogenous mevalonate metabolites in tumor cells</span></div><div class="casAuthors">Gober, Hans-Jurgen; Kistowska, Magdalena; Angman, Lena; Jeno, Paul; Mori, Lucia; De Libero, Gennaro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-168</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">T lymphocytes expressing the T cell receptor (TCR)-Î³Î´ recognize unknown antigens on tumor cells.  Here the authors identify metabolites of the mevalonate pathway as the tumor ligands that activate TCR-Î³Î´ cells.  In tumor cells, blockade of hydroxy-methylglutaryl-CoA reductase (HMGR), the rate limiting enzyme of the mevalonate pathway, prevents both accumulation of mevalonate metabolites and recognition by TCR-Î³Î´ cells.  When metabolite accumulation is induced by overexpressing HMGR or by treatment with nitrogen-contg. bisphosphonate drugs, tumor cells derived from many tissues acquire the capacity to stimulate the same TCR-Î³Î´ population.  Accumulation of mevalonate metabolites in tumor cells is a powerful danger signal that activates the immune response and may represent a novel target of tumor immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi_38RHDekMLVg90H21EOLACvtfcHk0ljw3v_YXaxelA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1Sjtg%253D%253D&md5=e4a887b66626558075c47fda7817f6cc</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1084%2Fjem.20021500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20021500%26sid%3Dliteratum%253Aachs%26aulast%3DGober%26aufirst%3DH.%2BJ.%26aulast%3DKistowska%26aufirst%3DM.%26aulast%3DAngman%26aufirst%3DL.%26aulast%3DJeno%26aufirst%3DP.%26aulast%3DMori%26aufirst%3DL.%26aulast%3DDe%2BLibero%26aufirst%3DG.%26atitle%3DHuman%2520T%2520cell%2520receptor%2520gammadelta%2520cells%2520recognize%2520endogenous%2520mevalonate%2520metabolites%2520in%2520tumor%2520cells%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2003%26volume%3D197%26spage%3D163%26epage%3D168%26doi%3D10.1084%2Fjem.20021500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarikonda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puan, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monkkonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, C. T.</span></span> <span> </span><span class="NLM_article-title">Indirect stimulation of human V gamma 2V delta 2 T cells through alterations in isoprenoid metabolism</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">5099</span>â <span class="NLM_lpage">5113</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1002697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.4049%2Fjimmunol.1002697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=22013129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSitb7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2011&pages=5099-5113&author=H.+Wangauthor=G.+Sarikondaauthor=K.+J.+Puanauthor=Y.+Tanakaauthor=J.+Fengauthor=J.+L.+Ginerauthor=R.+Caoauthor=J.+Monkkonenauthor=E.+Oldfieldauthor=C.+T.+Morita&title=Indirect+stimulation+of+human+V+gamma+2V+delta+2+T+cells+through+alterations+in+isoprenoid+metabolism&doi=10.4049%2Fjimmunol.1002697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Indirect Stimulation of Human VÎ³2VÎ´2 T Cells through Alterations in Isoprenoid Metabolism</span></div><div class="casAuthors">Wang, Hong; Sarikonda, Ghanashyam; Puan, Kia-Joo; Tanaka, Yoshimasa; Feng, Ju; Giner, Jose-Luis; Cao, Rong; Moenkkoenen, Jukka; Oldfield, Eric; Morita, Craig T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5099-5113</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Human VÎ³2VÎ´2 T cells monitor isoprenoid metab. by recognizing (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), an intermediate in the 2-C-methyl-D-erythritol-4-phosphate pathway used by microbes, and isopentenyl pyrophosphate (IPP), an intermediate in the mevalonate pathway used by humans.  Aminobisphosphonates and alkylamines indirectly stimulate VÎ³2VÎ´2 cells by inhibiting farnesyl diphosphate synthase (FDPS) in the mevalonate pathway, thereby increasing IPP/triphosphoric acid 1-adenosin-5'-yl ester 3-(3-methylbut-3-enyl) ester that directly stimulate.  In this study, we further characterize stimulation by these compds. and define pathways used by new classes of compds.  Consistent with FDPS inhibition, stimulation of VÎ³2VÎ´2 cells by aminobisphosphonates and alkylamines was much more sensitive to statin inhibition than stimulation by prenyl pyrophosphates; however, the continuous presence of aminobisphosphonates was toxic for T cells and blocked their proliferation.  Aminobisphosphonate stimulation was rapid and prolonged, independent of known Ag-presenting mols., and resistant to fixation.  New classes of stimulatory compds.-mevalonate, the alc. of HMBPP, and alkenyl phosphonates-likely stimulate differently.  Mevalonate, a rate-limiting metabolite, appears to enter cells to increase IPP levels, whereas the alc. of HMBPP and alkenyl phosphonates are directly recognized.  The crit. chem. feature of bisphosphonates is the amino moiety, because its loss switched aminobisphosphonates to direct Ags.  Transfection of APCs with small interfering RNA downregulating FDPS rendered them stimulatory for VÎ³2VÎ´2 cells and increased cellular IPP.  Small interfering RNAs for isopentenyl diphosphate isomerase functioned similarly.  Our results show that a variety of manipulations affecting isoprenoid metab. lead to stimulation of VÎ³2VÎ´2 T cells and that pulsing aminobisphosphonates would be more effective for the ex vivo expansion of VÎ³2VÎ´2 T cells for adoptive cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMbhsrGeBD-LVg90H21EOLACvtfcHk0lh-L7X3yzODCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSitb7O&md5=d80084026813ec29d63fc67cfc9fa65b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1002697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1002697%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSarikonda%26aufirst%3DG.%26aulast%3DPuan%26aufirst%3DK.%2BJ.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DGiner%26aufirst%3DJ.%2BL.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DMonkkonen%26aufirst%3DJ.%26aulast%3DOldfield%26aufirst%3DE.%26aulast%3DMorita%26aufirst%3DC.%2BT.%26atitle%3DIndirect%2520stimulation%2520of%2520human%2520V%2520gamma%25202V%2520delta%25202%2520T%2520cells%2520through%2520alterations%2520in%2520isoprenoid%2520metabolism%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D187%26spage%3D5099%26epage%3D5113%26doi%3D10.4049%2Fjimmunol.1002697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunzmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissinger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruediger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tony, H. P.</span></span> <span> </span><span class="NLM_article-title">Gammadelta T cells for immune therapy of patients with lymphoid malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">200</span>â <span class="NLM_lpage">206</span>, <span class="refDoi">Â DOI: 10.1182/blood-2002-12-3665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1182%2Fblood-2002-12-3665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=12623838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltFemurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=200-206&author=M.+Wilhelmauthor=V.+Kunzmannauthor=S.+Ecksteinauthor=P.+Reimerauthor=F.+Weissingerauthor=T.+Ruedigerauthor=H.+P.+Tony&title=Gammadelta+T+cells+for+immune+therapy+of+patients+with+lymphoid+malignancies&doi=10.1182%2Fblood-2002-12-3665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Î³Î´ T cells for immune therapy of patients with lymphoid malignancies</span></div><div class="casAuthors">Wilhelm, Martin; Kunzmann, Volker; Eckstein, Susanne; Reimer, Peter; Weissinger, Florian; Ruediger, Thomas; Tony, Hans-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">200-206</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">There is increasing evidence that Î³Î´ T cells have potent innate antitumor activity.  We described previously that synthetic aminobisphosphonates are potent Î³Î´ T cell stimulatory compds. that induce cytokine secretion (ie, interferon Î³ [IFN-Î³]) and cell-mediated cytotoxicity against lymphoma and myeloma cell lines in vitro.  To evaluate the antitumor activity of Î³Î´ T cells in vivo, we initiated a pilot study of low-dose interleukin 2 (IL-2) in combination with pamidronate in 19 patients with relapsed/refractory low-grade non-Hodgkin lymphoma (NHL) or multiple myeloma (MM).  The objectives of this trial were to det. toxicity, the most ED for in vivo activation/proliferation of Î³Î´ T cells, and antilymphoma efficacy of the combination of pamidronate and IL-2.  The first 10 patients (cohort A) who entered the study received 90 mg pamidronate i.v. on day 1 followed by increasing dose levels of continuous 24-h i.v. (IV) infusions of IL-2 (0.25 to 3Ã106 IU/m2) from day 3 to day 8.  Even at the highest IL-2 dose level in vivo, Î³Î´ T-cell activation/proliferation and response to treatment were disappointing with only 1 patient achieving stable disease.  Therefore, the next 9 patients were selected by pos. in vitro proliferation of Î³Î´ T cells in response to pamidronate/IL-2 and received a modified treatment schedule (6-h bolus IV IL-2 infusions from day 1-6).  In this patient group (cohort B), significant in vivo activation/proliferation of Î³Î´ T cells was obsd. in 5 patients (55%), and objective responses (PR) were achieved in 3 patients (33%).  Only patients with significant in vivo proliferation of Î³Î´ T cells responded to treatment, indicating that Î³Î´ T cells might contribute to this antilymphoma effect.  Overall, administration of pamidronate and low-dose IL-2 was well tolerated.  In conclusion, this clin. trial demonstrates, for the first time, that Î³Î´ T-cell-mediated immunotherapy is feasible and can induce objective tumor responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptCr_pzMH80rVg90H21EOLACvtfcHk0lh-L7X3yzODCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltFemurk%253D&md5=bb25a24f96a289c59d3419836682bcec</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-12-3665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-12-3665%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DM.%26aulast%3DKunzmann%26aufirst%3DV.%26aulast%3DEckstein%26aufirst%3DS.%26aulast%3DReimer%26aufirst%3DP.%26aulast%3DWeissinger%26aufirst%3DF.%26aulast%3DRuediger%26aufirst%3DT.%26aulast%3DTony%26aufirst%3DH.%2BP.%26atitle%3DGammadelta%2520T%2520cells%2520for%2520immune%2520therapy%2520of%2520patients%2520with%2520lymphoid%2520malignancies%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D200%26epage%3D206%26doi%3D10.1182%2Fblood-2002-12-3665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sicard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Saati, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delsol, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FourniÃ©, J.-J. J. M. M.</span></span> <span> </span><span class="NLM_article-title">Synthetic phosphoantigens enhance human V Î³ 9V Î´ 2 T lymphocytes killing of non-odgkinâs B lymphoma</span>. <i>Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">711</span>, <span class="refDoi">Â DOI: 10.1007/BF03401961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1007%2FBF03401961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=11713370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt12lu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=711&author=H.+Sicardauthor=T.+Al+Saatiauthor=G.+Delsolauthor=J.-J.+J.+M.+M.+Fourni%C3%A9&title=Synthetic+phosphoantigens+enhance+human+V+%CE%B3+9V+%CE%B4+2+T+lymphocytes+killing+of+non-odgkin%E2%80%99s+B+lymphoma&doi=10.1007%2FBF03401961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic phosphoantigens enhance human VÎ³9VÎ´2 T lymphocytes killing of non-Hodgkin's B lymphoma</span></div><div class="casAuthors">Sicard, Helene; Saati, Talal Al; Delsol, Georges; Fournie, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine (Baltimore, MD, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">711-722</span>CODEN:
                <span class="NLM_cas:coden">MOMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1076-1551</span>.
    
            (<span class="NLM_cas:orgname">Johns Hopkins University Press</span>)
        </div><div class="casAbstract">Background: Non-Hodgkin's B lymphomas (NHL) are often resistant to conventional treatments and, until now, immunotherapeutic approaches against NHL only aimed at inducing Î±Î² anti-tumor effectors.  Nevertheless, human blood VÎ³9VÎ´2 T lymphocytes represent an abundant pool of cytotoxic tumor-reactive cells.  VÎ³9VÎ´2 T cells are strongly activated by natural compds., from which powerful synthetic ligands have been derived.  These synthetic antigens induce efficient VÎ³9VÎ´2 T cell responses in vitro.  Materials and Methods: the authors set up a series of VÎ³9VÎ´2 T cell-activation expts., including cytotoxic activity and amplification from whole blood cells.  Several types of VÎ³9VÎ´2 effectors were challenged against a panel of 16 B lymphoma cell lines.  These tests have been performed in the absence and presence of Î³Î´-specific synthetic ligands to evaluate the effect of such mols. on Î³Î´ anti-tumor activity.  Results: the authors report here that VÎ³9VÎ´2 T cells recognize B lymphomas.  This recognition is assocd. with the cytotoxic activity against B-lymphoma cells and/or proliferative responses, and appears to be T-cell antigen receptor (TCR)-dependent.  Because few B lymphoma induce a complete set of VÎ³9VÎ´2 cell responses, a chem. ligand of VÎ³9VÎ´2 T cells was used to enhance both proliferation and cytotoxic activity of anti-B lymphoma effectors.  The authors show that such synthetic compd. improves VÎ³9VÎ´2 CTL nos. and lysis of B lymphoma lines, esp. when the targets are already spontaneously recognized by these effectors.  Conclusions: the authors report here that human VÎ³9VÎ´2 T cells anti-B lymphoma response can be improved by use of specific synthetic ligands, which enhance their cytotoxic activity and allows their rapid expansion ex vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFLDw8cfbQG7Vg90H21EOLACvtfcHk0lh-L7X3yzODCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt12lu7w%253D&md5=0d337ed13a26e6bf2b906625bdd60c28</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2FBF03401961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03401961%26sid%3Dliteratum%253Aachs%26aulast%3DSicard%26aufirst%3DH.%26aulast%3DAl%2BSaati%26aufirst%3DT.%26aulast%3DDelsol%26aufirst%3DG.%26aulast%3DFourni%25C3%25A9%26aufirst%3DJ.-J.%2BJ.%2BM.%2BM.%26atitle%3DSynthetic%2520phosphoantigens%2520enhance%2520human%2520V%2520%25CE%25B3%25209V%2520%25CE%25B4%25202%2520T%2520lymphocytes%2520killing%2520of%2520non-odgkin%25E2%2580%2599s%2520B%2520lymphoma%26jtitle%3DMol.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D711%26doi%3D10.1007%2FBF03401961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooff, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strandjord, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igbavboa, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volmer, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, W. G.</span></span> <span> </span><span class="NLM_article-title">Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">251</span>â <span class="NLM_lpage">257</span>, <span class="refDoi">Â DOI: 10.1016/j.nbd.2009.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.nbd.2009.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=19464372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCgt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=251-257&author=G.+P.+Eckertauthor=G.+P.+Hooffauthor=D.+M.+Strandjordauthor=U.+Igbavboaauthor=D.+A.+Volmerauthor=W.+E.+Mullerauthor=W.+G.+Wood&title=Regulation+of+the+brain+isoprenoids+farnesyl-+and+geranylgeranylpyrophosphate+is+altered+in+male+Alzheimer+patients&doi=10.1016%2Fj.nbd.2009.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients</span></div><div class="casAuthors">Eckert, Gunter P.; Hooff, Gero P.; Strandjord, Dana M.; Igbavboa, Urule; Volmer, Dietrich A.; Mueller, Walter E.; Wood, W. Gibson</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-257</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Post-translational modification of small GTPases by farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP) has generated much attention due to their potential contribution to cancer, cardiovascular and neurodegenerative diseases.  Prenylated proteins have been identified in numerous cell functions and elevated levels of FPP and GGPP have been previously proposed to occur in Alzheimer disease (AD) but have never been quantified.  In the present study, we detd. if the mevalonate derived compds. FPP and GGPP are increased in brain gray and white matter of male AD patients as compared with control samples.  This study demonstrates for the first time that FPP and GGPP levels are significantly elevated in human AD gray and white matter but not cholesterol, indicating a potentially disease-specific targeting of isoprenoid regulation independent of HMG-CoA-reductase.  Further suggesting a selective disruption of FPP and GGPP homeostasis in AD, we show that inhibition of HMG-CoA reductase in vivo significantly reduced FPP, GGPP and cholesterol abundance in mice with the largest effect on the isoprenoids.  A tentative conclusion is that if indeed regulation of FPP and GGPP is altered in AD brain such changes may stimulate protein prenylation and contribute to AD neuropathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkBOXbLdprrrVg90H21EOLACvtfcHk0ljXnCPZ5V0PRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCgt7g%253D&md5=e1287530d7d10a29ec21bc81047b1e9d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2009.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2009.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DEckert%26aufirst%3DG.%2BP.%26aulast%3DHooff%26aufirst%3DG.%2BP.%26aulast%3DStrandjord%26aufirst%3DD.%2BM.%26aulast%3DIgbavboa%26aufirst%3DU.%26aulast%3DVolmer%26aufirst%3DD.%2BA.%26aulast%3DMuller%26aufirst%3DW.%2BE.%26aulast%3DWood%26aufirst%3DW.%2BG.%26atitle%3DRegulation%2520of%2520the%2520brain%2520isoprenoids%2520farnesyl-%2520and%2520geranylgeranylpyrophosphate%2520is%2520altered%2520in%2520male%2520Alzheimer%2520patients%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2009%26volume%3D35%26spage%3D251%26epage%3D257%26doi%3D10.1016%2Fj.nbd.2009.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hooff, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, G. P.</span></span> <span> </span><span class="NLM_article-title">Isoprenoids, small GTPases and Alzheimerâs disease</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1801</i></span>,  <span class="NLM_fpage">896</span>â <span class="NLM_lpage">905</span>, <span class="refDoi">Â DOI: 10.1016/j.bbalip.2010.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.bbalip.2010.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=20382260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlags7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1801&publication_year=2010&pages=896-905&author=G.+P.+Hooffauthor=W.+G.+Woodauthor=W.+E.+Mullerauthor=G.+P.+Eckert&title=Isoprenoids%2C+small+GTPases+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.bbalip.2010.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Isoprenoids, small GTPases and Alzheimer's disease</span></div><div class="casAuthors">Hooff, Gero P.; Wood, W. Gibson; Mueller, Walter E.; Eckert, Gunter P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1801</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">896-905</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  The mevalonate pathway is a crucial metabolic pathway for most eukaryotic cells.  Cholesterol is a highly recognized product of this pathway but growing interest is being given to the synthesis and functions of isoprenoids.  Isoprenoids are a complex class of biol. active lipids including for example, dolichol, ubiquinone, farnesylpyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).  Early work had shown that the long-chain isoprenoid dolichol is decreased but that dolichyl phosphate and ubiquinone are elevated in brains of Alzheimer's disease (AD) patients.  Until recently, levels of their biol. active precursors FPP and GGPP were unknown.  These short-chain isoprenoids are crit. in the post-translational modification of certain proteins which function as mol. switches in numerous signaling pathways.  The major protein families belong to the superfamily of small GTPases, consisting of roughly 150 members.  Recent exptl. evidence indicated that members of the small GTPases are involved in AD pathogenesis and stimulated interest in the role of FPP and GGPP in protein prenylation and cell function.  A straightforward prediction derived from those studies was that FPP and GGPP levels would be elevated in AD brains as compared with normal neurol. controls.  For the first time, recent evidence shows significantly elevated levels of FPP and GGPP in human AD brain tissue.  Cholesterol levels did not differ between AD and control samples.  One obvious conclusion is that homeostasis of FPP and GGPP but not of cholesterol is specifically targeted in AD.  Since prenylation of small GTPases by FPP or GGPP is indispensable for their proper function we are proposing that these two isoprenoids are up-regulated in AD resulting in an over abundance of certain prenylated proteins which contributes to neuronal dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAA62l3GNXHrVg90H21EOLACvtfcHk0ljXnCPZ5V0PRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlags7k%253D&md5=ed5c6f229ce35b2e2a0948fdf33c094e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2010.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2010.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DHooff%26aufirst%3DG.%2BP.%26aulast%3DWood%26aufirst%3DW.%2BG.%26aulast%3DMuller%26aufirst%3DW.%2BE.%26aulast%3DEckert%26aufirst%3DG.%2BP.%26atitle%3DIsoprenoids%252C%2520small%2520GTPases%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2010%26volume%3D1801%26spage%3D896%26epage%3D905%26doi%3D10.1016%2Fj.bbalip.2010.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlineritsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoeger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luschin-Ebengreuth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poestlberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidtmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">62-Month follow-up of ABCSG-12: adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer</span>. <i>Bone</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">S17</span>â <span class="NLM_lpage">S17</span>, <span class="refDoi">Â DOI: 10.1016/j.bone.2010.10.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.bone.2010.10.045" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2011&pages=S17-S17&author=M.+Gnantauthor=B.+Mlineritschauthor=H.+Stoegerauthor=G.+Luschin-Ebengreuthauthor=S.+Poestlbergerauthor=G.+Stegerauthor=R.+Jakeszauthor=C.+Singerauthor=H.+Eidtmannauthor=R.+Greil&title=62-Month+follow-up+of+ABCSG-12%3A+adjuvant+endocrine+therapy%2C+alone+or+in+combination+with+zoledronic+acid%2C+in+premenopausal+patients+with+endocrine-responsive+early+breast+cancer&doi=10.1016%2Fj.bone.2010.10.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bone.2010.10.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bone.2010.10.045%26sid%3Dliteratum%253Aachs%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DMlineritsch%26aufirst%3DB.%26aulast%3DStoeger%26aufirst%3DH.%26aulast%3DLuschin-Ebengreuth%26aufirst%3DG.%26aulast%3DPoestlberger%26aufirst%3DS.%26aulast%3DSteger%26aufirst%3DG.%26aulast%3DJakesz%26aufirst%3DR.%26aulast%3DSinger%26aufirst%3DC.%26aulast%3DEidtmann%26aufirst%3DH.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3D62-Month%2520follow-up%2520of%2520ABCSG-12%253A%2520adjuvant%2520endocrine%2520therapy%252C%2520alone%2520or%2520in%2520combination%2520with%2520zoledronic%2520acid%252C%2520in%2520premenopausal%2520patients%2520with%2520endocrine-responsive%2520early%2520breast%2520cancer%26jtitle%3DBone%26date%3D2011%26volume%3D48%26spage%3DS17%26epage%3DS17%26doi%3D10.1016%2Fj.bone.2010.10.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlineritsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoeger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luschin-Ebengreuth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pristauz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauernhofer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidtmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwasny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochreiner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsthuber, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">631</span>â <span class="NLM_lpage">641</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(11)70122-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2FS1470-2045%2811%2970122-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=21641868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXot1ejtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=631-641&author=M.+Gnantauthor=B.+Mlineritschauthor=H.+Stoegerauthor=G.+Luschin-Ebengreuthauthor=D.+Heckauthor=C.+Menzelauthor=R.+Jakeszauthor=M.+Seifertauthor=M.+Hubalekauthor=G.+Pristauzauthor=T.+Bauernhoferauthor=H.+Eidtmannauthor=W.+Eiermannauthor=G.+Stegerauthor=W.+Kwasnyauthor=P.+Dubskyauthor=G.+Hochreinerauthor=E.+P.+Forsthuberauthor=C.+Feslauthor=R.+Greil&title=Adjuvant+endocrine+therapy+plus+zoledronic+acid+in+premenopausal+women+with+early-stage+breast+cancer%3A+62-month+follow-up+from+the+ABCSG-12+randomised+trial&doi=10.1016%2FS1470-2045%2811%2970122-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial</span></div><div class="casAuthors">Gnant, Michael; Mlineritsch, Brigitte; Stoeger, Herbert; Luschin-Ebengreuth, Gero; Heck, Dietmar; Menzel, Christian; Jakesz, Raimund; Seifert, Michael; Hubalek, Michael; Pristauz, Gunda; Bauernhofer, Thomas; Eidtmann, Holger; Eiermann, Wolfgang; Steger, Guenther; Kwasny, Werner; Dubsky, Peter; Hochreiner, Gerhard; Forsthuber, Ernst-Pius; Fesl, Christian; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-641</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Anal. of the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) at 48 mo' follow-up showed that addn. of zoledronic acid to adjuvant endocrine therapy significantly improved disease-free survival.  We have now assessed long-term clin. efficacy including disease-free survival and disease outcomes in patients receiving anastrozole or tamoxifen with or without zoledronic acid.  ABSCG-12 is a randomised, controlled, open-label, two-by-two factorial, multicentre trial in 1803 premenopausal women with endocrine-receptor-pos. early-stage (stage I-II) breast cancer receiving goserelin (3.6 mg every 28 days), comparing the efficacy and safety of anastrozole (1 mg per day) or tamoxifen (20 mg per day) with or without zoledronic acid (4 mg every 6 mo) for 3 years.  Randomisation (1:1:1:1 ratio) was computerized and based on the Pocock and Simon minimisation method to balance the four treatment arms across eight prognostic variables (age, neoadjuvant chemotherapy, pathol. tumor stage; lymph-node involvement, type of surgery or locoregional therapy, complete axillary dissection, intraoperative radiation therapy, and geog. region).  Treatment allocation was not masked.  The primary endpoint was disease-free survival (defined as disease recurrence or death) and anal. was by intention to treat.  This trial is registered with ClinicalTrials.gov, no. NCT00295646; follow-up is ongoing.  At a median follow-up of 62 mo (range 0-114.4 mo), more than 2 years after treatment completion, 186 disease-free survival events had been reported (53 events in 450 patients on tamoxifen alone, 57 in 453 patients on anastrozole alone, 36 in 450 patients on tamoxifen plus zoledronic acid, and 40 in 450 patients on anastrozole plus zoledronic acid).  Zoledronic acid reduced risk of disease-free survival events overall (HR 0.68, 95% CI 0.51-0.91; p=0.009), although the difference was not significant in the tamoxifen (HR 0.67, 95% CI 0.44-1.03; p=0.067) and anastrozole arms (HR 0.68, 95% CI 0.45-1.02; p=0.061) assessed sep.  Zoledronic acid did not significantly affect risk of death (30 deaths with zoledronic acid vs 43 deaths without; HR 0.67, 95% CI 0.41-1.07; p=0.09).  There was no difference in disease-free survival between patients on tamoxifen alone vs. anastrozole alone (HR 1.08, 95% CI 0.81-1.44; p=0.591), but overall survival was worse with anastrozole than with tamoxifen (46 vs 27 deaths; HR 1.75, 95% CI 1.08-2.83; p=0.02).  Treatments were generally well tolerated, with no reports of renal failure or osteonecrosis of the jaw.  Bone pain was reported in 601 patients (33%; 349 patients on zoledronic acid vs 252 not on the drug), fatigue in 361 (20%; 192 vs 169), headache in 280 (16%; 147 vs 133), and arthralgia in 266 (15%; 145 vs 121).  Addn. of zoledronic acid improved disease-free survival in the patients taking anastrozole or tamoxifen.  There was no difference in disease-free survival between patients receiving anastrozole and tamoxifen overall, but those on anastrozole alone had inferior overall survival.  These data show persistent benefits with zoledronic acid and support its addn. to adjuvant endocrine therapy in premenopausal patients with early-stage breast cancer.  Funding: AstraZeneca; Novartis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgMLLmua064rVg90H21EOLACvtfcHk0ljXnCPZ5V0PRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXot1ejtLc%253D&md5=4755e1a85528b14accc4cc95bfa3d6b3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970122-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970122-X%26sid%3Dliteratum%253Aachs%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DMlineritsch%26aufirst%3DB.%26aulast%3DStoeger%26aufirst%3DH.%26aulast%3DLuschin-Ebengreuth%26aufirst%3DG.%26aulast%3DHeck%26aufirst%3DD.%26aulast%3DMenzel%26aufirst%3DC.%26aulast%3DJakesz%26aufirst%3DR.%26aulast%3DSeifert%26aufirst%3DM.%26aulast%3DHubalek%26aufirst%3DM.%26aulast%3DPristauz%26aufirst%3DG.%26aulast%3DBauernhofer%26aufirst%3DT.%26aulast%3DEidtmann%26aufirst%3DH.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DSteger%26aufirst%3DG.%26aulast%3DKwasny%26aufirst%3DW.%26aulast%3DDubsky%26aufirst%3DP.%26aulast%3DHochreiner%26aufirst%3DG.%26aulast%3DForsthuber%26aufirst%3DE.%2BP.%26aulast%3DFesl%26aufirst%3DC.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DAdjuvant%2520endocrine%2520therapy%2520plus%2520zoledronic%2520acid%2520in%2520premenopausal%2520women%2520with%2520early-stage%2520breast%2520cancer%253A%252062-month%2520follow-up%2520from%2520the%2520ABCSG-12%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D631%26epage%3D641%26doi%3D10.1016%2FS1470-2045%2811%2970122-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valachis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nearchou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyzos, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lind, P. A.</span></span> <span> </span><span class="NLM_article-title">Adjuvant therapy with zoledronic acid in primary breast cancer: a systematic review and meta-analysis</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">S377</span>â <span class="NLM_lpage">S377</span>, <span class="refDoi">Â DOI: 10.1016/S0959-8049(11)71599-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2FS0959-8049%2811%2971599-4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=S377-S377&author=A.+Valachisauthor=A.+Nearchouauthor=N.+P.+Polyzosauthor=D.+Mauriauthor=P.+A.+Lind&title=Adjuvant+therapy+with+zoledronic+acid+in+primary+breast+cancer%3A+a+systematic+review+and+meta-analysis&doi=10.1016%2FS0959-8049%2811%2971599-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2811%2971599-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252811%252971599-4%26sid%3Dliteratum%253Aachs%26aulast%3DValachis%26aufirst%3DA.%26aulast%3DNearchou%26aufirst%3DA.%26aulast%3DPolyzos%26aufirst%3DN.%2BP.%26aulast%3DMauri%26aufirst%3DD.%26aulast%3DLind%26aufirst%3DP.%2BA.%26atitle%3DAdjuvant%2520therapy%2520with%2520zoledronic%2520acid%2520in%2520primary%2520breast%2520cancer%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2011%26volume%3D47%26spage%3DS377%26epage%3DS377%26doi%3D10.1016%2FS0959-8049%2811%2971599-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szubert, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drayson, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Child, J. A.</span></span> <span> </span><span class="NLM_article-title">Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">5374</span>â <span class="NLM_lpage">5383</span>, <span class="refDoi">Â DOI: 10.1182/blood-2011-11-392522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1182%2Fblood-2011-11-392522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=22498739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFantLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=5374-5383&author=G.+J.+Morganauthor=F.+E.+Daviesauthor=W.+M.+Gregoryauthor=A.+J.+Szubertauthor=S.+E.+Bellauthor=M.+T.+Draysonauthor=R.+G.+Owenauthor=A.+J.+Ashcroftauthor=G.+H.+Jacksonauthor=J.+A.+Child&title=Effects+of+induction+and+maintenance+plus+long-term+bisphosphonates+on+bone+disease+in+patients+with+multiple+myeloma%3A+the+Medical+Research+Council+Myeloma+IX+Trial&doi=10.1182%2Fblood-2011-11-392522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial</span></div><div class="casAuthors">Morgan, Gareth J.; Davies, Faith E.; Gregory, Walter M.; Szubert, Alex J.; Bell, Sue E.; Drayson, Mark T.; Owen, Roger G.; Ashcroft, A. John; Jackson, Graham H.; Child, J. Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5374-5383</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examd. traditional and thalidomide-based induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly diagnosed multiple myeloma.  Overall survival (OS) and skeletal-related event (SRE) data have been reported for the overall trial population.  The present anal. investigated optimal therapy regimens for different patient populations in Myeloma IX.  Patients were assigned to intensive or nonintensive treatment pathways and randomized to induction cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) vs. cyclophosphamide, thalidomide, and dexamethasone (CTD; intensive) or melphalan and prednisolone vs. attenuated oral CTD (CTDa; nonintensive).  Patients were also randomized to ZOL or CLO.  In the nonintensive pathway, CTDa produced better responses and lower SRE rates than melphalan and prednisolone.  ZOL improved OS compared with CLO independently of sex, stage, or myeloma subtype, most profoundly in patients with baseline bone disease or other SREs.  In patients treated for â¥ 2 years, ZOL improved OS compared with CLO from randomization (median not reached for either; P = .02) and also from first on-study disease progression (median, 34 mo for ZOL vs 27 mo for CLO; P = .03).  Thalidomide-contg. regimens had better efficacy than traditional regimens, and ZOL demonstrated greater benefits than CLO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn6bsYwhGflrVg90H21EOLACvtfcHk0limm8gB3VZy1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFantLg%253D&md5=b908fa4236bbad0d7585647e43a02fbf</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-11-392522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-11-392522%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DG.%2BJ.%26aulast%3DDavies%26aufirst%3DF.%2BE.%26aulast%3DGregory%26aufirst%3DW.%2BM.%26aulast%3DSzubert%26aufirst%3DA.%2BJ.%26aulast%3DBell%26aufirst%3DS.%2BE.%26aulast%3DDrayson%26aufirst%3DM.%2BT.%26aulast%3DOwen%26aufirst%3DR.%2BG.%26aulast%3DAshcroft%26aufirst%3DA.%2BJ.%26aulast%3DJackson%26aufirst%3DG.%2BH.%26aulast%3DChild%26aufirst%3DJ.%2BA.%26atitle%3DEffects%2520of%2520induction%2520and%2520maintenance%2520plus%2520long-term%2520bisphosphonates%2520on%2520bone%2520disease%2520in%2520patients%2520with%2520multiple%2520myeloma%253A%2520the%2520Medical%2520Research%2520Council%2520Myeloma%2520IX%2520Trial%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D5374%26epage%3D5383%26doi%3D10.1182%2Fblood-2011-11-392522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlineritsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schippinger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luschin-Ebengreuth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postlberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjelic-Radisic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samonigg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tausch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidtmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwasny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stierer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucklinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">Endocrine therapy plus zoledronic acid in premenopausal breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">679</span>â <span class="NLM_lpage">691</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa0806285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1056%2FNEJMoa0806285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=19213681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVyisbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=679-691&author=M.+Gnantauthor=B.+Mlineritschauthor=W.+Schippingerauthor=G.+Luschin-Ebengreuthauthor=S.+Postlbergerauthor=C.+Menzelauthor=R.+Jakeszauthor=M.+Seifertauthor=M.+Hubalekauthor=V.+Bjelic-Radisicauthor=H.+Samoniggauthor=C.+Tauschauthor=H.+Eidtmannauthor=G.+Stegerauthor=W.+Kwasnyauthor=P.+Dubskyauthor=M.+Fridrikauthor=F.+Fitzalauthor=M.+Stiererauthor=E.+Rucklingerauthor=R.+Greil&title=Endocrine+therapy+plus+zoledronic+acid+in+premenopausal+breast+cancer&doi=10.1056%2FNEJMoa0806285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine therapy plus zoledronic acid in premenopausal breast cancer</span></div><div class="casAuthors">Gnant, Michael; Mlineritsch, Brigitte; Schippinger, Walter; Luschin-Ebengreuth, Gero; Postlberger, Sabine; Menzel, Christian; Jakesz, Raimund; Seifert, Michael; Hubalek, Michael; Bjelic-Radisic, Vesna; Samonigg, Hellmut; Tausch, Christoph; Eidtmann, Holger; Steger, Gunther; Kwasny, Werner; Dubsky, Peter; Fridrik, Michael; Fitzal, Florian; Stierer, Michael; Rucklinger, Ernst; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">679-691</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ovarian suppression plus tamoxifen is a std. adjuvant treatment in premenopausal women with endocrine-responsive breast cancer.  Aromatase inhibitors are superior to tamoxifen in postmenopausal patients, and preclin. data suggest that zoledronic acid has antitumor properties.  We examd. the effect of adding zoledronic acid to a combination of either goserelin and tamoxifen or goserelin and anastrozole in premenopausal women with endocrine-responsive early breast cancer.  We randomly assigned 1803 patients to receive goserelin (3.6 mg given s.c. every 28 days) plus tamoxifen (20 mg per day given orally) or anastrozole (1 mg per day given orally) with or without zoledronic acid (4 mg given i.v. every 6 mo) for 3 years.  The primary end point was disease-free survival; recurrence-free survival and overall survival were secondary end points.  After a median follow-up of 47.8 mo, 137 events had occurred, with disease-free survival rates of 92.8% in the tamoxifen group, 92.0% in the anastrozole group, 90.8% in the group that received endocrine therapy alone, and 94.0% in the group that received endocrine therapy with zoledronic acid.  There was no significant difference in disease-free survival between the anastrozole and tamoxifen groups (hazard ratio for disease progression in the anastrozole group, 1.10; 95% confidence interval [CI], 0.78 to 1.53; P = 0.59).  The addn. of zoledronic acid to endocrine therapy, as compared with endocrine therapy without zoledronic acid, resulted in an abs. redn. of 3.2 percentage points and a relative redn. of 36% in the risk of disease progression (hazard ratio, 0.64; 95% CI, 0.46 to 0.91; P = 0.01); the addn. of zoledronic acid did not significantly reduce the risk of death (hazard ratio, 0.60; 95% CI, 0.32 to 1.11; P = 0.11).  Adverse events were consistent with known drug-safety profiles.  The addn. of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWZL1vqoy7LVg90H21EOLACvtfcHk0limm8gB3VZy1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVyisbk%253D&md5=f2c9103a7cfd4b4d14bf30f8a2e679d7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0806285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0806285%26sid%3Dliteratum%253Aachs%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DMlineritsch%26aufirst%3DB.%26aulast%3DSchippinger%26aufirst%3DW.%26aulast%3DLuschin-Ebengreuth%26aufirst%3DG.%26aulast%3DPostlberger%26aufirst%3DS.%26aulast%3DMenzel%26aufirst%3DC.%26aulast%3DJakesz%26aufirst%3DR.%26aulast%3DSeifert%26aufirst%3DM.%26aulast%3DHubalek%26aufirst%3DM.%26aulast%3DBjelic-Radisic%26aufirst%3DV.%26aulast%3DSamonigg%26aufirst%3DH.%26aulast%3DTausch%26aufirst%3DC.%26aulast%3DEidtmann%26aufirst%3DH.%26aulast%3DSteger%26aufirst%3DG.%26aulast%3DKwasny%26aufirst%3DW.%26aulast%3DDubsky%26aufirst%3DP.%26aulast%3DFridrik%26aufirst%3DM.%26aulast%3DFitzal%26aufirst%3DF.%26aulast%3DStierer%26aufirst%3DM.%26aulast%3DRucklinger%26aufirst%3DE.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DEndocrine%2520therapy%2520plus%2520zoledronic%2520acid%2520in%2520premenopausal%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D679%26epage%3D691%26doi%3D10.1056%2FNEJMoa0806285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hellrieqel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baerens, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von der
Assen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baier-Ebert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emons, G.</span></span> <span> </span><span class="NLM_article-title">The EXpand study - effect of zoledronic acid on prevention of bone loss, during extended adjuvant therapy with letrozole in postmenopausal women with primary hormone receptor positive breast cancer compared to letrozole alone</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">S390</span>â <span class="NLM_lpage">S390</span>, <span class="refDoi">Â DOI: 10.1016/S0959-8049(11)71643-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2FS0959-8049%2811%2971643-4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=S390-S390&author=M.+Hellrieqelauthor=M.+Muellerauthor=T.+Reimerauthor=D.+T.+Baerensauthor=A.+von+der%0AAssenauthor=J.+Hackmannauthor=K.+Schmidtauthor=M.+Baier-Ebertauthor=T.+Spallauthor=G.+Emons&title=The+EXpand+study+-+effect+of+zoledronic+acid+on+prevention+of+bone+loss%2C+during+extended+adjuvant+therapy+with+letrozole+in+postmenopausal+women+with+primary+hormone+receptor+positive+breast+cancer+compared+to+letrozole+alone&doi=10.1016%2FS0959-8049%2811%2971643-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2811%2971643-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252811%252971643-4%26sid%3Dliteratum%253Aachs%26aulast%3DHellrieqel%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DM.%26aulast%3DReimer%26aufirst%3DT.%26aulast%3DBaerens%26aufirst%3DD.%2BT.%26aulast%3Dvon%2Bder%2BAssen%26aufirst%3DA.%26aulast%3DHackmann%26aufirst%3DJ.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DBaier-Ebert%26aufirst%3DM.%26aulast%3DSpall%26aufirst%3DT.%26aulast%3DEmons%26aufirst%3DG.%26atitle%3DThe%2520EXpand%2520study%2520-%2520effect%2520of%2520zoledronic%2520acid%2520on%2520prevention%2520of%2520bone%2520loss%252C%2520during%2520extended%2520adjuvant%2520therapy%2520with%2520letrozole%2520in%2520postmenopausal%2520women%2520with%2520primary%2520hormone%2520receptor%2520positive%2520breast%2520cancer%2520compared%2520to%2520letrozole%2520alone%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2011%26volume%3D47%26spage%3DS390%26epage%3DS390%26doi%3D10.1016%2FS0959-8049%2811%2971643-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocks, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szubert, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro-Coy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drayson, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roddie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Child, J. A.</span></span> <span> </span><span class="NLM_article-title">First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1989</span>â <span class="NLM_lpage">1999</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(10)62051-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2FS0140-6736%2810%2962051-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=21131037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFCqsLnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=1989-1999&author=G.+J.+Morganauthor=F.+E.+Daviesauthor=W.+M.+Gregoryauthor=K.+Cocksauthor=S.+E.+Bellauthor=A.+J.+Szubertauthor=N.+Navarro-Coyauthor=M.+T.+Draysonauthor=R.+G.+Owenauthor=S.+Feylerauthor=A.+J.+Ashcroftauthor=F.+Rossauthor=J.+Byrneauthor=H.+Roddieauthor=C.+Rudinauthor=G.+Cookauthor=G.+H.+Jacksonauthor=J.+A.+Child&title=First-line+treatment+with+zoledronic+acid+as+compared+with+clodronic+acid+in+multiple+myeloma+%28MRC+Myeloma+IX%29%3A+a+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2810%2962051-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial</span></div><div class="casAuthors">Morgan, Gareth J.; Davies, Faith E.; Gregory, Walter M.; Cocks, Kim; Bell, Sue E.; Szubert, Alex J.; Navarro-Coy, Nuria; Drayson, Mark T.; Owen, Roger G.; Feyler, Sylvia; Ashcroft, A. John; Ross, Fiona; Byrne, Jennifer; Roddie, Huw; Rudin, Claudius; Cook, Gordon; Jackson, Graham H.; Child, J. Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9757</span>),
    <span class="NLM_cas:pages">1989-1999</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclin. and clin. studies.  We aimed to establish whether bisphosphonates can affect clin. outcomes in patients with multiple myeloma.  Patients of age 18 years or older with newly diagnosed multiple myeloma were enrolled from 120 centers in the UK.  Computer-generated randomisation sequence was used to allocate patients equally, via an automated telephone service, to receive 4 mg zoledronic acid as an infusion every 3-4 wk or 1600 mg oral clodronic acid daily.  Patients also received intensive or non-intensive induction chemotherapy.  No investigators, staff, or patients were masked to treatment allocation, and bisphosphonate and maintenance therapy continued at least until disease progression.  The primary endpoints were overall survival, progression-free survival, and overall response rate.  We assessed between-group differences with Cox proportional hazards models for progression-free survival and overall survival, and with logistic regression models for overall response rate.  Anal. was by intention to treat.  This trial is registered, no. ISRCTN68454111.  1970 patients were enrolled between May, 2003, and Nov., 2007, of whom 1960 were eligible for intention-to-treat anal.: 981 in the zoledronic acid group (555 on intensive chemotherapy, 426 on non-intensive chemotherapy); and 979 on clodronic acid (556 on intensive chemotherapy, 423 on non-intensive chemotherapy).  The treatment cutoff was Oct 5, 2009, with patients receiving bisphosphonates for a median of 350 days (IQR 137-632) before disease progression, with a median of 3.7 years' follow-up (IQR 2.9-4.7).  Zoledronic acid reduced mortality by 16% (95% CI 4-26) vs. clodronic acid (hazard ratio [HR] 0.84, 95% CI 0.74-0.96; p=0.0118), and extended median overall survival by 5.5 mo (50.0 mo, IQR 21.0 to not reached vs 44.5 mo, IQR 16.5 to not reached; p=0.04).  Zoledronic acid also significantly improved progression-free survival by 12% (95% CI 2-20) vs. clodronic acid (HR 0.88, 95% CI 0.80-0.98; p=0.0179), and increased median progression-free survival by 2.0 mo (19.5 mo, IQR 9.0-38.0 vs 17.5 mo, IQR 8.5-34.0; p=0.07).  Rates of complete, very good partial, or partial response did not differ significantly between the zoledronic acid and clodronic acid groups for patients receiving intensive induction chemotherapy (432 patients [78%] vs 422 [76%]; p=0.43) or non-intensive induction chemotherapy (215 [50%] vs 195 [46%]; p=0.18).  Both bisphosphonates were generally well tolerated, with similar occurrence of acute renal failure and treatment-emergent serious adverse events, but zoledronic acid was assocd. with higher rates of confirmed osteonecrosis of the jaw (35 [4%]) than was clodronic acid (3 [<1%]).  Consistent with the potential anticancer activity of zoledronic acid, overall survival improved independently of prevention of skeletal-related events, showing that zoledronic acid has treatment benefits beyond bone health.  These findings support immediate treatment with zoledronic acid in patients with newly diagnosed multiple myeloma, not only for prevention of skeletal-related events, but also for potential antimyeloma benefits.  Funding: Medical Research Council (London, UK), with unrestricted educational grants from Novartis, Schering Health Care, Chugai, Pharmion, Celgene, and Ortho Biotech.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXS5ilaeyX3rVg90H21EOLACvtfcHk0lhgg1emibXYog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFCqsLnL&md5=53e25efc3a82b57d286c73f7fba6a611</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2962051-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252962051-X%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DG.%2BJ.%26aulast%3DDavies%26aufirst%3DF.%2BE.%26aulast%3DGregory%26aufirst%3DW.%2BM.%26aulast%3DCocks%26aufirst%3DK.%26aulast%3DBell%26aufirst%3DS.%2BE.%26aulast%3DSzubert%26aufirst%3DA.%2BJ.%26aulast%3DNavarro-Coy%26aufirst%3DN.%26aulast%3DDrayson%26aufirst%3DM.%2BT.%26aulast%3DOwen%26aufirst%3DR.%2BG.%26aulast%3DFeyler%26aufirst%3DS.%26aulast%3DAshcroft%26aufirst%3DA.%2BJ.%26aulast%3DRoss%26aufirst%3DF.%26aulast%3DByrne%26aufirst%3DJ.%26aulast%3DRoddie%26aufirst%3DH.%26aulast%3DRudin%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DG.%26aulast%3DJackson%26aufirst%3DG.%2BH.%26aulast%3DChild%26aufirst%3DJ.%2BA.%26atitle%3DFirst-line%2520treatment%2520with%2520zoledronic%2520acid%2520as%2520compared%2520with%2520clodronic%2520acid%2520in%2520multiple%2520myeloma%2520%2528MRC%2520Myeloma%2520IX%2529%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D1989%26epage%3D1999%26doi%3D10.1016%2FS0140-6736%2810%2962051-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodwell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkinshaw, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grieve, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett-Lee, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, H.</span></span> <span> </span><span class="NLM_article-title">Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">429</span>â <span class="NLM_lpage">438</span>, <span class="refDoi">Â DOI: 10.1007/s10549-011-1429-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1007%2Fs10549-011-1429-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=21394500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Citbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2011&pages=429-438&author=R.+Colemanauthor=E.+Woodwardauthor=J.+Brownauthor=D.+Cameronauthor=R.+Bellauthor=D.+Dodwellauthor=M.+Keaneauthor=M.+Gilauthor=C.+Daviesauthor=R.+Burkinshawauthor=S.+J.+Houstonauthor=R.+J.+Grieveauthor=P.+J.+Barrett-Leeauthor=H.+Thorpe&title=Safety+of+zoledronic+acid+and+incidence+of+osteonecrosis+of+the+jaw+%28ONJ%29+during+adjuvant+therapy+in+a+randomised+phase+III+trial+%28AZURE%3A+BIG+01-04%29+for+women+with+stage+II%2FIII+breast+cancer&doi=10.1007%2Fs10549-011-1429-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer</span></div><div class="casAuthors">Coleman, R.; Woodward, E.; Brown, J.; Cameron, D.; Bell, R.; Dodwell, D.; Keane, M.; Gil, M.; Davies, C.; Burkinshaw, R.; Houston, S. J.; Grieve, R. J.; Barrett-Lee, P. J.; Thorpe, H.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">429-438</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The AZURE trial is an ongoing phase III, academic, multi-center, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer.  Here, we report the safety and tolerability profile of ZOL in this setting.  Eligible patients received (neo)adjuvant chemotherapy and/or endocrine therapy and were randomised to receive neither addnl. treatment nor i.v. ZOL 4 mg.  ZOL was administered after each chemotherapy cycle to exploit potential sequence-dependent synergy.  ZOL was continued for 60 mo post-randomisation (six doses in the first 6 mo, eight doses in the following 24 mo and five doses in the final 30 mo).  Serious (SAE) and non-serious adverse event (AE) data generated during the first 36 mo on study were analyzed for the safety population. 3,360 patients were recruited to the AZURE trial.  The safety population comprised 3,340 patients (ZOL 1,665; control 1,675).  The addn. of ZOL to std. treatment did not significantly impact on chemotherapy delivery.  SAE were similar in both treatment arms.  No significant safety differences were seen apart from the occurrence of osteonecrosis of the jaw (ONJ) in the ZOL group (11 confirmed cases; 0.7%; 95% confidence interval 0.3-1.1%).  ZOL in the adjuvant setting is well tolerated, and can be safely administered in addn. to adjuvant therapy including chemotherapy.  The adverse events were consistent with the known safety profile of ZOL, with a low incidence of ONJ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHOS2xzexrHLVg90H21EOLACvtfcHk0lhgg1emibXYog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Citbc%253D&md5=a3be69d7b9902510b10de77fb2db8243</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1429-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1429-y%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%26aulast%3DWoodward%26aufirst%3DE.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DCameron%26aufirst%3DD.%26aulast%3DBell%26aufirst%3DR.%26aulast%3DDodwell%26aufirst%3DD.%26aulast%3DKeane%26aufirst%3DM.%26aulast%3DGil%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DBurkinshaw%26aufirst%3DR.%26aulast%3DHouston%26aufirst%3DS.%2BJ.%26aulast%3DGrieve%26aufirst%3DR.%2BJ.%26aulast%3DBarrett-Lee%26aufirst%3DP.%2BJ.%26aulast%3DThorpe%26aufirst%3DH.%26atitle%3DSafety%2520of%2520zoledronic%2520acid%2520and%2520incidence%2520of%2520osteonecrosis%2520of%2520the%2520jaw%2520%2528ONJ%2529%2520during%2520adjuvant%2520therapy%2520in%2520a%2520randomised%2520phase%2520III%2520trial%2520%2528AZURE%253A%2520BIG%252001-04%2529%2520for%2520women%2520with%2520stage%2520II%252FIII%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D127%26spage%3D429%26epage%3D438%26doi%3D10.1007%2Fs10549-011-1429-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeddula, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, I. M.</span></span> <span> </span><span class="NLM_article-title">A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">263ra161</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3010382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1126%2Fscitranslmed.3010382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=25411474" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=263ra161&author=Y.+F.+Xiaauthor=Y.+L.+Liuauthor=Y.+H.+Xieauthor=W.+Zhuauthor=F.+Guerraauthor=S.+Shenauthor=N.+Yeddulaauthor=W.+G.+Fischerauthor=W.+Lowauthor=X.+Y.+Zhouauthor=Y.+H.+Zhangauthor=E.+Oldfieldauthor=I.+M.+Verma&title=A+combination+therapy+for+KRAS-driven+lung+adenocarcinomas+using+lipophilic+bisphosphonates+and+rapamycin&doi=10.1126%2Fscitranslmed.3010382"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3010382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3010382%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DY.%2BF.%26aulast%3DLiu%26aufirst%3DY.%2BL.%26aulast%3DXie%26aufirst%3DY.%2BH.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DGuerra%26aufirst%3DF.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DYeddula%26aufirst%3DN.%26aulast%3DFischer%26aufirst%3DW.%2BG.%26aulast%3DLow%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DX.%2BY.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DOldfield%26aufirst%3DE.%26aulast%3DVerma%26aufirst%3DI.%2BM.%26atitle%3DA%2520combination%2520therapy%2520for%2520KRAS-driven%2520lung%2520adenocarcinomas%2520using%2520lipophilic%2520bisphosphonates%2520and%2520rapamycin%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D263ra161%26doi%3D10.1126%2Fscitranslmed.3010382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotesta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinzik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelle, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitsch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roddy, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. R.</span></span> <span> </span><span class="NLM_article-title">Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">660</span>â <span class="NLM_lpage">666</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fnchembio.421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=20711197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaisLzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=660-666&author=W.+Jahnkeauthor=J.+M.+Rondeauauthor=S.+Cotestaauthor=A.+Marzinzikauthor=X.+Pelleauthor=M.+Geiserauthor=A.+Straussauthor=M.+Gotteauthor=F.+Bitschauthor=R.+Hemmigauthor=C.+Henryauthor=S.+Lehmannauthor=J.+F.+Glickmanauthor=T.+P.+Roddyauthor=S.+J.+Stoutauthor=J.+R.+Green&title=Allosteric+non-bisphosphonate+FPPS+inhibitors+identified+by+fragment-based+discovery&doi=10.1038%2Fnchembio.421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery</span></div><div class="casAuthors">Jahnke, Wolfgang; Rondeau, Jean-Michel; Cotesta, Simona; Marzinzik, Andreas; Pelle, Xavier; Geiser, Martin; Strauss, Andre; Goette, Marjo; Bitsch, Francis; Hemmig, Rene; Henry, Chrystele; Lehmann, Sylvie; Glickman, J. Fraser; Roddy, Thomas P.; Stout, Steven J.; Green, Jonathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">660-666</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bisphosphonates are potent inhibitors of farnesyl pyrophosphate synthase (FPPS) and are highly efficacious in the treatment of bone diseases such as osteoporosis, Paget's disease and tumor-induced osteolysis.  In addn., the potential for direct antitumor effects has been postulated on the basis of in vitro and in vivo studies and has recently been demonstrated clin. in early breast cancer patients treated with the potent bisphosphonate zoledronic acid.  However, the high affinity of bisphosphonates for bone mineral seems suboptimal for the direct treatment of soft-tissue tumors.  Here we report the discovery of the first potent non-bisphosphonate FPPS inhibitors.  These new inhibitors bind to a previously unknown allosteric site on FPPS, which was identified by fragment-based approaches using NMR and X-ray crystallog.  This allosteric and druggable pocket allows the development of a new generation of FPPS inhibitors that are optimized for direct antitumor effects in soft tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZFyA6x-XeY7Vg90H21EOLACvtfcHk0lhCR6rUU1uUAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaisLzO&md5=72e1bc45a05733c2748a2138d0e0824f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.421%26sid%3Dliteratum%253Aachs%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DRondeau%26aufirst%3DJ.%2BM.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DMarzinzik%26aufirst%3DA.%26aulast%3DPelle%26aufirst%3DX.%26aulast%3DGeiser%26aufirst%3DM.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DGotte%26aufirst%3DM.%26aulast%3DBitsch%26aufirst%3DF.%26aulast%3DHemmig%26aufirst%3DR.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DLehmann%26aufirst%3DS.%26aulast%3DGlickman%26aufirst%3DJ.%2BF.%26aulast%3DRoddy%26aufirst%3DT.%2BP.%26aulast%3DStout%26aufirst%3DS.%2BJ.%26aulast%3DGreen%26aufirst%3DJ.%2BR.%26atitle%3DAllosteric%2520non-bisphosphonate%2520FPPS%2520inhibitors%2520identified%2520by%2520fragment-based%2520discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D660%26epage%3D666%26doi%3D10.1038%2Fnchembio.421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCammon, J. A.</span></span> <span> </span><span class="NLM_article-title">Farnesyl diphosphate synthase inhibitors from in silico screening</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">742</span>â <span class="NLM_lpage">748</span>, <span class="refDoi">Â DOI: 10.1111/cbdd.12121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1111%2Fcbdd.12121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=23421555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptlOhs7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=742-748&author=S.+Lindertauthor=W.+Zhuauthor=Y.+L.+Liuauthor=R.+Pangauthor=E.+Oldfieldauthor=J.+A.+McCammon&title=Farnesyl+diphosphate+synthase+inhibitors+from+in+silico+screening&doi=10.1111%2Fcbdd.12121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyl diphosphate synthase inhibitors from in silico screening</span></div><div class="casAuthors">Lindert, Steffen; Zhu, Wei; Liu, Yi-Liang; Pang, Ran; Oldfield, Eric; McCammon, J. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">742-748</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The relaxed complex scheme is an in silico drug screening method that accounts for receptor flexibility using mol. dynamics simulations.  Here, we used this approach combined with similarity searches and exptl. inhibition assays to identify several low micromolar, non-bisphosphonate inhibitors, bisamidines, of farnesyl diphosphate synthase (FPPS), an enzyme targeted by some anticancer and antimicrobial agents and for the treatment of bone resorption diseases.  This novel class of farnesyl diphosphate synthase inhibitors have more drug-like properties than existing bisphosphonate inhibitors, making them interesting pharmaceutical leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb9blD2iTxOLVg90H21EOLACvtfcHk0lhCR6rUU1uUAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptlOhs7c%253D&md5=e7f1b923bdfd161dce4befe7e773463c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12121%26sid%3Dliteratum%253Aachs%26aulast%3DLindert%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%2BL.%26aulast%3DPang%26aufirst%3DR.%26aulast%3DOldfield%26aufirst%3DE.%26aulast%3DMcCammon%26aufirst%3DJ.%2BA.%26atitle%3DFarnesyl%2520diphosphate%2520synthase%2520inhibitors%2520from%2520in%2520silico%2520screening%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2013%26volume%3D81%26spage%3D742%26epage%3D748%26doi%3D10.1111%2Fcbdd.12121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span> <span> </span><span class="NLM_article-title">Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1840</i></span>,  <span class="NLM_fpage">1051</span>â <span class="NLM_lpage">1062</span>, <span class="refDoi">Â DOI: 10.1016/j.bbagen.2013.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.bbagen.2013.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=24246954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Gmt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1840&publication_year=2014&pages=1051-1062&author=J.+Liuauthor=W.+Liuauthor=H.+Geauthor=J.+Gaoauthor=Q.+Heauthor=L.+Suauthor=J.+Xuauthor=L.+Q.+Guauthor=Z.+S.+Huangauthor=D.+Li&title=Syntheses+and+characterization+of+non-bisphosphonate+quinoline+derivatives+as+new+FPPS+inhibitors&doi=10.1016%2Fj.bbagen.2013.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors</span></div><div class="casAuthors">Liu, Jinggong; Liu, Weilin; Ge, Hu; Gao, Jinbo; He, Qingqing; Su, Lijuan; Xu, Jun; Gu, Lian-quan; Huang, Zhi-shu; Li, Ding</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1840</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1051-1062</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background: Farnesyl pyrophosphate synthase (FPPS) is a key regulatory enzyme in the biosynthesis of cholesterol and in the post-translational modification of signaling proteins.  It has been reported that non-bisphosphonate FPPS inhibitors targeting its allosteric binding pocket are potentially important for the development of promising anti-cancer drugs.  Methods: The following methods were used: org. syntheses of non-bisphosphonate quinoline derivs., enzyme inhibition studies, fluorescence titrn. assays, synergistic effect studies of quinoline derivs. with zoledronate, ITC studies for the binding of FPPS with quinoline derivs., NMR-based HAP binding assays, mol. modeling studies, fluorescence imaging assay and MTT assays.  Results: We report our syntheses of a series of quinoline derivs. as new FPPS inhibitors possibly targeting the allosteric site of the enzyme.  Compd. 6b showed potent inhibition to FPPS without significant hydroxyapatite binding affinity.  The compd. showed synergistic inhibitory effect with active-site inhibitor zoledronate.  ITC expt. confirmed the good binding effect of compd. 6b to FPPS, and further indicated the binding ratio of 1:1.  Mol. modeling studies showed that 6b could possibly bind to the allosteric binding pocket of the enzyme.  The fluorescence microscopy indicated that these compds. could get into cancer cells.  Conclusions: Our results showed that quinoline deriv. 6b could become a new lead compd. for further optimization for cancer treatment.  General significance: The traditional FPPS active-site inhibitors bisphosphonates show poor membrane permeability to tumor cells, due to their strong polarity.  The development of new non-bisphosphonate FPPS inhibitors with good cell membrane permeability is potentially important.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGY0ZQ2_LQdLVg90H21EOLACvtfcHk0lh455484HknHQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Gmt74%253D&md5=ac2bf76352c08b6ccb8bddfe14a1e9df</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2013.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2013.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGe%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DSu%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DZ.%2BS.%26aulast%3DLi%26aufirst%3DD.%26atitle%3DSyntheses%2520and%2520characterization%2520of%2520non-bisphosphonate%2520quinoline%2520derivatives%2520as%2520new%2520FPPS%2520inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2014%26volume%3D1840%26spage%3D1051%26epage%3D1062%26doi%3D10.1016%2Fj.bbagen.2013.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCammon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Taxodione and arenarone inhibit farnesyl diphosphate synthase by binding to the isopentenyl diphosphate site</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">E2530</span>â <span class="NLM_lpage">2539</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1409061111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1073%2Fpnas.1409061111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=24927548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsValsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E2530-2539&author=Y.+L.+Liuauthor=S.+Lindertauthor=W.+Zhuauthor=K.+Wangauthor=J.+A.+McCammonauthor=E.+Oldfield&title=Taxodione+and+arenarone+inhibit+farnesyl+diphosphate+synthase+by+binding+to+the+isopentenyl+diphosphate+site&doi=10.1073%2Fpnas.1409061111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Taxodione and arenarone inhibit farnesyl diphosphate synthase by binding to the isopentenyl diphosphate site</span></div><div class="casAuthors">Liu, Yi-Liang; Lindert, Steffen; Zhu, Wei; Wang, Ke; McCammon, J. Andrew; Oldfield, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">E2530-E2539</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We used in silico methods to screen a library of 1,013 compds. for possible binding to the allosteric site in farnesyl diphosphate synthase (FPPS).  Two of the 50 predicted hits had activity against either human FPPS (HsFPPS) or Trypanosoma brucei FPPS (TbFPPS), the most active being the quinone methide celastrol (IC50 vs. TbFPPS â¼20 Î¼M).  Two rounds of similarity searching and activity testing then resulted in three leads that were active against HsFPPS with IC50 values in the range of â¼1-3 Î¼M (as compared with â¼0.5 Î¼M for the bisphosphonate inhibitor, zoledronate).  The three leads were the quinone methides taxodone and taxodione and the quinone arenarone, compds. with known antibacterial and/or antitumor activity.  We then obtained X-ray crystal structures of HsFPPS with taxodione+zoledronate, arenarone+zoledronate, and taxodione alone.  In the zoledronate-contg. structures, taxodione and arenarone bound solely to the homoallylic (isopentenyl diphosphate, IPP) site, not to the allosteric site, whereas zoledronate bound via Mg2+ to the same site as seen in other bisphosphonate-contg. structures.  In the taxodione-alone structure, one taxodione bound to the same site as seen in the taxodione+zoledronate structure, but the second located to a more surface-exposed site.  In differential scanning calorimetry expts., taxodione and arenarone broadened the native-to-unfolded thermal transition (Tm), quite different to the large increases in ÎTm seen with biphosphonate inhibitors.  The results identify new classes of FPPS inhibitors, diterpenoids and sesquiterpenoids, that bind to the IPP site and may be of interest as anticancer and antiinfective drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtuNMnxlrUELVg90H21EOLACvtfcHk0lh455484HknHQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsValsLY%253D&md5=1f6c5992bbf22c2ee6dcf678c34a9fff</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1409061111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1409061111%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BL.%26aulast%3DLindert%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DMcCammon%26aufirst%3DJ.%2BA.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DTaxodione%2520and%2520arenarone%2520inhibit%2520farnesyl%2520diphosphate%2520synthase%2520by%2520binding%2520to%2520the%2520isopentenyl%2520diphosphate%2520site%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3DE2530%26epage%3D2539%26doi%3D10.1073%2Fpnas.1409061111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">349</span>â <span class="NLM_lpage">354</span>, <span class="refDoi">Â DOI: 10.1021/ml500528x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500528x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeisb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=349-354&author=Y.+L.+Liuauthor=R.+Caoauthor=Y.+Wangauthor=E.+Oldfield&title=Farnesyl+diphosphate+synthase+inhibitors+with+unique+ligand-binding+geometries&doi=10.1021%2Fml500528x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyl Diphosphate Synthase Inhibitors With Unique Ligand-Binding Geometries</span></div><div class="casAuthors">Liu, Yi-Liang; Cao, Rong; Wang, Yang; Oldfield, Eric</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-354</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Farnesyl diphosphate synthase (FPPS) is an important drug target for bone resorption, cancer, and some infectious diseases.  Here, we report five new structures including two having unique bound ligand geometries.  The diamidine inhibitor 7 binds to human FPPS close to the homoallylic (S2) and allosteric (S3) sites and extends into a new site, here called S4.  With the bisphosphonate inhibitor 8, two mols. bind to Trypanosoma brucei FPPS, one mol. in the allylic site (S1) and the other close to S2, the first observation of two bisphosphonate mols. bound to FPPS.  We also report the structures of apo-FPPS from T. brucei, together with two more bisphosphonate-bound structures (2,9), for purposes of comparison.  The diamidine structure is of particular interest because 7 could represent a new lead for lipophilic FPPS inhibitors, while 8 has low micromolar activity against T. brucei, the causative agent of human African trypanosomiasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLFB2f4Alhi7Vg90H21EOLACvtfcHk0lh455484HknHQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeisb8%253D&md5=d531c00b4e036e8b7f39dafa6476ba46</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fml500528x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500528x%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BL.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DFarnesyl%2520diphosphate%2520synthase%2520inhibitors%2520with%2520unique%2520ligand-binding%2520geometries%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D349%26epage%3D354%26doi%3D10.1021%2Fml500528x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marzinzik, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amstutz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bold, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotesta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwieg, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ofner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelle, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roddy, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel allosteric non-bisphosphonate inhibitors of farnesyl pyrophosphate synthase by integrated lead finding</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1884</span>â <span class="NLM_lpage">1891</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201500338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1002%2Fcmdc.201500338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=26381451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWlsLnP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1884-1891&author=A.+L.+Marzinzikauthor=R.+Amstutzauthor=G.+Boldauthor=E.+Bourgierauthor=S.+Cotestaauthor=J.+F.+Glickmanauthor=M.+Gotteauthor=C.+Henryauthor=S.+Lehmannauthor=J.+C.+Hartwiegauthor=S.+Ofnerauthor=X.+Pelleauthor=T.+P.+Roddyauthor=J.+M.+Rondeauauthor=F.+Staufferauthor=S.+J.+Stoutauthor=A.+Widmerauthor=J.+Zimmermannauthor=T.+Zollerauthor=W.+Jahnke&title=Discovery+of+novel+allosteric+non-bisphosphonate+inhibitors+of+farnesyl+pyrophosphate+synthase+by+integrated+lead+finding&doi=10.1002%2Fcmdc.201500338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Allosteric Non-Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthase by Integrated Lead Finding</span></div><div class="casAuthors">Marzinzik, Andreas L.; Amstutz, Rene; Bold, Guido; Bourgier, Emmanuelle; Cotesta, Simona; Glickman, J. Fraser; Goette, Marjo; Henry, Christelle; Lehmann, Sylvie; Hartwieg, J. Constanze D.; Ofner, Silvio; Pelle, Xavier; Roddy, Thomas P.; Rondeau, Jean-Michel; Stauffer, Frederic; Stout, Steven J.; Widmer, Armin; Zimmermann, Johann; Zoller, Thomas; Jahnke, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1884-1891</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Farnesyl pyrophosphate synthase (FPPS) is an established target for the treatment of bone diseases, but also shows promise as an anticancer and anti-infective drug target.  Currently available anti-FPPS drugs are active-site-directed bisphosphonate inhibitors, the peculiar pharmacol. profile of which is inadequate for therapeutic indications beyond bone diseases.  The recent discovery of an allosteric binding site has paved the way toward the development of novel non-bisphosphonate FPPS inhibitors with broader therapeutic potential, notably as immunomodulators in oncol.  Herein we report the discovery, by an integrated lead finding approach, of two new chem. classes of allosteric FPPS inhibitors that belong to the salicylic acid and quinoline chemotypes.  We present their synthesis, biochem. and cellular activities, structure-activity relationships, and provide X-ray structures of several representative FPPS complexes.  These novel allosteric FPPS inhibitors are devoid of any affinity for bone mineral and could serve as leads to evaluate their potential in none-bone diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAr9SoyVzuV7Vg90H21EOLACvtfcHk0ljZhY_t_GzRvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWlsLnP&md5=a32eb3354fc3a50e6e0cfedc25a31d15</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500338%26sid%3Dliteratum%253Aachs%26aulast%3DMarzinzik%26aufirst%3DA.%2BL.%26aulast%3DAmstutz%26aufirst%3DR.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBourgier%26aufirst%3DE.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DGlickman%26aufirst%3DJ.%2BF.%26aulast%3DGotte%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DLehmann%26aufirst%3DS.%26aulast%3DHartwieg%26aufirst%3DJ.%2BC.%26aulast%3DOfner%26aufirst%3DS.%26aulast%3DPelle%26aufirst%3DX.%26aulast%3DRoddy%26aufirst%3DT.%2BP.%26aulast%3DRondeau%26aufirst%3DJ.%2BM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DStout%26aufirst%3DS.%2BJ.%26aulast%3DWidmer%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DZoller%26aufirst%3DT.%26aulast%3DJahnke%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%2520allosteric%2520non-bisphosphonate%2520inhibitors%2520of%2520farnesyl%2520pyrophosphate%2520synthase%2520by%2520integrated%2520lead%2520finding%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1884%26epage%3D1891%26doi%3D10.1002%2Fcmdc.201500338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matralis, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacbay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsakos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez De Troconiz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore mapping of thienopyrimidine-based monophosphonate (ThP-MP) inhibitors of the human farnesyl pyrophosphate synthase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2119</span>â <span class="NLM_lpage">2134</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01888</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01888" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivFSru74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2119-2134&author=J.+Parkauthor=C.+Y.+Leungauthor=A.+N.+Matralisauthor=C.+M.+Lacbayauthor=M.+Tsakosauthor=G.+Fernandez+De+Troconizauthor=A.+M.+Berghuisauthor=Y.+S.+Tsantrizos&title=Pharmacophore+mapping+of+thienopyrimidine-based+monophosphonate+%28ThP-MP%29+inhibitors+of+the+human+farnesyl+pyrophosphate+synthase&doi=10.1021%2Facs.jmedchem.6b01888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase</span></div><div class="casAuthors">Park, Jaeok; Leung, Chun Yuen; Matralis, Alexios N.; Lacbay, Cyrus M.; Tsakos, Michail; Fernandez De Troconiz, Guillermo; Berghuis, Albert M.; Tsantrizos, Youla S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2119-2134</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The human farnesyl pyrophosphate synthase (hFPPS), a key regulatory enzyme in the mevalonate pathway, catalyzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate (FPP).  FPP plays a crucial role in the post-translational prenylation of small GTPases that perform a plethora of cellular functions.  Although hFPPS is a well-established therapeutic target for lytic bone diseases, the currently available bisphosphonate drugs exhibit poor cellular uptake and distribution into non-skeletal tissues.  Recent drug discovery efforts have focused primarily on allosteric inhibition of hFPPS and the discovery of non-bisphosphonate drugs for potentially treating non-skeletal diseases.  Hit-to-lead optimization of a new series of thienopyrimidine-based monosphosphonates (ThP-MPs) led to the identification of analogs with nanomolar potency in inhibiting hFPPS.  Their interactions with the allosteric pocket of the enzyme were characterized by crystallog. and the results provide further insight into the pharmacophore requirements for allosteric inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyhrW7fwd66bVg90H21EOLACvtfcHk0ljZhY_t_GzRvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivFSru74%253D&md5=ac44083a7b20a199cd1cfb59bec71be1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01888%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DC.%2BY.%26aulast%3DMatralis%26aufirst%3DA.%2BN.%26aulast%3DLacbay%26aufirst%3DC.%2BM.%26aulast%3DTsakos%26aufirst%3DM.%26aulast%3DFernandez%2BDe%2BTroconiz%26aufirst%3DG.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DPharmacophore%2520mapping%2520of%2520thienopyrimidine-based%2520monophosphonate%2520%2528ThP-MP%2529%2520inhibitors%2520of%2520the%2520human%2520farnesyl%2520pyrophosphate%2520synthase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2119%26epage%3D2134%26doi%3D10.1021%2Facs.jmedchem.6b01888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span> <span> </span><span class="NLM_article-title">Human farnesyl pyrophosphate synthase is allosterically inhibited by its own product</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14132</span>, <span class="refDoi">Â DOI: 10.1038/ncomms14132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fncomms14132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=28098152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlarsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14132&author=J.+Parkauthor=M.+Zielinskiauthor=A.+Magderauthor=Y.+S.+Tsantrizosauthor=A.+M.+Berghuis&title=Human+farnesyl+pyrophosphate+synthase+is+allosterically+inhibited+by+its+own+product&doi=10.1038%2Fncomms14132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Human farnesyl pyrophosphate synthase is allosterically inhibited by its own product</span></div><div class="casAuthors">Park, Jaeok; Zielinski, Michal; Magder, Alexandr; Tsantrizos, Youla S.; Berghuis, Albert M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14132</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Farnesyl pyrophosphate synthase (FPPS) is an enzyme of the mevalonate pathway and a well-established therapeutic target.  Recent research has focused around a newly identified druggable pocket near the enzyme's active site.  Pharmacol. exploitation of this pocket is deemed promising; however, its natural biol. function, if any, is yet unknown.  Here we report that the product of FPPS, farnesyl pyrophosphate (FPP), can bind to this pocket and lock the enzyme in an inactive state.  The Kd for this binding is 5-6 Î¼M, within a catalytically relevant range.  These results indicate that FPPS activity is sensitive to the product concn.  Kinetic anal. shows that the enzyme is inhibited through FPP accumulation.  Having a specific physiol. effector, FPPS is a bona fide allosteric enzyme.  This allostery offers an exquisite mechanism for controlling prenyl pyrophosphate levels in vivo and thus contributes an addnl. layer of regulation to the mevalonate pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpnTdH3Q0qYrVg90H21EOLACvtfcHk0ljZhY_t_GzRvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlarsrg%253D&md5=a3042ec22d74c2c53aa806a52d37c4b3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fncomms14132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14132%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DZielinski%26aufirst%3DM.%26aulast%3DMagder%26aufirst%3DA.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26atitle%3DHuman%2520farnesyl%2520pyrophosphate%2520synthase%2520is%2520allosterically%2520inhibited%2520by%2520its%2520own%2520product%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14132%26doi%3D10.1038%2Fncomms14132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. J.</span></span> <span> </span><span class="NLM_article-title">Carnosol: a promising anti-cancer and anti-inflammatory agent</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>305</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">7</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2011.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.canlet.2011.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=21382660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktF2hsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2011&pages=1-7&author=J.+J.+Johnson&title=Carnosol%3A+a+promising+anti-cancer+and+anti-inflammatory+agent&doi=10.1016%2Fj.canlet.2011.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Carnosol: A promising anti-cancer and anti-inflammatory agent</span></div><div class="casAuthors">Johnson, Jeremy J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The Mediterranean diet and more specifically certain meats, fruits, vegetables, and olive oil found in certain parts of the Mediterranean region have been assocd. with a decreased cardiovascular and diabetes risk.  More recently, several population based studies have obsd. with these lifestyle choices have reported an overall reduced risk for several cancers.  One study in particular obsd. an inverse relationship between consumption of Mediterranean herbs such as rosemary, sage, parsley, and oregano with lung cancer.  In light of these findings there is a need to explore and identify the anti-cancer properties of these medicinal herbs and to identify the phytochems. therein.  One agent in particular, carnosol, has been evaluated for anti-cancer property in prostate, breast, skin, leukemia, and colon cancer with promising results.  These studies have provided evidence that carnosol targets multiple deregulated pathways assocd. with inflammation and cancer that include nuclear factor kappa B (NFÎºB), apoptotic related proteins, phosphatidylinositol-3-kinase (PI3 K)/Akt, androgen and estrogen receptors, as well as mol. targets.  In addn., carnosol appears to be well tolerated in that it has a selective toxicity towards cancer cells vs. non-tumorigenic cells and is well tolerated when administered to animals.  This mini-review reports on the pre-clin. studies that have been performed to date with carnosol describing mechanistic, efficacy, and safety/tolerability studies as a cancer chemoprevention and anti-cancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_5YBLrOhK1rVg90H21EOLACvtfcHk0lhgbI2gbJTgLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktF2hsrs%253D&md5=0cc74d436c660ac6ee1808fc5dd76f23</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2011.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2011.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DJ.%2BJ.%26atitle%3DCarnosol%253A%2520a%2520promising%2520anti-cancer%2520and%2520anti-inflammatory%2520agent%26jtitle%3DCancer%2520Lett.%26date%3D2011%26volume%3D305%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.canlet.2011.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, T.</span></span> <span> </span><span class="NLM_article-title">Cytotoxicity of abietane diterpenoids from Perovskia abrotanoides and of their semisynthetic analogues</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5285</span>â <span class="NLM_lpage">5291</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2006.03.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.bmc.2006.03.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=16626958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFyrurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=5285-5291&author=Y.+Aoyagiauthor=Y.+Takahashiauthor=Y.+Satakeauthor=K.+Takeyaauthor=R.+Aiyamaauthor=T.+Matsuzakiauthor=S.+Hashimotoauthor=T.+Kurihara&title=Cytotoxicity+of+abietane+diterpenoids+from+Perovskia+abrotanoides+and+of+their+semisynthetic+analogues&doi=10.1016%2Fj.bmc.2006.03.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Cytotoxicity of abietane diterpenoids from Perovskia abrotanoides and of their semisynthetic analogues</span></div><div class="casAuthors">Aoyagi, Yutaka; Takahashi, Yoshinao; Satake, Yudai; Takeya, Koichi; Aiyama, Ritsuo; Matsuzaki, Takeshi; Hashimoto, Shusuke; Kurihara, Teruo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5285-5291</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Seven known abietane diterpenoids and 11-O- and 12-O-acetylcarnosic acids were isolated from a methanol ext. of Perovskia abrotanoides (Labiatae).  Structure and cytotoxic activity relationships (SAR) of the natural and semisynthetic analogs of the presently isolated abietane diterpenoids were studied by using P388 murine leukemia cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6JKR0J99vdrVg90H21EOLACvtfcHk0lhgbI2gbJTgLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFyrurc%253D&md5=52a13a2f143e6f98f00ad0288510635c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.03.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.03.047%26sid%3Dliteratum%253Aachs%26aulast%3DAoyagi%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DSatake%26aufirst%3DY.%26aulast%3DTakeya%26aufirst%3DK.%26aulast%3DAiyama%26aufirst%3DR.%26aulast%3DMatsuzaki%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DS.%26aulast%3DKurihara%26aufirst%3DT.%26atitle%3DCytotoxicity%2520of%2520abietane%2520diterpenoids%2520from%2520Perovskia%2520abrotanoides%2520and%2520of%2520their%2520semisynthetic%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D5285%26epage%3D5291%26doi%3D10.1016%2Fj.bmc.2006.03.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Del
Campo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiot, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-The, C.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial effect of rosemary extracts</span>. <i>J. Food Prot.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1359</span>â <span class="NLM_lpage">1368</span>, <span class="refDoi">Â DOI: 10.4315/0362-028X-63.10.1359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.4315%2F0362-028X-63.10.1359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=11041135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntVaitr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2000&pages=1359-1368&author=J.+Del%0ACampoauthor=M.+J.+Amiotauthor=C.+Nguyen-The&title=Antimicrobial+effect+of+rosemary+extracts&doi=10.4315%2F0362-028X-63.10.1359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial effect of rosemary extracts</span></div><div class="casAuthors">Del Campo, Jose; Amiot, Marie-Josephe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Food Protection</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1359-1368</span>CODEN:
                <span class="NLM_cas:coden">JFPRDR</span>;
        ISSN:<span class="NLM_cas:issn">0362-028X</span>.
    
            (<span class="NLM_cas:orgname">International Association for Food Protection</span>)
        </div><div class="casAbstract">A rosemary ext. com. exploited (Oxy'less) as an antioxidant of lipids in foods was dissolved in ethanol (100 mg/mL), and the soln. was tested against foodborne microorganisms.  For gram-pos. bacteria, the MIC of the ethanolic soln. was 1% for Leuconostoc mesenteroides, 0.5% for Listeria monocytogenes, 0.5% for Staphylococcus aureus, 0.13% for Streptococcus mutans, and 0.06% for Bacillus cereus.  It slowed the growth of Penicillium roquefortii and Botrytis cinerea.  Up to 1% of the ethanolic soln. had no activity on the gram-neg. bacteria Escherichia coli, Salmonella enteritidis, and Erwinia carotovora and on the yeasts Rhodotorula glutinis and Cryptococcus laurentii.  Antibacterial activity of the rosemary ext. was strongly influenced by the compn. of the media.  The MIC was reduced by low pH, high NaCl contents, and low temps.  Low pH and high NaCl concn. had a synergistic effect on the MIC of the rosemary ext. for S. aureus.  Lipids, surface-active agents, and some proteins decreased its antibacterial activity, whereas pectin had no effect.  The inhibitory effect was little modified by heat treatment (100Â°C).  The natural microflora of pasteurized zucchini broth was inhibited by 0.5% of the rosemary ext.  The antibacterial activity was linked to the compds. extd. with hexane, which are presumably phenolic diterpenoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGiPP5jocxN7Vg90H21EOLACvtfcHk0lhgbI2gbJTgLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntVaitr8%253D&md5=f0c247fda8965594c0d285b46223376f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4315%2F0362-028X-63.10.1359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4315%252F0362-028X-63.10.1359%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BCampo%26aufirst%3DJ.%26aulast%3DAmiot%26aufirst%3DM.%2BJ.%26aulast%3DNguyen-The%26aufirst%3DC.%26atitle%3DAntimicrobial%2520effect%2520of%2520rosemary%2520extracts%26jtitle%3DJ.%2520Food%2520Prot.%26date%3D2000%26volume%3D63%26spage%3D1359%26epage%3D1368%26doi%3D10.4315%2F0362-028X-63.10.1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Jamal, A.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alqadi, T.</span></span> <span> </span><span class="NLM_article-title">Effects of rosemary (Rosmarinus officinalis) on lipid profile of diabetic rats</span>. <i>Jordan J. Biol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">199</span>â <span class="NLM_lpage">204</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=199-204&author=A.-R.+Al-Jamalauthor=T.+Alqadi&title=Effects+of+rosemary+%28Rosmarinus+officinalis%29+on+lipid+profile+of+diabetic+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Jamal%26aufirst%3DA.-R.%26aulast%3DAlqadi%26aufirst%3DT.%26atitle%3DEffects%2520of%2520rosemary%2520%2528Rosmarinus%2520officinalis%2529%2520on%2520lipid%2520profile%2520of%2520diabetic%2520rats%26jtitle%3DJordan%2520J.%2520Biol.%2520Sci.%26date%3D2011%26volume%3D4%26spage%3D199%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collin, H.</span></span> <span> </span><span class="NLM_article-title">Herbs, Spices and Cardiovascular Disease</span>.  <i>Handbook of Herbs and Spices</i>; <span class="NLM_publisher-name">Woodhead</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span>, <span class="NLM_year">2006</span>; pp  <span class="NLM_fpage">126</span>â <span class="NLM_lpage">137</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1533%2F9781845691717.2.126" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=126-137&author=H.+Collin&title=Handbook+of+Herbs+and+Spices"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1533%2F9781845691717.2.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1533%252F9781845691717.2.126%26sid%3Dliteratum%253Aachs%26aulast%3DCollin%26aufirst%3DH.%26atitle%3DHerbs%252C%2520Spices%2520and%2520Cardiovascular%2520Disease%26btitle%3DHandbook%2520of%2520Herbs%2520and%2520Spices%26pub%3DWoodhead%26date%3D2006%26spage%3D126%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romo-Vaquero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obiol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Villalba, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Barrio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issaly, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomas-Barberan, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Conesa, M. T.</span></span> <span> </span><span class="NLM_article-title">A rosemary extract rich in carnosic acid selectively modulates caecum microbiota and inhibits beta-glucosidase activity, altering fiber and short chain fatty acids fecal excretion in lean and obese female rats</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e94687</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0094687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1371%2Fjournal.pone.0094687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=24733124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1aqtbrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=M.+Romo-Vaqueroauthor=M.+V.+Selmaauthor=M.+Larrosaauthor=M.+Obiolauthor=R.+Garcia-Villalbaauthor=R.+Gonzalez-Barrioauthor=N.+Issalyauthor=J.+Flanaganauthor=M.+Rollerauthor=F.+A.+Tomas-Barberanauthor=M.+T.+Garcia-Conesa&title=A+rosemary+extract+rich+in+carnosic+acid+selectively+modulates+caecum+microbiota+and+inhibits+beta-glucosidase+activity%2C+altering+fiber+and+short+chain+fatty+acids+fecal+excretion+in+lean+and+obese+female+rats&doi=10.1371%2Fjournal.pone.0094687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A rosemary extract rich in carnosic acid selectively modulates caecum microbiota and inhibits Î²-glucosidase activity, altering fiber and short chain fatty acids fecal excretion in lean and obese female rats</span></div><div class="casAuthors">Romo-Vaquero, Maria; Selma, Maria-Victoria; Larrosa, Mar; Obiol, Maria; Garcia-Villalba, Rocio; Gonzalez-Barrio, Rocio; Issaly, Nicolas; Flanagan, John; Roller, Marc; Tomas-Barberan, Francisco A.; Garcia-Conesa, Maria-Teresa</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e94687/1-e94687/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Carnosic acid (CA) and rosemary exts. (RE) show body-wt., energy metab. and inflammation regulatory properties in animal models but the mechanisms are not yet understood.  Gut microbiota plays an important role in the host metab. and inflammatory status and is modulated by the diet.  The aim of this research was to investigate whether a RE enriched in CA affected caecum microbiota compn. and activity in a rat model of genetic obesity.  Methods and Principal Findings: A RE (40% CA) was administered with the diet (0.5% wt./wt.) to lean (fa/+) and obese (fa/fa) female Zucker rats for 64 days.  Changes in the microbiota compn. and Î²-glucosidase activity in the caecum and in the levels of macronutrients and short chain fatty acids (SCFA) in feces were examd.  The RE increased the Blautia coccoides and Bacteroides/Prevotella groups and reduced the Lactobacillus/Leuconostoc/Pediococccus group in both types of animals.  Clostridium leptum was significantly decreased and Bifidobacterium increased only in the lean rats. Î²-Glucosidase activity was significantly reduced and fecal fiber excretion increased in the two genotypes.  The RE also increased the main SCFA excreted in the feces of the obese rats but decreased them in the lean rats reflecting important differences in the uptake and metab. of these mols. between the two genotypes.  Conclusions: Our results indicate that the consumption of a RE enriched in CA modifies microbiota compn. and decreases Î²-glucosidase activity in the caecum of female Zucker rats while it increases fiber fecal elimination.  These results may contribute to explain the body wt. gain reducing effects of the RE.  The mutated leptin receptor of the obese animals significantly affects the microbiota compn., the SCFA fecal excretion and the host response to the RE intake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4S6CkPuTCULVg90H21EOLACvtfcHk0lg86oGaA6uDtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1aqtbrO&md5=416d0a355eae50d20a0cdb9647c58c4a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0094687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0094687%26sid%3Dliteratum%253Aachs%26aulast%3DRomo-Vaquero%26aufirst%3DM.%26aulast%3DSelma%26aufirst%3DM.%2BV.%26aulast%3DLarrosa%26aufirst%3DM.%26aulast%3DObiol%26aufirst%3DM.%26aulast%3DGarcia-Villalba%26aufirst%3DR.%26aulast%3DGonzalez-Barrio%26aufirst%3DR.%26aulast%3DIssaly%26aufirst%3DN.%26aulast%3DFlanagan%26aufirst%3DJ.%26aulast%3DRoller%26aufirst%3DM.%26aulast%3DTomas-Barberan%26aufirst%3DF.%2BA.%26aulast%3DGarcia-Conesa%26aufirst%3DM.%2BT.%26atitle%3DA%2520rosemary%2520extract%2520rich%2520in%2520carnosic%2520acid%2520selectively%2520modulates%2520caecum%2520microbiota%2520and%2520inhibits%2520beta-glucosidase%2520activity%252C%2520altering%2520fiber%2520and%2520short%2520chain%2520fatty%2520acids%2520fecal%2520excretion%2520in%2520lean%2520and%2520obese%2520female%2520rats%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0094687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birtic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussort, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bily, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, M.</span></span> <span> </span><span class="NLM_article-title">Carnosic acid</span>. <i>Phytochemistry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">19</span>, <span class="refDoi">Â DOI: 10.1016/j.phytochem.2014.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.phytochem.2014.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=25639596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWktLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=9-19&author=S.+Birticauthor=P.+Dussortauthor=F.+X.+Pierreauthor=A.+C.+Bilyauthor=M.+Roller&title=Carnosic+acid&doi=10.1016%2Fj.phytochem.2014.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Carnosic acid</span></div><div class="casAuthors">Birtic, Simona; Dussort, Pierre; Pierre, Francois-Xavier; Bily, Antoine C.; Roller, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry (Elsevier)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-19</span>CODEN:
                <span class="NLM_cas:coden">PYTCAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-9422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Carnosic acid (salvin), which possesses antioxidative and antimicrobial properties, is increasingly exploited within the food, nutritional health and cosmetics industries.  Since its first extn. from a Salvia species (â¼70 years ago) and its identification (â¼50 years ago), numerous articles and patents (â¼400) have been published on specific food and medicinal applications of Rosmarinus and Salvia plant exts. abundant in carnosic acid.  In contrast, relevant biochem., physiol. or mol. studies in planta have remained rare.  In this overview, recent advances in understanding of carnosic acid distribution, biosynthesis, accumulation and role in planta, and its applications are summarised.  We also discuss the deficiencies in our understanding of the relevant biochem. processes, and suggest the mol. targets of carnosic acid.  Finally, future perspectives and studies related to its potential roles are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPpABoMnX8gLVg90H21EOLACvtfcHk0lg86oGaA6uDtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWktLw%253D&md5=f17beb65000bf628cfc6f54d440af3f5</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.phytochem.2014.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phytochem.2014.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DBirtic%26aufirst%3DS.%26aulast%3DDussort%26aufirst%3DP.%26aulast%3DPierre%26aufirst%3DF.%2BX.%26aulast%3DBily%26aufirst%3DA.%2BC.%26aulast%3DRoller%26aufirst%3DM.%26atitle%3DCarnosic%2520acid%26jtitle%3DPhytochemistry%26date%3D2015%26volume%3D115%26spage%3D9%26epage%3D19%26doi%3D10.1016%2Fj.phytochem.2014.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, J. L.</span></span> <span> </span><span class="NLM_article-title">A continuous spectrophotometric assay for aspartate transcarbamylase and ATPases</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>246</i></span>,  <span class="NLM_fpage">86</span>â <span class="NLM_lpage">95</span>, <span class="refDoi">Â DOI: 10.1006/abio.1996.9962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1006%2Fabio.1996.9962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=9056187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADyaK2sXhsFKitrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=1997&pages=86-95&author=C.+E.+Riegerauthor=J.+Leeauthor=J.+L.+Turnbull&title=A+continuous+spectrophotometric+assay+for+aspartate+transcarbamylase+and+ATPases&doi=10.1006%2Fabio.1996.9962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A continuous spectrophotometric assay for aspartate transcarbamylase and ATPases</span></div><div class="casAuthors">Rieger, Colin E.; Lee, John; Turnbull, Joanne L.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">246</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-95</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A new continuous coupled uv-spectrophotometric assay is described for two phosphate-releasing enzymes, aspartate transcarbamylase and ATPase of herpes simplex virus (HSV).  Phosphate release is coupled to the phosphorolysis of the nucleoside analog 7-methylinosine (m7Ino) catalyzed by purine nucleoside phosphorylase.  When this reaction is monitored at 291 nm, the coupled assay can readily detect 10 nmol Pi released/min.  Our method offers advantages over a recently reported continuous assay devised for measuring aspartate transcarbamylase activity using the nucleoside methylthioguanosine (MESG) as the linking substrate.  In contrast to MESG, m7Ino is easily and inexpensively synthesized and is also com. available.  The spectrophotometric signal at 291 nm, produced by the difference in the extinction coeffs. between nucleoside substrate and the base product, is significant over a much wider pH range than the signal difference between MESG and its phosphorolysis product at 360 nm.  Satn. curves for aspartate and carbamyl phosphate and pH rate profiles have been reproduced using the purine nucleoside phosphorylase/m7Ino coupled assay.  Initial velocity patterns constructed over micromolar to millimolar concns. of aspartate and carbamyl phosphate yielded four kinetic parameters simultaneously.  To further illustrate the application of this coupled assay, kinetic parameters were detd. for the DNA-dependent ATPase reaction of HSV helicase-primase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocTZGAkdzztLVg90H21EOLACvtfcHk0ljJan-QIToO8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsFKitrs%253D&md5=2de451336c8c7082dc28adacdcdbc908</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1006%2Fabio.1996.9962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1996.9962%26sid%3Dliteratum%253Aachs%26aulast%3DRieger%26aufirst%3DC.%2BE.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTurnbull%26aufirst%3DJ.%2BL.%26atitle%3DA%2520continuous%2520spectrophotometric%2520assay%2520for%2520aspartate%2520transcarbamylase%2520and%2520ATPases%26jtitle%3DAnal.%2520Biochem.%26date%3D1997%26volume%3D246%26spage%3D86%26epage%3D95%26doi%3D10.1006%2Fabio.1996.9962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Webb, M. R.</span></span> <span> </span><span class="NLM_article-title">A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">4884</span>â <span class="NLM_lpage">4887</span>, <span class="refDoi">Â DOI: 10.1073/pnas.89.11.4884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1073%2Fpnas.89.11.4884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1534409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADyaK38Xks1Gktbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=4884-4887&author=M.+R.+Webb&title=A+continuous+spectrophotometric+assay+for+inorganic+phosphate+and+for+measuring+phosphate+release+kinetics+in+biological+systems&doi=10.1073%2Fpnas.89.11.4884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems</span></div><div class="casAuthors">Webb, Martin R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4884-7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A spectrophotometric method for the measurement of inorg. phosphate (Pi) has been developed by using 2-amino-6-mercapto-7-methylpurine ribonucleoside and purine-nucleoside phosphorylase (purine-nucleoside:orthophosphate ribosyltransferase, EC 2.4.2.1).  This substrate gives an absorbance increase at 360 nm on phosphorolysis at pH 6.5-8.5, and at pH 7.6 the change in extinction coeff. is 11,000 M-1Â·cm-1.  The Michaelis-Menten consts. of the two substrates with the enzyme are 70 Î¼M for the nucleoside and 26 Î¼M for Pi; the kcat is 40 s-1 (25 Â°C).  The assay was shown to quantitate Pi in soln. at concns. at least down to 2 Î¼M.  It can be used to measure the kinetics of Pi release from phosphatases, such as GTPases and ATPases, by coupling the two enzymic reactions.  The utility of this assay was shown by three test systems: glycerol kinase plus D-glyceraldehyde acting as an ATPase and actin-activated myosin ATPase, and myosin subfragment 1, hydrolyzing a single turnover of ATP, releasing Pi with a rate const. the same as the steady-state ATPase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz0LFKi_aD47Vg90H21EOLACvtfcHk0ljJan-QIToO8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xks1Gktbw%253D&md5=0283dff906ac14ac6c253fcf43957557</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1073%2Fpnas.89.11.4884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.89.11.4884%26sid%3Dliteratum%253Aachs%26aulast%3DWebb%26aufirst%3DM.%2BR.%26atitle%3DA%2520continuous%2520spectrophotometric%2520assay%2520for%2520inorganic%2520phosphate%2520and%2520for%2520measuring%2520phosphate%2520release%2520kinetics%2520in%2520biological%2520systems%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1992%26volume%3D89%26spage%3D4884%26epage%3D4887%26doi%3D10.1073%2Fpnas.89.11.4884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokoroyama, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Michael reaction</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2010</i></span>,  <span class="NLM_fpage">2009</span>â <span class="NLM_lpage">2016</span>, <span class="refDoi">Â DOI: 10.1002/ejoc.200901130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1002%2Fejoc.200901130" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=2009-2016&author=T.+Tokoroyama&title=Discovery+of+the+Michael+reaction&doi=10.1002%2Fejoc.200901130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200901130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200901130%26sid%3Dliteratum%253Aachs%26aulast%3DTokoroyama%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520the%2520Michael%2520reaction%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2010%26volume%3D2010%26spage%3D2009%26epage%3D2016%26doi%3D10.1002%2Fejoc.200901130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span> <span> </span><span class="NLM_article-title">Feeling natureâs PAINS: natural products, natural product drugs, and Pan Assay Interference Compounds (PAINS)</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">616</span>â <span class="NLM_lpage">628</span>, <span class="refDoi">Â DOI: 10.1021/acs.jnatprod.5b00947</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.5b00947" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVWktrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=616-628&author=J.+B.+Baell&title=Feeling+nature%E2%80%99s+PAINS%3A+natural+products%2C+natural+product+drugs%2C+and+Pan+Assay+Interference+Compounds+%28PAINS%29&doi=10.1021%2Facs.jnatprod.5b00947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Feeling Nature's PAINS: Natural Products, Natural Product Drugs, and Pan Assay Interference Compounds (PAINS)</span></div><div class="casAuthors">Baell, Jonathan B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">616-628</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">We have previously reported on classes of compds. that can interfere with bioassays via a no. of different mechanisms and termed such compds. Pan Assay INterference compds., or PAINS.  These compds. were defined on the basis of high-throughput data derived from vendor-supplied synthetics.  The question therefore arises whether the concept of PAINS is relevant to compds. of natural origin.  Here, it is shown that this is indeed the case, but that the context of the biol. readout is an important factor that must be brought into consideration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYFy3lN9vzSbVg90H21EOLACvtfcHk0ljJan-QIToO8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVWktrc%253D&md5=199b040b1f6f3d636521879acae0114d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.5b00947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.5b00947%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26atitle%3DFeeling%2520nature%25E2%2580%2599s%2520PAINS%253A%2520natural%2520products%252C%2520natural%2520product%2520drugs%252C%2520and%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2016%26volume%3D79%26spage%3D616%26epage%3D628%26doi%3D10.1021%2Facs.jnatprod.5b00947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiessling, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">The ecstasy and agony of assay interference compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2165</span>â <span class="NLM_lpage">2168</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00229</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00229" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtl2lsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2165-2168&author=C.+Aldrichauthor=C.+Bertozziauthor=G.+I.+Georgauthor=L.+Kiesslingauthor=C.+Lindsleyauthor=D.+Liottaauthor=K.+M.+Merzauthor=A.+Schepartzauthor=S.+Wang&title=The+ecstasy+and+agony+of+assay+interference+compounds&doi=10.1021%2Facs.jmedchem.7b00229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The Ecstasy and Agony of Assay Interference Compounds</span></div><div class="casAuthors">Aldrich, Courtney; Bertozzi, Carolyn; Georg, Gunda I.; Kiessling, Laura; Lindsley, Craig; Liotta, Dennis; Merz, Kenneth M.; Schepartz, Alanna; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2165-2168</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ecstasy of discovering a new hit from screening can lead to a highly productive research effort to discover new bioactive compds.  However, in too many cases this ecstasy is followed by the agony of realizing that the compds. are not active against the desired target.  Many of these false hits are Pan Assay INterference compds. (PAINS) 1 or colloidal aggregators.  Whether the screen is conducted in silico or in the lab. and whether screening libraries, natural products, or drugs are used, all discovery efforts that rely on some form of screening to identify bioactivity are susceptible to this phenomenon.  Studies that omit crit. controls against exptl. artifacts caused by PAINS may waste years of research effort as useless compds. are progressed.  The American Chem. Society (ACS) is eager to alert the scientific community to this problem and to recommend protocols that will eliminate the publication of research articles based on compds. with artificial activity.  This editorial aims to summarize relevant concepts and to set the framework by which relevant ACS journals will address this issue going forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJUf5u51VEpbVg90H21EOLACvtfcHk0liHn-jEiCg1IQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtl2lsLY%253D&md5=64bf087659a47fe7769208217ef8c989</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00229%26sid%3Dliteratum%253Aachs%26aulast%3DAldrich%26aufirst%3DC.%26aulast%3DBertozzi%26aufirst%3DC.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DKiessling%26aufirst%3DL.%26aulast%3DLindsley%26aufirst%3DC.%26aulast%3DLiotta%26aufirst%3DD.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26aulast%3DSchepartz%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DThe%2520ecstasy%2520and%2520agony%2520of%2520assay%2520interference%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2165%26epage%3D2168%26doi%3D10.1021%2Facs.jmedchem.7b00229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marma, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashemirov, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebetino, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triffitt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, C. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5967</span>â <span class="NLM_lpage">5975</span>, <span class="refDoi">Â DOI: 10.1021/jm0702884</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0702884" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1GrtL%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5967-5975&author=M.+S.+Marmaauthor=Z.+Xiaauthor=C.+Stewartauthor=F.+Coxonauthor=J.+E.+Dunfordauthor=R.+Baronauthor=B.+A.+Kashemirovauthor=F.+H.+Ebetinoauthor=J.+T.+Triffittauthor=R.+G.+Russellauthor=C.+E.+McKenna&title=Synthesis+and+biological+evaluation+of+alpha-halogenated+bisphosphonate+and+phosphonocarboxylate+analogues+of+risedronate&doi=10.1021%2Fjm0702884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Î±-Halogenated Bisphosphonate and Phosphonocarboxylate Analogues of Risedronate</span></div><div class="casAuthors">Marma, Mong S.; Xia, Zhidao; Stewart, Charlotte; Coxon, Fraser; Dunford, James E.; Baron, Rudi; Kashemirov, Boris A.; Ebetino, Frank H.; Triffitt, James T.; Russell, R. Graham G.; McKenna, Charles E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5967-5975</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Î±-Halogenated analogs of the anti-resorptive bisphosphonate risedronate (5, Ris) and its phosphonocarboxylate cognate (7, 3-PEHPC) were synthesized and compared with 5, 7, and the corresponding desoxy analogs in bone mineral affinity and mevalonate pathway inhibition assays.  The halogenated Ris and 3-PEHPC analogs had decreased bone mineral affinity, confirming that the Î±-OH group in 5 and 7 enhances bone affinity.  The 5 Î±-halo-analogs potently inhibited farnesyl pyrophosphate synthase (FPPS) with IC50 values from 16 (Î±-F) to 340 (Î±-Br) nM (5, 6 nM).  In contrast, 7 Î±-halo-analogs were ineffective vs. FPPS (IC50 > 600 Î¼M), but inhibited Rab geranylgeranyl transferase (RGGT) (IC50 = 16-35 Î¼M) similarly to 7 itself (IC50 = 24 Î¼M).  The 5 Î±-F analog was 1-2 times as active as 7 in J774 cell viability and Rab11 prenylation inhibition assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3DXQmDZ8NArVg90H21EOLACvtfcHk0liHn-jEiCg1IQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1GrtL%252FN&md5=13b8b41f154b7ff3556d3847df38223f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm0702884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0702884%26sid%3Dliteratum%253Aachs%26aulast%3DMarma%26aufirst%3DM.%2BS.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DStewart%26aufirst%3DC.%26aulast%3DCoxon%26aufirst%3DF.%26aulast%3DDunford%26aufirst%3DJ.%2BE.%26aulast%3DBaron%26aufirst%3DR.%26aulast%3DKashemirov%26aufirst%3DB.%2BA.%26aulast%3DEbetino%26aufirst%3DF.%2BH.%26aulast%3DTriffitt%26aufirst%3DJ.%2BT.%26aulast%3DRussell%26aufirst%3DR.%2BG.%26aulast%3DMcKenna%26aufirst%3DC.%2BE.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520alpha-halogenated%2520bisphosphonate%2520and%2520phosphonocarboxylate%2520analogues%2520of%2520risedronate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5967%26epage%3D5975%26doi%3D10.1021%2Fjm0702884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Schutter, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7939</span>â <span class="NLM_lpage">7950</span>, <span class="refDoi">Â DOI: 10.1021/jm400946f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400946f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlOktrrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7939-7950&author=C.+Y.+Leungauthor=J.+Parkauthor=J.+W.+De+Schutterauthor=M.+Sebagauthor=A.+M.+Berghuisauthor=Y.+S.+Tsantrizos&title=Thienopyrimidine+bisphosphonate+%28ThPBP%29+inhibitors+of+the+human+farnesyl+pyrophosphate+synthase%3A+optimization+and+characterization+of+the+mode+of+inhibition&doi=10.1021%2Fjm400946f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Thienopyrimidine Bisphosphonate (ThPBP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase: Optimization and Characterization of the Mode of Inhibition</span></div><div class="casAuthors">Leung, Chun Yuen; Park, Jaeok; De Schutter, Joris W.; Sebag, Michael; Berghuis, Albert M.; Tsantrizos, Youla S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7939-7950</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human farnesyl pyrophosphate synthase (hFPPS) controls the post-translational prenylation of small GTPase proteins that are essential for cell signaling, cell proliferation, and osteoclast-mediated bone resorption.  Inhibition of hFPPS is a clin. validated mechanism for the treatment of lytic bone diseases, including osteoporosis and cancer related bone metastases.  A new series of thienopyrimidine-based bisphosphonates (ThP-BPs) were identified that inhibit hFPPS with low nanomolar potency.  Crystallog. evidence revealed binding of ThP-BP inhibitors in the allylic subpocket of hFPPS.  Simultaneous binding of inorg. pyrophosphate in the IPP subpocket leads to conformational closing of the active site cavity.  The ThP-BP analogs are significantly less hydrophilic yet exhibit higher affinity for the bone mineral hydroxyapatite than the current N-BP drug risedronic acid.  The antiproliferation properties of a potent ThB-BP analog was assessed in a multiple myeloma cell line and found to be equipotent to the best current N-BP drugs.  Consequently, these compds. represent a new structural class of hFPPS inhibitors and a novel scaffold for the development of human therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsENEMSfNSo7Vg90H21EOLACvtfcHk0liHn-jEiCg1IQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlOktrrP&md5=0d8be8e382fe74521bd4b76ee2387257</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm400946f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400946f%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.%2BY.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DDe%2BSchutter%26aufirst%3DJ.%2BW.%26aulast%3DSebag%26aufirst%3DM.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DThienopyrimidine%2520bisphosphonate%2520%2528ThPBP%2529%2520inhibitors%2520of%2520the%2520human%2520farnesyl%2520pyrophosphate%2520synthase%253A%2520optimization%2520and%2520characterization%2520of%2520the%2520mode%2520of%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7939%26epage%3D7950%26doi%3D10.1021%2Fjm400946f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soares, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackmon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shun, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takyi, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wipf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. A.</span></span> <span> </span><span class="NLM_article-title">Profiling the NIH small molecule repository for compounds that generate H2O2 by redox cycling in reducing environments</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">152</span>â <span class="NLM_lpage">174</span>, <span class="refDoi">Â DOI: 10.1089/adt.2009.0247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1089%2Fadt.2009.0247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=20070233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFClur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=152-174&author=K.+M.+Soaresauthor=N.+Blackmonauthor=T.+Y.+Shunauthor=S.+N.+Shindeauthor=H.+K.+Takyiauthor=P.+Wipfauthor=J.+S.+Lazoauthor=P.+A.+Johnston&title=Profiling+the+NIH+small+molecule+repository+for+compounds+that+generate+H2O2+by+redox+cycling+in+reducing+environments&doi=10.1089%2Fadt.2009.0247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling the NIH Small Molecule Repository for Compounds That Generate H2O2 by Redox Cycling in Reducing Environments</span></div><div class="casAuthors">Soares, Karina M.; Blackmon, Nicole; Shun, Tong Ying; Shinde, Sunita N.; Takyi, Harold K.; Wipf, Peter; Lazo, John S.; Johnston, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-174</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">We have screened the Library of Pharmacol. Active Compds. (LOPAC) and the National Institutes of Health (NIH) Small Mol. Repository (SMR) libraries in a horseradish peroxidase-phenol red (HRP-PR) H2O2 detection assay to identify redox cycling compds. (RCCs) capable of generating H2O2 in buffers contg. dithiothreitol (DTT).  Two RCCs were identified in the LOPAC set, the ortho-naphthoquinone Î²-lapachone and the para-naphthoquinone NSC 95397.  Thirty-seven (0.02%) concn.-dependent RCCs were identified from 195,826 compds. in the NIH SMR library; 3 singleton structures, 9 ortho-quinones, 2 para-quinones, 4 pyrimidotriazinediones, 15 arylsulfonamides, 2 nitrothiophene-2-carboxylates, and 2 tolyl hydrazides.  60% Of the ortho-quinones and 80% of the pyrimidotriazinediones in the library were confirmed as RCCs.  In contrast, only 3.9% of the para-quinones were confirmed as RCCs.  Fifteen of the 251 arylsulfonamides in the library were confirmed as RCCs, and since we screened 17,868 compds. with a sulfonamide functional group we conclude that the redox cycling activity of the arylsulfonamide RCCs is due to peripheral reactive enone, arom., or heterocyclic functions.  Cross-target queries of the University of Pittsburgh Drug Discovery Institute (UPDDI) and PubChem databases revealed that the RCCs exhibited promiscuous bioactivity profiles and have populated both screening databases with significantly higher nos. of active flags than non-RCCs.  RCCs were promiscuously active against protein targets known to be susceptible to oxidn., but were also active in cell growth inhibition assays, and against other targets thought to be insensitive to oxidn.  Profiling compd. libraries or the hits from screening campaigns in the HRP-PR H2O2 detection assay significantly reduce the timelines and resources required to identify and eliminate promiscuous nuisance RCCs from the candidates for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxKHMWw0mf17Vg90H21EOLACvtfcHk0ljDKO5jYwFeSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFClur0%253D&md5=4baf5bc3cb807e069f27ce73cf66e7dc</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1089%2Fadt.2009.0247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2009.0247%26sid%3Dliteratum%253Aachs%26aulast%3DSoares%26aufirst%3DK.%2BM.%26aulast%3DBlackmon%26aufirst%3DN.%26aulast%3DShun%26aufirst%3DT.%2BY.%26aulast%3DShinde%26aufirst%3DS.%2BN.%26aulast%3DTakyi%26aufirst%3DH.%2BK.%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DLazo%26aufirst%3DJ.%2BS.%26aulast%3DJohnston%26aufirst%3DP.%2BA.%26atitle%3DProfiling%2520the%2520NIH%2520small%2520molecule%2520repository%2520for%2520compounds%2520that%2520generate%2520H2O2%2520by%2520redox%2520cycling%2520in%2520reducing%2520environments%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2010%26volume%3D8%26spage%3D152%26epage%3D174%26doi%3D10.1089%2Fadt.2009.0247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. A.</span></span> <span> </span><span class="NLM_article-title">Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents-real hits or promiscuous artifacts?</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">174</span>â <span class="NLM_lpage">182</span>, <span class="refDoi">Â DOI: 10.1016/j.cbpa.2010.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.cbpa.2010.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=21075044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFKitLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=174-182&author=P.+A.+Johnston&title=Redox+cycling+compounds+generate+H2O2+in+HTS+buffers+containing+strong+reducing+reagents-real+hits+or+promiscuous+artifacts%3F&doi=10.1016%2Fj.cbpa.2010.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents - real hits or promiscuous artifacts?</span></div><div class="casAuthors">Johnston, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-182</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Redox cycling compds. (RCCs) generate micromolar concns. of H2O2 in the presence of strong reducing agents, common buffer components used to maintain catalytic activity, and/or folding of target proteins for high-throughput screening (HTS) assays.  H2O2 generated by RCCs can indirectly inhibit the catalytic activity of proteins by oxidizing accessible Cys, Trp, Met, His, or Sec residues, and indeed several important classes of protein targets are susceptible to H2O2-mediated inactivation; protein tyrosine phosphatases, cysteine proteases, and metalloenzymes.  The main sources of H2O2 in cells are the NADPH oxidase/superoxide dismutase systems, peroxisome metab., and the autoxidn. of reactive chems. by enzyme mediated redox cycling at both the microsomal and mitochondrial sites of electron transport.  Given the role of H2O2 as a 2nd messenger involved in the regulation of many signaling pathways it is hardly surprising that compds. that can generate intracellular H2O2 by enzyme-mediated redox cycling would have pleiotropic effects.  RCCs can therefore have serious neg. consequences for the probe and/or lead generation process: primary HTS assay hit rates may be inflated by RCC false positives; crucial resources will be diverted to develop and implement follow-up assays to distinguish RCCs from real hits; and screening databases will become annotated with the promiscuous activity of RCCs.  In an attempt to mitigate the serious impact of RCCs on probe and lead generation, 2 groups have independently developed assays to identify RCCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAnhCpNOuGy7Vg90H21EOLACvtfcHk0ljDKO5jYwFeSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFKitLk%253D&md5=0ac517984e5b37d8839e13e6a6caa12f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DP.%2BA.%26atitle%3DRedox%2520cycling%2520compounds%2520generate%2520H2O2%2520in%2520HTS%2520buffers%2520containing%2520strong%2520reducing%2520reagents-real%2520hits%2520or%2520promiscuous%2520artifacts%253F%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D15%26spage%3D174%26epage%3D182%26doi%3D10.1016%2Fj.cbpa.2010.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, G. F.</span></span> <span> </span><span class="NLM_article-title">Redox-cycling and H<sub>2</sub>O<sub>2</sub> generation by fabricated catecholic films in the absence of enzymes</span>. <i>Biomacromolecules</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">880</span>â <span class="NLM_lpage">888</span>, <span class="refDoi">Â DOI: 10.1021/bm101499a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bm101499a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyls7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=880-888&author=E.+Kimauthor=Y.+Liuauthor=C.+J.+Bakerauthor=R.+Owensauthor=S.+Y.+Xiaoauthor=W.+E.+Bentleyauthor=G.+F.+Payne&title=Redox-cycling+and+H2O2+generation+by+fabricated+catecholic+films+in+the+absence+of+enzymes&doi=10.1021%2Fbm101499a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Redox-Cycling and H2O2 Generation by Fabricated Catecholic Films in the Absence of Enzymes</span></div><div class="casAuthors">Kim, Eunkyoung; Liu, Yi; Baker, C. Jacyn; Owens, Robert; Xiao, Shunyuan; Bentley, William E.; Payne, Gregory F.</div><div class="citationInfo"><span class="NLM_cas:title">Biomacromolecules</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">880-888</span>CODEN:
                <span class="NLM_cas:coden">BOMAF6</span>;
        ISSN:<span class="NLM_cas:issn">1525-7797</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phenolic matrixes are ubiquitous in nature (e.g., lignin, melanin, and humics) but remain largely intractable to characterize.  The authors examd. an abiotic phenol-polysaccharide matrix fabricated by the anodic grafting of catechol to chitosan films.  Previous studies have shown that catechol-modified chitosan films are redox-active and can be repeatedly interconverted between oxidized and reduced states.  Here the authors developed quant. electrochem. methods to characterize biorelevant redox properties of the catechol-modified chitosan films.  The authors' anal. demonstrates that these films can (i) accept electrons from biol. reductants (e.g., ascorbate and NADPH) and (ii) donate electrons in a model biol. oxidn. process.  Furthermore, these films can donate electrons to O2 to generate H2O2.  The demonstration that abiotic catechol-chitosan films possess catalytic activities in the absence of enzymes suggests the possibility that phenolic matrixes may play an important role in redox cycling and reactive oxygen species (ROS) signaling in biol. and the environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8NwMr70TOdrVg90H21EOLACvtfcHk0ljDKO5jYwFeSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyls7o%253D&md5=951acc03c808a1b4df9570dab0c55584</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fbm101499a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbm101499a%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBaker%26aufirst%3DC.%2BJ.%26aulast%3DOwens%26aufirst%3DR.%26aulast%3DXiao%26aufirst%3DS.%2BY.%26aulast%3DBentley%26aufirst%3DW.%2BE.%26aulast%3DPayne%26aufirst%3DG.%2BF.%26atitle%3DRedox-cycling%2520and%2520H2O2%2520generation%2520by%2520fabricated%2520catecholic%2520films%2520in%2520the%2520absence%2520of%2520enzymes%26jtitle%3DBiomacromolecules%26date%3D2011%26volume%3D12%26spage%3D880%26epage%3D888%26doi%3D10.1021%2Fbm101499a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torosyan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doak, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebart, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterling, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumanian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span> <span> </span><span class="NLM_article-title">An aggregation advisor for ligand discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7076</span>â <span class="NLM_lpage">7087</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01105</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOqu7zM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7076-7087&author=J.+J.+Irwinauthor=D.+Duanauthor=H.+Torosyanauthor=A.+K.+Doakauthor=K.+T.+Ziebartauthor=T.+Sterlingauthor=G.+Tumanianauthor=B.+K.+Shoichet&title=An+aggregation+advisor+for+ligand+discovery&doi=10.1021%2Facs.jmedchem.5b01105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">An Aggregation Advisor for Ligand Discovery</span></div><div class="casAuthors">Irwin, John J.; Duan, Da; Torosyan, Hayarpi; Doak, Allison K.; Ziebart, Kristin T.; Sterling, Teague; Tumanian, Gurgen; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7076-7087</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Colloidal aggregation of org. mols. is the dominant mechanism for artifactual inhibition of proteins, and controls against it are widely deployed.  Notwithstanding an increasingly detailed understanding of this phenomenon, a method to reliably predict aggregation has remained elusive.  Correspondingly, active mols. that act via aggregation continue to be found in early discovery campaigns and remain common in the literature.  Over the past decade, over 12 thousand aggregating org. mols. have been identified, potentially enabling a precedent-based approach to match known aggregators with new mols. that may be expected to aggregate and lead to artifacts.  We investigate an approach that uses lipophilicity, affinity, and similarity to known aggregators to advise on the likelihood that a candidate compd. is an aggregator.  In prospective exptl. testing, five of seven new mols. with Tanimoto coeffs. (Tc's) between 0.95 and 0.99 to known aggregators aggregated at relevant concns.  Ten of 19 with Tc's between 0.94 and 0.90 and three of seven with Tc's between 0.89 and 0.85 also aggregated.  Another three of the predicted compds. aggregated at higher concns.  This method finds that 61 827 or 5.1% of the ligands acting in the 0.1 to 10 Î¼M range in the medicinal chem. literature are at least 85% similar to a known aggregator with these phys. properties and may aggregate at relevant concns.  Intriguingly, only 0.73% of all drug-like com. available compds. resemble the known aggregators, suggesting that colloidal aggregators are enriched in the literature.  As a percentage of the literature, aggregator-like compds. have increased 9-fold since 1995, partly reflecting the advent of high-throughput and virtual screens against mol. targets.  Emerging from this study is an aggregator advisor database and tool (http://advisor.bkslab.org), free to the community, that may help distinguish between fruitful and artifactual screening hits acting by this mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTKGJSfIz30bVg90H21EOLACvtfcHk0lhA-odWvKD4QQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOqu7zM&md5=d3112f9f3a57a2ac61a4b32f31778b1d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01105%26sid%3Dliteratum%253Aachs%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DDuan%26aufirst%3DD.%26aulast%3DTorosyan%26aufirst%3DH.%26aulast%3DDoak%26aufirst%3DA.%2BK.%26aulast%3DZiebart%26aufirst%3DK.%2BT.%26aulast%3DSterling%26aufirst%3DT.%26aulast%3DTumanian%26aufirst%3DG.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DAn%2520aggregation%2520advisor%2520for%2520ligand%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7076%26epage%3D7087%26doi%3D10.1021%2Facs.jmedchem.5b01105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalvit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pevarello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundstrom, M.</span></span> <span> </span><span class="NLM_article-title">Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water</span>. <i>J. Biomol. NMR</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">65</span>â <span class="NLM_lpage">68</span>, <span class="refDoi">Â DOI: 10.1023/A:1008354229396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1023%2FA%3A1008354229396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=11061229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVGit7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=65-68&author=C.+Dalvitauthor=P.+Pevarelloauthor=M.+Tatoauthor=M.+Veronesiauthor=A.+Vulpettiauthor=M.+Sundstrom&title=Identification+of+compounds+with+binding+affinity+to+proteins+via+magnetization+transfer+from+bulk+water&doi=10.1023%2FA%3A1008354229396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water</span></div><div class="casAuthors">Dalvit, Claudio; Pevarello, Paolo; Tato, Marco; Veronesi, Marina; Vulpetti, Anna; Sundstrom, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular NMR</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-68</span>CODEN:
                <span class="NLM_cas:coden">JBNME9</span>;
        ISSN:<span class="NLM_cas:issn">0925-2738</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A powerful screening by NMR methodol. (WaterLOGSY), based on transfer of magnetization from bulk water, for the identification of compds. that interact with target biomols. (proteins, RNA and DNA fragments) is described.  The method exploits efficiently the large reservoir of H2O magnetization.  The high sensitivity of the technique reduces the amt. of biomol. and ligands needed for the screening, which constitutes an important requirement for high throughput screening by NMR of large libraries of compds.  Application of the method to a compd. mixt. against the cyclin-dependent kinase 2 (cdk2) protein is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR8Jo0PHYdALVg90H21EOLACvtfcHk0lhA-odWvKD4QQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVGit7o%253D&md5=e0fd0e5815f9bd20ed09d8033882feb6</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1023%2FA%3A1008354229396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1008354229396%26sid%3Dliteratum%253Aachs%26aulast%3DDalvit%26aufirst%3DC.%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DTato%26aufirst%3DM.%26aulast%3DVeronesi%26aufirst%3DM.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DSundstrom%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520compounds%2520with%2520binding%2520affinity%2520to%2520proteins%2520via%2520magnetization%2520transfer%2520from%2520bulk%2520water%26jtitle%3DJ.%2520Biomol.%2520NMR%26date%3D2000%26volume%3D18%26spage%3D65%26epage%3D68%26doi%3D10.1023%2FA%3A1008354229396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsamba, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myszka, D. G.</span></span> <span> </span><span class="NLM_article-title">Analyzing a kinetic titration series using affinity biosensors</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">136</span>â <span class="NLM_lpage">147</span>, <span class="refDoi">Â DOI: 10.1016/j.ab.2005.09.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.ab.2005.09.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=16337141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD28XotVGmtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2006&pages=136-147&author=R.+Karlssonauthor=P.+S.+Katsambaauthor=H.+Nordinauthor=E.+Polauthor=D.+G.+Myszka&title=Analyzing+a+kinetic+titration+series+using+affinity+biosensors&doi=10.1016%2Fj.ab.2005.09.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Analyzing a kinetic titration series using affinity biosensors</span></div><div class="casAuthors">Karlsson, Robert; Katsamba, Phinikoula S.; Nordin, Helena; Pol, Ewa; Myszka, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">136-147</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The classical method of measuring binding consts. with affinity-based biosensors involves testing several analyte concns. over the same ligand surface and regenerating the surface between binding cycles.  Here the authors describe an alternative approach to collecting kinetic binding data, which the authors call "kinetic titrn.".  This method involves sequentially injecting an analyte concn. series without any regeneration steps.  Through a combination of simulation and experimentation, the authors show that this method can be as robust as the classical method of anal.  In addn., kinetic titrns. can be more efficient than the conventional data collection method and allow the authors to fully characterize analyte binding to ligand surfaces that are difficult to regenerate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2pCiATVSchbVg90H21EOLACvtfcHk0lhA-odWvKD4QQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotVGmtg%253D%253D&md5=cb5460e9b1bb9850335785f183cd7acb</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2005.09.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2005.09.034%26sid%3Dliteratum%253Aachs%26aulast%3DKarlsson%26aufirst%3DR.%26aulast%3DKatsamba%26aufirst%3DP.%2BS.%26aulast%3DNordin%26aufirst%3DH.%26aulast%3DPol%26aufirst%3DE.%26aulast%3DMyszka%26aufirst%3DD.%2BG.%26atitle%3DAnalyzing%2520a%2520kinetic%2520titration%2520series%2520using%2520affinity%2520biosensors%26jtitle%3DAnal.%2520Biochem.%26date%3D2006%26volume%3D349%26spage%3D136%26epage%3D147%26doi%3D10.1016%2Fj.ab.2005.09.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palau, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Primo, C.</span></span> <span> </span><span class="NLM_article-title">Simulated single-cycle kinetics improves the design of surface plasmon resonance assays</span>. <i>Talanta</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">211</span>â <span class="NLM_lpage">216</span>, <span class="refDoi">Â DOI: 10.1016/j.talanta.2013.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.talanta.2013.04.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=23953462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ylu73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2013&pages=211-216&author=W.+Palauauthor=C.+Di+Primo&title=Simulated+single-cycle+kinetics+improves+the+design+of+surface+plasmon+resonance+assays&doi=10.1016%2Fj.talanta.2013.04.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Simulated single-cycle kinetics improves the design of surface plasmon resonance assays</span></div><div class="casAuthors">Palau, William; Di Primo, Carmelo</div><div class="citationInfo"><span class="NLM_cas:title">Talanta</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">211-216</span>CODEN:
                <span class="NLM_cas:coden">TLNTA2</span>;
        ISSN:<span class="NLM_cas:issn">0039-9140</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Instruments based on the surface plasmon resonance (SPR) principle are widely used to monitor in real time mol. interactions between a partner, immobilized on a sensor chip surface and another one injected in a continuous flow of buffer.  In a classical SPR expt., several cycles of binding and regeneration of the surface are performed in order to det. the rate and the equil. consts. of the reaction.  In 2006, Karlsson and co-workers introduced a new method named single-cycle kinetics (SCK) to perform SPR assays.  The method consists in injecting sequentially increasing concns. of the partner in soln., with only one regeneration step performed at the end of the complete binding cycle.  A 10 base-pair DNA duplex was characterized kinetically to show how simulated sensorgrams generated by the BiaEvaluation software provided by Biacore could really improve the design of SPR assays performed with the SCK method.  The DNA duplex was investigated at three temps., 10, 20 and 30 Â°C, to analyze fast and slow rate consts.  The results show that after a short obligatory preliminary expt., simulations provide users with the best exptl. conditions to be used, in particular, the max. concn. used to reach satn., the diln. factor for the serial dilns. of the sample injected and the duration of the dissocn. and assocn. phases.  The use of simulated single-cycle kinetics saves time and reduces sample consumption.  Simulations can also be used to design SPR expts. with ternary complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrPip6Mc_w_7Vg90H21EOLACvtfcHk0ljIPQCLKLV47A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ylu73K&md5=aa9b5b14cb3d1d292f2bd95692963a30</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.talanta.2013.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.talanta.2013.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DPalau%26aufirst%3DW.%26aulast%3DDi%2BPrimo%26aufirst%3DC.%26atitle%3DSimulated%2520single-cycle%2520kinetics%2520improves%2520the%2520design%2520of%2520surface%2520plasmon%2520resonance%2520assays%26jtitle%3DTalanta%26date%3D2013%26volume%3D114%26spage%3D211%26epage%3D216%26doi%3D10.1016%2Fj.talanta.2013.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <span> </span><span class="NLM_article-title">The drug-target residence time model: a 10-year retrospective</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">87</span>â <span class="NLM_lpage">95</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2015.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fnrd.2015.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=26678621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVCrurnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=87-95&author=R.+A.+Copeland&title=The+drug-target+residence+time+model%3A+a+10-year+retrospective&doi=10.1038%2Fnrd.2015.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The drug-target residence time model: a 10-year retrospective</span></div><div class="casAuthors">Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The drug-target residence time model was first introduced in 2006 and has been broadly adopted across the chem. biol., biotechnol. and pharmaceutical communities.  While traditional in vitro methods view drug-target interactions exclusively in terms of equil. affinity, the residence time model takes into account the conformational dynamics of target macromols. that affect drug binding and dissocn.  The key tenet of this model is that the lifetime (or residence time) of the binary drug-target complex, and not the binding affinity per se, dictates much of the in vivo pharmacol. activity.  Here, this model is revisited and key applications of it over the past 10 years are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwNrhp9U8kwLVg90H21EOLACvtfcHk0ljIPQCLKLV47A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVCrurnE&md5=23f4a6973d77804292ff0af6c81358c0</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.18%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DThe%2520drug-target%2520residence%2520time%2520model%253A%2520a%252010-year%2520retrospective%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D87%26epage%3D95%26doi%3D10.1038%2Fnrd.2015.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompliano, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">730</span>â <span class="NLM_lpage">739</span>, <span class="refDoi">Â DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lh5Ni87xd2WGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosfield, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tari, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, J.</span></span> <span> </span><span class="NLM_article-title">Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">8526</span>â <span class="NLM_lpage">8529</span>, <span class="refDoi">Â DOI: 10.1074/jbc.C300511200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1074%2Fjbc.C300511200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=14672944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1Onsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=8526-8529&author=D.+J.+Hosfieldauthor=Y.+Zhangauthor=D.+R.+Douganauthor=A.+Brounauthor=L.+W.+Tariauthor=R.+V.+Swansonauthor=J.+Finn&title=Structural+basis+for+bisphosphonate-mediated+inhibition+of+isoprenoid+biosynthesis&doi=10.1074%2Fjbc.C300511200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Bisphosphonate-mediated Inhibition of Isoprenoid Biosynthesis</span></div><div class="casAuthors">Hosfield, David J.; Zhang, Yanming; Dougan, Douglas R.; Broun, Alexei; Tari, Leslie W.; Swanson, Ronald V.; Finn, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">8526-8529</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Farnesyl pyrophosphate synthetase (FPPS) synthesizes farnesyl pyrophosphate through successive condensations of isopentyl pyrophosphate with dimethylallyl pyrophosphate and geranyl pyrophosphate.  Nitrogen-contg. bisphosphonate drugs used to treat osteoclast-mediated bone resorption and tumor-induced hypercalcemia are potent inhibitors of the enzyme.  Here we present crystal structures of substrate and bisphosphonate complexes of FPPS.  The structures reveal how enzyme conformational changes organize conserved active site residues to exploit metal-induced ionization and substrate positioning for catalysis.  The structures further demonstrate how nitrogen-contg. bisphosphonates mimic a carbocation intermediate to inhibit the enzyme.  Together, these FPPS complexes provide a structural template for the design of novel inhibitors that may prove useful for the treatment of osteoporosis and other clin. indications including cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMQ2ycptNThbVg90H21EOLACvtfcHk0lh5Ni87xd2WGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1Onsbk%253D&md5=c7b7fc1ead39a9bcc9365ad0acd63a1a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C300511200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C300511200%26sid%3Dliteratum%253Aachs%26aulast%3DHosfield%26aufirst%3DD.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DBroun%26aufirst%3DA.%26aulast%3DTari%26aufirst%3DL.%2BW.%26aulast%3DSwanson%26aufirst%3DR.%2BV.%26aulast%3DFinn%26aufirst%3DJ.%26atitle%3DStructural%2520basis%2520for%2520bisphosphonate-mediated%2520inhibition%2520of%2520isoprenoid%2520biosynthesis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D8526%26epage%3D8529%26doi%3D10.1074%2Fjbc.C300511200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kavanagh, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebetino, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, U.</span></span> <span> </span><span class="NLM_article-title">The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">7829</span>â <span class="NLM_lpage">7834</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0601643103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1073%2Fpnas.0601643103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=16684881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVGksL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=7829-7834&author=K.+L.+Kavanaghauthor=K.+Guoauthor=J.+E.+Dunfordauthor=X.+Wuauthor=S.+Knappauthor=F.+H.+Ebetinoauthor=M.+J.+Rogersauthor=R.+G.+Russellauthor=U.+Oppermann&title=The+molecular+mechanism+of+nitrogen-containing+bisphosphonates+as+antiosteoporosis+drugs&doi=10.1073%2Fpnas.0601643103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs</span></div><div class="casAuthors">Kavanagh, Kathryn L.; Guo, Kunde; Dunford, James E.; Wu, Xiaoqiu; Knapp, Stefan; Ebetino, Frank H.; Rogers, Michael J.; Russell, R. Graham G.; Oppermann, Udo</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7829-7834</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Osteoporosis and low bone mass are currently estd. to be a major public health risk affecting > 50% of the female population over the age of 50.  Because of their bone-selective pharmacokinetics, nitrogen-contg. bisphosphonates (N-BPs), currently used as clin. inhibitors of bone-resorption diseases, target osteoclast farnesyl pyrophosphate synthase (FPPS) and inhibit protein prenylation.  FPPS, a key branchpoint of the mevalonate pathway, catalyzes the successive condensation of isopentenyl pyrophosphate with dimethylallyl pyrophosphate and geranyl pyrophosphate.  To understand the mol. events involved in inhibition of FPPS by N-BPs, we used protein crystallog., enzyme kinetics, and isothermal titrn. calorimetry.  We report here high-resoln. x-ray structures of the human enzyme in complexes with risedronate and zoledronate, two of the leading N-BPs in clin. use.  These agents bind to the dimethylallyl/geranyl pyrophosphate ligand pocket and induce a conformational change.  The interactions of the N-BP cyclic nitrogen with Thr-201 and Lys-200 suggest that these inhibitors achieve potency by positioning their nitrogen in the proposed carbocation-binding site.  Kinetic analyses reveal that inhibition is competitive with geranyl pyrophosphate and is of a slow, tight binding character, indicating that isomerization of an initial enzyme-inhibitor complex occurs with inhibitor binding.  Isothermal titrn. calorimetry indicates that binding of N-BPs to the apoenzyme is entropy-driven, presumably through desolvation entropy effects.  These expts. reveal the mol. binding characteristics of an important pharmacol. target and provide a route for further optimization of these important drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1EVLSV5J3IrVg90H21EOLACvtfcHk0lh5Ni87xd2WGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVGksL0%253D&md5=d422e7cb8cfd588daa4c4a76756dc45b</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0601643103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0601643103%26sid%3Dliteratum%253Aachs%26aulast%3DKavanagh%26aufirst%3DK.%2BL.%26aulast%3DGuo%26aufirst%3DK.%26aulast%3DDunford%26aufirst%3DJ.%2BE.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DEbetino%26aufirst%3DF.%2BH.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26aulast%3DRussell%26aufirst%3DR.%2BG.%26aulast%3DOppermann%26aufirst%3DU.%26atitle%3DThe%2520molecular%2520mechanism%2520of%2520nitrogen-containing%2520bisphosphonates%2520as%2520antiosteoporosis%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D7829%26epage%3D7834%26doi%3D10.1073%2Fpnas.0601643103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klicic, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainz, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoll, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenkin, P. S.</span></span> <span> </span><span class="NLM_article-title">Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1739</span>â <span class="NLM_lpage">1749</span>, <span class="refDoi">Â DOI: 10.1021/jm0306430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0306430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1739-1749&author=R.+A.+Friesnerauthor=J.+L.+Banksauthor=R.+B.+Murphyauthor=T.+A.+Halgrenauthor=J.+J.+Klicicauthor=D.+T.+Mainzauthor=M.+P.+Repaskyauthor=E.+H.+Knollauthor=M.+Shelleyauthor=J.+K.+Perryauthor=D.+E.+Shawauthor=P.+Francisauthor=P.+S.+Shenkin&title=Glide%3A+a+new+approach+for+rapid%2C+accurate+docking+and+scoring.+1.+Method+and+assessment+of+docking+accuracy&doi=10.1021%2Fjm0306430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</span></div><div class="casAuthors">Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B.; Halgren, Thomas A.; Klicic, Jasna J.; Mainz, Daniel T.; Repasky, Matthew P.; Knoll, Eric H.; Shelley, Mee; Perry, Jason K.; Shaw, David E.; Francis, Perry; Shenkin, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand.  In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses.  The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose.  Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms.  Docking accuracy is assessed by redocking ligands from 282 cocrystd. PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose.  Errors in geometry for the top-ranked pose are less than 1 Ã in nearly half of the cases and are greater than 2 Ã in only about one-third of them.  Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds.  Glide is also found to be more accurate than the recently described Surflex method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPuigu31qMMLVg90H21EOLACvtfcHk0lipr1xAyVSKPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D&md5=8cc2f0022318b12dd972e9c493375bf9</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm0306430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0306430%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DKlicic%26aufirst%3DJ.%2BJ.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DShenkin%26aufirst%3DP.%2BS.%26atitle%3DGlide%253A%2520a%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25201.%2520Method%2520and%2520assessment%2520of%2520docking%2520accuracy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1739%26epage%3D1749%26doi%3D10.1021%2Fjm0306430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waters, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">KRAS: The critical driver and therapeutic target for pancreatic cancer</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">a031435</span>, <span class="refDoi">Â DOI: 10.1101/cshperspect.a031435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1101%2Fcshperspect.a031435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=29229669" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=a031435&author=A.+M.+Watersauthor=C.+J.+Der&title=KRAS%3A+The+critical+driver+and+therapeutic+target+for+pancreatic+cancer&doi=10.1101%2Fcshperspect.a031435"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a031435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a031435%26sid%3Dliteratum%253Aachs%26aulast%3DWaters%26aufirst%3DA.%2BM.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DKRAS%253A%2520The%2520critical%2520driver%2520and%2520therapeutic%2520target%2520for%2520pancreatic%2520cancer%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2018%26volume%3D8%26spage%3Da031435%26doi%3D10.1101%2Fcshperspect.a031435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendifar, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span> <span> </span><span class="NLM_article-title">Statins and pancreatic cancer</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1035</span>â <span class="NLM_lpage">1040</span>, <span class="refDoi">Â DOI: 10.3892/ol.2017.5572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.3892%2Fol.2017.5572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=28454210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGjtLvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=1035-1040&author=J.+Gongauthor=E.+Sachdevauthor=L.+A.+Robbinsauthor=E.+Linauthor=A.+E.+Hendifarauthor=M.+M.+Mita&title=Statins+and+pancreatic+cancer&doi=10.3892%2Fol.2017.5572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Statins and pancreatic cancer (Review)</span></div><div class="casAuthors">Gong, Jun; Sachdev, Esha; Robbins, Lori A.; Lin, Emily; Hendifar, andrew E.; Mita, Monica M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1035-1040</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1082</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Pancreatic cancer remains among the most lethal cancers, despite ongoing advances in treatment for all stages of the disease.  Disease prevention represents another oppor- tunity to improve patient outcome, with metabolic syndrome and its components, such as diabetes, obesity and dyslipid- emia, having been recognized as modifiable risk factors for pancreatic cancer.  In addn., statins have been shown to potentially reduce pancreatic cancer risk and to improve survival in patients with a combination of metabolic syndrome and pancreatic cancer.  Furthermore, preclin. studies have demonstrated that statins exhibit antitumor effects in pancre- atic cancer cell lines in vitro and animal models in vivo, in addn. to delaying the progression of pancreatic intraepithe- lial neoplasia to pancreatic ductal adenocarcinoma (PDAC) and inhibiting PDAC formation in conditional K-Ras mutant mice.  The mechanisms by which statins produce anticancer effects remain poorly understood, although appear to involve inhibition of the mevalonate/cholesterol synthesis pathway, thus blocking the synthesis of intermediates important for prenylation and activation of the Ras/mitogen-activated protein kinase 1 signaling pathway.  Furthermore, statins have been identified to modulate the phosphoinositide 3-kinase/Akt serine/threonine kinase 1 and inflammation signaling path- ways, and to alter the expression of genes involved in lipid metab., which are important for PDAC growth and prolif- eration.  In addn., statins have been demonstrated to exhibit further antitumor mechanisms in a no. of other cancer types, which are beyond the scope of the present review.  In the present review, current evidence highlighting the potential of statins as chemopreventive agents in pancreatic cancer is presented, and the antitumor mechanisms of statins elucidated thus far in this disease are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLr16pDI4rl7Vg90H21EOLACvtfcHk0lipr1xAyVSKPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGjtLvP&md5=1cec51b31773184798db38409d2a326d</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3892%2Fol.2017.5572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2017.5572%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DSachdev%26aufirst%3DE.%26aulast%3DRobbins%26aufirst%3DL.%2BA.%26aulast%3DLin%26aufirst%3DE.%26aulast%3DHendifar%26aufirst%3DA.%2BE.%26aulast%3DMita%26aufirst%3DM.%2BM.%26atitle%3DStatins%2520and%2520pancreatic%2520cancer%26jtitle%3DOncol.%2520Lett.%26date%3D2017%26volume%3D13%26spage%3D1035%26epage%3D1040%26doi%3D10.3892%2Fol.2017.5572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akedo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4885</span>â <span class="NLM_lpage">4891</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=11406567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1Gru7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=4885-4891&author=T.+Kusamaauthor=M.+Mukaiauthor=T.+Iwasakiauthor=M.+Tatsutaauthor=Y.+Matsumotoauthor=H.+Akedoauthor=H.+Nakamura&title=Inhibition+of+epidermal+growth+factor-induced+RhoA+translocation+and+invasion+of+human+pancreatic+cancer+cells+by+3-hydroxy-3-methylglutaryl-coenzyme+A+reductase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors</span></div><div class="casAuthors">Kusama, Toshiyuki; Mukai, Mutsuko; Iwasaki, Teruo; Tatsuta, Masaharu; Matsumoto, Yoshirou; Akedo, Hitoshi; Nakamura, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4885-4891</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors prevent the conversion of HMG-CoA to mevalonate and thereby inhibit the synthesis of other products derived from this metabolite.  This includes a no. of small prenylated GTPases involved in cell growth, motility, and invasion.  The authors studied the effect of HMG-CoA reductase inhibitors (fluvastatin and lovastatin) on in vitro invasion of human pancreatic cancer PANC-1 cells.  Epidermal growth factor (EGF) induced a dose-dependent increase of PANC-1 cell invasion in a modified Boyden chamber assay.  Stimulation of cancer cells with EGF induced translocation of RhoA from the cytosol to the membrane fraction and actin stress fiber assembly.  Furthermore, Clostridium botulinum C3 transferase, a specific inhibitor of Rho, inhibited the ability of EGF to promote invasion, indicating that EGF-induced cancer cell invasion is regulated by Rho signaling.  Treatment of PANC-1 cells with fluvastatin markedly attenuated EGF-induced translocation of RhoA from the cytosol to the membrane fraction and actin stress fiber assembly, whereas it did not inhibit the tyrosine phosphorylation of EGF receptor and c-erbB-2.  The induction of cancer cell invasion by EGF was inhibited by the addn. of fluvastatin or lovastatin in a dose-dependent manner.  The effects of fluvastatin or lovastatin on cell morphol. and invasion were reversed by the addn. of all-trans-geranylgeraniol but not by the addn. of all-trans-farnesol.  These results suggest that HMG-CoA reductase inhibitors affect RhoA activation by preventing geranylgeranylation, which results in inhibition of EGF-induced invasiveness of human pancreatic cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGperpQZsHWGMbVg90H21EOLACvtfcHk0lipr1xAyVSKPw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1Gru7s%253D&md5=e2d5f21f127a2427ff21e725d1ac4180</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKusama%26aufirst%3DT.%26aulast%3DMukai%26aufirst%3DM.%26aulast%3DIwasaki%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DM.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DAkedo%26aufirst%3DH.%26aulast%3DNakamura%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520epidermal%2520growth%2520factor-induced%2520RhoA%2520translocation%2520and%2520invasion%2520of%2520human%2520pancreatic%2520cancer%2520cells%2520by%25203-hydroxy-3-methylglutaryl-coenzyme%2520A%2520reductase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D4885%26epage%3D4891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akedo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span> <span> </span><span class="NLM_article-title">3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">308</span>â <span class="NLM_lpage">317</span>, <span class="refDoi">Â DOI: 10.1053/gast.2002.31093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1053%2Fgast.2002.31093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=11832446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVGnsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2002&pages=308-317&author=T.+Kusamaauthor=M.+Mukaiauthor=T.+Iwasakiauthor=M.+Tatsutaauthor=Y.+Matsumotoauthor=H.+Akedoauthor=M.+Inoueauthor=H.+Nakamura&title=3-hydroxy-3-methylglutaryl-coenzyme+A+reductase+inhibitors+reduce+human+pancreatic+cancer+cell+invasion+and+metastasis&doi=10.1053%2Fgast.2002.31093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis</span></div><div class="casAuthors">Kusama, Toshiyuki; Mukai, Mutsuko; Iwasaki, Teruo; Tatsuta, Masaharu; Matsumoto, Yoshirou; Akedo, Hitoshi; Inoue, Masahiro; Nakamura, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">308-317</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">Background & Aims: Inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase blocks the mevalonate metabolic pathway, which is necessary for the isoprenylation of a no. of small guanosine triphosphatases.  We examd. the effects of HMG-CoA reductase inhibitors, fluvastatin and lovastatin, on human pancreatic cancer cell invasion in vitro and exptl. liver metastasis in vivo.  Methods: Cell invasion was studied in a modified Boyden chamber assay.  The translocation of RhoA was assessed by immunoblotting.  Exptl. liver metastases were induced in nude mice by intrasplenic inoculation of ASPC-1 human pancreatic cancer cells.  Results: Fluvastatin and lovastatin inhibited the in vitro cancer cell invasion induced by epidermal growth factor (EGF) in a manner sensitive to C3 transferase, a specific inhibitor of Rho.  Treatment of ASPC-1 cells with fluvastatin markedly attenuated the EGF-induced translocation of RhoA from the cytosol to the membrane fraction and caused cell rounding.  The effects of fluvastatin could be reversed by the addn. of all-trans-geranylgeraniol.  Administration of fluvastatin to nude mice reduced both metastatic tumor formation in the liver and the growth of established liver metastases at doses recommended for the treatment of hypercholesterolemia in humans.  Conclusions: HMG-CoA reductase inhibitors can be antimetastatic agents with the potential for useful clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKnLA3qbxPbLVg90H21EOLACvtfcHk0ljmgocR7TjqLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVGnsrc%253D&md5=8fd6e3972e31d008deac9eb1ae3aae5c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1053%2Fgast.2002.31093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fgast.2002.31093%26sid%3Dliteratum%253Aachs%26aulast%3DKusama%26aufirst%3DT.%26aulast%3DMukai%26aufirst%3DM.%26aulast%3DIwasaki%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DM.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DAkedo%26aufirst%3DH.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DH.%26atitle%3D3-hydroxy-3-methylglutaryl-coenzyme%2520A%2520reductase%2520inhibitors%2520reduce%2520human%2520pancreatic%2520cancer%2520cell%2520invasion%2520and%2520metastasis%26jtitle%3DGastroenterology%26date%3D2002%26volume%3D122%26spage%3D308%26epage%3D317%26doi%3D10.1053%2Fgast.2002.31093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bocci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collecchi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Tacca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danesi, R.</span></span> <span> </span><span class="NLM_article-title">Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">319</span>â <span class="NLM_lpage">330</span>, <span class="refDoi">Â DOI: 10.1038/sj.bjc.6602720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fsj.bjc.6602720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=16052215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFensb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2005&pages=319-330&author=G.+Bocciauthor=A.+Fioravantiauthor=P.+Orlandiauthor=N.+Bernardiniauthor=P.+Collecchiauthor=M.+Del+Taccaauthor=R.+Danesi&title=Fluvastatin+synergistically+enhances+the+antiproliferative+effect+of+gemcitabine+in+human+pancreatic+cancer+MIAPaCa-2+cells&doi=10.1038%2Fsj.bjc.6602720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells</span></div><div class="casAuthors">Bocci, G.; Fioravanti, A.; Orlandi, P.; Bernardini, N.; Collecchi, P.; Del Tacca, M.; Danesi, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-330</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The new combination between the nucleoside analog gemcitabine and the cholesterol-lowering drug fluvastatin was investigated in vitro and in vivo on the human pancreatic tumor cell line MIAPaCa-2.  The present study demonstrates that fluvastatin inhibits proliferation, induces apoptosis in pancreatic cancer cells harboring a p21ras mutation at codon 12 and synergistically potentiates the cytotoxic effect of gemcitabine.  The pharmacol. activities of fluvastatin are prevented by administration of mevalonic acid, suggesting that the shown inhibition of geranyl-geranylation and farnesylation of cellular proteins, including p21rhoA and p21ras, plays a major role in its anticancer effect.  Fluvastatin treatment also indirectly inhibits the phosphorylation of p42ERK2/mitogen-activated protein kinase, the cellular effector of ras and other signal transduction peptides.  Moreover, fluvastatin administration significantly increases the expression of the deoxycytidine kinase, the enzyme required for the activation of gemcitabine, and simultaneously reduces the 5'-nucleotidase, responsible for deactivation of gemcitabine, suggesting a possible addnl. role of these enzymes in the enhanced cytotoxic activity of gemcitabine.  Finally, a significant in vivo antitumor effect on MIAPaCa-2 xenografts was obsd. with the simultaneous combination of fluvastatin and gemcitabine, resulting in an almost complete suppression and a marked delay in relapse of tumor growth.  In conclusion, the combination of fluvastatin and gemcitabine is an effective cytotoxic, proapoptotic treatment in vitro and in vivo against MIAPaCa-2 cells by a mechanism of action mediated, at least in part, by the inhibition of p21ras and rhoA prenylation.  The obtained exptl. findings might constitute the basis for a novel translational research in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl8pbWZepbKrVg90H21EOLACvtfcHk0ljmgocR7TjqLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFensb0%253D&md5=ddf12edf69898780a2368031c96f609b</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6602720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6602720%26sid%3Dliteratum%253Aachs%26aulast%3DBocci%26aufirst%3DG.%26aulast%3DFioravanti%26aufirst%3DA.%26aulast%3DOrlandi%26aufirst%3DP.%26aulast%3DBernardini%26aufirst%3DN.%26aulast%3DCollecchi%26aufirst%3DP.%26aulast%3DDel%2BTacca%26aufirst%3DM.%26aulast%3DDanesi%26aufirst%3DR.%26atitle%3DFluvastatin%2520synergistically%2520enhances%2520the%2520antiproliferative%2520effect%2520of%2520gemcitabine%2520in%2520human%2520pancreatic%2520cancer%2520MIAPaCa-2%2520cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D93%26spage%3D319%26epage%3D330%26doi%3D10.1038%2Fsj.bjc.6602720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tassone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagliaferri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viscomi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caraglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAlessandro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galea, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbruzzese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boland, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venuta, S.</span></span> <span> </span><span class="NLM_article-title">Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">1971</span>â <span class="NLM_lpage">1978</span>, <span class="refDoi">Â DOI: 10.1038/sj.bjc.6600986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fsj.bjc.6600986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=12799645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksVKjtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2003&pages=1971-1978&author=P.+Tassoneauthor=P.+Tagliaferriauthor=C.+Viscomiauthor=C.+Palmieriauthor=M.+Caragliaauthor=A.+D%E2%80%99Alessandroauthor=E.+Galeaauthor=A.+Goelauthor=A.+Abbruzzeseauthor=C.+R.+Bolandauthor=S.+Venuta&title=Zoledronic+acid+induces+antiproliferative+and+apoptotic+effects+in+human+pancreatic+cancer+cells+in+vitro&doi=10.1038%2Fsj.bjc.6600986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro</span></div><div class="casAuthors">Tassone, P.; Tagliaferri, P.; Viscomi, C.; Palmieri, C.; Caraglia, M.; D'Alessandro, A.; Galea, E.; Goel, A.; Abbruzzese, A.; Boland, C. R.; Venuta, S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1971-1978</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bisphosphonates (BPs) are an emerging class of drugs mostly used in the palliative care of cancer patients.  The authors investigated the in vitro activity of the most potent antiresorptive BP, zoledronic acid (ZOL), on the growth and survival of three human pancreatic cancer (PC) cell lines (BxPC-3, CFPAC-1 and PANC-1).  Pancreatic cancer frequently has a dysregulated p21ras pathway and therefore appears to be a suitable target for BPs that interfere with the prenylation of small GTP-binding proteins such as p21ras.  The authors found that ZOL induces growth inhibition (IC50:10-50 Î¼M) and apoptotic death of PC cells.  The proapoptotic effect was correlated to cleavage/activation of caspase-9 and poly(ADP)-ribose polymerase, but not of caspase-3.  Moreover, the authors studied the p21ras signaling in cells exposed to ZOL and detected a redn. of p21ras and Raf-1 content and functional downregulation of the terminal enzyme ERK/MAPkinase and of the pKB/Akt survival pathway.  Finally, the authors obsd. that ZOL induces significant cytoskeletal rearrangements.  In conclusion, the authors demonstrated that ZOL induces growth inhibition and apoptosis on PC cells and interferes with growth and survival pathways downstream to p21ras.  These findings might be relevant for expanding application of BPs in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW9UukUWEf4rVg90H21EOLACvtfcHk0ljmgocR7TjqLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksVKjtb8%253D&md5=7329ecc3946ae9bbe132b8827529a1dd</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600986%26sid%3Dliteratum%253Aachs%26aulast%3DTassone%26aufirst%3DP.%26aulast%3DTagliaferri%26aufirst%3DP.%26aulast%3DViscomi%26aufirst%3DC.%26aulast%3DPalmieri%26aufirst%3DC.%26aulast%3DCaraglia%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Alessandro%26aufirst%3DA.%26aulast%3DGalea%26aufirst%3DE.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DAbbruzzese%26aufirst%3DA.%26aulast%3DBoland%26aufirst%3DC.%2BR.%26aulast%3DVenuta%26aufirst%3DS.%26atitle%3DZoledronic%2520acid%2520induces%2520antiproliferative%2520and%2520apoptotic%2520effects%2520in%2520human%2520pancreatic%2520cancer%2520cells%2520in%2520vitro%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D88%26spage%3D1971%26epage%3D1978%26doi%3D10.1038%2Fsj.bjc.6600986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haney, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chhonker, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murry, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holstein, S. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">5308</span>â <span class="NLM_lpage">5320</span>, <span class="refDoi">Â DOI: 10.1038/s41388-019-0794-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fs41388-019-0794-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=30918331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1Kisbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=5308-5320&author=S.+L.+Haneyauthor=M.+L.+Varneyauthor=Y.+S.+Chhonkerauthor=S.+Shinauthor=K.+Mehlaauthor=A.+J.+Crawfordauthor=H.+J.+Smithauthor=L.+M.+Smithauthor=D.+J.+Murryauthor=M.+A.+Hollingsworthauthor=S.+A.+Holstein&title=Inhibition+of+geranylgeranyl+diphosphate+synthase+is+a+novel+therapeutic+strategy+for+pancreatic+ductal+adenocarcinoma&doi=10.1038%2Fs41388-019-0794-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Haney, Staci L.; Varney, Michelle L.; Chhonker, Yashpal S.; Shin, Simon; Mehla, Kamiya; Crawford, Ayrianne J.; Smith, Heather Jensen; Smith, Lynette M.; Murry, Daryl J.; Hollingsworth, Michael A.; Holstein, Sarah A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">5308-5320</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Rab proteins play an essential role in regulating intracellular membrane trafficking processes.  Rab activity is dependent upon geranylgeranylation, a post-translational modification that involves the addn. of 20-carbon isoprenoid chains via the enzyme geranylgeranyl transferase (GGTase) II.  We have focused on the development of inhibitors against geranylgeranyl diphosphate synthase (GGDPS), which generates the isoprenoid donor (GGPP), as anti-Rab agents.  Pancreatic ductal adenocarcinoma (PDAC) is characterized by abnormal mucin prodn. and these mucins play important roles in tumor development, metastasis and chemo-resistance.  We hypothesized that GGDPS inhibitor (GGDPSi) treatment would induce PDAC cell death by disrupting mucin trafficking, thereby inducing the unfolded protein response pathway (UPR) and apoptosis.  To this end, we evaluated the effects of RAM2061, a potent GGDPSi, against PDAC.  Our studies revealed that GGDPSi treatment activates the UPR and triggers apoptosis in a variety of human and mouse PDAC cell lines.  Furthermore, GGDPSi treatment was found to disrupt the intracellular trafficking of key mucins such as MUC1.  These effects could be recapitulated by incubation with a specific GGTase II inhibitor, but not a GGTase I inhibitor, consistent with the effect being dependent on disruption of Rab-mediated activities.  In addn., siRNA-mediated knockdown of GGDPS induces upregulation of UPR markers and disrupts MUC1 trafficking in PDAC cells.  Expts. in two mouse models of PDAC demonstrated that GGDPSi treatment significantly slows tumor growth.  Collectively, these data support further development of GGDPSi therapy as a novel strategy for the treatment of PDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEnq8v0pZgI7Vg90H21EOLACvtfcHk0lhpM2-g8gDmYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1Kisbo%253D&md5=511c7c9357df4755ab435f84d33930d7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fs41388-019-0794-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-019-0794-6%26sid%3Dliteratum%253Aachs%26aulast%3DHaney%26aufirst%3DS.%2BL.%26aulast%3DVarney%26aufirst%3DM.%2BL.%26aulast%3DChhonker%26aufirst%3DY.%2BS.%26aulast%3DShin%26aufirst%3DS.%26aulast%3DMehla%26aufirst%3DK.%26aulast%3DCrawford%26aufirst%3DA.%2BJ.%26aulast%3DSmith%26aufirst%3DH.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BM.%26aulast%3DMurry%26aufirst%3DD.%2BJ.%26aulast%3DHollingsworth%26aufirst%3DM.%2BA.%26aulast%3DHolstein%26aufirst%3DS.%2BA.%26atitle%3DInhibition%2520of%2520geranylgeranyl%2520diphosphate%2520synthase%2520is%2520a%2520novel%2520therapeutic%2520strategy%2520for%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26spage%3D5308%26epage%3D5320%26doi%3D10.1038%2Fs41388-019-0794-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiezewska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallner, G.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">191</span>â <span class="NLM_lpage">198</span>, <span class="refDoi">Â DOI: 10.1006/abbi.1998.0611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1006%2Fabbi.1998.0611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=9606952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADyaK1cXjt1Kgsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=1998&pages=191-198&author=M.+Bentingerauthor=J.+Grunlerauthor=E.+Petersonauthor=E.+Swiezewskaauthor=G.+Dallner&title=Phosphorylation+of+farnesol+in+rat+liver+microsomes%3A+properties+of+farnesol+kinase+and+farnesyl+phosphate+kinase&doi=10.1006%2Fabbi.1998.0611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase</span></div><div class="casAuthors">Bentinger, Magnus; Gruenler, Jacob; Peterson, Elisabeth; Swiezewska, Ewa; Dallner, Gustav</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-198</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">As farnesol may serve as a nonsterol endogenous regulator of the mevalonate pathway, the possibility that a kinase specific for its phosphorylation is present in the rat liver was investigated.  In the 10,000g supernatant of rat liver, farnesyl monophosphate was synthesized in the presence of ATP.  The Km value for farnesol was 2.3 Î¼M.  Various detergents inhibited the activity of the enzyme.  The farnesol kinase was present in rough and in smooth I microsomes, but not in smooth II microsomes, mitochondria, peroxisomes, Golgi, or plasma membranes.  The enzyme was assocd. with the inner, luminal surface of the vesicles.  Further analyses have demonstrated that an enzymic mechanism exists which catalyzes the phosphorylation of farnesyl-P to farnesyl-PP.  Activity of the farnesyl phosphate kinase resulted in the phosphorylation of the monophosphate by CTP but not by ATP, GTP, or UTP.  This enzyme is activated by low concns. of detergents.  Treatment with proteases and chem. probes indicate that this second phosphorylation reaction probably takes place on the outer, cytoplasmic surface of microsomal vesicles.  These results demonstrate that rat liver microsomes contain two enzymes for the consecutive phosphorylation of farnesol to farnesyl-PP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO0_Na3H33OLVg90H21EOLACvtfcHk0lhpM2-g8gDmYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjt1Kgsbg%253D&md5=d0141328747a9563fbe389c7a50c6d7e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1006%2Fabbi.1998.0611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabbi.1998.0611%26sid%3Dliteratum%253Aachs%26aulast%3DBentinger%26aufirst%3DM.%26aulast%3DGrunler%26aufirst%3DJ.%26aulast%3DPeterson%26aufirst%3DE.%26aulast%3DSwiezewska%26aufirst%3DE.%26aulast%3DDallner%26aufirst%3DG.%26atitle%3DPhosphorylation%2520of%2520farnesol%2520in%2520rat%2520liver%2520microsomes%253A%2520properties%2520of%2520farnesol%2520kinase%2520and%2520farnesyl%2520phosphate%2520kinase%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D1998%26volume%3D353%26spage%3D191%26epage%3D198%26doi%3D10.1006%2Fabbi.1998.0611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matise, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diers, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largaespada, D. A.</span></span> <span> </span><span class="NLM_article-title">RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1086</span>â <span class="NLM_lpage">1096</span>, <span class="refDoi">Â DOI: 10.1182/blood-2008-01-132316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1182%2Fblood-2008-01-132316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=18952898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A280%3ADC%252BD1M7gtlOmsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=1086-1096&author=W.+I.+Kimauthor=I.+Matiseauthor=M.+D.+Diersauthor=D.+A.+Largaespada&title=RAS+oncogene+suppression+induces+apoptosis+followed+by+more+differentiated+and+less+myelosuppressive+disease+upon+relapse+of+acute+myeloid+leukemia&doi=10.1182%2Fblood-2008-01-132316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia</span></div><div class="casAuthors">Kim Won-Il; Matise Ilze; Diers Miechaleen D; Largaespada David A</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1086-96</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To study the oncogenic role of the NRAS oncogene (NRAS(G12V)) in the context of acute myeloid leukemia (AML), we used a Vav promoter-tetracycline transactivator (Vav-tTA)-driven repressible TRE-NRAS(G12V) transgene system in Mll-AF9 knock-in mice developing AML.  Conditional repression of NRAS(G12V) expression greatly reduced peripheral white blood cell (WBC) counts in leukemia recipient mice and induced apoptosis in the transplanted AML cells correlated with reduced Ras/Erk signaling.  After marked decrease of AML blast cells, myeloproliferative disease (MPD)-like AML relapsed characterized by cells that did not express NRAS(G12V).  In comparison with primary AML, the MPD-like AML showed significantly reduced aggressiveness, reduced myelosuppression, and a more differentiated phenotype.  We conclude that, in AML induced by an Mll-AF9 transgene, NRAS(G12V) expression contributes to acute leukemia maintenance by suppressing apoptosis and reducing differentiation of leukemia cells.  Moreover, NRAS(G12V) oncogene has a cell nonautonomous role in suppressing erythropoiesis that results in the MPD-like AML show significantly reduced ability to induce anemia.  Our results imply that targeting NRAS or RAS oncogene-activated pathways is a good therapeutic strategy for AML and attenuating aggressiveness of relapsed AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaPf2e-GZBYJagfuraLLzSfW6udTcc2eYwhcfJ6oWzU7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7gtlOmsQ%253D%253D&md5=963673a542ef53f9309ad591c5cfc3ea</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-01-132316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-01-132316%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%2BI.%26aulast%3DMatise%26aufirst%3DI.%26aulast%3DDiers%26aufirst%3DM.%2BD.%26aulast%3DLargaespada%26aufirst%3DD.%2BA.%26atitle%3DRAS%2520oncogene%2520suppression%2520induces%2520apoptosis%2520followed%2520by%2520more%2520differentiated%2520and%2520less%2520myelosuppressive%2520disease%2520upon%2520relapse%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D1086%26epage%3D1096%26doi%3D10.1182%2Fblood-2008-01-132316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">The dark side of Ras: regulation of apoptosis</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">8999</span>â <span class="NLM_lpage">9006</span>, <span class="refDoi">Â DOI: 10.1038/sj.onc.1207111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fsj.onc.1207111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=14663478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsFOmsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=8999-9006&author=A.+D.+Coxauthor=C.+J.+Der&title=The+dark+side+of+Ras%3A+regulation+of+apoptosis&doi=10.1038%2Fsj.onc.1207111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The dark side of Ras: regulation of apoptosis</span></div><div class="casAuthors">Cox, Adrienne D.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">56</span>),
    <span class="NLM_cas:pages">8999-9006</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mutational activation of Ras promotes oncogenesis by disrupting a multitude of normal cellular processes.  Perhaps, best characterized and understood are the mechanisms by which oncogenic Ras promotes deregulated cell cycle progression and uncontrolled cellular proliferation.  However, it is now clear that oncogenic Ras can also deregulate processes that control apoptosis.  In light of the diversity of downstream effector targets known to facilitate Ras function, it is perhaps not surprising that Ras regulation of cell survival is complex, involving the balance and interplay of multiple signaling networks.  While our understanding of these events is still far from complete, and is complicated by cell type and signaling context differences, several important mechanisms have begun to emerge.  We review the role and mechanism of specific effectors in regulating the antiapoptotic (Raf, phosphatidylinositol 3-kinase and Tiam1) and apoptotic (Nore1 and RASSF1) actions of oncogenic Ras, and discuss the possibility that the effector actions of p120RasGAP make a significant contribution to Ras regulation of apoptotic events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVFAJRj7yjhbVg90H21EOLACvtfcHk0lh_IK0g3CUUiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsFOmsro%253D&md5=9b1b257ddc3638c187ea260c4817ca98</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207111%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520dark%2520side%2520of%2520Ras%253A%2520regulation%2520of%2520apoptosis%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D8999%26epage%3D9006%26doi%3D10.1038%2Fsj.onc.1207111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scagliotti, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmidis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreurs, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel-Riedel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schallier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manegold, C.</span></span> <span> </span><span class="NLM_article-title">Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2082</span>â <span class="NLM_lpage">2087</span>, <span class="refDoi">Â DOI: 10.1093/annonc/mds128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1093%2Fannonc%2Fmds128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=22730101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A280%3ADC%252BC38jksFGntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=2082-2087&author=G.+V.+Scagliottiauthor=P.+Kosmidisauthor=F.+de+Marinisauthor=A.+J.+Schreursauthor=I.+Albertauthor=W.+Engel-Riedelauthor=D.+Schallierauthor=S.+Barberaauthor=H.+P.+Kuoauthor=V.+Salloauthor=J.+R.+Perezauthor=C.+Manegold&title=Zoledronic+acid+in+patients+with+stage+IIIA%2FB+NSCLC%3A+results+of+a+randomized%2C+phase+III+study&doi=10.1093%2Fannonc%2Fmds128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study</span></div><div class="casAuthors">Scagliotti G V; Kosmidis P; de Marinis F; Schreurs A J M; Albert I; Engel-Riedel W; Schallier D; Barbera S; Kuo H-P; Sallo V; Perez J R; Manegold C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2082-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Bone metastases are common in patients with advanced non-small-cell lung cancer (NSCLC) and can have devastating consequences.  Preventing or delaying bone metastases may improve outcomes.  PATIENTS AND METHODS:  This study evaluated whether zoledronic acid (ZOL) delayed disease progression or recurrence in patients with controlled stage IIIA/B NSCLC after first-line therapy.  Patients received vitamin D and calcium supplementation and were randomized to i.v.  ZOL (every 3-4 weeks) or no treatment (control).  The primary end point was progression-free survival (PFS).  RESULTS:  No significant intergroup differences were observed in PFS or overall survival (OS).  Median PFS was 9.0 months with ZOL versus 11.3 months for control.  Fifteen ZOL-treated (6.6%) and 19 control patients (9.0%) developed bone metastases.  Estimated 1-year OS was 81.8% for each group.  ZOL safety profile was consistent with previous clinical data, but with higher discontinuations versus control.  Fifteen ZOL-treated (6.6%) and five control patients (2.3%) had renal adverse events.  Two cases of osteonecrosis of the jaw were reported.  CONCLUSIONS:  ZOL did not significantly affect PFS or OS in stage IIIA/B NSCLC patients with controlled disease, with a trend toward worsening PFS in the longer-term follow-up.  Few patients experienced bone metastases, possibly limiting the potential ZOL impact on disease course.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6N1RIViUs1kmhnSqMnvzDfW6udTcc2ea9XyLVOQrTmrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jksFGntA%253D%253D&md5=5d6f2d638e91d946bbc16d3a83d7953e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds128%26sid%3Dliteratum%253Aachs%26aulast%3DScagliotti%26aufirst%3DG.%2BV.%26aulast%3DKosmidis%26aufirst%3DP.%26aulast%3Dde%2BMarinis%26aufirst%3DF.%26aulast%3DSchreurs%26aufirst%3DA.%2BJ.%26aulast%3DAlbert%26aufirst%3DI.%26aulast%3DEngel-Riedel%26aufirst%3DW.%26aulast%3DSchallier%26aufirst%3DD.%26aulast%3DBarbera%26aufirst%3DS.%26aulast%3DKuo%26aufirst%3DH.%2BP.%26aulast%3DSallo%26aufirst%3DV.%26aulast%3DPerez%26aufirst%3DJ.%2BR.%26aulast%3DManegold%26aufirst%3DC.%26atitle%3DZoledronic%2520acid%2520in%2520patients%2520with%2520stage%2520IIIA%252FB%2520NSCLC%253A%2520results%2520of%2520a%2520randomized%252C%2520phase%2520III%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3D2082%26epage%3D2087%26doi%3D10.1093%2Fannonc%2Fmds128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janni, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedl, T. W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenegger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blohmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forstbauer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juckstock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneeweiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brucker, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rack, B.</span></span> <span> </span><span class="NLM_article-title">Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: phase III data from the SUCCESS A study</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">GS1-06</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.SABCS17-GS1-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1158%2F1538-7445.SABCS17-GS1-06" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=GS1-06&issue=4&author=W.+Janniauthor=T.+W.+P.+Friedlauthor=T.+Fehmauthor=V.+Mullerauthor=W.+Lichteneggerauthor=J.+Blohmerauthor=R.+Lorenzauthor=H.+Forstbauerauthor=E.+Bauerauthor=V.+Finkauthor=I.+Bekesauthor=J.+Juckstockauthor=A.+Schneeweissauthor=H.+Teschauthor=S.+Mahnerauthor=S.+Y.+Bruckerauthor=G.+Heinrichauthor=M.+W.+Beckmannauthor=R.+Colemanauthor=B.+Rack&title=Extended+adjuvant+bisphosphonate+treatment+over+five+years+in+early+breast+cancer+does+not+improve+disease-free+and+overall+survival+compared+to+two+years+of+treatment%3A+phase+III+data+from+the+SUCCESS+A+study&doi=10.1158%2F1538-7445.SABCS17-GS1-06"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.SABCS17-GS1-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.SABCS17-GS1-06%26sid%3Dliteratum%253Aachs%26aulast%3DJanni%26aufirst%3DW.%26aulast%3DFriedl%26aufirst%3DT.%2BW.%2BP.%26aulast%3DFehm%26aufirst%3DT.%26aulast%3DMuller%26aufirst%3DV.%26aulast%3DLichtenegger%26aufirst%3DW.%26aulast%3DBlohmer%26aufirst%3DJ.%26aulast%3DLorenz%26aufirst%3DR.%26aulast%3DForstbauer%26aufirst%3DH.%26aulast%3DBauer%26aufirst%3DE.%26aulast%3DFink%26aufirst%3DV.%26aulast%3DBekes%26aufirst%3DI.%26aulast%3DJuckstock%26aufirst%3DJ.%26aulast%3DSchneeweiss%26aufirst%3DA.%26aulast%3DTesch%26aufirst%3DH.%26aulast%3DMahner%26aufirst%3DS.%26aulast%3DBrucker%26aufirst%3DS.%2BY.%26aulast%3DHeinrich%26aufirst%3DG.%26aulast%3DBeckmann%26aufirst%3DM.%2BW.%26aulast%3DColeman%26aufirst%3DR.%26aulast%3DRack%26aufirst%3DB.%26atitle%3DExtended%2520adjuvant%2520bisphosphonate%2520treatment%2520over%2520five%2520years%2520in%2520early%2520breast%2520cancer%2520does%2520not%2520improve%2520disease-free%2520and%2520overall%2520survival%2520compared%2520to%2520two%2520years%2520of%2520treatment%253A%2520phase%2520III%2520data%2520from%2520the%2520SUCCESS%2520A%2520study%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D4%26spage%3DGS1-06%26doi%3D10.1158%2F1538-7445.SABCS17-GS1-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodwell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkinshaw, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grieve, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett-Lee, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaunt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiley, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R.</span></span> <span> </span><span class="NLM_article-title">Breast-cancer adjuvant therapy with zoledronic acid</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">1396</span>â <span class="NLM_lpage">1405</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1105195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1056%2FNEJMoa1105195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=21995387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlals7jP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1396-1405&author=R.+E.+Colemanauthor=H.+Marshallauthor=D.+Cameronauthor=D.+Dodwellauthor=R.+Burkinshawauthor=M.+Keaneauthor=M.+Gilauthor=S.+J.+Houstonauthor=R.+J.+Grieveauthor=P.+J.+Barrett-Leeauthor=D.+Ritchieauthor=J.+Pughauthor=C.+Gauntauthor=U.+Reaauthor=J.+Petersonauthor=C.+Daviesauthor=V.+Hileyauthor=W.+Gregoryauthor=R.+Bell&title=Breast-cancer+adjuvant+therapy+with+zoledronic+acid&doi=10.1056%2FNEJMoa1105195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Breast-cancer adjuvant therapy with zoledronic acid</span></div><div class="casAuthors">Coleman, Robert E.; Marshall, Helen; Cameron, David; Dodwell, David; Burkinshaw, Roger; Keane, Maccon; Gil, Miguel; Houston, Stephen.; Grieve, Robert J.; Barrett-Lee, Peter J.; Ritchie, Diana; Pugh, Julia; Gaunt, Claire; Rea, Una; Peterson, Jennifer; Davies, Claire; Hiley, Victoria; Gregory, Walter; Bell, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1396-1405</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in patients with early-stage breast cancer.  We conducted a study to det. whether treatment with zoledronic acid, in addn. to std. adjuvant therapy, would improve disease outcomes in such patients.  METHODS: In this open-label phase 3 study, we randomly assigned 3360 patients to receive std. adjuvant systemic therapy either with or without zoledronic acid.  The zoledronic acid was administered every 3 to 4 wk for 6 doses and then every 3 to 6 mo to complete 5 years of treatment.  The primary end point of the study was disease-free survival.  A second interim anal. revealed that a prespecified boundary for lack of benefit had been crossed.  RESULTS: At a median follow-up of 59 mo, there was no significant between-group difference in the primary end point, with a rate of disease-free survival of 77% in each group (adjusted hazard ratio in the zoledronic acid group, 0.98; 95% confidence interval [CI], 0.85 to 1.13; P = 0.79). Disease recurrence or death occurred in 377 patients in the zoledronic acid group and 375 of those in the control group.  The nos. of deaths - 243 in the zoledronic acid group and 276 in the control group - were also similar, resulting in rates of overall survival of 85.4% in the zoledronic acid group and 83.1% in the control group (adjusted hazard ratio, 0.85; 95% CI, 0.72 to 1.01; P = 0.07).  In the zoledronic acid group, there were 17 confirmed cases of osteonecrosis of the jaw (cumulative incidence, 1.1%; 95% CI, 0.6 to 1.7; P < 0.001) and 9 suspected cases; there were no cases in the control group.  Rates of other adverse effects were similar in the two study groups.  CONCLUSIONS: These findings do not support the routine use of zoledronic acid in the adjuvant management of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpISmlJLPnAebVg90H21EOLACvtfcHk0lionZIsqVrKmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlals7jP&md5=3c61150ab39db154b5370ea59896c73f</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105195%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%2BE.%26aulast%3DMarshall%26aufirst%3DH.%26aulast%3DCameron%26aufirst%3DD.%26aulast%3DDodwell%26aufirst%3DD.%26aulast%3DBurkinshaw%26aufirst%3DR.%26aulast%3DKeane%26aufirst%3DM.%26aulast%3DGil%26aufirst%3DM.%26aulast%3DHouston%26aufirst%3DS.%2BJ.%26aulast%3DGrieve%26aufirst%3DR.%2BJ.%26aulast%3DBarrett-Lee%26aufirst%3DP.%2BJ.%26aulast%3DRitchie%26aufirst%3DD.%26aulast%3DPugh%26aufirst%3DJ.%26aulast%3DGaunt%26aufirst%3DC.%26aulast%3DRea%26aufirst%3DU.%26aulast%3DPeterson%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DHiley%26aufirst%3DV.%26aulast%3DGregory%26aufirst%3DW.%26aulast%3DBell%26aufirst%3DR.%26atitle%3DBreast-cancer%2520adjuvant%2520therapy%2520with%2520zoledronic%2520acid%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1396%26epage%3D1405%26doi%3D10.1056%2FNEJMoa1105195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudock, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cass, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Beek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papapoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukkamala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">5153</span>â <span class="NLM_lpage">5162</span>, <span class="refDoi">Â DOI: 10.1021/ja808285e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja808285e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFKnsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=5153-5162&author=Y.+H.+Zhangauthor=R.+Caoauthor=F.+Yinauthor=M.+P.+Hudockauthor=R.+T.+Guoauthor=K.+Krysiakauthor=S.+Mukherjeeauthor=Y.+G.+Gaoauthor=H.+Robinsonauthor=Y.+Songauthor=J.+H.+Noauthor=K.+Berganauthor=A.+Leonauthor=L.+Cassauthor=A.+Goddardauthor=T.+K.+Changauthor=F.+Y.+Linauthor=E.+Van+Beekauthor=S.+Papapoulosauthor=A.+H.+J.+Wangauthor=T.+Kuboauthor=M.+Ochiauthor=D.+Mukkamalaauthor=E.+Oldfield&title=Lipophilic+bisphosphonates+as+dual+farnesyl%2Fgeranylgeranyl+diphosphate+synthase+inhibitors%3A+an+X-ray+and+NMR+investigation&doi=10.1021%2Fja808285e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR Investigation</span></div><div class="casAuthors">Zhang, Yonghui; Cao, Rong; Yin, Fenglin; Hudock, Michael P.; Guo, Rey-Ting; Krysiak, Kilannin; Mukherjee, Sujoy; Gao, Yi-Gui; Robinson, Howard; Song, Yongcheng; No, Joo Hwan; Bergan, Kyle; Leon, Annette; Cass, Lauren; Goddard, Amanda; Chang, Ting-Kai; Lin, Fu-Yang; Van Beek, Ermond; Papapoulos, Socrates; Wang, Andrew H.-J.; Kubo, Tadahiko; Ochi, Mitsuo; Mukkamala, Dushyant; Oldfield, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5153-5162</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Considerable effort has focused on the development of selective protein farnesyl transferase (FTase) and protein geranylgeranyl transferase (GGTase) inhibitors as cancer chemotherapeutics.  Here, we report a new strategy for anticancer therapeutic agents involving inhibition of farnesyl diphosphate synthase (FPPS) and geranylgeranyl diphosphate synthase (GGPPS), the two enzymes upstream of FTase and GGTase, by lipophilic bisphosphonates.  Due to dual site targeting and decreased polarity, the compds. have activities far greater than do current bisphosphonate drugs in inhibiting tumor cell growth and invasiveness, both in vitro and in vivo.  We explore how these compds. inhibit cell growth and how cell activity can be predicted based on enzyme inhibition data, and using X-ray diffraction, solid state NMR, and isothermal titrn. calorimetry, we show how these compds. bind to FPPS and/or GGPPS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHhFMAMouc-rVg90H21EOLACvtfcHk0lionZIsqVrKmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFKnsLw%253D&md5=373a71c889ed9f0ae6510d2503127e94</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fja808285e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja808285e%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DYin%26aufirst%3DF.%26aulast%3DHudock%26aufirst%3DM.%2BP.%26aulast%3DGuo%26aufirst%3DR.%2BT.%26aulast%3DKrysiak%26aufirst%3DK.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.%2BG.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DNo%26aufirst%3DJ.%2BH.%26aulast%3DBergan%26aufirst%3DK.%26aulast%3DLeon%26aufirst%3DA.%26aulast%3DCass%26aufirst%3DL.%26aulast%3DGoddard%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DT.%2BK.%26aulast%3DLin%26aufirst%3DF.%2BY.%26aulast%3DVan%2BBeek%26aufirst%3DE.%26aulast%3DPapapoulos%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DA.%2BH.%2BJ.%26aulast%3DKubo%26aufirst%3DT.%26aulast%3DOchi%26aufirst%3DM.%26aulast%3DMukkamala%26aufirst%3DD.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DLipophilic%2520bisphosphonates%2520as%2520dual%2520farnesyl%252Fgeranylgeranyl%2520diphosphate%2520synthase%2520inhibitors%253A%2520an%2520X-ray%2520and%2520NMR%2520investigation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D5153%26epage%3D5162%26doi%3D10.1021%2Fja808285e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sastry, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adzhigirey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annabhimoju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span> <span> </span><span class="NLM_article-title">Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">221</span>â <span class="NLM_lpage">234</span>, <span class="refDoi">Â DOI: 10.1007/s10822-013-9644-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1007%2Fs10822-013-9644-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=23579614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A280%3ADC%252BC3srksFekug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=221-234&author=G.+M.+Sastryauthor=M.+Adzhigireyauthor=T.+Dayauthor=R.+Annabhimojuauthor=W.+Sherman&title=Protein+and+ligand+preparation%3A+parameters%2C+protocols%2C+and+influence+on+virtual+screening+enrichments&doi=10.1007%2Fs10822-013-9644-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments</span></div><div class="casAuthors">Sastry G Madhavi; Adzhigirey Matvey; Day Tyler; Annabhimoju Ramakrishna; Sherman Woody</div><div class="citationInfo"><span class="NLM_cas:title">Journal of computer-aided molecular design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Structure-based virtual screening plays an important role in drug discovery and complements other screening approaches.  In general, protein crystal structures are prepared prior to docking in order to add hydrogen atoms, optimize hydrogen bonds, remove atomic clashes, and perform other operations that are not part of the x-ray crystal structure refinement process.  In addition, ligands must be prepared to create 3-dimensional geometries, assign proper bond orders, and generate accessible tautomer and ionization states prior to virtual screening.  While the prerequisite for proper system preparation is generally accepted in the field, an extensive study of the preparation steps and their effect on virtual screening enrichments has not been performed.  In this work, we systematically explore each of the steps involved in preparing a system for virtual screening.  We first explore a large number of parameters using the Glide validation set of 36 crystal structures and 1,000 decoys.  We then apply a subset of protocols to the DUD database.  We show that database enrichment is improved with proper preparation and that neglecting certain steps of the preparation process produces a systematic degradation in enrichments, which can be large for some targets.  We provide examples illustrating the structural changes introduced by the preparation that impact database enrichment.  While the work presented here was performed with the Protein Preparation Wizard and Glide, the insights and guidance are expected to be generalizable to structure-based virtual screening with other docking methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQd2Qiai-OqeXqj_yg7twvpfW6udTcc2eZd4uXKkKmP1Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srksFekug%253D%253D&md5=9eb1a820e121aca2742ed53f24481ace</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1007%2Fs10822-013-9644-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-013-9644-8%26sid%3Dliteratum%253Aachs%26aulast%3DSastry%26aufirst%3DG.%2BM.%26aulast%3DAdzhigirey%26aufirst%3DM.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DAnnabhimoju%26aufirst%3DR.%26aulast%3DSherman%26aufirst%3DW.%26atitle%3DProtein%2520and%2520ligand%2520preparation%253A%2520parameters%252C%2520protocols%252C%2520and%2520influence%2520on%2520virtual%2520screening%2520enrichments%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2013%26volume%3D27%26spage%3D221%26epage%3D234%26doi%3D10.1007%2Fs10822-013-9644-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viegas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobrega, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrita, E. J.</span></span> <span> </span><span class="NLM_article-title">Saturation-transfer difference (STD) NMR: a simple and fast method for ligand screening and characterization of protein binding</span>. <i>J. Chem. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">990</span>â <span class="NLM_lpage">994</span>, <span class="refDoi">Â DOI: 10.1021/ed101169t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ed101169t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVant7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2011&pages=990-994&author=A.+Viegasauthor=J.+Mansoauthor=F.+L.+Nobregaauthor=E.+J.+Cabrita&title=Saturation-transfer+difference+%28STD%29+NMR%3A+a+simple+and+fast+method+for+ligand+screening+and+characterization+of+protein+binding&doi=10.1021%2Fed101169t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Saturation-Transfer Difference (STD) NMR: A Simple and Fast Method for Ligand Screening and Characterization of Protein Binding</span></div><div class="casAuthors">Viegas, Aldino; Manso, Joao; Nobrega, Franklin L.; Cabrita, Eurico J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Education</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">990-994</span>CODEN:
                <span class="NLM_cas:coden">JCEDA8</span>;
        ISSN:<span class="NLM_cas:issn">0021-9584</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society and Division of Chemical Education, Inc.</span>)
        </div><div class="casAbstract">Satn. transfer difference (STD) NMR has emerged as one of the most popular ligand-based NMR techniques for the study of protein-ligand interactions.  The success of this technique is a consequence of its robustness and the fact that it is focused on the signals of the ligand, without any need of processing NMR information about the receptor and only using small quantities of nonlabeled macromol.  Moreover, the attractiveness of this expt. is also extendable to the classroom.  In the context of a practical NMR class, this expt. is ideal to illustrate some fundamental NMR concepts, such as the nuclear Overhauser effect and relaxation in a multidisciplinary context, bridging chem. and biochem. with a taste of medicinal chem.  We use the readily available human serum albumin (HSA), 6-D,L-methyl-tryptophan (6-CH3-Trp), and 7- D,L-methyl-tryptophan (7-CH3-Trp) to introduce the STD-NMR expt. and to illustrate its applicability for ligand screening, mapping of binding moieties, and detn. of the dissocn. const., in a context that can be explored or adapted to the student's course level and topic (chem. or biochem.).  We also cover the most important theor. aspects of the STD expt., calling attention to some of its limitations and drawbacks without a complex theor. approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo29sluoDoJ87Vg90H21EOLACvtfcHk0ljiaYCK17PdFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVant7c%253D&md5=807194fdb33d075121408463767cbf74</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fed101169t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fed101169t%26sid%3Dliteratum%253Aachs%26aulast%3DViegas%26aufirst%3DA.%26aulast%3DManso%26aufirst%3DJ.%26aulast%3DNobrega%26aufirst%3DF.%2BL.%26aulast%3DCabrita%26aufirst%3DE.%2BJ.%26atitle%3DSaturation-transfer%2520difference%2520%2528STD%2529%2520NMR%253A%2520a%2520simple%2520and%2520fast%2520method%2520for%2520ligand%2520screening%2520and%2520characterization%2520of%2520protein%2520binding%26jtitle%3DJ.%2520Chem.%2520Educ.%26date%3D2011%26volume%3D88%26spage%3D990%26epage%3D994%26doi%3D10.1021%2Fed101169t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shelley, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholleti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timlin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchimaya, M.</span></span> <span> </span><span class="NLM_article-title">Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">681</span>â <span class="NLM_lpage">691</span>, <span class="refDoi">Â DOI: 10.1007/s10822-007-9133-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1007%2Fs10822-007-9133-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=17899391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKrtbzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=681-691&author=J.+C.+Shelleyauthor=A.+Cholletiauthor=L.+L.+Fryeauthor=J.+R.+Greenwoodauthor=M.+R.+Timlinauthor=M.+Uchimaya&title=Epik%3A+a+software+program+for+pK%28a%29+prediction+and+protonation+state+generation+for+drug-like+molecules&doi=10.1007%2Fs10822-007-9133-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Epik: a software program for pKa prediction and protonation state generation for drug-like molecules</span></div><div class="casAuthors">Shelley, John C.; Cholleti, Anuradha; Frye, Leah L.; Greenwood, Jeremy R.; Timlin, Mathew R.; Uchimaya, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">681-691</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Epik is a computer program for predicting pKa values for drug-like mols.  Epik can use this capability in combination with technol. for tautomerization to adjust the protonation state of small drug-like mols. to automatically generate one or more of the most probable forms for use in further mol. modeling studies.  Many medicinal chems. can exchange protons with their environment, resulting in various ionization and tautomeric states, collectively known as protonation states.  The protonation state of a drug can affect its soly. and membrane permeability.  In modeling, the protonation state of a ligand will also affect which conformations are predicted for the mol., as well as predictions for binding modes and ligand affinities based upon protein-ligand interactions.  Despite the importance of the protonation state, many databases of candidate mols. used in drug development do not store reliable information on the most probable protonation states.  Epik is sufficiently rapid and accurate to process large databases of drug-like mols. to provide this information.  Several new technologies are employed.  Extensions to the well-established Hammett and Taft approaches are used for pKa prediction, namely, mesomer standardization, charge cancellation, and charge spreading to make the predicted results reflect the nature of the mol. itself rather just for the particular Lewis structure used on input.  In addn., a new iterative technol. for generating, ranking and culling the generated protonation states is employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC6PRLT1xT8LVg90H21EOLACvtfcHk0ljiaYCK17PdFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKrtbzP&md5=f4f429ea3894e1ad2519cdf3333a5645</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs10822-007-9133-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-007-9133-z%26sid%3Dliteratum%253Aachs%26aulast%3DShelley%26aufirst%3DJ.%2BC.%26aulast%3DCholleti%26aufirst%3DA.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DTimlin%26aufirst%3DM.%2BR.%26aulast%3DUchimaya%26aufirst%3DM.%26atitle%3DEpik%253A%2520a%2520software%2520program%2520for%2520pK%2528a%2529%2520prediction%2520and%2520protonation%2520state%2520generation%2520for%2520drug-like%2520molecules%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2007%26volume%3D21%26spage%3D681%26epage%3D691%26doi%3D10.1007%2Fs10822-007-9133-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span> <i>PyMOL Molecular
Graphics System</i>, version <span class="NLM_edition">2.0</span>; <span class="NLM_publisher-name">SchrÃ¶dinger, LLC</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PyMOL+Molecular%0AGraphics+System%2C+version+2.0%3B+Schr%C3%B6dinger%2C+LLC."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPyMOL%2520Molecular%250AGraphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wei Cao, Tingting Liu, Shuting Yang, Moude Liu, Zhenghong Pan, Yingjun Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Xu Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis of Icetexane Diterpenes and Apoptosis Inducing Effect by Upregulating BiP-ATF4-CHOP Axis in Colorectal Cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2021,</strong> <em>84 </em>
                                    (7)
                                     , 2012-2019. <a href="https://doi.org/10.1021/acs.jnatprod.1c00310" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.1c00310</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.1c00310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.1c00310%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DEfficient%252BSynthesis%252Bof%252BIcetexane%252BDiterpenes%252Band%252BApoptosis%252BInducing%252BEffect%252Bby%252BUpregulating%252BBiP-ATF4-CHOP%252BAxis%252Bin%252BColorectal%252BCells%26aulast%3DCao%26aufirst%3DWei%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01042021%26date%3D25062021%26volume%3D84%26issue%3D7%26spage%3D2012%26epage%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Junfeng Song, Satish R. Malwal, Noman Baig, Lici A. Schurig-Briccio, Zijun Gao, Girija S. Vaidya, Kailing Yang, Nader S. Abutaleb, Mohamed N. Seleem, Robert B. Gennis, Taras V. Pogorelov, Eric Oldfield, <span class="NLM_string-name hlFld-ContribAuthor">Xinxin Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Prenyltransferase Inhibitors with In Vitro and In Vivo Antibacterial Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2020,</strong> <em>6 </em>
                                    (11)
                                     , 2979-2993. <a href="https://doi.org/10.1021/acsinfecdis.0c00472" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00472%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DDiscovery%252Bof%252BPrenyltransferase%252BInhibitors%252Bwith%252BIn%252BVitro%252Band%252BIn%252BVivo%252BAntibacterial%252BActivity%26aulast%3DSong%26aufirst%3DJunfeng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04072020%26date%3D21102020%26volume%3D6%26issue%3D11%26spage%3D2979%26epage%3D2993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavel  Ershov</span>, <span class="hlFld-ContribAuthor ">Leonid  Kaluzhskiy</span>, <span class="hlFld-ContribAuthor ">Yuri  Mezentsev</span>, <span class="hlFld-ContribAuthor ">Evgeniy  Yablokov</span>, <span class="hlFld-ContribAuthor ">Oksana  Gnedenko</span>, <span class="hlFld-ContribAuthor ">Alexis  Ivanov</span>. </span><span class="cited-content_cbyCitation_article-title">Enzymes in the Cholesterol Synthesis Pathway: Interactomics in the Cancer Context. </span><span class="cited-content_cbyCitation_journal-name">Biomedicines</span><span> <strong>2021,</strong> <em>9 </em>
                                    (8)
                                     , 895. <a href="https://doi.org/10.3390/biomedicines9080895" title="DOI URL">https://doi.org/10.3390/biomedicines9080895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biomedicines9080895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiomedicines9080895%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicines%26atitle%3DEnzymes%252Bin%252Bthe%252BCholesterol%252BSynthesis%252BPathway%25253A%252BInteractomics%252Bin%252Bthe%252BCancer%252BContext%26aulast%3DErshov%26aufirst%3DPavel%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D8%26spage%3D895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yangyang  Guo</span>, <span class="hlFld-ContribAuthor ">Yanyi  Xiao</span>, <span class="hlFld-ContribAuthor ">Hangcheng  Guo</span>, <span class="hlFld-ContribAuthor ">Hengyue  Zhu</span>, <span class="hlFld-ContribAuthor ">Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Jilong  Wang</span>, <span class="hlFld-ContribAuthor ">Junjie  Deng</span>, <span class="hlFld-ContribAuthor ">Junjie  Lan</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Liu</span>, <span class="hlFld-ContribAuthor ">Qiyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongheng  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation. </span><span class="cited-content_cbyCitation_journal-name">Aging</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.18632/aging.203301" title="DOI URL">https://doi.org/10.18632/aging.203301</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/aging.203301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Faging.203301%26sid%3Dliteratum%253Aachs%26jtitle%3DAging%26atitle%3DThe%252Banti-dysenteric%252Bdrug%252Bfraxetin%252Benhances%252Banti-tumor%252Befficacy%252Bof%252Bgemcitabine%252Band%252Bsuppresses%252Bpancreatic%252Bcancer%252Bdevelopment%252Bby%252Bantagonizing%252BSTAT3%252Bactivation%26aulast%3DGuo%26aufirst%3DYangyang%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samo  LeÅ¡nik</span>, <span class="hlFld-ContribAuthor ">Veronika  Furlan</span>, <span class="hlFld-ContribAuthor ">Urban  Bren</span>. </span><span class="cited-content_cbyCitation_article-title">Rosemary (Rosmarinus officinalis L.): extraction techniques, analytical methods and health-promoting biological effects. </span><span class="cited-content_cbyCitation_journal-name">Phytochemistry Reviews</span><span> <strong>2021,</strong> <em>18 </em><a href="https://doi.org/10.1007/s11101-021-09745-5" title="DOI URL">https://doi.org/10.1007/s11101-021-09745-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11101-021-09745-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11101-021-09745-5%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytochemistry%2520Reviews%26atitle%3DRosemary%252B%252528Rosmarinus%252Bofficinalis%252BL.%252529%25253A%252Bextraction%252Btechniques%25252C%252Banalytical%252Bmethods%252Band%252Bhealth-promoting%252Bbiological%252Beffects%26aulast%3DLe%25C5%25A1nik%26aufirst%3DSamo%26date%3D2021%26date%3D2021%26volume%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of isoprenoid biosynthesis pathway and its associated biological processes in human cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative <i>Hs</i>FPPS inhibitors together with X-ray crystallographic structures illustrating ligand binding to sites S1, S2, S3, and S4. (a) Inhibitor structures. (b) Superimposition of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4N1Z">4N1Z</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N6K">3N6K</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RXA">4RXA</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0W">4P0W</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JA0">5JA0</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV2">5JV2</a> showing sites S1, S2, S3, and S4. (c) <b>7</b> (red, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4N1Z">4N1Z</a>). (d) <b>8</b> (magenta, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N6K">3N6K</a>). (e) <b>6</b> + <b>9</b> (slate, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0W">4P0W</a>). (f) <b>10</b> (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RXA">4RXA</a>). (g) <b>4</b> (wheat, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JA0">5JA0</a>). (h) <b>11</b> (yellow, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV2">5JV2</a>). Asp residues in the first aspartate-rich domain (DDXXD) are shown in blue; Asp residues in the second aspartate-rich domain are shown in orange.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of carnosic acid and carnosol, abietane-skeleton diterpenes from rosemary and sage, together with known <i>Hs</i>FPPS inhibitors, taxodone (<b>12</b>) and taxodione (<b>13</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Three major routes for compound synthesis. Note that the numbering here is that of <b>CA</b> and is based on the IUPAC nomenclature of octahydrophenanthrene and varies in some analogs, depending on the actual substituents, and is also not the popular non-IUPAC form used for abietane diterpenes that have the same ring structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>CA1</b>,<b>2</b>, <b>CA5a</b>â<b>l</b>, and <b>CA7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ac<sub>2</sub>O, DMAP, DCM, rt, 12 h; (b) (i) (COCl)<sub>2</sub>, dry DMF (catalytic amount), dry DCM, rt, 8â12 h; (ii). R<sub>1</sub>NH<sub>2</sub>, DMAP, dry DCM, 0 Â°C to rt, 0.5â2 h; (c<sub>1</sub>) <i>p-</i>toluenesulfonic acid, toluene, Ar, 80 Â°C,12 h; (c<sub>2</sub>) LiAlH<sub>4</sub>, dry THF, 0 Â°C to rt, 0.5â4 h; (d) TMSCHN<sub>2</sub>, toluene/MeOH = 5:1, 0 Â°C; (e) CrO<sub>3</sub>, AcOH, rt, 12 h; (f<sub>1</sub>) DDQ, 1,4-dioxane, 0.5 h; (f<sub>2</sub>) Ag<sub>2</sub>O, DCM, N<sub>2</sub>, 0.5 h.</p><p class="last"><span class="fn-label"><sup>b</sup></span><b>CA4l</b> was synthesized from <b>CA4h</b> under the following conditions: <i>N</i>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-alanine, HATU, <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA), DCM, rt, 12 h.</p></p></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>CA8a</b>â<b>c</b>, <b>CA10</b>, <b>CA11a</b>,<b>b</b>, and <b>CA12</b>â<b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a<sub>1</sub>) TBSCl, imidazole, DCM, rt, 12 h; (a<sub>2</sub>) BnBr, K<sub>2</sub>CO<sub>3</sub>, acetone, rt, 4.5 h; (a<sub>3</sub>) Ac<sub>2</sub>O, DMAP, DCM, rt, 12 h; (b) CrO<sub>3</sub>, AcOH, rt, 12 h; (c) <i>p-</i>toluenesulfonic acid, toluene, Ar, 80 Â°C,12 h; (d) DDQ, 1,4-dioxane, 0.5 h; (e<sub>1</sub>) SO<sub>2</sub>Cl<sub>2</sub>, CCl<sub>4</sub>, 60 Â°C, 40 h; (e<sub>2</sub>) Br<sub>2</sub>, Et<sub>2</sub>O, 0 Â°C, 0.5 h.</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>CA15a</b>â<b>f</b>, <b>CA16a</b>â<b>c</b>, and <b>CA17</b>â<b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DCC, DMAP, DCM, rt, 2.5 h; (b) (1) TMSCHN<sub>2</sub>, toluene/MeOH = 5:1, 0 Â°C; (2) LiAlH<sub>4</sub>, dry THF, Ar, reflux; (c<sub>1</sub>) DDQ (1 equiv), 1,4-dioxane, 0.5â1 h; (c<sub>2</sub>) Ag<sub>2</sub>O, DCM, Ar; (d) R<sub>4</sub>-X<sub>2</sub>H, MeOH, Ar, 0 Â°C, 4â5 h (when X<sub>2</sub> = S); R<sub>4</sub>-X<sub>2</sub>H, Ar, rt, 2â12 h (when X<sub>2</sub> = O).</p></p></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>CA25a</b>â<b>g</b>, <b>CA27a</b>â<b>e</b>, and <b>CA28a</b>â<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a<sub>1</sub>) (i) (COCl)<sub>2</sub>, dry DMF (catalytic amount), dry DCM, Ar, rt, 8â12 h; (ii) R<sub>5</sub>CONHNH<sub>2</sub>, DMAP, dry DCM, 0 Â°C to rt, 0.5â2 h; (a<sub>2</sub>) (i) (COCl)<sub>2</sub>, dry DMF (catalytic amount), dry DCM, Ar, rt, 8â12 h; (ii) NH<sub>2</sub>NH<sub>2</sub>Â·H<sub>2</sub>O, DMAP, DCM, 0 Â°C to rt, 0.5â2 h; (iii). R<sub>5</sub>COOH, HATU, DIEA, DCM, rt, 6â12 h; (b<sub>1</sub>) <i>p</i>-TsCl, DIEA, DCM/CH<sub>3</sub>CN, rt/65 Â°C, 12 h; (b<sub>2</sub>) POCl<sub>3</sub>, 80 Â°C, 1â5 h; (c<sub>1</sub>) <i>p-</i>toluenesulfonic acid, toluene, Ar, 80 Â°C,12 h; (c<sub>2</sub>) LiAlH<sub>4</sub>, dry THF, 0 Â°C to rt, 0.5â12 h; (d) CrO<sub>3</sub>, AcOH, rt, 4â12 h; (e) NaHCO<sub>3</sub>, MeOH/H<sub>2</sub>O = 4:1, 65 Â°C, 10 h; (f) DDQ, 1,4-dioxane, 0.5 h; (g) TFA, DCM, rt, 1â2 h.</p><p><span class="fn-label"><sup>b</sup></span><b>CA25a</b>/<b>CA25b</b> were synthesized from <b>CA4i</b>/<b>CA4j</b> under condition b<sub>2</sub>, <b>CA24a/CA24b</b> were the intermediates. For the synthesis of <b>CA26a</b>, procedure b<sub>1</sub> was chosen for <b>CA4i</b>âs ring closure.</p><p class="last"><span class="fn-label"><sup>c</sup></span>Note that the <i>S</i> configuration shown is the overall moleculeâs stereochemistry not the fragmentâs.</p></p></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. SAR summary of (a) catechol series and (b) quinone series <b>CA</b>-derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. WaterLOGSY results for <b>CA28a</b> (200 Î¼M) without and with <i>Hs</i>FPPS (10 Î¼M). (a) WaterLOGSY spectra. The spectrum shown in red is that of <b>CA28a</b> alone in Tris buffer (pH 7.5). The spectrum shown in blue is that of <b>CA28a</b> + <i>Hs</i>FPPS in Tris buffer (pH 7.5). Peaks due to Tris, DMSO, and HOD are not shown, for clarity. Shift assignments are shown above each peak. (b) Numbering system used for <b>CA28a</b>, based on general terpene numbering system since IUPAC nomenclatures vary with the substituents. (c) Proposed <b>CA28a</b> geometry that leads to shielding of H19 due to a ring current interaction with the oxadiazole ring. The distances shown are in Ã.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Binding kinetics of some compounds. (a) Binding kinetics profiles of <b>CA1</b>, <b>CA5l</b>, <b>CA13</b>, and <b>CA28a</b>: <i>K</i><sub>D</sub> = <i>k</i><sub>off</sub>/<i>k</i><sub>on</sub>, Ï = 1/<i>k</i><sub>off</sub>. (b) Single cycle kinetic analysis graphs of the above compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Preincubation assay and enzyme kinetics studies. (a) Preincubation assay of positive control <b>6</b> with GPP + Mg<sup>2+</sup> or IPP. <i>V</i><sub>0</sub> represents the initial velocity of the reaction. (b) Preincubation assay of <b>CA28a</b> with GPP + Mg<sup>2+</sup>, GPP, or IPP. <i>V</i><sub>0</sub> represents the initial velocity of the reaction. (c) MichaelisâMenten kinetics of <i>Hs</i>FPPS with IPP set at 35 Î¼M and GPP varying. (d) MichaelisâMenten kinetics of <i>Hs</i>FPPS with GPP set at 70 Î¼M and IPP varying. Data are presented as the mean Â± SD, <i>n</i> = 4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Four candidate docking poses. ÏâÏ stacking and H-bonds are represented by yellow dashes with numbers showing the distances between heavy atoms in angstrom. (a) <b>CA28a</b> docked into <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0X">4P0X</a>. ÏâÏ stacking with Phe-239, H-bonding with protein backbone and water1127. (b) <b>CA28a</b> docked into <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV1">5JV1</a> (without sulfate and crystal waters, pose 1). H-bonding with Asn-59, Arg-60, and backbone of Lys-57. (c) <b>CA28a</b> docked into <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV1">5JV1</a> (without sulfate and crystal waters, pose 2). H-bonding with Asn-59 and Arg-60. (d) <b>CA28a</b> docked into <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV1">5JV1</a> (with sulfate and crystal waters). H-bonding is with Asn-59.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Mutagenesis results, overlay of four candidate poses, and STD results. Doseâresponse curves of <b>CA28a</b> against (a) <i>Hs</i>FPPS WT, (b) <i>Hs</i>FPPS N59A, and (c) <i>Hs</i>FPPS F239A. Data are shown as the mean Â± SD, <i>n</i> = 4. (d) Overlay of four candidate poses. Poses of <b>CA28a</b> in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>aâd are shown in green, cyan, magenta, and yellow, respectively. (e) STD spectrum of <b>CA28a</b> (400 Î¼M) + <i>Hs</i>FPPS (10 Î¼M) in Hepes buffer (pH 7.4). (f) <b>CA28a</b> structure and numbering system.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Schematic illustration of the inhibition of <i>Hs</i>FPPS by <b>CA28a</b> and its analogs, and zoledronic acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Correlation between <i>Hs</i>FPPS inhibition and cellular activity. (a) PANC-1 results. The blue curve is the fitted linear regression trend (<i>R</i><sup>2</sup> = 0.81) for the eight compounds indicated. The dotted lines are the 95% confidence intervals. (b) As in (a) but MIA PaCa-2 results shown in orange, superimposed with the PANC-1 data (in blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. <b>CA5d</b> induces apoptosis in pancreatic cancer cells. (a) Flow cytometry analysis of apoptosis rates of PANC-1 cell upon <b>6</b> and <b>CA5d</b> 48 h treatment using annexin V and PI staining. (b) Apoptosis rates in different groups (early stage plus late stage apoptosis, Q3 + Q2). (c) Statistical results for late stage apoptosis (Q2) in different groups. (d) Statistical results for early stage apoptosis (Q3) in different groups. Data are presented as the mean Â± SD, <i>n</i> = 3: *<i>P</i> < 0.05 vs Ctrl; **<i>P</i> < 0.01 vs Ctrl; ***<i>P</i> < 0.001 vs Ctrl; ****<i>P</i> < 0.0001 vs Ctrl. Unpaired Studentâs <i>t</i> test was used for significance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/medium/jm9b01405_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. PANC-1 apoptosis rescues by GGOH + FOH, Ras prenylation results, and mechanism summary. (a) Statistical graph of apoptosis rate in different groups. Concentrations of GGOH and FOH were 10 Î¼M in different groups; inhibitors were at 20 Î¼M. Data are presented as the mean Â± SD, <i>n</i> = 3: ****<i>P</i> < 0.0001 vs corresponding groups. Unpaired Studentâs <i>t</i> test was used for significance. (b) Downregulation of Ras prenylation upon <b>CA5d</b>âs treatment on PANC-1 cells. Western blot shows the membrane Ras and total Ras level upon a 24 h treatment with <b>CA25d</b>. Na<sup>+</sup>/K<sup>+</sup> ATPase and Î²-tubulin are internal references. (c) Schematic representation of <b>CA5d</b> mechanism of action in PANC-1 cells. Ras proteins in green represent the increase parts of membrane Ras after rescue of GGOH and FOH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b01405/20191205/images/large/jm9b01405_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01405&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i109">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80656" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80656" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 77 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Firn, R.</span></span> <i>Natureâs Chemicals. The Natural Products That Shaped Our World</i>; <span class="NLM_publisher-name">Oxford University Press</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=R.+Firn&title=Nature%E2%80%99s+Chemicals.+The+Natural+Products+That+Shaped+Our+World"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DFirn%26aufirst%3DR.%26btitle%3DNature%25E2%2580%2599s%2520Chemicals.%2520The%2520Natural%2520Products%2520That%2520Shaped%2520Our%2520World%26pub%3DOxford%2520University%2520Press%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">The mevalonate pathway is a druggable target for vaccine adjuvant discovery</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">1059</span>â <span class="NLM_lpage">1073</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2018.08.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.cell.2018.08.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=30270039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVahsb7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=1059-1073&author=Y.+Xiaauthor=Y.+Xieauthor=Z.+Yuauthor=H.+Xiaoauthor=G.+Jiangauthor=X.+Zhouauthor=Y.+Yangauthor=X.+Liauthor=M.+Zhaoauthor=L.+Liauthor=M.+Zhengauthor=S.+Hanauthor=Z.+Zongauthor=X.+Mengauthor=H.+Dengauthor=H.+Yeauthor=Y.+Faauthor=H.+Wuauthor=E.+Oldfieldauthor=X.+Huauthor=W.+Liuauthor=Y.+Shiauthor=Y.+Zhang&title=The+mevalonate+pathway+is+a+druggable+target+for+vaccine+adjuvant+discovery&doi=10.1016%2Fj.cell.2018.08.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery</span></div><div class="casAuthors">Xia, Yun; Xie, Yonghua; Yu, Zhengsen; Xiao, Hongying; Jiang, Guimei; Zhou, Xiaoying; Yang, Yunyun; Li, Xin; Zhao, Meng; Li, Liping; Zheng, Mingke; Han, Shuai; Zong, Zhaoyun; Meng, Xianbin; Deng, Haiteng; Ye, Huahu; Fa, Yunzhi; Wu, Haitao; Oldfield, Eric; Hu, Xiaoyu; Liu, Wanli; Shi, Yan; Zhang, Yonghui</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1059-1073.e21</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Motivated by the clin. observation that interruption of the mevalonate pathway stimulates immune responses, the authors hypothesized that this pathway may function as a druggable target for vaccine adjuvant discovery.  The authors found that lipophilic statin drugs and rationally designed bisphosphonates that target three distinct enzymes in the mevalonate pathway have potent adjuvant activities in mice and cynomolgus monkeys.  These inhibitors function independently of conventional "danger sensing.".  Instead, they inhibit the geranylgeranylation of small GTPases, including Rab5 in antigen-presenting cells, resulting in arrested endosomal maturation, prolonged antigen retention, enhanced antigen presentation, and T cell activation.  Addnl., inhibiting the mevalonate pathway enhances antigen-specific anti-tumor immunity, inducing both Th1 and cytolytic T cell responses.  As demonstrated in multiple mouse cancer models, the mevalonate pathway inhibitors are robust for cancer vaccinations and synergize with anti-PD-1 antibodies.  The authors' research thus defines the mevalonate pathway as a druggable target for vaccine adjuvants and cancer immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpbTJq8U36HLVg90H21EOLACvtfcHk0lgpULO7HddZMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVahsb7K&md5=64063b0872662a46e146e183f47067d6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.08.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.08.070%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DZong%26aufirst%3DZ.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DFa%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DOldfield%26aufirst%3DE.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DThe%2520mevalonate%2520pathway%2520is%2520a%2520druggable%2520target%2520for%2520vaccine%2520adjuvant%2520discovery%26jtitle%3DCell%26date%3D2018%26volume%3D175%26spage%3D1059%26epage%3D1073%26doi%3D10.1016%2Fj.cell.2018.08.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Schutter, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5764</span>â <span class="NLM_lpage">5776</span>, <span class="refDoi">Â DOI: 10.1021/jm500629e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500629e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVegtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5764-5776&author=J.+W.+De%0ASchutterauthor=J.+Parkauthor=C.+Y.+Leungauthor=P.+Gormleyauthor=Y.+S.+Linauthor=Z.+Huauthor=A.+M.+Berghuisauthor=J.+Poirierauthor=Y.+S.+Tsantrizos&title=Multistage+screening+reveals+chameleon+ligands+of+the+human+farnesyl+pyrophosphate+synthase%3A+implications+to+drug+discovery+for+neurodegenerative+diseases&doi=10.1021%2Fjm500629e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multistage Screening Reveals Chameleon Ligands of the Human Farnesyl Pyrophosphate Synthase: Implications to Drug Discovery for Neurodegenerative Diseases</span></div><div class="casAuthors">De Schutter, Joris W.; Park, Jaeok; Leung, Chun Yuen; Gormley, Patrick; Lin, Yih-Shyan; Hu, Zheping; Berghuis, Albert M.; Poirier, Judes; Tsantrizos, Youla S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5764-5776</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human farnesyl pyrophosphate synthase (hFPPS) is the gate-keeper of mammalian isoprenoids and the key target of bisphosphonate drugs.  Bisphosphonates suffer from poor "drug-like" properties and are mainly effective in treating skeletal diseases.  Recent investigations have implicated hFPPS in various nonskeletal diseases, including Alzheimer's disease (AD).  Anal. of single nucleotide polymorphisms in the hFPPS gene and mRNA levels in autopsy-confirmed AD subjects was undertaken, and a genetic link between hFPPS and phosphorylated tau (P-Tau) levels in the human brain was identified.  Elevated P-Tau levels are strongly implicated in AD progression.  The development of nonbisphosphonate inhibitors can provide mol. tools for validating hFPPS as a therapeutic target for tauopathy-assocd. neurodegeneration.  A multistage screening protocol led to the identification of a new monophosphonate chemotype that bind in an allosteric pocket of hFPPS.  Optimization of these compds. could lead to human therapeutics that block tau metab. and arrest the progression of neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrenHVATZq2I7Vg90H21EOLACvtfcHk0lhLvD4MMR4VUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVegtLo%253D&md5=b54b5f0f17e867c4c8707e3d58f26eab</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm500629e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500629e%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSchutter%26aufirst%3DJ.%2BW.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DC.%2BY.%26aulast%3DGormley%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DY.%2BS.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26aulast%3DPoirier%26aufirst%3DJ.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DMultistage%2520screening%2520reveals%2520chameleon%2520ligands%2520of%2520the%2520human%2520farnesyl%2520pyrophosphate%2520synthase%253A%2520implications%2520to%2520drug%2520discovery%2520for%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5764%26epage%3D5776%26doi%3D10.1021%2Fjm500629e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukkamala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houlihan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Lipophilic pyridinium bisphosphonates: potent gammadelta T cell stimulators</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1136</span>â <span class="NLM_lpage">1138</span>, <span class="refDoi">Â DOI: 10.1002/anie.200905933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1002%2Fanie.200905933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGktbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=1136-1138&author=Y.+Zhangauthor=R.+Caoauthor=F.+Yinauthor=F.+Y.+Linauthor=H.+Wangauthor=K.+Krysiakauthor=J.+H.+Noauthor=D.+Mukkamalaauthor=K.+Houlihanauthor=J.+Liauthor=C.+T.+Moritaauthor=E.+Oldfield&title=Lipophilic+pyridinium+bisphosphonates%3A+potent+gammadelta+T+cell+stimulators&doi=10.1002%2Fanie.200905933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Pyridinium Bisphosphonates: Potent Î³Î´ T Cell Stimulators</span></div><div class="casAuthors">Zhang, Yonghui; Cao, Rong; Yin, Fenglin; Lin, Fu-Yang; Wang, Hong; Krysiak, Kilannin; No, Joo-Hwan; Mukkamala, Dushyant; Houlihan, Kevin; Li, Jikun; Morita, Craig T.; Oldfield, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1136-1138, S1136/1-S1136/10</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Novel lipophilic Pyridinium bisphosphonates are shown to be approx. 250 times more effective than any other bisphosphonate drugs in Î³Î´ T Cell activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFABM7NZO2NLVg90H21EOLACvtfcHk0lhLvD4MMR4VUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGktbs%253D&md5=cfa33355fbd51f711ea1d6165cc400cb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fanie.200905933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200905933%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DYin%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DF.%2BY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DKrysiak%26aufirst%3DK.%26aulast%3DNo%26aufirst%3DJ.%2BH.%26aulast%3DMukkamala%26aufirst%3DD.%26aulast%3DHoulihan%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMorita%26aufirst%3DC.%2BT.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DLipophilic%2520pyridinium%2520bisphosphonates%253A%2520potent%2520gammadelta%2520T%2520cell%2520stimulators%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D1136%26epage%3D1138%26doi%3D10.1002%2Fanie.200905933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, P. J.</span></span> <span> </span><span class="NLM_article-title">Protein prenylation: unique fats make their mark on biology</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">110</span>â <span class="NLM_lpage">122</span>, <span class="refDoi">Â DOI: 10.1038/nrm.2015.11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fnrm.2015.11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=26790532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOrsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=110-122&author=M.+Wangauthor=P.+J.+Casey&title=Protein+prenylation%3A+unique+fats+make+their+mark+on+biology&doi=10.1038%2Fnrm.2015.11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Protein prenylation: unique fats make their mark on biology</span></div><div class="casAuthors">Wang, Mei; Casey, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">110-122</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The modification of eukaryotic proteins by isoprenoid lipids, which is known as prenylation, controls the localization and activity of a range of proteins that have crucial functions in biol. regulation.  The roles of prenylated proteins in cells are well conserved across species, underscoring the biol. and evolutionary importance of this lipid modification pathway.  Genetic suppression and pharmacol. inhibition of the protein prenylation machinery have provided insights into several cellular processes and into the etiol. of diseases in which prenylation is involved.  The functional dependence of prenylation substrates, such as RAS proteins, on this modification and the therapeutic potential of targeting the prenylation process in pathol. conditions accentuate the need to fully understand this form of post-translational modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr08TXPqy6XorVg90H21EOLACvtfcHk0lhLvD4MMR4VUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOrsrk%253D&md5=b6694153ce758f85c4e01c499d8de74a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2015.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2015.11%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DCasey%26aufirst%3DP.%2BJ.%26atitle%3DProtein%2520prenylation%253A%2520unique%2520fats%2520make%2520their%2520mark%2520on%2520biology%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2016%26volume%3D17%26spage%3D110%26epage%3D122%26doi%3D10.1038%2Fnrm.2015.11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">ten
Klooster, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hordijk, P. L.</span></span> <span> </span><span class="NLM_article-title">Targeting and localized signalling by small GTPases</span>. <i>Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">12</span>, <span class="refDoi">Â DOI: 10.1042/BC20060071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1042%2FBC20060071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=17155934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlWnurvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2007&pages=1-12&author=J.+P.+ten%0AKloosterauthor=P.+L.+Hordijk&title=Targeting+and+localized+signalling+by+small+GTPases&doi=10.1042%2FBC20060071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting and localized signalling by small GTPases</span></div><div class="casAuthors">ten Klooster, Jean Paul; Hordijk, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Biology of the Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">BCELDF</span>;
        ISSN:<span class="NLM_cas:issn">0248-4900</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Polarized cellular responses, for example, cell migration, require the coordinated assembly of signalling complexes at a particular subcellular location, such as the leading edge of cells.  Small GTPases of the Ras superfamily play central roles in many (polarized) responses to growth factors, chemokines or integrin ligands.  These small GTPases are functionally distinct, yet remarkably homologous in their primary sequence and esp. in their effector domains.  Therefore it has long been unclear how GTPase signalling specificity is regulated.  Small GTPases carry a lipid anchor, in the context of a hypervariable region, which mediates membrane assocn.  However, whereas the lipid has long been proposed to be the crit. regulator of subcellular GTPase targeting, there is now increasing evidence that specific protein-protein interactions are important as well.  This review discusses recent findings on GTPase targeting and proposes a revised model for GTPase signalling.  In this model, the hypervariable domain acts in conjunction with the lipid tail to target the GTPase to specific membrane-assocd. protein complexes.  Here, local GTPase activation occurs, leading to subsequent exposure of the effector domain, binding to effector proteins and the initiation of downstream signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0_6O2lhvmT7Vg90H21EOLACvtfcHk0lizEryLbz4jFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlWnurvO&md5=283d8f42fee85bc98c094dbb8709589b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1042%2FBC20060071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBC20060071%26sid%3Dliteratum%253Aachs%26aulast%3Dten%2BKlooster%26aufirst%3DJ.%2BP.%26aulast%3DHordijk%26aufirst%3DP.%2BL.%26atitle%3DTargeting%2520and%2520localized%2520signalling%2520by%2520small%2520GTPases%26jtitle%3DBiol.%2520Cell%26date%3D2007%26volume%3D99%26spage%3D1%26epage%3D12%26doi%3D10.1042%2FBC20060071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baines, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Ras for cancer treatment: the search continues</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1787</span>â <span class="NLM_lpage">1808</span>, <span class="refDoi">Â DOI: 10.4155/fmc.11.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.4155%2Ffmc.11.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=22004085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlertbjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1787-1808&author=A.+T.+Bainesauthor=D.+Xuauthor=C.+J.+Der&title=Inhibition+of+Ras+for+cancer+treatment%3A+the+search+continues&doi=10.4155%2Ffmc.11.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Ras for cancer treatment: the search continues</span></div><div class="casAuthors">Baines, Antonio T.; Xu, Dapeng; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1787-1808</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in human cancers (33%), thus stimulating intensive effort in developing anti-Ras inhibitors for cancer treatment.  Despite intensive effort, to date, no effective anti-Ras strategies have successfully made it to the clinic.  We present an overview of past and ongoing strategies to inhibit oncogenic Ras in cancer.  Since approaches to directly target mutant Ras have not been successful, most efforts have focused on indirect approaches to block Ras membrane assocn. or downstream effector signaling.  While inhibitors of effector signaling are currently under clin. evaluation, genome-wide unbiased genetic screens have identified novel directions for future anti-Ras drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSljlfnR2TbVg90H21EOLACvtfcHk0lizEryLbz4jFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlertbjJ&md5=bb810b0cf2b8dc975d5a476907f5c2ec</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.121%26sid%3Dliteratum%253Aachs%26aulast%3DBaines%26aufirst%3DA.%2BT.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DInhibition%2520of%2520Ras%2520for%2520cancer%2520treatment%253A%2520the%2520search%2520continues%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1787%26epage%3D1808%26doi%3D10.4155%2Ffmc.11.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prior, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattos, C.</span></span> <span> </span><span class="NLM_article-title">A comprehensive survey of Ras mutations in cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2457</span>â <span class="NLM_lpage">2467</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-11-2612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1158%2F0008-5472.CAN-11-2612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=22589270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvF2ntL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2457-2467&author=I.+A.+Priorauthor=P.+D.+Lewisauthor=C.+Mattos&title=A+comprehensive+survey+of+Ras+mutations+in+cancer&doi=10.1158%2F0008-5472.CAN-11-2612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Survey of Ras Mutations in Cancer</span></div><div class="casAuthors">Prior, Ian A.; Lewis, Paul D.; Mattos, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2457-2467</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  All mammalian cells express 3 closely related Ras proteins, termed H-Ras, K-Ras, and N-Ras, that promote oncogenesis when they are mutationally activated at codon 12, 13, or 61.  Although there is a high degree of similarity among the isoforms, K-Ras mutations are far more frequently obsd. in cancer, and each isoform displays preferential coupling to particular cancer types.  We examd. the mutational spectra of Ras isoforms curated from large-scale tumor profiling and found that each isoform exhibits surprisingly distinctive codon mutation and amino-acid substitution biases.  These findings were unexpected given that these mutations occur in regions that share 100% amino-acid sequence identity among the 3 isoforms.  Of importance, many of these mutational biases were not due to differences in exposure to mutagens, because the patterns were still evident when compared within specific cancer types.  We discuss potential genetic and epigenetic mechanisms, as well as isoform-specific differences in protein structure and signaling, that may promote these distinct mutation patterns and differential coupling to specific cancers.  Cancer Res; 72(10); 2457-67.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg2lqiicosOLVg90H21EOLACvtfcHk0lizEryLbz4jFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvF2ntL4%253D&md5=6d1894847015468f77c8b08b57c6d62a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-2612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-2612%26sid%3Dliteratum%253Aachs%26aulast%3DPrior%26aufirst%3DI.%2BA.%26aulast%3DLewis%26aufirst%3DP.%2BD.%26aulast%3DMattos%26aufirst%3DC.%26atitle%3DA%2520comprehensive%2520survey%2520of%2520Ras%2520mutations%2520in%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2457%26epage%3D2467%26doi%3D10.1158%2F0008-5472.CAN-11-2612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karnoub, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Ras oncogenes: split personalities</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">517</span>â <span class="NLM_lpage">531</span>, <span class="refDoi">Â DOI: 10.1038/nrm2438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fnrm2438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=18568040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFGnsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=517-531&author=A.+E.+Karnoubauthor=R.+A.+Weinberg&title=Ras+oncogenes%3A+split+personalities&doi=10.1038%2Fnrm2438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Ras oncogenes: split personalities</span></div><div class="casAuthors">Karnoub, Antoine E.; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">517-531</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Extensive research over the past 30 years has revealed the involvement of Ras not only in tumorigenesis but also in many developmental disorders.  The complexity of the mol. and cell biol. mechanisms of action of Ras proteins indicates that much remains to be learns.  Extensive research on the Ras proteins and their functions in cell physiol. over the past 30 years has led to numerous insights that have revealed the involvement of Ras not only in tumorigenesis but also in many developmental disorders.  Despite great strides in our understanding of the mol. and cellular mechanisms of action of the Ras proteins, the expanding roster of their downstream effectors and the complexity of the signaling cascades that they regulate indicate that much remains to be learns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocptUdlhqaM7Vg90H21EOLACvtfcHk0lizEryLbz4jFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFGnsr0%253D&md5=9de78b17b953b2560238d7a98f3bea6a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrm2438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2438%26sid%3Dliteratum%253Aachs%26aulast%3DKarnoub%26aufirst%3DA.%2BE.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DRas%2520oncogenes%253A%2520split%2520personalities%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D517%26epage%3D531%26doi%3D10.1038%2Fnrm2438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieves, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, B. R.</span></span> <span> </span><span class="NLM_article-title">Natural and synthetic non-peptide antigens recognized by human gamma delta T cells</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">155</span>â <span class="NLM_lpage">158</span>, <span class="refDoi">Â DOI: 10.1038/375155a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2F375155a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=7753173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADyaK2MXls1Wisrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=1995&pages=155-158&author=Y.+Tanakaauthor=C.+T.+Moritaauthor=Y.+Tanakaauthor=E.+Nievesauthor=M.+B.+Brennerauthor=B.+R.+Bloom&title=Natural+and+synthetic+non-peptide+antigens+recognized+by+human+gamma+delta+T+cells&doi=10.1038%2F375155a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Natural and synthetic non-peptide antigens recognized by human Î³Î´ T cells</span></div><div class="casAuthors">Tanaka, Yoshimasa; Morita, Craig T.; Tanaka, Yoko; Nieves, Edward; Brenner, Michael B.; Bloom, Barry R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">6527</span>),
    <span class="NLM_cas:pages">155-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A major human Î³Î´ T-cell subset expressing VÎ³2 and VÎ´2 germline genes, but having diverse junctional sequences, is found in human mycobacterial lesions and responds in vitro to antigens of bacteria and parasites.  VÎ³2VÎ´2-bearing T cells were shown to recognize mycobacterial antigens that are protease-resistant and phosphatase-sensitive.  Because of the difficulty in isolating natural antigens from mycobacterial culture filtrates or exts., the authors synthesized a series of monoalkyl phosphates, and found that some, particularly monoethyl phosphate, could mimic the activity of mycobacterial antigens in simulating these Î³Î´ T cells.  Here, natural antigens produced by mycobacteria recognized by human VÎ³2VÎ´2-bearing T cells were identified as isopentenyl pyrophosphate and related prenyl pyrophosphate derivs., compds. involved in the synthesis of complex polyisoprenoid compds. in microbial and mammalian cells.  Substitution of phosphate for the pyrophosphate moiety, or elimination of the double bond, greatly reduced antigenic activity of these compds.  These results provide formal evidence that, in contrast to recognition of major histocompatibility complex-bound peptide antigens by Î±Î² T cells, human Î³Î´ T cells can recognize naturally occurring small non-peptidic antigens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH74R45PP7ULVg90H21EOLACvtfcHk0liPQofPYZZw_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXls1Wisrk%253D&md5=a0e1c8698010db1d164f066556fa7080</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2F375155a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F375155a0%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DMorita%26aufirst%3DC.%2BT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DNieves%26aufirst%3DE.%26aulast%3DBrenner%26aufirst%3DM.%2BB.%26aulast%3DBloom%26aufirst%3DB.%2BR.%26atitle%3DNatural%2520and%2520synthetic%2520non-peptide%2520antigens%2520recognized%2520by%2520human%2520gamma%2520delta%2520T%2520cells%26jtitle%3DNature%26date%3D1995%26volume%3D375%26spage%3D155%26epage%3D158%26doi%3D10.1038%2F375155a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gober, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kistowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeno, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Libero, G.</span></span> <span> </span><span class="NLM_article-title">Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">163</span>â <span class="NLM_lpage">168</span>, <span class="refDoi">Â DOI: 10.1084/jem.20021500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1084%2Fjem.20021500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=12538656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1Sjtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2003&pages=163-168&author=H.+J.+Goberauthor=M.+Kistowskaauthor=L.+Angmanauthor=P.+Jenoauthor=L.+Moriauthor=G.+De+Libero&title=Human+T+cell+receptor+gammadelta+cells+recognize+endogenous+mevalonate+metabolites+in+tumor+cells&doi=10.1084%2Fjem.20021500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Human T cell receptor Î³Î´ cells recognize endogenous mevalonate metabolites in tumor cells</span></div><div class="casAuthors">Gober, Hans-Jurgen; Kistowska, Magdalena; Angman, Lena; Jeno, Paul; Mori, Lucia; De Libero, Gennaro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-168</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">T lymphocytes expressing the T cell receptor (TCR)-Î³Î´ recognize unknown antigens on tumor cells.  Here the authors identify metabolites of the mevalonate pathway as the tumor ligands that activate TCR-Î³Î´ cells.  In tumor cells, blockade of hydroxy-methylglutaryl-CoA reductase (HMGR), the rate limiting enzyme of the mevalonate pathway, prevents both accumulation of mevalonate metabolites and recognition by TCR-Î³Î´ cells.  When metabolite accumulation is induced by overexpressing HMGR or by treatment with nitrogen-contg. bisphosphonate drugs, tumor cells derived from many tissues acquire the capacity to stimulate the same TCR-Î³Î´ population.  Accumulation of mevalonate metabolites in tumor cells is a powerful danger signal that activates the immune response and may represent a novel target of tumor immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi_38RHDekMLVg90H21EOLACvtfcHk0liPQofPYZZw_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1Sjtg%253D%253D&md5=e4a887b66626558075c47fda7817f6cc</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1084%2Fjem.20021500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20021500%26sid%3Dliteratum%253Aachs%26aulast%3DGober%26aufirst%3DH.%2BJ.%26aulast%3DKistowska%26aufirst%3DM.%26aulast%3DAngman%26aufirst%3DL.%26aulast%3DJeno%26aufirst%3DP.%26aulast%3DMori%26aufirst%3DL.%26aulast%3DDe%2BLibero%26aufirst%3DG.%26atitle%3DHuman%2520T%2520cell%2520receptor%2520gammadelta%2520cells%2520recognize%2520endogenous%2520mevalonate%2520metabolites%2520in%2520tumor%2520cells%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2003%26volume%3D197%26spage%3D163%26epage%3D168%26doi%3D10.1084%2Fjem.20021500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarikonda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puan, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monkkonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, C. T.</span></span> <span> </span><span class="NLM_article-title">Indirect stimulation of human V gamma 2V delta 2 T cells through alterations in isoprenoid metabolism</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">5099</span>â <span class="NLM_lpage">5113</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1002697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.4049%2Fjimmunol.1002697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=22013129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSitb7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2011&pages=5099-5113&author=H.+Wangauthor=G.+Sarikondaauthor=K.+J.+Puanauthor=Y.+Tanakaauthor=J.+Fengauthor=J.+L.+Ginerauthor=R.+Caoauthor=J.+Monkkonenauthor=E.+Oldfieldauthor=C.+T.+Morita&title=Indirect+stimulation+of+human+V+gamma+2V+delta+2+T+cells+through+alterations+in+isoprenoid+metabolism&doi=10.4049%2Fjimmunol.1002697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Indirect Stimulation of Human VÎ³2VÎ´2 T Cells through Alterations in Isoprenoid Metabolism</span></div><div class="casAuthors">Wang, Hong; Sarikonda, Ghanashyam; Puan, Kia-Joo; Tanaka, Yoshimasa; Feng, Ju; Giner, Jose-Luis; Cao, Rong; Moenkkoenen, Jukka; Oldfield, Eric; Morita, Craig T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5099-5113</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Human VÎ³2VÎ´2 T cells monitor isoprenoid metab. by recognizing (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), an intermediate in the 2-C-methyl-D-erythritol-4-phosphate pathway used by microbes, and isopentenyl pyrophosphate (IPP), an intermediate in the mevalonate pathway used by humans.  Aminobisphosphonates and alkylamines indirectly stimulate VÎ³2VÎ´2 cells by inhibiting farnesyl diphosphate synthase (FDPS) in the mevalonate pathway, thereby increasing IPP/triphosphoric acid 1-adenosin-5'-yl ester 3-(3-methylbut-3-enyl) ester that directly stimulate.  In this study, we further characterize stimulation by these compds. and define pathways used by new classes of compds.  Consistent with FDPS inhibition, stimulation of VÎ³2VÎ´2 cells by aminobisphosphonates and alkylamines was much more sensitive to statin inhibition than stimulation by prenyl pyrophosphates; however, the continuous presence of aminobisphosphonates was toxic for T cells and blocked their proliferation.  Aminobisphosphonate stimulation was rapid and prolonged, independent of known Ag-presenting mols., and resistant to fixation.  New classes of stimulatory compds.-mevalonate, the alc. of HMBPP, and alkenyl phosphonates-likely stimulate differently.  Mevalonate, a rate-limiting metabolite, appears to enter cells to increase IPP levels, whereas the alc. of HMBPP and alkenyl phosphonates are directly recognized.  The crit. chem. feature of bisphosphonates is the amino moiety, because its loss switched aminobisphosphonates to direct Ags.  Transfection of APCs with small interfering RNA downregulating FDPS rendered them stimulatory for VÎ³2VÎ´2 cells and increased cellular IPP.  Small interfering RNAs for isopentenyl diphosphate isomerase functioned similarly.  Our results show that a variety of manipulations affecting isoprenoid metab. lead to stimulation of VÎ³2VÎ´2 T cells and that pulsing aminobisphosphonates would be more effective for the ex vivo expansion of VÎ³2VÎ´2 T cells for adoptive cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMbhsrGeBD-LVg90H21EOLACvtfcHk0liPQofPYZZw_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSitb7O&md5=d80084026813ec29d63fc67cfc9fa65b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1002697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1002697%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSarikonda%26aufirst%3DG.%26aulast%3DPuan%26aufirst%3DK.%2BJ.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DGiner%26aufirst%3DJ.%2BL.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DMonkkonen%26aufirst%3DJ.%26aulast%3DOldfield%26aufirst%3DE.%26aulast%3DMorita%26aufirst%3DC.%2BT.%26atitle%3DIndirect%2520stimulation%2520of%2520human%2520V%2520gamma%25202V%2520delta%25202%2520T%2520cells%2520through%2520alterations%2520in%2520isoprenoid%2520metabolism%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D187%26spage%3D5099%26epage%3D5113%26doi%3D10.4049%2Fjimmunol.1002697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunzmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissinger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruediger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tony, H. P.</span></span> <span> </span><span class="NLM_article-title">Gammadelta T cells for immune therapy of patients with lymphoid malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">200</span>â <span class="NLM_lpage">206</span>, <span class="refDoi">Â DOI: 10.1182/blood-2002-12-3665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1182%2Fblood-2002-12-3665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=12623838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltFemurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=200-206&author=M.+Wilhelmauthor=V.+Kunzmannauthor=S.+Ecksteinauthor=P.+Reimerauthor=F.+Weissingerauthor=T.+Ruedigerauthor=H.+P.+Tony&title=Gammadelta+T+cells+for+immune+therapy+of+patients+with+lymphoid+malignancies&doi=10.1182%2Fblood-2002-12-3665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Î³Î´ T cells for immune therapy of patients with lymphoid malignancies</span></div><div class="casAuthors">Wilhelm, Martin; Kunzmann, Volker; Eckstein, Susanne; Reimer, Peter; Weissinger, Florian; Ruediger, Thomas; Tony, Hans-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">200-206</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">There is increasing evidence that Î³Î´ T cells have potent innate antitumor activity.  We described previously that synthetic aminobisphosphonates are potent Î³Î´ T cell stimulatory compds. that induce cytokine secretion (ie, interferon Î³ [IFN-Î³]) and cell-mediated cytotoxicity against lymphoma and myeloma cell lines in vitro.  To evaluate the antitumor activity of Î³Î´ T cells in vivo, we initiated a pilot study of low-dose interleukin 2 (IL-2) in combination with pamidronate in 19 patients with relapsed/refractory low-grade non-Hodgkin lymphoma (NHL) or multiple myeloma (MM).  The objectives of this trial were to det. toxicity, the most ED for in vivo activation/proliferation of Î³Î´ T cells, and antilymphoma efficacy of the combination of pamidronate and IL-2.  The first 10 patients (cohort A) who entered the study received 90 mg pamidronate i.v. on day 1 followed by increasing dose levels of continuous 24-h i.v. (IV) infusions of IL-2 (0.25 to 3Ã106 IU/m2) from day 3 to day 8.  Even at the highest IL-2 dose level in vivo, Î³Î´ T-cell activation/proliferation and response to treatment were disappointing with only 1 patient achieving stable disease.  Therefore, the next 9 patients were selected by pos. in vitro proliferation of Î³Î´ T cells in response to pamidronate/IL-2 and received a modified treatment schedule (6-h bolus IV IL-2 infusions from day 1-6).  In this patient group (cohort B), significant in vivo activation/proliferation of Î³Î´ T cells was obsd. in 5 patients (55%), and objective responses (PR) were achieved in 3 patients (33%).  Only patients with significant in vivo proliferation of Î³Î´ T cells responded to treatment, indicating that Î³Î´ T cells might contribute to this antilymphoma effect.  Overall, administration of pamidronate and low-dose IL-2 was well tolerated.  In conclusion, this clin. trial demonstrates, for the first time, that Î³Î´ T-cell-mediated immunotherapy is feasible and can induce objective tumor responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptCr_pzMH80rVg90H21EOLACvtfcHk0litAVJj3OFZOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltFemurk%253D&md5=bb25a24f96a289c59d3419836682bcec</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-12-3665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-12-3665%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DM.%26aulast%3DKunzmann%26aufirst%3DV.%26aulast%3DEckstein%26aufirst%3DS.%26aulast%3DReimer%26aufirst%3DP.%26aulast%3DWeissinger%26aufirst%3DF.%26aulast%3DRuediger%26aufirst%3DT.%26aulast%3DTony%26aufirst%3DH.%2BP.%26atitle%3DGammadelta%2520T%2520cells%2520for%2520immune%2520therapy%2520of%2520patients%2520with%2520lymphoid%2520malignancies%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D200%26epage%3D206%26doi%3D10.1182%2Fblood-2002-12-3665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sicard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Saati, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delsol, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FourniÃ©, J.-J. J. M. M.</span></span> <span> </span><span class="NLM_article-title">Synthetic phosphoantigens enhance human V Î³ 9V Î´ 2 T lymphocytes killing of non-odgkinâs B lymphoma</span>. <i>Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">711</span>, <span class="refDoi">Â DOI: 10.1007/BF03401961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1007%2FBF03401961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=11713370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt12lu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=711&author=H.+Sicardauthor=T.+Al+Saatiauthor=G.+Delsolauthor=J.-J.+J.+M.+M.+Fourni%C3%A9&title=Synthetic+phosphoantigens+enhance+human+V+%CE%B3+9V+%CE%B4+2+T+lymphocytes+killing+of+non-odgkin%E2%80%99s+B+lymphoma&doi=10.1007%2FBF03401961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic phosphoantigens enhance human VÎ³9VÎ´2 T lymphocytes killing of non-Hodgkin's B lymphoma</span></div><div class="casAuthors">Sicard, Helene; Saati, Talal Al; Delsol, Georges; Fournie, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine (Baltimore, MD, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">711-722</span>CODEN:
                <span class="NLM_cas:coden">MOMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1076-1551</span>.
    
            (<span class="NLM_cas:orgname">Johns Hopkins University Press</span>)
        </div><div class="casAbstract">Background: Non-Hodgkin's B lymphomas (NHL) are often resistant to conventional treatments and, until now, immunotherapeutic approaches against NHL only aimed at inducing Î±Î² anti-tumor effectors.  Nevertheless, human blood VÎ³9VÎ´2 T lymphocytes represent an abundant pool of cytotoxic tumor-reactive cells.  VÎ³9VÎ´2 T cells are strongly activated by natural compds., from which powerful synthetic ligands have been derived.  These synthetic antigens induce efficient VÎ³9VÎ´2 T cell responses in vitro.  Materials and Methods: the authors set up a series of VÎ³9VÎ´2 T cell-activation expts., including cytotoxic activity and amplification from whole blood cells.  Several types of VÎ³9VÎ´2 effectors were challenged against a panel of 16 B lymphoma cell lines.  These tests have been performed in the absence and presence of Î³Î´-specific synthetic ligands to evaluate the effect of such mols. on Î³Î´ anti-tumor activity.  Results: the authors report here that VÎ³9VÎ´2 T cells recognize B lymphomas.  This recognition is assocd. with the cytotoxic activity against B-lymphoma cells and/or proliferative responses, and appears to be T-cell antigen receptor (TCR)-dependent.  Because few B lymphoma induce a complete set of VÎ³9VÎ´2 cell responses, a chem. ligand of VÎ³9VÎ´2 T cells was used to enhance both proliferation and cytotoxic activity of anti-B lymphoma effectors.  The authors show that such synthetic compd. improves VÎ³9VÎ´2 CTL nos. and lysis of B lymphoma lines, esp. when the targets are already spontaneously recognized by these effectors.  Conclusions: the authors report here that human VÎ³9VÎ´2 T cells anti-B lymphoma response can be improved by use of specific synthetic ligands, which enhance their cytotoxic activity and allows their rapid expansion ex vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFLDw8cfbQG7Vg90H21EOLACvtfcHk0litAVJj3OFZOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt12lu7w%253D&md5=0d337ed13a26e6bf2b906625bdd60c28</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2FBF03401961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03401961%26sid%3Dliteratum%253Aachs%26aulast%3DSicard%26aufirst%3DH.%26aulast%3DAl%2BSaati%26aufirst%3DT.%26aulast%3DDelsol%26aufirst%3DG.%26aulast%3DFourni%25C3%25A9%26aufirst%3DJ.-J.%2BJ.%2BM.%2BM.%26atitle%3DSynthetic%2520phosphoantigens%2520enhance%2520human%2520V%2520%25CE%25B3%25209V%2520%25CE%25B4%25202%2520T%2520lymphocytes%2520killing%2520of%2520non-odgkin%25E2%2580%2599s%2520B%2520lymphoma%26jtitle%3DMol.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D711%26doi%3D10.1007%2FBF03401961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooff, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strandjord, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igbavboa, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volmer, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, W. G.</span></span> <span> </span><span class="NLM_article-title">Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">251</span>â <span class="NLM_lpage">257</span>, <span class="refDoi">Â DOI: 10.1016/j.nbd.2009.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.nbd.2009.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=19464372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCgt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=251-257&author=G.+P.+Eckertauthor=G.+P.+Hooffauthor=D.+M.+Strandjordauthor=U.+Igbavboaauthor=D.+A.+Volmerauthor=W.+E.+Mullerauthor=W.+G.+Wood&title=Regulation+of+the+brain+isoprenoids+farnesyl-+and+geranylgeranylpyrophosphate+is+altered+in+male+Alzheimer+patients&doi=10.1016%2Fj.nbd.2009.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients</span></div><div class="casAuthors">Eckert, Gunter P.; Hooff, Gero P.; Strandjord, Dana M.; Igbavboa, Urule; Volmer, Dietrich A.; Mueller, Walter E.; Wood, W. Gibson</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-257</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Post-translational modification of small GTPases by farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP) has generated much attention due to their potential contribution to cancer, cardiovascular and neurodegenerative diseases.  Prenylated proteins have been identified in numerous cell functions and elevated levels of FPP and GGPP have been previously proposed to occur in Alzheimer disease (AD) but have never been quantified.  In the present study, we detd. if the mevalonate derived compds. FPP and GGPP are increased in brain gray and white matter of male AD patients as compared with control samples.  This study demonstrates for the first time that FPP and GGPP levels are significantly elevated in human AD gray and white matter but not cholesterol, indicating a potentially disease-specific targeting of isoprenoid regulation independent of HMG-CoA-reductase.  Further suggesting a selective disruption of FPP and GGPP homeostasis in AD, we show that inhibition of HMG-CoA reductase in vivo significantly reduced FPP, GGPP and cholesterol abundance in mice with the largest effect on the isoprenoids.  A tentative conclusion is that if indeed regulation of FPP and GGPP is altered in AD brain such changes may stimulate protein prenylation and contribute to AD neuropathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkBOXbLdprrrVg90H21EOLACvtfcHk0litAVJj3OFZOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCgt7g%253D&md5=e1287530d7d10a29ec21bc81047b1e9d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2009.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2009.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DEckert%26aufirst%3DG.%2BP.%26aulast%3DHooff%26aufirst%3DG.%2BP.%26aulast%3DStrandjord%26aufirst%3DD.%2BM.%26aulast%3DIgbavboa%26aufirst%3DU.%26aulast%3DVolmer%26aufirst%3DD.%2BA.%26aulast%3DMuller%26aufirst%3DW.%2BE.%26aulast%3DWood%26aufirst%3DW.%2BG.%26atitle%3DRegulation%2520of%2520the%2520brain%2520isoprenoids%2520farnesyl-%2520and%2520geranylgeranylpyrophosphate%2520is%2520altered%2520in%2520male%2520Alzheimer%2520patients%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2009%26volume%3D35%26spage%3D251%26epage%3D257%26doi%3D10.1016%2Fj.nbd.2009.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hooff, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, G. P.</span></span> <span> </span><span class="NLM_article-title">Isoprenoids, small GTPases and Alzheimerâs disease</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1801</i></span>,  <span class="NLM_fpage">896</span>â <span class="NLM_lpage">905</span>, <span class="refDoi">Â DOI: 10.1016/j.bbalip.2010.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.bbalip.2010.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=20382260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlags7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1801&publication_year=2010&pages=896-905&author=G.+P.+Hooffauthor=W.+G.+Woodauthor=W.+E.+Mullerauthor=G.+P.+Eckert&title=Isoprenoids%2C+small+GTPases+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.bbalip.2010.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Isoprenoids, small GTPases and Alzheimer's disease</span></div><div class="casAuthors">Hooff, Gero P.; Wood, W. Gibson; Mueller, Walter E.; Eckert, Gunter P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1801</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">896-905</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  The mevalonate pathway is a crucial metabolic pathway for most eukaryotic cells.  Cholesterol is a highly recognized product of this pathway but growing interest is being given to the synthesis and functions of isoprenoids.  Isoprenoids are a complex class of biol. active lipids including for example, dolichol, ubiquinone, farnesylpyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).  Early work had shown that the long-chain isoprenoid dolichol is decreased but that dolichyl phosphate and ubiquinone are elevated in brains of Alzheimer's disease (AD) patients.  Until recently, levels of their biol. active precursors FPP and GGPP were unknown.  These short-chain isoprenoids are crit. in the post-translational modification of certain proteins which function as mol. switches in numerous signaling pathways.  The major protein families belong to the superfamily of small GTPases, consisting of roughly 150 members.  Recent exptl. evidence indicated that members of the small GTPases are involved in AD pathogenesis and stimulated interest in the role of FPP and GGPP in protein prenylation and cell function.  A straightforward prediction derived from those studies was that FPP and GGPP levels would be elevated in AD brains as compared with normal neurol. controls.  For the first time, recent evidence shows significantly elevated levels of FPP and GGPP in human AD brain tissue.  Cholesterol levels did not differ between AD and control samples.  One obvious conclusion is that homeostasis of FPP and GGPP but not of cholesterol is specifically targeted in AD.  Since prenylation of small GTPases by FPP or GGPP is indispensable for their proper function we are proposing that these two isoprenoids are up-regulated in AD resulting in an over abundance of certain prenylated proteins which contributes to neuronal dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAA62l3GNXHrVg90H21EOLACvtfcHk0lhuZucybQLM3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlags7k%253D&md5=ed5c6f229ce35b2e2a0948fdf33c094e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2010.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2010.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DHooff%26aufirst%3DG.%2BP.%26aulast%3DWood%26aufirst%3DW.%2BG.%26aulast%3DMuller%26aufirst%3DW.%2BE.%26aulast%3DEckert%26aufirst%3DG.%2BP.%26atitle%3DIsoprenoids%252C%2520small%2520GTPases%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2010%26volume%3D1801%26spage%3D896%26epage%3D905%26doi%3D10.1016%2Fj.bbalip.2010.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlineritsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoeger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luschin-Ebengreuth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poestlberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidtmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">62-Month follow-up of ABCSG-12: adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer</span>. <i>Bone</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">S17</span>â <span class="NLM_lpage">S17</span>, <span class="refDoi">Â DOI: 10.1016/j.bone.2010.10.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.bone.2010.10.045" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2011&pages=S17-S17&author=M.+Gnantauthor=B.+Mlineritschauthor=H.+Stoegerauthor=G.+Luschin-Ebengreuthauthor=S.+Poestlbergerauthor=G.+Stegerauthor=R.+Jakeszauthor=C.+Singerauthor=H.+Eidtmannauthor=R.+Greil&title=62-Month+follow-up+of+ABCSG-12%3A+adjuvant+endocrine+therapy%2C+alone+or+in+combination+with+zoledronic+acid%2C+in+premenopausal+patients+with+endocrine-responsive+early+breast+cancer&doi=10.1016%2Fj.bone.2010.10.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bone.2010.10.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bone.2010.10.045%26sid%3Dliteratum%253Aachs%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DMlineritsch%26aufirst%3DB.%26aulast%3DStoeger%26aufirst%3DH.%26aulast%3DLuschin-Ebengreuth%26aufirst%3DG.%26aulast%3DPoestlberger%26aufirst%3DS.%26aulast%3DSteger%26aufirst%3DG.%26aulast%3DJakesz%26aufirst%3DR.%26aulast%3DSinger%26aufirst%3DC.%26aulast%3DEidtmann%26aufirst%3DH.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3D62-Month%2520follow-up%2520of%2520ABCSG-12%253A%2520adjuvant%2520endocrine%2520therapy%252C%2520alone%2520or%2520in%2520combination%2520with%2520zoledronic%2520acid%252C%2520in%2520premenopausal%2520patients%2520with%2520endocrine-responsive%2520early%2520breast%2520cancer%26jtitle%3DBone%26date%3D2011%26volume%3D48%26spage%3DS17%26epage%3DS17%26doi%3D10.1016%2Fj.bone.2010.10.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlineritsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoeger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luschin-Ebengreuth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pristauz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauernhofer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidtmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwasny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochreiner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsthuber, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">631</span>â <span class="NLM_lpage">641</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(11)70122-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2FS1470-2045%2811%2970122-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=21641868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXot1ejtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=631-641&author=M.+Gnantauthor=B.+Mlineritschauthor=H.+Stoegerauthor=G.+Luschin-Ebengreuthauthor=D.+Heckauthor=C.+Menzelauthor=R.+Jakeszauthor=M.+Seifertauthor=M.+Hubalekauthor=G.+Pristauzauthor=T.+Bauernhoferauthor=H.+Eidtmannauthor=W.+Eiermannauthor=G.+Stegerauthor=W.+Kwasnyauthor=P.+Dubskyauthor=G.+Hochreinerauthor=E.+P.+Forsthuberauthor=C.+Feslauthor=R.+Greil&title=Adjuvant+endocrine+therapy+plus+zoledronic+acid+in+premenopausal+women+with+early-stage+breast+cancer%3A+62-month+follow-up+from+the+ABCSG-12+randomised+trial&doi=10.1016%2FS1470-2045%2811%2970122-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial</span></div><div class="casAuthors">Gnant, Michael; Mlineritsch, Brigitte; Stoeger, Herbert; Luschin-Ebengreuth, Gero; Heck, Dietmar; Menzel, Christian; Jakesz, Raimund; Seifert, Michael; Hubalek, Michael; Pristauz, Gunda; Bauernhofer, Thomas; Eidtmann, Holger; Eiermann, Wolfgang; Steger, Guenther; Kwasny, Werner; Dubsky, Peter; Hochreiner, Gerhard; Forsthuber, Ernst-Pius; Fesl, Christian; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-641</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Anal. of the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) at 48 mo' follow-up showed that addn. of zoledronic acid to adjuvant endocrine therapy significantly improved disease-free survival.  We have now assessed long-term clin. efficacy including disease-free survival and disease outcomes in patients receiving anastrozole or tamoxifen with or without zoledronic acid.  ABSCG-12 is a randomised, controlled, open-label, two-by-two factorial, multicentre trial in 1803 premenopausal women with endocrine-receptor-pos. early-stage (stage I-II) breast cancer receiving goserelin (3.6 mg every 28 days), comparing the efficacy and safety of anastrozole (1 mg per day) or tamoxifen (20 mg per day) with or without zoledronic acid (4 mg every 6 mo) for 3 years.  Randomisation (1:1:1:1 ratio) was computerized and based on the Pocock and Simon minimisation method to balance the four treatment arms across eight prognostic variables (age, neoadjuvant chemotherapy, pathol. tumor stage; lymph-node involvement, type of surgery or locoregional therapy, complete axillary dissection, intraoperative radiation therapy, and geog. region).  Treatment allocation was not masked.  The primary endpoint was disease-free survival (defined as disease recurrence or death) and anal. was by intention to treat.  This trial is registered with ClinicalTrials.gov, no. NCT00295646; follow-up is ongoing.  At a median follow-up of 62 mo (range 0-114.4 mo), more than 2 years after treatment completion, 186 disease-free survival events had been reported (53 events in 450 patients on tamoxifen alone, 57 in 453 patients on anastrozole alone, 36 in 450 patients on tamoxifen plus zoledronic acid, and 40 in 450 patients on anastrozole plus zoledronic acid).  Zoledronic acid reduced risk of disease-free survival events overall (HR 0.68, 95% CI 0.51-0.91; p=0.009), although the difference was not significant in the tamoxifen (HR 0.67, 95% CI 0.44-1.03; p=0.067) and anastrozole arms (HR 0.68, 95% CI 0.45-1.02; p=0.061) assessed sep.  Zoledronic acid did not significantly affect risk of death (30 deaths with zoledronic acid vs 43 deaths without; HR 0.67, 95% CI 0.41-1.07; p=0.09).  There was no difference in disease-free survival between patients on tamoxifen alone vs. anastrozole alone (HR 1.08, 95% CI 0.81-1.44; p=0.591), but overall survival was worse with anastrozole than with tamoxifen (46 vs 27 deaths; HR 1.75, 95% CI 1.08-2.83; p=0.02).  Treatments were generally well tolerated, with no reports of renal failure or osteonecrosis of the jaw.  Bone pain was reported in 601 patients (33%; 349 patients on zoledronic acid vs 252 not on the drug), fatigue in 361 (20%; 192 vs 169), headache in 280 (16%; 147 vs 133), and arthralgia in 266 (15%; 145 vs 121).  Addn. of zoledronic acid improved disease-free survival in the patients taking anastrozole or tamoxifen.  There was no difference in disease-free survival between patients receiving anastrozole and tamoxifen overall, but those on anastrozole alone had inferior overall survival.  These data show persistent benefits with zoledronic acid and support its addn. to adjuvant endocrine therapy in premenopausal patients with early-stage breast cancer.  Funding: AstraZeneca; Novartis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgMLLmua064rVg90H21EOLACvtfcHk0lhuZucybQLM3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXot1ejtLc%253D&md5=4755e1a85528b14accc4cc95bfa3d6b3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970122-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970122-X%26sid%3Dliteratum%253Aachs%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DMlineritsch%26aufirst%3DB.%26aulast%3DStoeger%26aufirst%3DH.%26aulast%3DLuschin-Ebengreuth%26aufirst%3DG.%26aulast%3DHeck%26aufirst%3DD.%26aulast%3DMenzel%26aufirst%3DC.%26aulast%3DJakesz%26aufirst%3DR.%26aulast%3DSeifert%26aufirst%3DM.%26aulast%3DHubalek%26aufirst%3DM.%26aulast%3DPristauz%26aufirst%3DG.%26aulast%3DBauernhofer%26aufirst%3DT.%26aulast%3DEidtmann%26aufirst%3DH.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DSteger%26aufirst%3DG.%26aulast%3DKwasny%26aufirst%3DW.%26aulast%3DDubsky%26aufirst%3DP.%26aulast%3DHochreiner%26aufirst%3DG.%26aulast%3DForsthuber%26aufirst%3DE.%2BP.%26aulast%3DFesl%26aufirst%3DC.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DAdjuvant%2520endocrine%2520therapy%2520plus%2520zoledronic%2520acid%2520in%2520premenopausal%2520women%2520with%2520early-stage%2520breast%2520cancer%253A%252062-month%2520follow-up%2520from%2520the%2520ABCSG-12%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D631%26epage%3D641%26doi%3D10.1016%2FS1470-2045%2811%2970122-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valachis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nearchou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyzos, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lind, P. A.</span></span> <span> </span><span class="NLM_article-title">Adjuvant therapy with zoledronic acid in primary breast cancer: a systematic review and meta-analysis</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">S377</span>â <span class="NLM_lpage">S377</span>, <span class="refDoi">Â DOI: 10.1016/S0959-8049(11)71599-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2FS0959-8049%2811%2971599-4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=S377-S377&author=A.+Valachisauthor=A.+Nearchouauthor=N.+P.+Polyzosauthor=D.+Mauriauthor=P.+A.+Lind&title=Adjuvant+therapy+with+zoledronic+acid+in+primary+breast+cancer%3A+a+systematic+review+and+meta-analysis&doi=10.1016%2FS0959-8049%2811%2971599-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2811%2971599-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252811%252971599-4%26sid%3Dliteratum%253Aachs%26aulast%3DValachis%26aufirst%3DA.%26aulast%3DNearchou%26aufirst%3DA.%26aulast%3DPolyzos%26aufirst%3DN.%2BP.%26aulast%3DMauri%26aufirst%3DD.%26aulast%3DLind%26aufirst%3DP.%2BA.%26atitle%3DAdjuvant%2520therapy%2520with%2520zoledronic%2520acid%2520in%2520primary%2520breast%2520cancer%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2011%26volume%3D47%26spage%3DS377%26epage%3DS377%26doi%3D10.1016%2FS0959-8049%2811%2971599-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szubert, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drayson, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Child, J. A.</span></span> <span> </span><span class="NLM_article-title">Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">5374</span>â <span class="NLM_lpage">5383</span>, <span class="refDoi">Â DOI: 10.1182/blood-2011-11-392522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1182%2Fblood-2011-11-392522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=22498739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFantLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=5374-5383&author=G.+J.+Morganauthor=F.+E.+Daviesauthor=W.+M.+Gregoryauthor=A.+J.+Szubertauthor=S.+E.+Bellauthor=M.+T.+Draysonauthor=R.+G.+Owenauthor=A.+J.+Ashcroftauthor=G.+H.+Jacksonauthor=J.+A.+Child&title=Effects+of+induction+and+maintenance+plus+long-term+bisphosphonates+on+bone+disease+in+patients+with+multiple+myeloma%3A+the+Medical+Research+Council+Myeloma+IX+Trial&doi=10.1182%2Fblood-2011-11-392522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial</span></div><div class="casAuthors">Morgan, Gareth J.; Davies, Faith E.; Gregory, Walter M.; Szubert, Alex J.; Bell, Sue E.; Drayson, Mark T.; Owen, Roger G.; Ashcroft, A. John; Jackson, Graham H.; Child, J. Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5374-5383</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examd. traditional and thalidomide-based induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly diagnosed multiple myeloma.  Overall survival (OS) and skeletal-related event (SRE) data have been reported for the overall trial population.  The present anal. investigated optimal therapy regimens for different patient populations in Myeloma IX.  Patients were assigned to intensive or nonintensive treatment pathways and randomized to induction cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) vs. cyclophosphamide, thalidomide, and dexamethasone (CTD; intensive) or melphalan and prednisolone vs. attenuated oral CTD (CTDa; nonintensive).  Patients were also randomized to ZOL or CLO.  In the nonintensive pathway, CTDa produced better responses and lower SRE rates than melphalan and prednisolone.  ZOL improved OS compared with CLO independently of sex, stage, or myeloma subtype, most profoundly in patients with baseline bone disease or other SREs.  In patients treated for â¥ 2 years, ZOL improved OS compared with CLO from randomization (median not reached for either; P = .02) and also from first on-study disease progression (median, 34 mo for ZOL vs 27 mo for CLO; P = .03).  Thalidomide-contg. regimens had better efficacy than traditional regimens, and ZOL demonstrated greater benefits than CLO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn6bsYwhGflrVg90H21EOLACvtfcHk0ljwXUwbohi-zw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFantLg%253D&md5=b908fa4236bbad0d7585647e43a02fbf</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-11-392522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-11-392522%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DG.%2BJ.%26aulast%3DDavies%26aufirst%3DF.%2BE.%26aulast%3DGregory%26aufirst%3DW.%2BM.%26aulast%3DSzubert%26aufirst%3DA.%2BJ.%26aulast%3DBell%26aufirst%3DS.%2BE.%26aulast%3DDrayson%26aufirst%3DM.%2BT.%26aulast%3DOwen%26aufirst%3DR.%2BG.%26aulast%3DAshcroft%26aufirst%3DA.%2BJ.%26aulast%3DJackson%26aufirst%3DG.%2BH.%26aulast%3DChild%26aufirst%3DJ.%2BA.%26atitle%3DEffects%2520of%2520induction%2520and%2520maintenance%2520plus%2520long-term%2520bisphosphonates%2520on%2520bone%2520disease%2520in%2520patients%2520with%2520multiple%2520myeloma%253A%2520the%2520Medical%2520Research%2520Council%2520Myeloma%2520IX%2520Trial%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D5374%26epage%3D5383%26doi%3D10.1182%2Fblood-2011-11-392522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlineritsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schippinger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luschin-Ebengreuth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postlberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjelic-Radisic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samonigg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tausch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidtmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwasny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridrik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stierer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucklinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">Endocrine therapy plus zoledronic acid in premenopausal breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">679</span>â <span class="NLM_lpage">691</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa0806285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1056%2FNEJMoa0806285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=19213681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVyisbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=679-691&author=M.+Gnantauthor=B.+Mlineritschauthor=W.+Schippingerauthor=G.+Luschin-Ebengreuthauthor=S.+Postlbergerauthor=C.+Menzelauthor=R.+Jakeszauthor=M.+Seifertauthor=M.+Hubalekauthor=V.+Bjelic-Radisicauthor=H.+Samoniggauthor=C.+Tauschauthor=H.+Eidtmannauthor=G.+Stegerauthor=W.+Kwasnyauthor=P.+Dubskyauthor=M.+Fridrikauthor=F.+Fitzalauthor=M.+Stiererauthor=E.+Rucklingerauthor=R.+Greil&title=Endocrine+therapy+plus+zoledronic+acid+in+premenopausal+breast+cancer&doi=10.1056%2FNEJMoa0806285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine therapy plus zoledronic acid in premenopausal breast cancer</span></div><div class="casAuthors">Gnant, Michael; Mlineritsch, Brigitte; Schippinger, Walter; Luschin-Ebengreuth, Gero; Postlberger, Sabine; Menzel, Christian; Jakesz, Raimund; Seifert, Michael; Hubalek, Michael; Bjelic-Radisic, Vesna; Samonigg, Hellmut; Tausch, Christoph; Eidtmann, Holger; Steger, Gunther; Kwasny, Werner; Dubsky, Peter; Fridrik, Michael; Fitzal, Florian; Stierer, Michael; Rucklinger, Ernst; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">679-691</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ovarian suppression plus tamoxifen is a std. adjuvant treatment in premenopausal women with endocrine-responsive breast cancer.  Aromatase inhibitors are superior to tamoxifen in postmenopausal patients, and preclin. data suggest that zoledronic acid has antitumor properties.  We examd. the effect of adding zoledronic acid to a combination of either goserelin and tamoxifen or goserelin and anastrozole in premenopausal women with endocrine-responsive early breast cancer.  We randomly assigned 1803 patients to receive goserelin (3.6 mg given s.c. every 28 days) plus tamoxifen (20 mg per day given orally) or anastrozole (1 mg per day given orally) with or without zoledronic acid (4 mg given i.v. every 6 mo) for 3 years.  The primary end point was disease-free survival; recurrence-free survival and overall survival were secondary end points.  After a median follow-up of 47.8 mo, 137 events had occurred, with disease-free survival rates of 92.8% in the tamoxifen group, 92.0% in the anastrozole group, 90.8% in the group that received endocrine therapy alone, and 94.0% in the group that received endocrine therapy with zoledronic acid.  There was no significant difference in disease-free survival between the anastrozole and tamoxifen groups (hazard ratio for disease progression in the anastrozole group, 1.10; 95% confidence interval [CI], 0.78 to 1.53; P = 0.59).  The addn. of zoledronic acid to endocrine therapy, as compared with endocrine therapy without zoledronic acid, resulted in an abs. redn. of 3.2 percentage points and a relative redn. of 36% in the risk of disease progression (hazard ratio, 0.64; 95% CI, 0.46 to 0.91; P = 0.01); the addn. of zoledronic acid did not significantly reduce the risk of death (hazard ratio, 0.60; 95% CI, 0.32 to 1.11; P = 0.11).  Adverse events were consistent with known drug-safety profiles.  The addn. of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWZL1vqoy7LVg90H21EOLACvtfcHk0ljwXUwbohi-zw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVyisbk%253D&md5=f2c9103a7cfd4b4d14bf30f8a2e679d7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0806285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0806285%26sid%3Dliteratum%253Aachs%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DMlineritsch%26aufirst%3DB.%26aulast%3DSchippinger%26aufirst%3DW.%26aulast%3DLuschin-Ebengreuth%26aufirst%3DG.%26aulast%3DPostlberger%26aufirst%3DS.%26aulast%3DMenzel%26aufirst%3DC.%26aulast%3DJakesz%26aufirst%3DR.%26aulast%3DSeifert%26aufirst%3DM.%26aulast%3DHubalek%26aufirst%3DM.%26aulast%3DBjelic-Radisic%26aufirst%3DV.%26aulast%3DSamonigg%26aufirst%3DH.%26aulast%3DTausch%26aufirst%3DC.%26aulast%3DEidtmann%26aufirst%3DH.%26aulast%3DSteger%26aufirst%3DG.%26aulast%3DKwasny%26aufirst%3DW.%26aulast%3DDubsky%26aufirst%3DP.%26aulast%3DFridrik%26aufirst%3DM.%26aulast%3DFitzal%26aufirst%3DF.%26aulast%3DStierer%26aufirst%3DM.%26aulast%3DRucklinger%26aufirst%3DE.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DEndocrine%2520therapy%2520plus%2520zoledronic%2520acid%2520in%2520premenopausal%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D679%26epage%3D691%26doi%3D10.1056%2FNEJMoa0806285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hellrieqel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baerens, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von der
Assen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baier-Ebert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emons, G.</span></span> <span> </span><span class="NLM_article-title">The EXpand study - effect of zoledronic acid on prevention of bone loss, during extended adjuvant therapy with letrozole in postmenopausal women with primary hormone receptor positive breast cancer compared to letrozole alone</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">S390</span>â <span class="NLM_lpage">S390</span>, <span class="refDoi">Â DOI: 10.1016/S0959-8049(11)71643-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2FS0959-8049%2811%2971643-4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=S390-S390&author=M.+Hellrieqelauthor=M.+Muellerauthor=T.+Reimerauthor=D.+T.+Baerensauthor=A.+von+der%0AAssenauthor=J.+Hackmannauthor=K.+Schmidtauthor=M.+Baier-Ebertauthor=T.+Spallauthor=G.+Emons&title=The+EXpand+study+-+effect+of+zoledronic+acid+on+prevention+of+bone+loss%2C+during+extended+adjuvant+therapy+with+letrozole+in+postmenopausal+women+with+primary+hormone+receptor+positive+breast+cancer+compared+to+letrozole+alone&doi=10.1016%2FS0959-8049%2811%2971643-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2811%2971643-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252811%252971643-4%26sid%3Dliteratum%253Aachs%26aulast%3DHellrieqel%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DM.%26aulast%3DReimer%26aufirst%3DT.%26aulast%3DBaerens%26aufirst%3DD.%2BT.%26aulast%3Dvon%2Bder%2BAssen%26aufirst%3DA.%26aulast%3DHackmann%26aufirst%3DJ.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DBaier-Ebert%26aufirst%3DM.%26aulast%3DSpall%26aufirst%3DT.%26aulast%3DEmons%26aufirst%3DG.%26atitle%3DThe%2520EXpand%2520study%2520-%2520effect%2520of%2520zoledronic%2520acid%2520on%2520prevention%2520of%2520bone%2520loss%252C%2520during%2520extended%2520adjuvant%2520therapy%2520with%2520letrozole%2520in%2520postmenopausal%2520women%2520with%2520primary%2520hormone%2520receptor%2520positive%2520breast%2520cancer%2520compared%2520to%2520letrozole%2520alone%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2011%26volume%3D47%26spage%3DS390%26epage%3DS390%26doi%3D10.1016%2FS0959-8049%2811%2971643-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocks, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szubert, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro-Coy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drayson, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roddie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Child, J. A.</span></span> <span> </span><span class="NLM_article-title">First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1989</span>â <span class="NLM_lpage">1999</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(10)62051-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2FS0140-6736%2810%2962051-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=21131037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFCqsLnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=1989-1999&author=G.+J.+Morganauthor=F.+E.+Daviesauthor=W.+M.+Gregoryauthor=K.+Cocksauthor=S.+E.+Bellauthor=A.+J.+Szubertauthor=N.+Navarro-Coyauthor=M.+T.+Draysonauthor=R.+G.+Owenauthor=S.+Feylerauthor=A.+J.+Ashcroftauthor=F.+Rossauthor=J.+Byrneauthor=H.+Roddieauthor=C.+Rudinauthor=G.+Cookauthor=G.+H.+Jacksonauthor=J.+A.+Child&title=First-line+treatment+with+zoledronic+acid+as+compared+with+clodronic+acid+in+multiple+myeloma+%28MRC+Myeloma+IX%29%3A+a+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2810%2962051-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial</span></div><div class="casAuthors">Morgan, Gareth J.; Davies, Faith E.; Gregory, Walter M.; Cocks, Kim; Bell, Sue E.; Szubert, Alex J.; Navarro-Coy, Nuria; Drayson, Mark T.; Owen, Roger G.; Feyler, Sylvia; Ashcroft, A. John; Ross, Fiona; Byrne, Jennifer; Roddie, Huw; Rudin, Claudius; Cook, Gordon; Jackson, Graham H.; Child, J. Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9757</span>),
    <span class="NLM_cas:pages">1989-1999</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclin. and clin. studies.  We aimed to establish whether bisphosphonates can affect clin. outcomes in patients with multiple myeloma.  Patients of age 18 years or older with newly diagnosed multiple myeloma were enrolled from 120 centers in the UK.  Computer-generated randomisation sequence was used to allocate patients equally, via an automated telephone service, to receive 4 mg zoledronic acid as an infusion every 3-4 wk or 1600 mg oral clodronic acid daily.  Patients also received intensive or non-intensive induction chemotherapy.  No investigators, staff, or patients were masked to treatment allocation, and bisphosphonate and maintenance therapy continued at least until disease progression.  The primary endpoints were overall survival, progression-free survival, and overall response rate.  We assessed between-group differences with Cox proportional hazards models for progression-free survival and overall survival, and with logistic regression models for overall response rate.  Anal. was by intention to treat.  This trial is registered, no. ISRCTN68454111.  1970 patients were enrolled between May, 2003, and Nov., 2007, of whom 1960 were eligible for intention-to-treat anal.: 981 in the zoledronic acid group (555 on intensive chemotherapy, 426 on non-intensive chemotherapy); and 979 on clodronic acid (556 on intensive chemotherapy, 423 on non-intensive chemotherapy).  The treatment cutoff was Oct 5, 2009, with patients receiving bisphosphonates for a median of 350 days (IQR 137-632) before disease progression, with a median of 3.7 years' follow-up (IQR 2.9-4.7).  Zoledronic acid reduced mortality by 16% (95% CI 4-26) vs. clodronic acid (hazard ratio [HR] 0.84, 95% CI 0.74-0.96; p=0.0118), and extended median overall survival by 5.5 mo (50.0 mo, IQR 21.0 to not reached vs 44.5 mo, IQR 16.5 to not reached; p=0.04).  Zoledronic acid also significantly improved progression-free survival by 12% (95% CI 2-20) vs. clodronic acid (HR 0.88, 95% CI 0.80-0.98; p=0.0179), and increased median progression-free survival by 2.0 mo (19.5 mo, IQR 9.0-38.0 vs 17.5 mo, IQR 8.5-34.0; p=0.07).  Rates of complete, very good partial, or partial response did not differ significantly between the zoledronic acid and clodronic acid groups for patients receiving intensive induction chemotherapy (432 patients [78%] vs 422 [76%]; p=0.43) or non-intensive induction chemotherapy (215 [50%] vs 195 [46%]; p=0.18).  Both bisphosphonates were generally well tolerated, with similar occurrence of acute renal failure and treatment-emergent serious adverse events, but zoledronic acid was assocd. with higher rates of confirmed osteonecrosis of the jaw (35 [4%]) than was clodronic acid (3 [<1%]).  Consistent with the potential anticancer activity of zoledronic acid, overall survival improved independently of prevention of skeletal-related events, showing that zoledronic acid has treatment benefits beyond bone health.  These findings support immediate treatment with zoledronic acid in patients with newly diagnosed multiple myeloma, not only for prevention of skeletal-related events, but also for potential antimyeloma benefits.  Funding: Medical Research Council (London, UK), with unrestricted educational grants from Novartis, Schering Health Care, Chugai, Pharmion, Celgene, and Ortho Biotech.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXS5ilaeyX3rVg90H21EOLACvtfcHk0ljvVlF-kHe7dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFCqsLnL&md5=53e25efc3a82b57d286c73f7fba6a611</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2962051-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252962051-X%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DG.%2BJ.%26aulast%3DDavies%26aufirst%3DF.%2BE.%26aulast%3DGregory%26aufirst%3DW.%2BM.%26aulast%3DCocks%26aufirst%3DK.%26aulast%3DBell%26aufirst%3DS.%2BE.%26aulast%3DSzubert%26aufirst%3DA.%2BJ.%26aulast%3DNavarro-Coy%26aufirst%3DN.%26aulast%3DDrayson%26aufirst%3DM.%2BT.%26aulast%3DOwen%26aufirst%3DR.%2BG.%26aulast%3DFeyler%26aufirst%3DS.%26aulast%3DAshcroft%26aufirst%3DA.%2BJ.%26aulast%3DRoss%26aufirst%3DF.%26aulast%3DByrne%26aufirst%3DJ.%26aulast%3DRoddie%26aufirst%3DH.%26aulast%3DRudin%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DG.%26aulast%3DJackson%26aufirst%3DG.%2BH.%26aulast%3DChild%26aufirst%3DJ.%2BA.%26atitle%3DFirst-line%2520treatment%2520with%2520zoledronic%2520acid%2520as%2520compared%2520with%2520clodronic%2520acid%2520in%2520multiple%2520myeloma%2520%2528MRC%2520Myeloma%2520IX%2529%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D1989%26epage%3D1999%26doi%3D10.1016%2FS0140-6736%2810%2962051-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodwell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkinshaw, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grieve, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett-Lee, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, H.</span></span> <span> </span><span class="NLM_article-title">Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">429</span>â <span class="NLM_lpage">438</span>, <span class="refDoi">Â DOI: 10.1007/s10549-011-1429-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1007%2Fs10549-011-1429-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=21394500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Citbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2011&pages=429-438&author=R.+Colemanauthor=E.+Woodwardauthor=J.+Brownauthor=D.+Cameronauthor=R.+Bellauthor=D.+Dodwellauthor=M.+Keaneauthor=M.+Gilauthor=C.+Daviesauthor=R.+Burkinshawauthor=S.+J.+Houstonauthor=R.+J.+Grieveauthor=P.+J.+Barrett-Leeauthor=H.+Thorpe&title=Safety+of+zoledronic+acid+and+incidence+of+osteonecrosis+of+the+jaw+%28ONJ%29+during+adjuvant+therapy+in+a+randomised+phase+III+trial+%28AZURE%3A+BIG+01-04%29+for+women+with+stage+II%2FIII+breast+cancer&doi=10.1007%2Fs10549-011-1429-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer</span></div><div class="casAuthors">Coleman, R.; Woodward, E.; Brown, J.; Cameron, D.; Bell, R.; Dodwell, D.; Keane, M.; Gil, M.; Davies, C.; Burkinshaw, R.; Houston, S. J.; Grieve, R. J.; Barrett-Lee, P. J.; Thorpe, H.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">429-438</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The AZURE trial is an ongoing phase III, academic, multi-center, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer.  Here, we report the safety and tolerability profile of ZOL in this setting.  Eligible patients received (neo)adjuvant chemotherapy and/or endocrine therapy and were randomised to receive neither addnl. treatment nor i.v. ZOL 4 mg.  ZOL was administered after each chemotherapy cycle to exploit potential sequence-dependent synergy.  ZOL was continued for 60 mo post-randomisation (six doses in the first 6 mo, eight doses in the following 24 mo and five doses in the final 30 mo).  Serious (SAE) and non-serious adverse event (AE) data generated during the first 36 mo on study were analyzed for the safety population. 3,360 patients were recruited to the AZURE trial.  The safety population comprised 3,340 patients (ZOL 1,665; control 1,675).  The addn. of ZOL to std. treatment did not significantly impact on chemotherapy delivery.  SAE were similar in both treatment arms.  No significant safety differences were seen apart from the occurrence of osteonecrosis of the jaw (ONJ) in the ZOL group (11 confirmed cases; 0.7%; 95% confidence interval 0.3-1.1%).  ZOL in the adjuvant setting is well tolerated, and can be safely administered in addn. to adjuvant therapy including chemotherapy.  The adverse events were consistent with the known safety profile of ZOL, with a low incidence of ONJ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHOS2xzexrHLVg90H21EOLACvtfcHk0ljvVlF-kHe7dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Citbc%253D&md5=a3be69d7b9902510b10de77fb2db8243</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1429-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1429-y%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%26aulast%3DWoodward%26aufirst%3DE.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DCameron%26aufirst%3DD.%26aulast%3DBell%26aufirst%3DR.%26aulast%3DDodwell%26aufirst%3DD.%26aulast%3DKeane%26aufirst%3DM.%26aulast%3DGil%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DBurkinshaw%26aufirst%3DR.%26aulast%3DHouston%26aufirst%3DS.%2BJ.%26aulast%3DGrieve%26aufirst%3DR.%2BJ.%26aulast%3DBarrett-Lee%26aufirst%3DP.%2BJ.%26aulast%3DThorpe%26aufirst%3DH.%26atitle%3DSafety%2520of%2520zoledronic%2520acid%2520and%2520incidence%2520of%2520osteonecrosis%2520of%2520the%2520jaw%2520%2528ONJ%2529%2520during%2520adjuvant%2520therapy%2520in%2520a%2520randomised%2520phase%2520III%2520trial%2520%2528AZURE%253A%2520BIG%252001-04%2529%2520for%2520women%2520with%2520stage%2520II%252FIII%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D127%26spage%3D429%26epage%3D438%26doi%3D10.1007%2Fs10549-011-1429-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeddula, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, I. M.</span></span> <span> </span><span class="NLM_article-title">A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">263ra161</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3010382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1126%2Fscitranslmed.3010382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=25411474" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=263ra161&author=Y.+F.+Xiaauthor=Y.+L.+Liuauthor=Y.+H.+Xieauthor=W.+Zhuauthor=F.+Guerraauthor=S.+Shenauthor=N.+Yeddulaauthor=W.+G.+Fischerauthor=W.+Lowauthor=X.+Y.+Zhouauthor=Y.+H.+Zhangauthor=E.+Oldfieldauthor=I.+M.+Verma&title=A+combination+therapy+for+KRAS-driven+lung+adenocarcinomas+using+lipophilic+bisphosphonates+and+rapamycin&doi=10.1126%2Fscitranslmed.3010382"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3010382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3010382%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DY.%2BF.%26aulast%3DLiu%26aufirst%3DY.%2BL.%26aulast%3DXie%26aufirst%3DY.%2BH.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DGuerra%26aufirst%3DF.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DYeddula%26aufirst%3DN.%26aulast%3DFischer%26aufirst%3DW.%2BG.%26aulast%3DLow%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DX.%2BY.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DOldfield%26aufirst%3DE.%26aulast%3DVerma%26aufirst%3DI.%2BM.%26atitle%3DA%2520combination%2520therapy%2520for%2520KRAS-driven%2520lung%2520adenocarcinomas%2520using%2520lipophilic%2520bisphosphonates%2520and%2520rapamycin%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D263ra161%26doi%3D10.1126%2Fscitranslmed.3010382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotesta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinzik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelle, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitsch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roddy, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. R.</span></span> <span> </span><span class="NLM_article-title">Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">660</span>â <span class="NLM_lpage">666</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fnchembio.421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=20711197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaisLzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=660-666&author=W.+Jahnkeauthor=J.+M.+Rondeauauthor=S.+Cotestaauthor=A.+Marzinzikauthor=X.+Pelleauthor=M.+Geiserauthor=A.+Straussauthor=M.+Gotteauthor=F.+Bitschauthor=R.+Hemmigauthor=C.+Henryauthor=S.+Lehmannauthor=J.+F.+Glickmanauthor=T.+P.+Roddyauthor=S.+J.+Stoutauthor=J.+R.+Green&title=Allosteric+non-bisphosphonate+FPPS+inhibitors+identified+by+fragment-based+discovery&doi=10.1038%2Fnchembio.421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery</span></div><div class="casAuthors">Jahnke, Wolfgang; Rondeau, Jean-Michel; Cotesta, Simona; Marzinzik, Andreas; Pelle, Xavier; Geiser, Martin; Strauss, Andre; Goette, Marjo; Bitsch, Francis; Hemmig, Rene; Henry, Chrystele; Lehmann, Sylvie; Glickman, J. Fraser; Roddy, Thomas P.; Stout, Steven J.; Green, Jonathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">660-666</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bisphosphonates are potent inhibitors of farnesyl pyrophosphate synthase (FPPS) and are highly efficacious in the treatment of bone diseases such as osteoporosis, Paget's disease and tumor-induced osteolysis.  In addn., the potential for direct antitumor effects has been postulated on the basis of in vitro and in vivo studies and has recently been demonstrated clin. in early breast cancer patients treated with the potent bisphosphonate zoledronic acid.  However, the high affinity of bisphosphonates for bone mineral seems suboptimal for the direct treatment of soft-tissue tumors.  Here we report the discovery of the first potent non-bisphosphonate FPPS inhibitors.  These new inhibitors bind to a previously unknown allosteric site on FPPS, which was identified by fragment-based approaches using NMR and X-ray crystallog.  This allosteric and druggable pocket allows the development of a new generation of FPPS inhibitors that are optimized for direct antitumor effects in soft tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZFyA6x-XeY7Vg90H21EOLACvtfcHk0ljFZ_PTkslQBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaisLzO&md5=72e1bc45a05733c2748a2138d0e0824f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.421%26sid%3Dliteratum%253Aachs%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DRondeau%26aufirst%3DJ.%2BM.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DMarzinzik%26aufirst%3DA.%26aulast%3DPelle%26aufirst%3DX.%26aulast%3DGeiser%26aufirst%3DM.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DGotte%26aufirst%3DM.%26aulast%3DBitsch%26aufirst%3DF.%26aulast%3DHemmig%26aufirst%3DR.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DLehmann%26aufirst%3DS.%26aulast%3DGlickman%26aufirst%3DJ.%2BF.%26aulast%3DRoddy%26aufirst%3DT.%2BP.%26aulast%3DStout%26aufirst%3DS.%2BJ.%26aulast%3DGreen%26aufirst%3DJ.%2BR.%26atitle%3DAllosteric%2520non-bisphosphonate%2520FPPS%2520inhibitors%2520identified%2520by%2520fragment-based%2520discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D660%26epage%3D666%26doi%3D10.1038%2Fnchembio.421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCammon, J. A.</span></span> <span> </span><span class="NLM_article-title">Farnesyl diphosphate synthase inhibitors from in silico screening</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">742</span>â <span class="NLM_lpage">748</span>, <span class="refDoi">Â DOI: 10.1111/cbdd.12121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1111%2Fcbdd.12121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=23421555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptlOhs7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=742-748&author=S.+Lindertauthor=W.+Zhuauthor=Y.+L.+Liuauthor=R.+Pangauthor=E.+Oldfieldauthor=J.+A.+McCammon&title=Farnesyl+diphosphate+synthase+inhibitors+from+in+silico+screening&doi=10.1111%2Fcbdd.12121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyl diphosphate synthase inhibitors from in silico screening</span></div><div class="casAuthors">Lindert, Steffen; Zhu, Wei; Liu, Yi-Liang; Pang, Ran; Oldfield, Eric; McCammon, J. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">742-748</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The relaxed complex scheme is an in silico drug screening method that accounts for receptor flexibility using mol. dynamics simulations.  Here, we used this approach combined with similarity searches and exptl. inhibition assays to identify several low micromolar, non-bisphosphonate inhibitors, bisamidines, of farnesyl diphosphate synthase (FPPS), an enzyme targeted by some anticancer and antimicrobial agents and for the treatment of bone resorption diseases.  This novel class of farnesyl diphosphate synthase inhibitors have more drug-like properties than existing bisphosphonate inhibitors, making them interesting pharmaceutical leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb9blD2iTxOLVg90H21EOLACvtfcHk0ljFZ_PTkslQBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptlOhs7c%253D&md5=e7f1b923bdfd161dce4befe7e773463c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12121%26sid%3Dliteratum%253Aachs%26aulast%3DLindert%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%2BL.%26aulast%3DPang%26aufirst%3DR.%26aulast%3DOldfield%26aufirst%3DE.%26aulast%3DMcCammon%26aufirst%3DJ.%2BA.%26atitle%3DFarnesyl%2520diphosphate%2520synthase%2520inhibitors%2520from%2520in%2520silico%2520screening%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2013%26volume%3D81%26spage%3D742%26epage%3D748%26doi%3D10.1111%2Fcbdd.12121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span> <span> </span><span class="NLM_article-title">Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1840</i></span>,  <span class="NLM_fpage">1051</span>â <span class="NLM_lpage">1062</span>, <span class="refDoi">Â DOI: 10.1016/j.bbagen.2013.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.bbagen.2013.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=24246954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Gmt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1840&publication_year=2014&pages=1051-1062&author=J.+Liuauthor=W.+Liuauthor=H.+Geauthor=J.+Gaoauthor=Q.+Heauthor=L.+Suauthor=J.+Xuauthor=L.+Q.+Guauthor=Z.+S.+Huangauthor=D.+Li&title=Syntheses+and+characterization+of+non-bisphosphonate+quinoline+derivatives+as+new+FPPS+inhibitors&doi=10.1016%2Fj.bbagen.2013.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors</span></div><div class="casAuthors">Liu, Jinggong; Liu, Weilin; Ge, Hu; Gao, Jinbo; He, Qingqing; Su, Lijuan; Xu, Jun; Gu, Lian-quan; Huang, Zhi-shu; Li, Ding</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1840</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1051-1062</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background: Farnesyl pyrophosphate synthase (FPPS) is a key regulatory enzyme in the biosynthesis of cholesterol and in the post-translational modification of signaling proteins.  It has been reported that non-bisphosphonate FPPS inhibitors targeting its allosteric binding pocket are potentially important for the development of promising anti-cancer drugs.  Methods: The following methods were used: org. syntheses of non-bisphosphonate quinoline derivs., enzyme inhibition studies, fluorescence titrn. assays, synergistic effect studies of quinoline derivs. with zoledronate, ITC studies for the binding of FPPS with quinoline derivs., NMR-based HAP binding assays, mol. modeling studies, fluorescence imaging assay and MTT assays.  Results: We report our syntheses of a series of quinoline derivs. as new FPPS inhibitors possibly targeting the allosteric site of the enzyme.  Compd. 6b showed potent inhibition to FPPS without significant hydroxyapatite binding affinity.  The compd. showed synergistic inhibitory effect with active-site inhibitor zoledronate.  ITC expt. confirmed the good binding effect of compd. 6b to FPPS, and further indicated the binding ratio of 1:1.  Mol. modeling studies showed that 6b could possibly bind to the allosteric binding pocket of the enzyme.  The fluorescence microscopy indicated that these compds. could get into cancer cells.  Conclusions: Our results showed that quinoline deriv. 6b could become a new lead compd. for further optimization for cancer treatment.  General significance: The traditional FPPS active-site inhibitors bisphosphonates show poor membrane permeability to tumor cells, due to their strong polarity.  The development of new non-bisphosphonate FPPS inhibitors with good cell membrane permeability is potentially important.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGY0ZQ2_LQdLVg90H21EOLACvtfcHk0lj4SFHigyKLRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Gmt74%253D&md5=ac2bf76352c08b6ccb8bddfe14a1e9df</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2013.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2013.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGe%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DSu%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DZ.%2BS.%26aulast%3DLi%26aufirst%3DD.%26atitle%3DSyntheses%2520and%2520characterization%2520of%2520non-bisphosphonate%2520quinoline%2520derivatives%2520as%2520new%2520FPPS%2520inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2014%26volume%3D1840%26spage%3D1051%26epage%3D1062%26doi%3D10.1016%2Fj.bbagen.2013.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCammon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Taxodione and arenarone inhibit farnesyl diphosphate synthase by binding to the isopentenyl diphosphate site</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">E2530</span>â <span class="NLM_lpage">2539</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1409061111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1073%2Fpnas.1409061111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=24927548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsValsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E2530-2539&author=Y.+L.+Liuauthor=S.+Lindertauthor=W.+Zhuauthor=K.+Wangauthor=J.+A.+McCammonauthor=E.+Oldfield&title=Taxodione+and+arenarone+inhibit+farnesyl+diphosphate+synthase+by+binding+to+the+isopentenyl+diphosphate+site&doi=10.1073%2Fpnas.1409061111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Taxodione and arenarone inhibit farnesyl diphosphate synthase by binding to the isopentenyl diphosphate site</span></div><div class="casAuthors">Liu, Yi-Liang; Lindert, Steffen; Zhu, Wei; Wang, Ke; McCammon, J. Andrew; Oldfield, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">E2530-E2539</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We used in silico methods to screen a library of 1,013 compds. for possible binding to the allosteric site in farnesyl diphosphate synthase (FPPS).  Two of the 50 predicted hits had activity against either human FPPS (HsFPPS) or Trypanosoma brucei FPPS (TbFPPS), the most active being the quinone methide celastrol (IC50 vs. TbFPPS â¼20 Î¼M).  Two rounds of similarity searching and activity testing then resulted in three leads that were active against HsFPPS with IC50 values in the range of â¼1-3 Î¼M (as compared with â¼0.5 Î¼M for the bisphosphonate inhibitor, zoledronate).  The three leads were the quinone methides taxodone and taxodione and the quinone arenarone, compds. with known antibacterial and/or antitumor activity.  We then obtained X-ray crystal structures of HsFPPS with taxodione+zoledronate, arenarone+zoledronate, and taxodione alone.  In the zoledronate-contg. structures, taxodione and arenarone bound solely to the homoallylic (isopentenyl diphosphate, IPP) site, not to the allosteric site, whereas zoledronate bound via Mg2+ to the same site as seen in other bisphosphonate-contg. structures.  In the taxodione-alone structure, one taxodione bound to the same site as seen in the taxodione+zoledronate structure, but the second located to a more surface-exposed site.  In differential scanning calorimetry expts., taxodione and arenarone broadened the native-to-unfolded thermal transition (Tm), quite different to the large increases in ÎTm seen with biphosphonate inhibitors.  The results identify new classes of FPPS inhibitors, diterpenoids and sesquiterpenoids, that bind to the IPP site and may be of interest as anticancer and antiinfective drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtuNMnxlrUELVg90H21EOLACvtfcHk0lj4SFHigyKLRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsValsLY%253D&md5=1f6c5992bbf22c2ee6dcf678c34a9fff</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1409061111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1409061111%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BL.%26aulast%3DLindert%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DMcCammon%26aufirst%3DJ.%2BA.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DTaxodione%2520and%2520arenarone%2520inhibit%2520farnesyl%2520diphosphate%2520synthase%2520by%2520binding%2520to%2520the%2520isopentenyl%2520diphosphate%2520site%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3DE2530%26epage%3D2539%26doi%3D10.1073%2Fpnas.1409061111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">349</span>â <span class="NLM_lpage">354</span>, <span class="refDoi">Â DOI: 10.1021/ml500528x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500528x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeisb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=349-354&author=Y.+L.+Liuauthor=R.+Caoauthor=Y.+Wangauthor=E.+Oldfield&title=Farnesyl+diphosphate+synthase+inhibitors+with+unique+ligand-binding+geometries&doi=10.1021%2Fml500528x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyl Diphosphate Synthase Inhibitors With Unique Ligand-Binding Geometries</span></div><div class="casAuthors">Liu, Yi-Liang; Cao, Rong; Wang, Yang; Oldfield, Eric</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-354</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Farnesyl diphosphate synthase (FPPS) is an important drug target for bone resorption, cancer, and some infectious diseases.  Here, we report five new structures including two having unique bound ligand geometries.  The diamidine inhibitor 7 binds to human FPPS close to the homoallylic (S2) and allosteric (S3) sites and extends into a new site, here called S4.  With the bisphosphonate inhibitor 8, two mols. bind to Trypanosoma brucei FPPS, one mol. in the allylic site (S1) and the other close to S2, the first observation of two bisphosphonate mols. bound to FPPS.  We also report the structures of apo-FPPS from T. brucei, together with two more bisphosphonate-bound structures (2,9), for purposes of comparison.  The diamidine structure is of particular interest because 7 could represent a new lead for lipophilic FPPS inhibitors, while 8 has low micromolar activity against T. brucei, the causative agent of human African trypanosomiasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLFB2f4Alhi7Vg90H21EOLACvtfcHk0lj4SFHigyKLRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeisb8%253D&md5=d531c00b4e036e8b7f39dafa6476ba46</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fml500528x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500528x%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BL.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DFarnesyl%2520diphosphate%2520synthase%2520inhibitors%2520with%2520unique%2520ligand-binding%2520geometries%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D349%26epage%3D354%26doi%3D10.1021%2Fml500528x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marzinzik, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amstutz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bold, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotesta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwieg, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ofner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelle, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roddy, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel allosteric non-bisphosphonate inhibitors of farnesyl pyrophosphate synthase by integrated lead finding</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1884</span>â <span class="NLM_lpage">1891</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201500338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1002%2Fcmdc.201500338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=26381451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWlsLnP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1884-1891&author=A.+L.+Marzinzikauthor=R.+Amstutzauthor=G.+Boldauthor=E.+Bourgierauthor=S.+Cotestaauthor=J.+F.+Glickmanauthor=M.+Gotteauthor=C.+Henryauthor=S.+Lehmannauthor=J.+C.+Hartwiegauthor=S.+Ofnerauthor=X.+Pelleauthor=T.+P.+Roddyauthor=J.+M.+Rondeauauthor=F.+Staufferauthor=S.+J.+Stoutauthor=A.+Widmerauthor=J.+Zimmermannauthor=T.+Zollerauthor=W.+Jahnke&title=Discovery+of+novel+allosteric+non-bisphosphonate+inhibitors+of+farnesyl+pyrophosphate+synthase+by+integrated+lead+finding&doi=10.1002%2Fcmdc.201500338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Allosteric Non-Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthase by Integrated Lead Finding</span></div><div class="casAuthors">Marzinzik, Andreas L.; Amstutz, Rene; Bold, Guido; Bourgier, Emmanuelle; Cotesta, Simona; Glickman, J. Fraser; Goette, Marjo; Henry, Christelle; Lehmann, Sylvie; Hartwieg, J. Constanze D.; Ofner, Silvio; Pelle, Xavier; Roddy, Thomas P.; Rondeau, Jean-Michel; Stauffer, Frederic; Stout, Steven J.; Widmer, Armin; Zimmermann, Johann; Zoller, Thomas; Jahnke, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1884-1891</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Farnesyl pyrophosphate synthase (FPPS) is an established target for the treatment of bone diseases, but also shows promise as an anticancer and anti-infective drug target.  Currently available anti-FPPS drugs are active-site-directed bisphosphonate inhibitors, the peculiar pharmacol. profile of which is inadequate for therapeutic indications beyond bone diseases.  The recent discovery of an allosteric binding site has paved the way toward the development of novel non-bisphosphonate FPPS inhibitors with broader therapeutic potential, notably as immunomodulators in oncol.  Herein we report the discovery, by an integrated lead finding approach, of two new chem. classes of allosteric FPPS inhibitors that belong to the salicylic acid and quinoline chemotypes.  We present their synthesis, biochem. and cellular activities, structure-activity relationships, and provide X-ray structures of several representative FPPS complexes.  These novel allosteric FPPS inhibitors are devoid of any affinity for bone mineral and could serve as leads to evaluate their potential in none-bone diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAr9SoyVzuV7Vg90H21EOLACvtfcHk0lgYEhlddUo7jw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWlsLnP&md5=a32eb3354fc3a50e6e0cfedc25a31d15</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500338%26sid%3Dliteratum%253Aachs%26aulast%3DMarzinzik%26aufirst%3DA.%2BL.%26aulast%3DAmstutz%26aufirst%3DR.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBourgier%26aufirst%3DE.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DGlickman%26aufirst%3DJ.%2BF.%26aulast%3DGotte%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DC.%26aulast%3DLehmann%26aufirst%3DS.%26aulast%3DHartwieg%26aufirst%3DJ.%2BC.%26aulast%3DOfner%26aufirst%3DS.%26aulast%3DPelle%26aufirst%3DX.%26aulast%3DRoddy%26aufirst%3DT.%2BP.%26aulast%3DRondeau%26aufirst%3DJ.%2BM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DStout%26aufirst%3DS.%2BJ.%26aulast%3DWidmer%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DZoller%26aufirst%3DT.%26aulast%3DJahnke%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%2520allosteric%2520non-bisphosphonate%2520inhibitors%2520of%2520farnesyl%2520pyrophosphate%2520synthase%2520by%2520integrated%2520lead%2520finding%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1884%26epage%3D1891%26doi%3D10.1002%2Fcmdc.201500338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matralis, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacbay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsakos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez De Troconiz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore mapping of thienopyrimidine-based monophosphonate (ThP-MP) inhibitors of the human farnesyl pyrophosphate synthase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2119</span>â <span class="NLM_lpage">2134</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01888</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01888" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivFSru74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2119-2134&author=J.+Parkauthor=C.+Y.+Leungauthor=A.+N.+Matralisauthor=C.+M.+Lacbayauthor=M.+Tsakosauthor=G.+Fernandez+De+Troconizauthor=A.+M.+Berghuisauthor=Y.+S.+Tsantrizos&title=Pharmacophore+mapping+of+thienopyrimidine-based+monophosphonate+%28ThP-MP%29+inhibitors+of+the+human+farnesyl+pyrophosphate+synthase&doi=10.1021%2Facs.jmedchem.6b01888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase</span></div><div class="casAuthors">Park, Jaeok; Leung, Chun Yuen; Matralis, Alexios N.; Lacbay, Cyrus M.; Tsakos, Michail; Fernandez De Troconiz, Guillermo; Berghuis, Albert M.; Tsantrizos, Youla S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2119-2134</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The human farnesyl pyrophosphate synthase (hFPPS), a key regulatory enzyme in the mevalonate pathway, catalyzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate (FPP).  FPP plays a crucial role in the post-translational prenylation of small GTPases that perform a plethora of cellular functions.  Although hFPPS is a well-established therapeutic target for lytic bone diseases, the currently available bisphosphonate drugs exhibit poor cellular uptake and distribution into non-skeletal tissues.  Recent drug discovery efforts have focused primarily on allosteric inhibition of hFPPS and the discovery of non-bisphosphonate drugs for potentially treating non-skeletal diseases.  Hit-to-lead optimization of a new series of thienopyrimidine-based monosphosphonates (ThP-MPs) led to the identification of analogs with nanomolar potency in inhibiting hFPPS.  Their interactions with the allosteric pocket of the enzyme were characterized by crystallog. and the results provide further insight into the pharmacophore requirements for allosteric inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyhrW7fwd66bVg90H21EOLACvtfcHk0lgYEhlddUo7jw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivFSru74%253D&md5=ac44083a7b20a199cd1cfb59bec71be1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01888%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DC.%2BY.%26aulast%3DMatralis%26aufirst%3DA.%2BN.%26aulast%3DLacbay%26aufirst%3DC.%2BM.%26aulast%3DTsakos%26aufirst%3DM.%26aulast%3DFernandez%2BDe%2BTroconiz%26aufirst%3DG.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DPharmacophore%2520mapping%2520of%2520thienopyrimidine-based%2520monophosphonate%2520%2528ThP-MP%2529%2520inhibitors%2520of%2520the%2520human%2520farnesyl%2520pyrophosphate%2520synthase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2119%26epage%3D2134%26doi%3D10.1021%2Facs.jmedchem.6b01888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span> <span> </span><span class="NLM_article-title">Human farnesyl pyrophosphate synthase is allosterically inhibited by its own product</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14132</span>, <span class="refDoi">Â DOI: 10.1038/ncomms14132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fncomms14132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=28098152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlarsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14132&author=J.+Parkauthor=M.+Zielinskiauthor=A.+Magderauthor=Y.+S.+Tsantrizosauthor=A.+M.+Berghuis&title=Human+farnesyl+pyrophosphate+synthase+is+allosterically+inhibited+by+its+own+product&doi=10.1038%2Fncomms14132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Human farnesyl pyrophosphate synthase is allosterically inhibited by its own product</span></div><div class="casAuthors">Park, Jaeok; Zielinski, Michal; Magder, Alexandr; Tsantrizos, Youla S.; Berghuis, Albert M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14132</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Farnesyl pyrophosphate synthase (FPPS) is an enzyme of the mevalonate pathway and a well-established therapeutic target.  Recent research has focused around a newly identified druggable pocket near the enzyme's active site.  Pharmacol. exploitation of this pocket is deemed promising; however, its natural biol. function, if any, is yet unknown.  Here we report that the product of FPPS, farnesyl pyrophosphate (FPP), can bind to this pocket and lock the enzyme in an inactive state.  The Kd for this binding is 5-6 Î¼M, within a catalytically relevant range.  These results indicate that FPPS activity is sensitive to the product concn.  Kinetic anal. shows that the enzyme is inhibited through FPP accumulation.  Having a specific physiol. effector, FPPS is a bona fide allosteric enzyme.  This allostery offers an exquisite mechanism for controlling prenyl pyrophosphate levels in vivo and thus contributes an addnl. layer of regulation to the mevalonate pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpnTdH3Q0qYrVg90H21EOLACvtfcHk0lgYEhlddUo7jw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlarsrg%253D&md5=a3042ec22d74c2c53aa806a52d37c4b3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fncomms14132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14132%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DZielinski%26aufirst%3DM.%26aulast%3DMagder%26aufirst%3DA.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26atitle%3DHuman%2520farnesyl%2520pyrophosphate%2520synthase%2520is%2520allosterically%2520inhibited%2520by%2520its%2520own%2520product%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14132%26doi%3D10.1038%2Fncomms14132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. J.</span></span> <span> </span><span class="NLM_article-title">Carnosol: a promising anti-cancer and anti-inflammatory agent</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>305</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">7</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2011.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.canlet.2011.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=21382660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktF2hsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2011&pages=1-7&author=J.+J.+Johnson&title=Carnosol%3A+a+promising+anti-cancer+and+anti-inflammatory+agent&doi=10.1016%2Fj.canlet.2011.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Carnosol: A promising anti-cancer and anti-inflammatory agent</span></div><div class="casAuthors">Johnson, Jeremy J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The Mediterranean diet and more specifically certain meats, fruits, vegetables, and olive oil found in certain parts of the Mediterranean region have been assocd. with a decreased cardiovascular and diabetes risk.  More recently, several population based studies have obsd. with these lifestyle choices have reported an overall reduced risk for several cancers.  One study in particular obsd. an inverse relationship between consumption of Mediterranean herbs such as rosemary, sage, parsley, and oregano with lung cancer.  In light of these findings there is a need to explore and identify the anti-cancer properties of these medicinal herbs and to identify the phytochems. therein.  One agent in particular, carnosol, has been evaluated for anti-cancer property in prostate, breast, skin, leukemia, and colon cancer with promising results.  These studies have provided evidence that carnosol targets multiple deregulated pathways assocd. with inflammation and cancer that include nuclear factor kappa B (NFÎºB), apoptotic related proteins, phosphatidylinositol-3-kinase (PI3 K)/Akt, androgen and estrogen receptors, as well as mol. targets.  In addn., carnosol appears to be well tolerated in that it has a selective toxicity towards cancer cells vs. non-tumorigenic cells and is well tolerated when administered to animals.  This mini-review reports on the pre-clin. studies that have been performed to date with carnosol describing mechanistic, efficacy, and safety/tolerability studies as a cancer chemoprevention and anti-cancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_5YBLrOhK1rVg90H21EOLACvtfcHk0lhxyGMuq6KGCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktF2hsrs%253D&md5=0cc74d436c660ac6ee1808fc5dd76f23</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2011.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2011.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DJ.%2BJ.%26atitle%3DCarnosol%253A%2520a%2520promising%2520anti-cancer%2520and%2520anti-inflammatory%2520agent%26jtitle%3DCancer%2520Lett.%26date%3D2011%26volume%3D305%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.canlet.2011.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, T.</span></span> <span> </span><span class="NLM_article-title">Cytotoxicity of abietane diterpenoids from Perovskia abrotanoides and of their semisynthetic analogues</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5285</span>â <span class="NLM_lpage">5291</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2006.03.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.bmc.2006.03.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=16626958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFyrurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=5285-5291&author=Y.+Aoyagiauthor=Y.+Takahashiauthor=Y.+Satakeauthor=K.+Takeyaauthor=R.+Aiyamaauthor=T.+Matsuzakiauthor=S.+Hashimotoauthor=T.+Kurihara&title=Cytotoxicity+of+abietane+diterpenoids+from+Perovskia+abrotanoides+and+of+their+semisynthetic+analogues&doi=10.1016%2Fj.bmc.2006.03.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Cytotoxicity of abietane diterpenoids from Perovskia abrotanoides and of their semisynthetic analogues</span></div><div class="casAuthors">Aoyagi, Yutaka; Takahashi, Yoshinao; Satake, Yudai; Takeya, Koichi; Aiyama, Ritsuo; Matsuzaki, Takeshi; Hashimoto, Shusuke; Kurihara, Teruo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5285-5291</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Seven known abietane diterpenoids and 11-O- and 12-O-acetylcarnosic acids were isolated from a methanol ext. of Perovskia abrotanoides (Labiatae).  Structure and cytotoxic activity relationships (SAR) of the natural and semisynthetic analogs of the presently isolated abietane diterpenoids were studied by using P388 murine leukemia cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6JKR0J99vdrVg90H21EOLACvtfcHk0lhxyGMuq6KGCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFyrurc%253D&md5=52a13a2f143e6f98f00ad0288510635c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.03.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.03.047%26sid%3Dliteratum%253Aachs%26aulast%3DAoyagi%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DSatake%26aufirst%3DY.%26aulast%3DTakeya%26aufirst%3DK.%26aulast%3DAiyama%26aufirst%3DR.%26aulast%3DMatsuzaki%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DS.%26aulast%3DKurihara%26aufirst%3DT.%26atitle%3DCytotoxicity%2520of%2520abietane%2520diterpenoids%2520from%2520Perovskia%2520abrotanoides%2520and%2520of%2520their%2520semisynthetic%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D5285%26epage%3D5291%26doi%3D10.1016%2Fj.bmc.2006.03.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Del
Campo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiot, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-The, C.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial effect of rosemary extracts</span>. <i>J. Food Prot.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1359</span>â <span class="NLM_lpage">1368</span>, <span class="refDoi">Â DOI: 10.4315/0362-028X-63.10.1359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.4315%2F0362-028X-63.10.1359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=11041135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntVaitr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2000&pages=1359-1368&author=J.+Del%0ACampoauthor=M.+J.+Amiotauthor=C.+Nguyen-The&title=Antimicrobial+effect+of+rosemary+extracts&doi=10.4315%2F0362-028X-63.10.1359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial effect of rosemary extracts</span></div><div class="casAuthors">Del Campo, Jose; Amiot, Marie-Josephe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Food Protection</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1359-1368</span>CODEN:
                <span class="NLM_cas:coden">JFPRDR</span>;
        ISSN:<span class="NLM_cas:issn">0362-028X</span>.
    
            (<span class="NLM_cas:orgname">International Association for Food Protection</span>)
        </div><div class="casAbstract">A rosemary ext. com. exploited (Oxy'less) as an antioxidant of lipids in foods was dissolved in ethanol (100 mg/mL), and the soln. was tested against foodborne microorganisms.  For gram-pos. bacteria, the MIC of the ethanolic soln. was 1% for Leuconostoc mesenteroides, 0.5% for Listeria monocytogenes, 0.5% for Staphylococcus aureus, 0.13% for Streptococcus mutans, and 0.06% for Bacillus cereus.  It slowed the growth of Penicillium roquefortii and Botrytis cinerea.  Up to 1% of the ethanolic soln. had no activity on the gram-neg. bacteria Escherichia coli, Salmonella enteritidis, and Erwinia carotovora and on the yeasts Rhodotorula glutinis and Cryptococcus laurentii.  Antibacterial activity of the rosemary ext. was strongly influenced by the compn. of the media.  The MIC was reduced by low pH, high NaCl contents, and low temps.  Low pH and high NaCl concn. had a synergistic effect on the MIC of the rosemary ext. for S. aureus.  Lipids, surface-active agents, and some proteins decreased its antibacterial activity, whereas pectin had no effect.  The inhibitory effect was little modified by heat treatment (100Â°C).  The natural microflora of pasteurized zucchini broth was inhibited by 0.5% of the rosemary ext.  The antibacterial activity was linked to the compds. extd. with hexane, which are presumably phenolic diterpenoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGiPP5jocxN7Vg90H21EOLACvtfcHk0lhxyGMuq6KGCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntVaitr8%253D&md5=f0c247fda8965594c0d285b46223376f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4315%2F0362-028X-63.10.1359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4315%252F0362-028X-63.10.1359%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BCampo%26aufirst%3DJ.%26aulast%3DAmiot%26aufirst%3DM.%2BJ.%26aulast%3DNguyen-The%26aufirst%3DC.%26atitle%3DAntimicrobial%2520effect%2520of%2520rosemary%2520extracts%26jtitle%3DJ.%2520Food%2520Prot.%26date%3D2000%26volume%3D63%26spage%3D1359%26epage%3D1368%26doi%3D10.4315%2F0362-028X-63.10.1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Jamal, A.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alqadi, T.</span></span> <span> </span><span class="NLM_article-title">Effects of rosemary (Rosmarinus officinalis) on lipid profile of diabetic rats</span>. <i>Jordan J. Biol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">199</span>â <span class="NLM_lpage">204</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=199-204&author=A.-R.+Al-Jamalauthor=T.+Alqadi&title=Effects+of+rosemary+%28Rosmarinus+officinalis%29+on+lipid+profile+of+diabetic+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Jamal%26aufirst%3DA.-R.%26aulast%3DAlqadi%26aufirst%3DT.%26atitle%3DEffects%2520of%2520rosemary%2520%2528Rosmarinus%2520officinalis%2529%2520on%2520lipid%2520profile%2520of%2520diabetic%2520rats%26jtitle%3DJordan%2520J.%2520Biol.%2520Sci.%26date%3D2011%26volume%3D4%26spage%3D199%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collin, H.</span></span> <span> </span><span class="NLM_article-title">Herbs, Spices and Cardiovascular Disease</span>.  <i>Handbook of Herbs and Spices</i>; <span class="NLM_publisher-name">Woodhead</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span>, <span class="NLM_year">2006</span>; pp  <span class="NLM_fpage">126</span>â <span class="NLM_lpage">137</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1533%2F9781845691717.2.126" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=126-137&author=H.+Collin&title=Handbook+of+Herbs+and+Spices"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1533%2F9781845691717.2.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1533%252F9781845691717.2.126%26sid%3Dliteratum%253Aachs%26aulast%3DCollin%26aufirst%3DH.%26atitle%3DHerbs%252C%2520Spices%2520and%2520Cardiovascular%2520Disease%26btitle%3DHandbook%2520of%2520Herbs%2520and%2520Spices%26pub%3DWoodhead%26date%3D2006%26spage%3D126%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romo-Vaquero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obiol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Villalba, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Barrio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issaly, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomas-Barberan, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Conesa, M. T.</span></span> <span> </span><span class="NLM_article-title">A rosemary extract rich in carnosic acid selectively modulates caecum microbiota and inhibits beta-glucosidase activity, altering fiber and short chain fatty acids fecal excretion in lean and obese female rats</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e94687</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0094687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1371%2Fjournal.pone.0094687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=24733124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1aqtbrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=M.+Romo-Vaqueroauthor=M.+V.+Selmaauthor=M.+Larrosaauthor=M.+Obiolauthor=R.+Garcia-Villalbaauthor=R.+Gonzalez-Barrioauthor=N.+Issalyauthor=J.+Flanaganauthor=M.+Rollerauthor=F.+A.+Tomas-Barberanauthor=M.+T.+Garcia-Conesa&title=A+rosemary+extract+rich+in+carnosic+acid+selectively+modulates+caecum+microbiota+and+inhibits+beta-glucosidase+activity%2C+altering+fiber+and+short+chain+fatty+acids+fecal+excretion+in+lean+and+obese+female+rats&doi=10.1371%2Fjournal.pone.0094687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A rosemary extract rich in carnosic acid selectively modulates caecum microbiota and inhibits Î²-glucosidase activity, altering fiber and short chain fatty acids fecal excretion in lean and obese female rats</span></div><div class="casAuthors">Romo-Vaquero, Maria; Selma, Maria-Victoria; Larrosa, Mar; Obiol, Maria; Garcia-Villalba, Rocio; Gonzalez-Barrio, Rocio; Issaly, Nicolas; Flanagan, John; Roller, Marc; Tomas-Barberan, Francisco A.; Garcia-Conesa, Maria-Teresa</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e94687/1-e94687/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Carnosic acid (CA) and rosemary exts. (RE) show body-wt., energy metab. and inflammation regulatory properties in animal models but the mechanisms are not yet understood.  Gut microbiota plays an important role in the host metab. and inflammatory status and is modulated by the diet.  The aim of this research was to investigate whether a RE enriched in CA affected caecum microbiota compn. and activity in a rat model of genetic obesity.  Methods and Principal Findings: A RE (40% CA) was administered with the diet (0.5% wt./wt.) to lean (fa/+) and obese (fa/fa) female Zucker rats for 64 days.  Changes in the microbiota compn. and Î²-glucosidase activity in the caecum and in the levels of macronutrients and short chain fatty acids (SCFA) in feces were examd.  The RE increased the Blautia coccoides and Bacteroides/Prevotella groups and reduced the Lactobacillus/Leuconostoc/Pediococccus group in both types of animals.  Clostridium leptum was significantly decreased and Bifidobacterium increased only in the lean rats. Î²-Glucosidase activity was significantly reduced and fecal fiber excretion increased in the two genotypes.  The RE also increased the main SCFA excreted in the feces of the obese rats but decreased them in the lean rats reflecting important differences in the uptake and metab. of these mols. between the two genotypes.  Conclusions: Our results indicate that the consumption of a RE enriched in CA modifies microbiota compn. and decreases Î²-glucosidase activity in the caecum of female Zucker rats while it increases fiber fecal elimination.  These results may contribute to explain the body wt. gain reducing effects of the RE.  The mutated leptin receptor of the obese animals significantly affects the microbiota compn., the SCFA fecal excretion and the host response to the RE intake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4S6CkPuTCULVg90H21EOLACvtfcHk0lj71KGmRiYtSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1aqtbrO&md5=416d0a355eae50d20a0cdb9647c58c4a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0094687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0094687%26sid%3Dliteratum%253Aachs%26aulast%3DRomo-Vaquero%26aufirst%3DM.%26aulast%3DSelma%26aufirst%3DM.%2BV.%26aulast%3DLarrosa%26aufirst%3DM.%26aulast%3DObiol%26aufirst%3DM.%26aulast%3DGarcia-Villalba%26aufirst%3DR.%26aulast%3DGonzalez-Barrio%26aufirst%3DR.%26aulast%3DIssaly%26aufirst%3DN.%26aulast%3DFlanagan%26aufirst%3DJ.%26aulast%3DRoller%26aufirst%3DM.%26aulast%3DTomas-Barberan%26aufirst%3DF.%2BA.%26aulast%3DGarcia-Conesa%26aufirst%3DM.%2BT.%26atitle%3DA%2520rosemary%2520extract%2520rich%2520in%2520carnosic%2520acid%2520selectively%2520modulates%2520caecum%2520microbiota%2520and%2520inhibits%2520beta-glucosidase%2520activity%252C%2520altering%2520fiber%2520and%2520short%2520chain%2520fatty%2520acids%2520fecal%2520excretion%2520in%2520lean%2520and%2520obese%2520female%2520rats%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0094687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birtic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussort, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bily, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, M.</span></span> <span> </span><span class="NLM_article-title">Carnosic acid</span>. <i>Phytochemistry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">19</span>, <span class="refDoi">Â DOI: 10.1016/j.phytochem.2014.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.phytochem.2014.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=25639596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWktLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=9-19&author=S.+Birticauthor=P.+Dussortauthor=F.+X.+Pierreauthor=A.+C.+Bilyauthor=M.+Roller&title=Carnosic+acid&doi=10.1016%2Fj.phytochem.2014.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Carnosic acid</span></div><div class="casAuthors">Birtic, Simona; Dussort, Pierre; Pierre, Francois-Xavier; Bily, Antoine C.; Roller, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry (Elsevier)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-19</span>CODEN:
                <span class="NLM_cas:coden">PYTCAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-9422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Carnosic acid (salvin), which possesses antioxidative and antimicrobial properties, is increasingly exploited within the food, nutritional health and cosmetics industries.  Since its first extn. from a Salvia species (â¼70 years ago) and its identification (â¼50 years ago), numerous articles and patents (â¼400) have been published on specific food and medicinal applications of Rosmarinus and Salvia plant exts. abundant in carnosic acid.  In contrast, relevant biochem., physiol. or mol. studies in planta have remained rare.  In this overview, recent advances in understanding of carnosic acid distribution, biosynthesis, accumulation and role in planta, and its applications are summarised.  We also discuss the deficiencies in our understanding of the relevant biochem. processes, and suggest the mol. targets of carnosic acid.  Finally, future perspectives and studies related to its potential roles are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPpABoMnX8gLVg90H21EOLACvtfcHk0lj71KGmRiYtSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWktLw%253D&md5=f17beb65000bf628cfc6f54d440af3f5</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.phytochem.2014.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phytochem.2014.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DBirtic%26aufirst%3DS.%26aulast%3DDussort%26aufirst%3DP.%26aulast%3DPierre%26aufirst%3DF.%2BX.%26aulast%3DBily%26aufirst%3DA.%2BC.%26aulast%3DRoller%26aufirst%3DM.%26atitle%3DCarnosic%2520acid%26jtitle%3DPhytochemistry%26date%3D2015%26volume%3D115%26spage%3D9%26epage%3D19%26doi%3D10.1016%2Fj.phytochem.2014.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, J. L.</span></span> <span> </span><span class="NLM_article-title">A continuous spectrophotometric assay for aspartate transcarbamylase and ATPases</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>246</i></span>,  <span class="NLM_fpage">86</span>â <span class="NLM_lpage">95</span>, <span class="refDoi">Â DOI: 10.1006/abio.1996.9962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1006%2Fabio.1996.9962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=9056187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADyaK2sXhsFKitrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=1997&pages=86-95&author=C.+E.+Riegerauthor=J.+Leeauthor=J.+L.+Turnbull&title=A+continuous+spectrophotometric+assay+for+aspartate+transcarbamylase+and+ATPases&doi=10.1006%2Fabio.1996.9962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A continuous spectrophotometric assay for aspartate transcarbamylase and ATPases</span></div><div class="casAuthors">Rieger, Colin E.; Lee, John; Turnbull, Joanne L.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">246</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-95</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A new continuous coupled uv-spectrophotometric assay is described for two phosphate-releasing enzymes, aspartate transcarbamylase and ATPase of herpes simplex virus (HSV).  Phosphate release is coupled to the phosphorolysis of the nucleoside analog 7-methylinosine (m7Ino) catalyzed by purine nucleoside phosphorylase.  When this reaction is monitored at 291 nm, the coupled assay can readily detect 10 nmol Pi released/min.  Our method offers advantages over a recently reported continuous assay devised for measuring aspartate transcarbamylase activity using the nucleoside methylthioguanosine (MESG) as the linking substrate.  In contrast to MESG, m7Ino is easily and inexpensively synthesized and is also com. available.  The spectrophotometric signal at 291 nm, produced by the difference in the extinction coeffs. between nucleoside substrate and the base product, is significant over a much wider pH range than the signal difference between MESG and its phosphorolysis product at 360 nm.  Satn. curves for aspartate and carbamyl phosphate and pH rate profiles have been reproduced using the purine nucleoside phosphorylase/m7Ino coupled assay.  Initial velocity patterns constructed over micromolar to millimolar concns. of aspartate and carbamyl phosphate yielded four kinetic parameters simultaneously.  To further illustrate the application of this coupled assay, kinetic parameters were detd. for the DNA-dependent ATPase reaction of HSV helicase-primase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocTZGAkdzztLVg90H21EOLACvtfcHk0lj71KGmRiYtSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsFKitrs%253D&md5=2de451336c8c7082dc28adacdcdbc908</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1006%2Fabio.1996.9962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1996.9962%26sid%3Dliteratum%253Aachs%26aulast%3DRieger%26aufirst%3DC.%2BE.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTurnbull%26aufirst%3DJ.%2BL.%26atitle%3DA%2520continuous%2520spectrophotometric%2520assay%2520for%2520aspartate%2520transcarbamylase%2520and%2520ATPases%26jtitle%3DAnal.%2520Biochem.%26date%3D1997%26volume%3D246%26spage%3D86%26epage%3D95%26doi%3D10.1006%2Fabio.1996.9962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Webb, M. R.</span></span> <span> </span><span class="NLM_article-title">A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">4884</span>â <span class="NLM_lpage">4887</span>, <span class="refDoi">Â DOI: 10.1073/pnas.89.11.4884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1073%2Fpnas.89.11.4884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1534409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADyaK38Xks1Gktbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=4884-4887&author=M.+R.+Webb&title=A+continuous+spectrophotometric+assay+for+inorganic+phosphate+and+for+measuring+phosphate+release+kinetics+in+biological+systems&doi=10.1073%2Fpnas.89.11.4884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems</span></div><div class="casAuthors">Webb, Martin R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4884-7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A spectrophotometric method for the measurement of inorg. phosphate (Pi) has been developed by using 2-amino-6-mercapto-7-methylpurine ribonucleoside and purine-nucleoside phosphorylase (purine-nucleoside:orthophosphate ribosyltransferase, EC 2.4.2.1).  This substrate gives an absorbance increase at 360 nm on phosphorolysis at pH 6.5-8.5, and at pH 7.6 the change in extinction coeff. is 11,000 M-1Â·cm-1.  The Michaelis-Menten consts. of the two substrates with the enzyme are 70 Î¼M for the nucleoside and 26 Î¼M for Pi; the kcat is 40 s-1 (25 Â°C).  The assay was shown to quantitate Pi in soln. at concns. at least down to 2 Î¼M.  It can be used to measure the kinetics of Pi release from phosphatases, such as GTPases and ATPases, by coupling the two enzymic reactions.  The utility of this assay was shown by three test systems: glycerol kinase plus D-glyceraldehyde acting as an ATPase and actin-activated myosin ATPase, and myosin subfragment 1, hydrolyzing a single turnover of ATP, releasing Pi with a rate const. the same as the steady-state ATPase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz0LFKi_aD47Vg90H21EOLACvtfcHk0ljhNk6XlRmoTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xks1Gktbw%253D&md5=0283dff906ac14ac6c253fcf43957557</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1073%2Fpnas.89.11.4884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.89.11.4884%26sid%3Dliteratum%253Aachs%26aulast%3DWebb%26aufirst%3DM.%2BR.%26atitle%3DA%2520continuous%2520spectrophotometric%2520assay%2520for%2520inorganic%2520phosphate%2520and%2520for%2520measuring%2520phosphate%2520release%2520kinetics%2520in%2520biological%2520systems%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1992%26volume%3D89%26spage%3D4884%26epage%3D4887%26doi%3D10.1073%2Fpnas.89.11.4884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokoroyama, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Michael reaction</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2010</i></span>,  <span class="NLM_fpage">2009</span>â <span class="NLM_lpage">2016</span>, <span class="refDoi">Â DOI: 10.1002/ejoc.200901130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1002%2Fejoc.200901130" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=2009-2016&author=T.+Tokoroyama&title=Discovery+of+the+Michael+reaction&doi=10.1002%2Fejoc.200901130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200901130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200901130%26sid%3Dliteratum%253Aachs%26aulast%3DTokoroyama%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520the%2520Michael%2520reaction%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2010%26volume%3D2010%26spage%3D2009%26epage%3D2016%26doi%3D10.1002%2Fejoc.200901130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span> <span> </span><span class="NLM_article-title">Feeling natureâs PAINS: natural products, natural product drugs, and Pan Assay Interference Compounds (PAINS)</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">616</span>â <span class="NLM_lpage">628</span>, <span class="refDoi">Â DOI: 10.1021/acs.jnatprod.5b00947</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.5b00947" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVWktrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=616-628&author=J.+B.+Baell&title=Feeling+nature%E2%80%99s+PAINS%3A+natural+products%2C+natural+product+drugs%2C+and+Pan+Assay+Interference+Compounds+%28PAINS%29&doi=10.1021%2Facs.jnatprod.5b00947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Feeling Nature's PAINS: Natural Products, Natural Product Drugs, and Pan Assay Interference Compounds (PAINS)</span></div><div class="casAuthors">Baell, Jonathan B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">616-628</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">We have previously reported on classes of compds. that can interfere with bioassays via a no. of different mechanisms and termed such compds. Pan Assay INterference compds., or PAINS.  These compds. were defined on the basis of high-throughput data derived from vendor-supplied synthetics.  The question therefore arises whether the concept of PAINS is relevant to compds. of natural origin.  Here, it is shown that this is indeed the case, but that the context of the biol. readout is an important factor that must be brought into consideration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYFy3lN9vzSbVg90H21EOLACvtfcHk0ljhNk6XlRmoTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVWktrc%253D&md5=199b040b1f6f3d636521879acae0114d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.5b00947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.5b00947%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26atitle%3DFeeling%2520nature%25E2%2580%2599s%2520PAINS%253A%2520natural%2520products%252C%2520natural%2520product%2520drugs%252C%2520and%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2016%26volume%3D79%26spage%3D616%26epage%3D628%26doi%3D10.1021%2Facs.jnatprod.5b00947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiessling, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">The ecstasy and agony of assay interference compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2165</span>â <span class="NLM_lpage">2168</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00229</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00229" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtl2lsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2165-2168&author=C.+Aldrichauthor=C.+Bertozziauthor=G.+I.+Georgauthor=L.+Kiesslingauthor=C.+Lindsleyauthor=D.+Liottaauthor=K.+M.+Merzauthor=A.+Schepartzauthor=S.+Wang&title=The+ecstasy+and+agony+of+assay+interference+compounds&doi=10.1021%2Facs.jmedchem.7b00229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The Ecstasy and Agony of Assay Interference Compounds</span></div><div class="casAuthors">Aldrich, Courtney; Bertozzi, Carolyn; Georg, Gunda I.; Kiessling, Laura; Lindsley, Craig; Liotta, Dennis; Merz, Kenneth M.; Schepartz, Alanna; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2165-2168</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ecstasy of discovering a new hit from screening can lead to a highly productive research effort to discover new bioactive compds.  However, in too many cases this ecstasy is followed by the agony of realizing that the compds. are not active against the desired target.  Many of these false hits are Pan Assay INterference compds. (PAINS) 1 or colloidal aggregators.  Whether the screen is conducted in silico or in the lab. and whether screening libraries, natural products, or drugs are used, all discovery efforts that rely on some form of screening to identify bioactivity are susceptible to this phenomenon.  Studies that omit crit. controls against exptl. artifacts caused by PAINS may waste years of research effort as useless compds. are progressed.  The American Chem. Society (ACS) is eager to alert the scientific community to this problem and to recommend protocols that will eliminate the publication of research articles based on compds. with artificial activity.  This editorial aims to summarize relevant concepts and to set the framework by which relevant ACS journals will address this issue going forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJUf5u51VEpbVg90H21EOLACvtfcHk0ljhNk6XlRmoTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtl2lsLY%253D&md5=64bf087659a47fe7769208217ef8c989</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00229%26sid%3Dliteratum%253Aachs%26aulast%3DAldrich%26aufirst%3DC.%26aulast%3DBertozzi%26aufirst%3DC.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DKiessling%26aufirst%3DL.%26aulast%3DLindsley%26aufirst%3DC.%26aulast%3DLiotta%26aufirst%3DD.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26aulast%3DSchepartz%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DThe%2520ecstasy%2520and%2520agony%2520of%2520assay%2520interference%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2165%26epage%3D2168%26doi%3D10.1021%2Facs.jmedchem.7b00229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marma, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashemirov, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebetino, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triffitt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, C. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5967</span>â <span class="NLM_lpage">5975</span>, <span class="refDoi">Â DOI: 10.1021/jm0702884</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0702884" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1GrtL%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5967-5975&author=M.+S.+Marmaauthor=Z.+Xiaauthor=C.+Stewartauthor=F.+Coxonauthor=J.+E.+Dunfordauthor=R.+Baronauthor=B.+A.+Kashemirovauthor=F.+H.+Ebetinoauthor=J.+T.+Triffittauthor=R.+G.+Russellauthor=C.+E.+McKenna&title=Synthesis+and+biological+evaluation+of+alpha-halogenated+bisphosphonate+and+phosphonocarboxylate+analogues+of+risedronate&doi=10.1021%2Fjm0702884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Î±-Halogenated Bisphosphonate and Phosphonocarboxylate Analogues of Risedronate</span></div><div class="casAuthors">Marma, Mong S.; Xia, Zhidao; Stewart, Charlotte; Coxon, Fraser; Dunford, James E.; Baron, Rudi; Kashemirov, Boris A.; Ebetino, Frank H.; Triffitt, James T.; Russell, R. Graham G.; McKenna, Charles E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5967-5975</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Î±-Halogenated analogs of the anti-resorptive bisphosphonate risedronate (5, Ris) and its phosphonocarboxylate cognate (7, 3-PEHPC) were synthesized and compared with 5, 7, and the corresponding desoxy analogs in bone mineral affinity and mevalonate pathway inhibition assays.  The halogenated Ris and 3-PEHPC analogs had decreased bone mineral affinity, confirming that the Î±-OH group in 5 and 7 enhances bone affinity.  The 5 Î±-halo-analogs potently inhibited farnesyl pyrophosphate synthase (FPPS) with IC50 values from 16 (Î±-F) to 340 (Î±-Br) nM (5, 6 nM).  In contrast, 7 Î±-halo-analogs were ineffective vs. FPPS (IC50 > 600 Î¼M), but inhibited Rab geranylgeranyl transferase (RGGT) (IC50 = 16-35 Î¼M) similarly to 7 itself (IC50 = 24 Î¼M).  The 5 Î±-F analog was 1-2 times as active as 7 in J774 cell viability and Rab11 prenylation inhibition assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3DXQmDZ8NArVg90H21EOLACvtfcHk0lhBm7KRjktxhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1GrtL%252FN&md5=13b8b41f154b7ff3556d3847df38223f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm0702884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0702884%26sid%3Dliteratum%253Aachs%26aulast%3DMarma%26aufirst%3DM.%2BS.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DStewart%26aufirst%3DC.%26aulast%3DCoxon%26aufirst%3DF.%26aulast%3DDunford%26aufirst%3DJ.%2BE.%26aulast%3DBaron%26aufirst%3DR.%26aulast%3DKashemirov%26aufirst%3DB.%2BA.%26aulast%3DEbetino%26aufirst%3DF.%2BH.%26aulast%3DTriffitt%26aufirst%3DJ.%2BT.%26aulast%3DRussell%26aufirst%3DR.%2BG.%26aulast%3DMcKenna%26aufirst%3DC.%2BE.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520alpha-halogenated%2520bisphosphonate%2520and%2520phosphonocarboxylate%2520analogues%2520of%2520risedronate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5967%26epage%3D5975%26doi%3D10.1021%2Fjm0702884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Schutter, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghuis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7939</span>â <span class="NLM_lpage">7950</span>, <span class="refDoi">Â DOI: 10.1021/jm400946f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400946f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlOktrrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7939-7950&author=C.+Y.+Leungauthor=J.+Parkauthor=J.+W.+De+Schutterauthor=M.+Sebagauthor=A.+M.+Berghuisauthor=Y.+S.+Tsantrizos&title=Thienopyrimidine+bisphosphonate+%28ThPBP%29+inhibitors+of+the+human+farnesyl+pyrophosphate+synthase%3A+optimization+and+characterization+of+the+mode+of+inhibition&doi=10.1021%2Fjm400946f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Thienopyrimidine Bisphosphonate (ThPBP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase: Optimization and Characterization of the Mode of Inhibition</span></div><div class="casAuthors">Leung, Chun Yuen; Park, Jaeok; De Schutter, Joris W.; Sebag, Michael; Berghuis, Albert M.; Tsantrizos, Youla S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7939-7950</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human farnesyl pyrophosphate synthase (hFPPS) controls the post-translational prenylation of small GTPase proteins that are essential for cell signaling, cell proliferation, and osteoclast-mediated bone resorption.  Inhibition of hFPPS is a clin. validated mechanism for the treatment of lytic bone diseases, including osteoporosis and cancer related bone metastases.  A new series of thienopyrimidine-based bisphosphonates (ThP-BPs) were identified that inhibit hFPPS with low nanomolar potency.  Crystallog. evidence revealed binding of ThP-BP inhibitors in the allylic subpocket of hFPPS.  Simultaneous binding of inorg. pyrophosphate in the IPP subpocket leads to conformational closing of the active site cavity.  The ThP-BP analogs are significantly less hydrophilic yet exhibit higher affinity for the bone mineral hydroxyapatite than the current N-BP drug risedronic acid.  The antiproliferation properties of a potent ThB-BP analog was assessed in a multiple myeloma cell line and found to be equipotent to the best current N-BP drugs.  Consequently, these compds. represent a new structural class of hFPPS inhibitors and a novel scaffold for the development of human therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsENEMSfNSo7Vg90H21EOLACvtfcHk0lhBm7KRjktxhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlOktrrP&md5=0d8be8e382fe74521bd4b76ee2387257</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm400946f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400946f%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.%2BY.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DDe%2BSchutter%26aufirst%3DJ.%2BW.%26aulast%3DSebag%26aufirst%3DM.%26aulast%3DBerghuis%26aufirst%3DA.%2BM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DThienopyrimidine%2520bisphosphonate%2520%2528ThPBP%2529%2520inhibitors%2520of%2520the%2520human%2520farnesyl%2520pyrophosphate%2520synthase%253A%2520optimization%2520and%2520characterization%2520of%2520the%2520mode%2520of%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7939%26epage%3D7950%26doi%3D10.1021%2Fjm400946f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soares, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackmon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shun, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takyi, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wipf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. A.</span></span> <span> </span><span class="NLM_article-title">Profiling the NIH small molecule repository for compounds that generate H2O2 by redox cycling in reducing environments</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">152</span>â <span class="NLM_lpage">174</span>, <span class="refDoi">Â DOI: 10.1089/adt.2009.0247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1089%2Fadt.2009.0247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=20070233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFClur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=152-174&author=K.+M.+Soaresauthor=N.+Blackmonauthor=T.+Y.+Shunauthor=S.+N.+Shindeauthor=H.+K.+Takyiauthor=P.+Wipfauthor=J.+S.+Lazoauthor=P.+A.+Johnston&title=Profiling+the+NIH+small+molecule+repository+for+compounds+that+generate+H2O2+by+redox+cycling+in+reducing+environments&doi=10.1089%2Fadt.2009.0247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling the NIH Small Molecule Repository for Compounds That Generate H2O2 by Redox Cycling in Reducing Environments</span></div><div class="casAuthors">Soares, Karina M.; Blackmon, Nicole; Shun, Tong Ying; Shinde, Sunita N.; Takyi, Harold K.; Wipf, Peter; Lazo, John S.; Johnston, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-174</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">We have screened the Library of Pharmacol. Active Compds. (LOPAC) and the National Institutes of Health (NIH) Small Mol. Repository (SMR) libraries in a horseradish peroxidase-phenol red (HRP-PR) H2O2 detection assay to identify redox cycling compds. (RCCs) capable of generating H2O2 in buffers contg. dithiothreitol (DTT).  Two RCCs were identified in the LOPAC set, the ortho-naphthoquinone Î²-lapachone and the para-naphthoquinone NSC 95397.  Thirty-seven (0.02%) concn.-dependent RCCs were identified from 195,826 compds. in the NIH SMR library; 3 singleton structures, 9 ortho-quinones, 2 para-quinones, 4 pyrimidotriazinediones, 15 arylsulfonamides, 2 nitrothiophene-2-carboxylates, and 2 tolyl hydrazides.  60% Of the ortho-quinones and 80% of the pyrimidotriazinediones in the library were confirmed as RCCs.  In contrast, only 3.9% of the para-quinones were confirmed as RCCs.  Fifteen of the 251 arylsulfonamides in the library were confirmed as RCCs, and since we screened 17,868 compds. with a sulfonamide functional group we conclude that the redox cycling activity of the arylsulfonamide RCCs is due to peripheral reactive enone, arom., or heterocyclic functions.  Cross-target queries of the University of Pittsburgh Drug Discovery Institute (UPDDI) and PubChem databases revealed that the RCCs exhibited promiscuous bioactivity profiles and have populated both screening databases with significantly higher nos. of active flags than non-RCCs.  RCCs were promiscuously active against protein targets known to be susceptible to oxidn., but were also active in cell growth inhibition assays, and against other targets thought to be insensitive to oxidn.  Profiling compd. libraries or the hits from screening campaigns in the HRP-PR H2O2 detection assay significantly reduce the timelines and resources required to identify and eliminate promiscuous nuisance RCCs from the candidates for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxKHMWw0mf17Vg90H21EOLACvtfcHk0lhBm7KRjktxhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFClur0%253D&md5=4baf5bc3cb807e069f27ce73cf66e7dc</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1089%2Fadt.2009.0247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2009.0247%26sid%3Dliteratum%253Aachs%26aulast%3DSoares%26aufirst%3DK.%2BM.%26aulast%3DBlackmon%26aufirst%3DN.%26aulast%3DShun%26aufirst%3DT.%2BY.%26aulast%3DShinde%26aufirst%3DS.%2BN.%26aulast%3DTakyi%26aufirst%3DH.%2BK.%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DLazo%26aufirst%3DJ.%2BS.%26aulast%3DJohnston%26aufirst%3DP.%2BA.%26atitle%3DProfiling%2520the%2520NIH%2520small%2520molecule%2520repository%2520for%2520compounds%2520that%2520generate%2520H2O2%2520by%2520redox%2520cycling%2520in%2520reducing%2520environments%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2010%26volume%3D8%26spage%3D152%26epage%3D174%26doi%3D10.1089%2Fadt.2009.0247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. A.</span></span> <span> </span><span class="NLM_article-title">Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents-real hits or promiscuous artifacts?</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">174</span>â <span class="NLM_lpage">182</span>, <span class="refDoi">Â DOI: 10.1016/j.cbpa.2010.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.cbpa.2010.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=21075044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFKitLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=174-182&author=P.+A.+Johnston&title=Redox+cycling+compounds+generate+H2O2+in+HTS+buffers+containing+strong+reducing+reagents-real+hits+or+promiscuous+artifacts%3F&doi=10.1016%2Fj.cbpa.2010.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents - real hits or promiscuous artifacts?</span></div><div class="casAuthors">Johnston, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-182</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Redox cycling compds. (RCCs) generate micromolar concns. of H2O2 in the presence of strong reducing agents, common buffer components used to maintain catalytic activity, and/or folding of target proteins for high-throughput screening (HTS) assays.  H2O2 generated by RCCs can indirectly inhibit the catalytic activity of proteins by oxidizing accessible Cys, Trp, Met, His, or Sec residues, and indeed several important classes of protein targets are susceptible to H2O2-mediated inactivation; protein tyrosine phosphatases, cysteine proteases, and metalloenzymes.  The main sources of H2O2 in cells are the NADPH oxidase/superoxide dismutase systems, peroxisome metab., and the autoxidn. of reactive chems. by enzyme mediated redox cycling at both the microsomal and mitochondrial sites of electron transport.  Given the role of H2O2 as a 2nd messenger involved in the regulation of many signaling pathways it is hardly surprising that compds. that can generate intracellular H2O2 by enzyme-mediated redox cycling would have pleiotropic effects.  RCCs can therefore have serious neg. consequences for the probe and/or lead generation process: primary HTS assay hit rates may be inflated by RCC false positives; crucial resources will be diverted to develop and implement follow-up assays to distinguish RCCs from real hits; and screening databases will become annotated with the promiscuous activity of RCCs.  In an attempt to mitigate the serious impact of RCCs on probe and lead generation, 2 groups have independently developed assays to identify RCCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAnhCpNOuGy7Vg90H21EOLACvtfcHk0lh54sSuNrHsPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFKitLk%253D&md5=0ac517984e5b37d8839e13e6a6caa12f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DP.%2BA.%26atitle%3DRedox%2520cycling%2520compounds%2520generate%2520H2O2%2520in%2520HTS%2520buffers%2520containing%2520strong%2520reducing%2520reagents-real%2520hits%2520or%2520promiscuous%2520artifacts%253F%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D15%26spage%3D174%26epage%3D182%26doi%3D10.1016%2Fj.cbpa.2010.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, G. F.</span></span> <span> </span><span class="NLM_article-title">Redox-cycling and H<sub>2</sub>O<sub>2</sub> generation by fabricated catecholic films in the absence of enzymes</span>. <i>Biomacromolecules</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">880</span>â <span class="NLM_lpage">888</span>, <span class="refDoi">Â DOI: 10.1021/bm101499a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bm101499a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyls7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=880-888&author=E.+Kimauthor=Y.+Liuauthor=C.+J.+Bakerauthor=R.+Owensauthor=S.+Y.+Xiaoauthor=W.+E.+Bentleyauthor=G.+F.+Payne&title=Redox-cycling+and+H2O2+generation+by+fabricated+catecholic+films+in+the+absence+of+enzymes&doi=10.1021%2Fbm101499a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Redox-Cycling and H2O2 Generation by Fabricated Catecholic Films in the Absence of Enzymes</span></div><div class="casAuthors">Kim, Eunkyoung; Liu, Yi; Baker, C. Jacyn; Owens, Robert; Xiao, Shunyuan; Bentley, William E.; Payne, Gregory F.</div><div class="citationInfo"><span class="NLM_cas:title">Biomacromolecules</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">880-888</span>CODEN:
                <span class="NLM_cas:coden">BOMAF6</span>;
        ISSN:<span class="NLM_cas:issn">1525-7797</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phenolic matrixes are ubiquitous in nature (e.g., lignin, melanin, and humics) but remain largely intractable to characterize.  The authors examd. an abiotic phenol-polysaccharide matrix fabricated by the anodic grafting of catechol to chitosan films.  Previous studies have shown that catechol-modified chitosan films are redox-active and can be repeatedly interconverted between oxidized and reduced states.  Here the authors developed quant. electrochem. methods to characterize biorelevant redox properties of the catechol-modified chitosan films.  The authors' anal. demonstrates that these films can (i) accept electrons from biol. reductants (e.g., ascorbate and NADPH) and (ii) donate electrons in a model biol. oxidn. process.  Furthermore, these films can donate electrons to O2 to generate H2O2.  The demonstration that abiotic catechol-chitosan films possess catalytic activities in the absence of enzymes suggests the possibility that phenolic matrixes may play an important role in redox cycling and reactive oxygen species (ROS) signaling in biol. and the environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8NwMr70TOdrVg90H21EOLACvtfcHk0lh54sSuNrHsPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyls7o%253D&md5=951acc03c808a1b4df9570dab0c55584</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fbm101499a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbm101499a%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBaker%26aufirst%3DC.%2BJ.%26aulast%3DOwens%26aufirst%3DR.%26aulast%3DXiao%26aufirst%3DS.%2BY.%26aulast%3DBentley%26aufirst%3DW.%2BE.%26aulast%3DPayne%26aufirst%3DG.%2BF.%26atitle%3DRedox-cycling%2520and%2520H2O2%2520generation%2520by%2520fabricated%2520catecholic%2520films%2520in%2520the%2520absence%2520of%2520enzymes%26jtitle%3DBiomacromolecules%26date%3D2011%26volume%3D12%26spage%3D880%26epage%3D888%26doi%3D10.1021%2Fbm101499a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torosyan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doak, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebart, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterling, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumanian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span> <span> </span><span class="NLM_article-title">An aggregation advisor for ligand discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7076</span>â <span class="NLM_lpage">7087</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01105</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOqu7zM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7076-7087&author=J.+J.+Irwinauthor=D.+Duanauthor=H.+Torosyanauthor=A.+K.+Doakauthor=K.+T.+Ziebartauthor=T.+Sterlingauthor=G.+Tumanianauthor=B.+K.+Shoichet&title=An+aggregation+advisor+for+ligand+discovery&doi=10.1021%2Facs.jmedchem.5b01105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">An Aggregation Advisor for Ligand Discovery</span></div><div class="casAuthors">Irwin, John J.; Duan, Da; Torosyan, Hayarpi; Doak, Allison K.; Ziebart, Kristin T.; Sterling, Teague; Tumanian, Gurgen; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7076-7087</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Colloidal aggregation of org. mols. is the dominant mechanism for artifactual inhibition of proteins, and controls against it are widely deployed.  Notwithstanding an increasingly detailed understanding of this phenomenon, a method to reliably predict aggregation has remained elusive.  Correspondingly, active mols. that act via aggregation continue to be found in early discovery campaigns and remain common in the literature.  Over the past decade, over 12 thousand aggregating org. mols. have been identified, potentially enabling a precedent-based approach to match known aggregators with new mols. that may be expected to aggregate and lead to artifacts.  We investigate an approach that uses lipophilicity, affinity, and similarity to known aggregators to advise on the likelihood that a candidate compd. is an aggregator.  In prospective exptl. testing, five of seven new mols. with Tanimoto coeffs. (Tc's) between 0.95 and 0.99 to known aggregators aggregated at relevant concns.  Ten of 19 with Tc's between 0.94 and 0.90 and three of seven with Tc's between 0.89 and 0.85 also aggregated.  Another three of the predicted compds. aggregated at higher concns.  This method finds that 61 827 or 5.1% of the ligands acting in the 0.1 to 10 Î¼M range in the medicinal chem. literature are at least 85% similar to a known aggregator with these phys. properties and may aggregate at relevant concns.  Intriguingly, only 0.73% of all drug-like com. available compds. resemble the known aggregators, suggesting that colloidal aggregators are enriched in the literature.  As a percentage of the literature, aggregator-like compds. have increased 9-fold since 1995, partly reflecting the advent of high-throughput and virtual screens against mol. targets.  Emerging from this study is an aggregator advisor database and tool (http://advisor.bkslab.org), free to the community, that may help distinguish between fruitful and artifactual screening hits acting by this mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTKGJSfIz30bVg90H21EOLACvtfcHk0lh54sSuNrHsPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOqu7zM&md5=d3112f9f3a57a2ac61a4b32f31778b1d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01105%26sid%3Dliteratum%253Aachs%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DDuan%26aufirst%3DD.%26aulast%3DTorosyan%26aufirst%3DH.%26aulast%3DDoak%26aufirst%3DA.%2BK.%26aulast%3DZiebart%26aufirst%3DK.%2BT.%26aulast%3DSterling%26aufirst%3DT.%26aulast%3DTumanian%26aufirst%3DG.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DAn%2520aggregation%2520advisor%2520for%2520ligand%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7076%26epage%3D7087%26doi%3D10.1021%2Facs.jmedchem.5b01105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalvit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pevarello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundstrom, M.</span></span> <span> </span><span class="NLM_article-title">Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water</span>. <i>J. Biomol. NMR</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">65</span>â <span class="NLM_lpage">68</span>, <span class="refDoi">Â DOI: 10.1023/A:1008354229396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1023%2FA%3A1008354229396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=11061229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVGit7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=65-68&author=C.+Dalvitauthor=P.+Pevarelloauthor=M.+Tatoauthor=M.+Veronesiauthor=A.+Vulpettiauthor=M.+Sundstrom&title=Identification+of+compounds+with+binding+affinity+to+proteins+via+magnetization+transfer+from+bulk+water&doi=10.1023%2FA%3A1008354229396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water</span></div><div class="casAuthors">Dalvit, Claudio; Pevarello, Paolo; Tato, Marco; Veronesi, Marina; Vulpetti, Anna; Sundstrom, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular NMR</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-68</span>CODEN:
                <span class="NLM_cas:coden">JBNME9</span>;
        ISSN:<span class="NLM_cas:issn">0925-2738</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A powerful screening by NMR methodol. (WaterLOGSY), based on transfer of magnetization from bulk water, for the identification of compds. that interact with target biomols. (proteins, RNA and DNA fragments) is described.  The method exploits efficiently the large reservoir of H2O magnetization.  The high sensitivity of the technique reduces the amt. of biomol. and ligands needed for the screening, which constitutes an important requirement for high throughput screening by NMR of large libraries of compds.  Application of the method to a compd. mixt. against the cyclin-dependent kinase 2 (cdk2) protein is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR8Jo0PHYdALVg90H21EOLACvtfcHk0ljDEmnTm80mwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVGit7o%253D&md5=e0fd0e5815f9bd20ed09d8033882feb6</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1023%2FA%3A1008354229396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1008354229396%26sid%3Dliteratum%253Aachs%26aulast%3DDalvit%26aufirst%3DC.%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DTato%26aufirst%3DM.%26aulast%3DVeronesi%26aufirst%3DM.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DSundstrom%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520compounds%2520with%2520binding%2520affinity%2520to%2520proteins%2520via%2520magnetization%2520transfer%2520from%2520bulk%2520water%26jtitle%3DJ.%2520Biomol.%2520NMR%26date%3D2000%26volume%3D18%26spage%3D65%26epage%3D68%26doi%3D10.1023%2FA%3A1008354229396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsamba, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myszka, D. G.</span></span> <span> </span><span class="NLM_article-title">Analyzing a kinetic titration series using affinity biosensors</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">136</span>â <span class="NLM_lpage">147</span>, <span class="refDoi">Â DOI: 10.1016/j.ab.2005.09.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.ab.2005.09.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=16337141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD28XotVGmtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2006&pages=136-147&author=R.+Karlssonauthor=P.+S.+Katsambaauthor=H.+Nordinauthor=E.+Polauthor=D.+G.+Myszka&title=Analyzing+a+kinetic+titration+series+using+affinity+biosensors&doi=10.1016%2Fj.ab.2005.09.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Analyzing a kinetic titration series using affinity biosensors</span></div><div class="casAuthors">Karlsson, Robert; Katsamba, Phinikoula S.; Nordin, Helena; Pol, Ewa; Myszka, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">136-147</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The classical method of measuring binding consts. with affinity-based biosensors involves testing several analyte concns. over the same ligand surface and regenerating the surface between binding cycles.  Here the authors describe an alternative approach to collecting kinetic binding data, which the authors call "kinetic titrn.".  This method involves sequentially injecting an analyte concn. series without any regeneration steps.  Through a combination of simulation and experimentation, the authors show that this method can be as robust as the classical method of anal.  In addn., kinetic titrns. can be more efficient than the conventional data collection method and allow the authors to fully characterize analyte binding to ligand surfaces that are difficult to regenerate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2pCiATVSchbVg90H21EOLACvtfcHk0ljDEmnTm80mwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotVGmtg%253D%253D&md5=cb5460e9b1bb9850335785f183cd7acb</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2005.09.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2005.09.034%26sid%3Dliteratum%253Aachs%26aulast%3DKarlsson%26aufirst%3DR.%26aulast%3DKatsamba%26aufirst%3DP.%2BS.%26aulast%3DNordin%26aufirst%3DH.%26aulast%3DPol%26aufirst%3DE.%26aulast%3DMyszka%26aufirst%3DD.%2BG.%26atitle%3DAnalyzing%2520a%2520kinetic%2520titration%2520series%2520using%2520affinity%2520biosensors%26jtitle%3DAnal.%2520Biochem.%26date%3D2006%26volume%3D349%26spage%3D136%26epage%3D147%26doi%3D10.1016%2Fj.ab.2005.09.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palau, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Primo, C.</span></span> <span> </span><span class="NLM_article-title">Simulated single-cycle kinetics improves the design of surface plasmon resonance assays</span>. <i>Talanta</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">211</span>â <span class="NLM_lpage">216</span>, <span class="refDoi">Â DOI: 10.1016/j.talanta.2013.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1016%2Fj.talanta.2013.04.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=23953462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ylu73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2013&pages=211-216&author=W.+Palauauthor=C.+Di+Primo&title=Simulated+single-cycle+kinetics+improves+the+design+of+surface+plasmon+resonance+assays&doi=10.1016%2Fj.talanta.2013.04.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Simulated single-cycle kinetics improves the design of surface plasmon resonance assays</span></div><div class="casAuthors">Palau, William; Di Primo, Carmelo</div><div class="citationInfo"><span class="NLM_cas:title">Talanta</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">211-216</span>CODEN:
                <span class="NLM_cas:coden">TLNTA2</span>;
        ISSN:<span class="NLM_cas:issn">0039-9140</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Instruments based on the surface plasmon resonance (SPR) principle are widely used to monitor in real time mol. interactions between a partner, immobilized on a sensor chip surface and another one injected in a continuous flow of buffer.  In a classical SPR expt., several cycles of binding and regeneration of the surface are performed in order to det. the rate and the equil. consts. of the reaction.  In 2006, Karlsson and co-workers introduced a new method named single-cycle kinetics (SCK) to perform SPR assays.  The method consists in injecting sequentially increasing concns. of the partner in soln., with only one regeneration step performed at the end of the complete binding cycle.  A 10 base-pair DNA duplex was characterized kinetically to show how simulated sensorgrams generated by the BiaEvaluation software provided by Biacore could really improve the design of SPR assays performed with the SCK method.  The DNA duplex was investigated at three temps., 10, 20 and 30 Â°C, to analyze fast and slow rate consts.  The results show that after a short obligatory preliminary expt., simulations provide users with the best exptl. conditions to be used, in particular, the max. concn. used to reach satn., the diln. factor for the serial dilns. of the sample injected and the duration of the dissocn. and assocn. phases.  The use of simulated single-cycle kinetics saves time and reduces sample consumption.  Simulations can also be used to design SPR expts. with ternary complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrPip6Mc_w_7Vg90H21EOLACvtfcHk0ljDEmnTm80mwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ylu73K&md5=aa9b5b14cb3d1d292f2bd95692963a30</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.talanta.2013.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.talanta.2013.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DPalau%26aufirst%3DW.%26aulast%3DDi%2BPrimo%26aufirst%3DC.%26atitle%3DSimulated%2520single-cycle%2520kinetics%2520improves%2520the%2520design%2520of%2520surface%2520plasmon%2520resonance%2520assays%26jtitle%3DTalanta%26date%3D2013%26volume%3D114%26spage%3D211%26epage%3D216%26doi%3D10.1016%2Fj.talanta.2013.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <span> </span><span class="NLM_article-title">The drug-target residence time model: a 10-year retrospective</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">87</span>â <span class="NLM_lpage">95</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2015.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fnrd.2015.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=26678621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVCrurnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=87-95&author=R.+A.+Copeland&title=The+drug-target+residence+time+model%3A+a+10-year+retrospective&doi=10.1038%2Fnrd.2015.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The drug-target residence time model: a 10-year retrospective</span></div><div class="casAuthors">Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The drug-target residence time model was first introduced in 2006 and has been broadly adopted across the chem. biol., biotechnol. and pharmaceutical communities.  While traditional in vitro methods view drug-target interactions exclusively in terms of equil. affinity, the residence time model takes into account the conformational dynamics of target macromols. that affect drug binding and dissocn.  The key tenet of this model is that the lifetime (or residence time) of the binary drug-target complex, and not the binding affinity per se, dictates much of the in vivo pharmacol. activity.  Here, this model is revisited and key applications of it over the past 10 years are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwNrhp9U8kwLVg90H21EOLACvtfcHk0liSAYmbbVG5KQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVCrurnE&md5=23f4a6973d77804292ff0af6c81358c0</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.18%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DThe%2520drug-target%2520residence%2520time%2520model%253A%2520a%252010-year%2520retrospective%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D87%26epage%3D95%26doi%3D10.1038%2Fnrd.2015.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompliano, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">730</span>â <span class="NLM_lpage">739</span>, <span class="refDoi">Â DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0liSAYmbbVG5KQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosfield, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tari, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, J.</span></span> <span> </span><span class="NLM_article-title">Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">8526</span>â <span class="NLM_lpage">8529</span>, <span class="refDoi">Â DOI: 10.1074/jbc.C300511200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1074%2Fjbc.C300511200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=14672944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1Onsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=8526-8529&author=D.+J.+Hosfieldauthor=Y.+Zhangauthor=D.+R.+Douganauthor=A.+Brounauthor=L.+W.+Tariauthor=R.+V.+Swansonauthor=J.+Finn&title=Structural+basis+for+bisphosphonate-mediated+inhibition+of+isoprenoid+biosynthesis&doi=10.1074%2Fjbc.C300511200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Bisphosphonate-mediated Inhibition of Isoprenoid Biosynthesis</span></div><div class="casAuthors">Hosfield, David J.; Zhang, Yanming; Dougan, Douglas R.; Broun, Alexei; Tari, Leslie W.; Swanson, Ronald V.; Finn, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">8526-8529</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Farnesyl pyrophosphate synthetase (FPPS) synthesizes farnesyl pyrophosphate through successive condensations of isopentyl pyrophosphate with dimethylallyl pyrophosphate and geranyl pyrophosphate.  Nitrogen-contg. bisphosphonate drugs used to treat osteoclast-mediated bone resorption and tumor-induced hypercalcemia are potent inhibitors of the enzyme.  Here we present crystal structures of substrate and bisphosphonate complexes of FPPS.  The structures reveal how enzyme conformational changes organize conserved active site residues to exploit metal-induced ionization and substrate positioning for catalysis.  The structures further demonstrate how nitrogen-contg. bisphosphonates mimic a carbocation intermediate to inhibit the enzyme.  Together, these FPPS complexes provide a structural template for the design of novel inhibitors that may prove useful for the treatment of osteoporosis and other clin. indications including cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMQ2ycptNThbVg90H21EOLACvtfcHk0liSAYmbbVG5KQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1Onsbk%253D&md5=c7b7fc1ead39a9bcc9365ad0acd63a1a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C300511200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C300511200%26sid%3Dliteratum%253Aachs%26aulast%3DHosfield%26aufirst%3DD.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DBroun%26aufirst%3DA.%26aulast%3DTari%26aufirst%3DL.%2BW.%26aulast%3DSwanson%26aufirst%3DR.%2BV.%26aulast%3DFinn%26aufirst%3DJ.%26atitle%3DStructural%2520basis%2520for%2520bisphosphonate-mediated%2520inhibition%2520of%2520isoprenoid%2520biosynthesis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D8526%26epage%3D8529%26doi%3D10.1074%2Fjbc.C300511200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kavanagh, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebetino, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, U.</span></span> <span> </span><span class="NLM_article-title">The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">7829</span>â <span class="NLM_lpage">7834</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0601643103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1073%2Fpnas.0601643103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=16684881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVGksL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=7829-7834&author=K.+L.+Kavanaghauthor=K.+Guoauthor=J.+E.+Dunfordauthor=X.+Wuauthor=S.+Knappauthor=F.+H.+Ebetinoauthor=M.+J.+Rogersauthor=R.+G.+Russellauthor=U.+Oppermann&title=The+molecular+mechanism+of+nitrogen-containing+bisphosphonates+as+antiosteoporosis+drugs&doi=10.1073%2Fpnas.0601643103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs</span></div><div class="casAuthors">Kavanagh, Kathryn L.; Guo, Kunde; Dunford, James E.; Wu, Xiaoqiu; Knapp, Stefan; Ebetino, Frank H.; Rogers, Michael J.; Russell, R. Graham G.; Oppermann, Udo</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7829-7834</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Osteoporosis and low bone mass are currently estd. to be a major public health risk affecting > 50% of the female population over the age of 50.  Because of their bone-selective pharmacokinetics, nitrogen-contg. bisphosphonates (N-BPs), currently used as clin. inhibitors of bone-resorption diseases, target osteoclast farnesyl pyrophosphate synthase (FPPS) and inhibit protein prenylation.  FPPS, a key branchpoint of the mevalonate pathway, catalyzes the successive condensation of isopentenyl pyrophosphate with dimethylallyl pyrophosphate and geranyl pyrophosphate.  To understand the mol. events involved in inhibition of FPPS by N-BPs, we used protein crystallog., enzyme kinetics, and isothermal titrn. calorimetry.  We report here high-resoln. x-ray structures of the human enzyme in complexes with risedronate and zoledronate, two of the leading N-BPs in clin. use.  These agents bind to the dimethylallyl/geranyl pyrophosphate ligand pocket and induce a conformational change.  The interactions of the N-BP cyclic nitrogen with Thr-201 and Lys-200 suggest that these inhibitors achieve potency by positioning their nitrogen in the proposed carbocation-binding site.  Kinetic analyses reveal that inhibition is competitive with geranyl pyrophosphate and is of a slow, tight binding character, indicating that isomerization of an initial enzyme-inhibitor complex occurs with inhibitor binding.  Isothermal titrn. calorimetry indicates that binding of N-BPs to the apoenzyme is entropy-driven, presumably through desolvation entropy effects.  These expts. reveal the mol. binding characteristics of an important pharmacol. target and provide a route for further optimization of these important drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1EVLSV5J3IrVg90H21EOLACvtfcHk0liSAYmbbVG5KQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVGksL0%253D&md5=d422e7cb8cfd588daa4c4a76756dc45b</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0601643103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0601643103%26sid%3Dliteratum%253Aachs%26aulast%3DKavanagh%26aufirst%3DK.%2BL.%26aulast%3DGuo%26aufirst%3DK.%26aulast%3DDunford%26aufirst%3DJ.%2BE.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DEbetino%26aufirst%3DF.%2BH.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26aulast%3DRussell%26aufirst%3DR.%2BG.%26aulast%3DOppermann%26aufirst%3DU.%26atitle%3DThe%2520molecular%2520mechanism%2520of%2520nitrogen-containing%2520bisphosphonates%2520as%2520antiosteoporosis%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D7829%26epage%3D7834%26doi%3D10.1073%2Fpnas.0601643103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klicic, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainz, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoll, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenkin, P. S.</span></span> <span> </span><span class="NLM_article-title">Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1739</span>â <span class="NLM_lpage">1749</span>, <span class="refDoi">Â DOI: 10.1021/jm0306430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0306430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1739-1749&author=R.+A.+Friesnerauthor=J.+L.+Banksauthor=R.+B.+Murphyauthor=T.+A.+Halgrenauthor=J.+J.+Klicicauthor=D.+T.+Mainzauthor=M.+P.+Repaskyauthor=E.+H.+Knollauthor=M.+Shelleyauthor=J.+K.+Perryauthor=D.+E.+Shawauthor=P.+Francisauthor=P.+S.+Shenkin&title=Glide%3A+a+new+approach+for+rapid%2C+accurate+docking+and+scoring.+1.+Method+and+assessment+of+docking+accuracy&doi=10.1021%2Fjm0306430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</span></div><div class="casAuthors">Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B.; Halgren, Thomas A.; Klicic, Jasna J.; Mainz, Daniel T.; Repasky, Matthew P.; Knoll, Eric H.; Shelley, Mee; Perry, Jason K.; Shaw, David E.; Francis, Perry; Shenkin, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand.  In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses.  The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose.  Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms.  Docking accuracy is assessed by redocking ligands from 282 cocrystd. PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose.  Errors in geometry for the top-ranked pose are less than 1 Ã in nearly half of the cases and are greater than 2 Ã in only about one-third of them.  Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds.  Glide is also found to be more accurate than the recently described Surflex method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPuigu31qMMLVg90H21EOLACvtfcHk0ljf0BzY0cU1xQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D&md5=8cc2f0022318b12dd972e9c493375bf9</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm0306430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0306430%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DKlicic%26aufirst%3DJ.%2BJ.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DShenkin%26aufirst%3DP.%2BS.%26atitle%3DGlide%253A%2520a%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25201.%2520Method%2520and%2520assessment%2520of%2520docking%2520accuracy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1739%26epage%3D1749%26doi%3D10.1021%2Fjm0306430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waters, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">KRAS: The critical driver and therapeutic target for pancreatic cancer</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">a031435</span>, <span class="refDoi">Â DOI: 10.1101/cshperspect.a031435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1101%2Fcshperspect.a031435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=29229669" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=a031435&author=A.+M.+Watersauthor=C.+J.+Der&title=KRAS%3A+The+critical+driver+and+therapeutic+target+for+pancreatic+cancer&doi=10.1101%2Fcshperspect.a031435"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a031435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a031435%26sid%3Dliteratum%253Aachs%26aulast%3DWaters%26aufirst%3DA.%2BM.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DKRAS%253A%2520The%2520critical%2520driver%2520and%2520therapeutic%2520target%2520for%2520pancreatic%2520cancer%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2018%26volume%3D8%26spage%3Da031435%26doi%3D10.1101%2Fcshperspect.a031435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendifar, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span> <span> </span><span class="NLM_article-title">Statins and pancreatic cancer</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1035</span>â <span class="NLM_lpage">1040</span>, <span class="refDoi">Â DOI: 10.3892/ol.2017.5572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.3892%2Fol.2017.5572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=28454210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGjtLvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=1035-1040&author=J.+Gongauthor=E.+Sachdevauthor=L.+A.+Robbinsauthor=E.+Linauthor=A.+E.+Hendifarauthor=M.+M.+Mita&title=Statins+and+pancreatic+cancer&doi=10.3892%2Fol.2017.5572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Statins and pancreatic cancer (Review)</span></div><div class="casAuthors">Gong, Jun; Sachdev, Esha; Robbins, Lori A.; Lin, Emily; Hendifar, andrew E.; Mita, Monica M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1035-1040</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1082</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Pancreatic cancer remains among the most lethal cancers, despite ongoing advances in treatment for all stages of the disease.  Disease prevention represents another oppor- tunity to improve patient outcome, with metabolic syndrome and its components, such as diabetes, obesity and dyslipid- emia, having been recognized as modifiable risk factors for pancreatic cancer.  In addn., statins have been shown to potentially reduce pancreatic cancer risk and to improve survival in patients with a combination of metabolic syndrome and pancreatic cancer.  Furthermore, preclin. studies have demonstrated that statins exhibit antitumor effects in pancre- atic cancer cell lines in vitro and animal models in vivo, in addn. to delaying the progression of pancreatic intraepithe- lial neoplasia to pancreatic ductal adenocarcinoma (PDAC) and inhibiting PDAC formation in conditional K-Ras mutant mice.  The mechanisms by which statins produce anticancer effects remain poorly understood, although appear to involve inhibition of the mevalonate/cholesterol synthesis pathway, thus blocking the synthesis of intermediates important for prenylation and activation of the Ras/mitogen-activated protein kinase 1 signaling pathway.  Furthermore, statins have been identified to modulate the phosphoinositide 3-kinase/Akt serine/threonine kinase 1 and inflammation signaling path- ways, and to alter the expression of genes involved in lipid metab., which are important for PDAC growth and prolif- eration.  In addn., statins have been demonstrated to exhibit further antitumor mechanisms in a no. of other cancer types, which are beyond the scope of the present review.  In the present review, current evidence highlighting the potential of statins as chemopreventive agents in pancreatic cancer is presented, and the antitumor mechanisms of statins elucidated thus far in this disease are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLr16pDI4rl7Vg90H21EOLACvtfcHk0ljf0BzY0cU1xQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGjtLvP&md5=1cec51b31773184798db38409d2a326d</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3892%2Fol.2017.5572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2017.5572%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DSachdev%26aufirst%3DE.%26aulast%3DRobbins%26aufirst%3DL.%2BA.%26aulast%3DLin%26aufirst%3DE.%26aulast%3DHendifar%26aufirst%3DA.%2BE.%26aulast%3DMita%26aufirst%3DM.%2BM.%26atitle%3DStatins%2520and%2520pancreatic%2520cancer%26jtitle%3DOncol.%2520Lett.%26date%3D2017%26volume%3D13%26spage%3D1035%26epage%3D1040%26doi%3D10.3892%2Fol.2017.5572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akedo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4885</span>â <span class="NLM_lpage">4891</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=11406567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1Gru7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=4885-4891&author=T.+Kusamaauthor=M.+Mukaiauthor=T.+Iwasakiauthor=M.+Tatsutaauthor=Y.+Matsumotoauthor=H.+Akedoauthor=H.+Nakamura&title=Inhibition+of+epidermal+growth+factor-induced+RhoA+translocation+and+invasion+of+human+pancreatic+cancer+cells+by+3-hydroxy-3-methylglutaryl-coenzyme+A+reductase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors</span></div><div class="casAuthors">Kusama, Toshiyuki; Mukai, Mutsuko; Iwasaki, Teruo; Tatsuta, Masaharu; Matsumoto, Yoshirou; Akedo, Hitoshi; Nakamura, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4885-4891</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors prevent the conversion of HMG-CoA to mevalonate and thereby inhibit the synthesis of other products derived from this metabolite.  This includes a no. of small prenylated GTPases involved in cell growth, motility, and invasion.  The authors studied the effect of HMG-CoA reductase inhibitors (fluvastatin and lovastatin) on in vitro invasion of human pancreatic cancer PANC-1 cells.  Epidermal growth factor (EGF) induced a dose-dependent increase of PANC-1 cell invasion in a modified Boyden chamber assay.  Stimulation of cancer cells with EGF induced translocation of RhoA from the cytosol to the membrane fraction and actin stress fiber assembly.  Furthermore, Clostridium botulinum C3 transferase, a specific inhibitor of Rho, inhibited the ability of EGF to promote invasion, indicating that EGF-induced cancer cell invasion is regulated by Rho signaling.  Treatment of PANC-1 cells with fluvastatin markedly attenuated EGF-induced translocation of RhoA from the cytosol to the membrane fraction and actin stress fiber assembly, whereas it did not inhibit the tyrosine phosphorylation of EGF receptor and c-erbB-2.  The induction of cancer cell invasion by EGF was inhibited by the addn. of fluvastatin or lovastatin in a dose-dependent manner.  The effects of fluvastatin or lovastatin on cell morphol. and invasion were reversed by the addn. of all-trans-geranylgeraniol but not by the addn. of all-trans-farnesol.  These results suggest that HMG-CoA reductase inhibitors affect RhoA activation by preventing geranylgeranylation, which results in inhibition of EGF-induced invasiveness of human pancreatic cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGperpQZsHWGMbVg90H21EOLACvtfcHk0lggPvybroyfFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1Gru7s%253D&md5=e2d5f21f127a2427ff21e725d1ac4180</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKusama%26aufirst%3DT.%26aulast%3DMukai%26aufirst%3DM.%26aulast%3DIwasaki%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DM.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DAkedo%26aufirst%3DH.%26aulast%3DNakamura%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520epidermal%2520growth%2520factor-induced%2520RhoA%2520translocation%2520and%2520invasion%2520of%2520human%2520pancreatic%2520cancer%2520cells%2520by%25203-hydroxy-3-methylglutaryl-coenzyme%2520A%2520reductase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D4885%26epage%3D4891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akedo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span> <span> </span><span class="NLM_article-title">3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">308</span>â <span class="NLM_lpage">317</span>, <span class="refDoi">Â DOI: 10.1053/gast.2002.31093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1053%2Fgast.2002.31093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=11832446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVGnsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2002&pages=308-317&author=T.+Kusamaauthor=M.+Mukaiauthor=T.+Iwasakiauthor=M.+Tatsutaauthor=Y.+Matsumotoauthor=H.+Akedoauthor=M.+Inoueauthor=H.+Nakamura&title=3-hydroxy-3-methylglutaryl-coenzyme+A+reductase+inhibitors+reduce+human+pancreatic+cancer+cell+invasion+and+metastasis&doi=10.1053%2Fgast.2002.31093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis</span></div><div class="casAuthors">Kusama, Toshiyuki; Mukai, Mutsuko; Iwasaki, Teruo; Tatsuta, Masaharu; Matsumoto, Yoshirou; Akedo, Hitoshi; Inoue, Masahiro; Nakamura, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">308-317</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">Background & Aims: Inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase blocks the mevalonate metabolic pathway, which is necessary for the isoprenylation of a no. of small guanosine triphosphatases.  We examd. the effects of HMG-CoA reductase inhibitors, fluvastatin and lovastatin, on human pancreatic cancer cell invasion in vitro and exptl. liver metastasis in vivo.  Methods: Cell invasion was studied in a modified Boyden chamber assay.  The translocation of RhoA was assessed by immunoblotting.  Exptl. liver metastases were induced in nude mice by intrasplenic inoculation of ASPC-1 human pancreatic cancer cells.  Results: Fluvastatin and lovastatin inhibited the in vitro cancer cell invasion induced by epidermal growth factor (EGF) in a manner sensitive to C3 transferase, a specific inhibitor of Rho.  Treatment of ASPC-1 cells with fluvastatin markedly attenuated the EGF-induced translocation of RhoA from the cytosol to the membrane fraction and caused cell rounding.  The effects of fluvastatin could be reversed by the addn. of all-trans-geranylgeraniol.  Administration of fluvastatin to nude mice reduced both metastatic tumor formation in the liver and the growth of established liver metastases at doses recommended for the treatment of hypercholesterolemia in humans.  Conclusions: HMG-CoA reductase inhibitors can be antimetastatic agents with the potential for useful clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKnLA3qbxPbLVg90H21EOLACvtfcHk0lggPvybroyfFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVGnsrc%253D&md5=8fd6e3972e31d008deac9eb1ae3aae5c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1053%2Fgast.2002.31093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fgast.2002.31093%26sid%3Dliteratum%253Aachs%26aulast%3DKusama%26aufirst%3DT.%26aulast%3DMukai%26aufirst%3DM.%26aulast%3DIwasaki%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DM.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DAkedo%26aufirst%3DH.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DH.%26atitle%3D3-hydroxy-3-methylglutaryl-coenzyme%2520A%2520reductase%2520inhibitors%2520reduce%2520human%2520pancreatic%2520cancer%2520cell%2520invasion%2520and%2520metastasis%26jtitle%3DGastroenterology%26date%3D2002%26volume%3D122%26spage%3D308%26epage%3D317%26doi%3D10.1053%2Fgast.2002.31093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bocci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collecchi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Tacca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danesi, R.</span></span> <span> </span><span class="NLM_article-title">Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">319</span>â <span class="NLM_lpage">330</span>, <span class="refDoi">Â DOI: 10.1038/sj.bjc.6602720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fsj.bjc.6602720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=16052215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFensb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2005&pages=319-330&author=G.+Bocciauthor=A.+Fioravantiauthor=P.+Orlandiauthor=N.+Bernardiniauthor=P.+Collecchiauthor=M.+Del+Taccaauthor=R.+Danesi&title=Fluvastatin+synergistically+enhances+the+antiproliferative+effect+of+gemcitabine+in+human+pancreatic+cancer+MIAPaCa-2+cells&doi=10.1038%2Fsj.bjc.6602720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells</span></div><div class="casAuthors">Bocci, G.; Fioravanti, A.; Orlandi, P.; Bernardini, N.; Collecchi, P.; Del Tacca, M.; Danesi, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-330</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The new combination between the nucleoside analog gemcitabine and the cholesterol-lowering drug fluvastatin was investigated in vitro and in vivo on the human pancreatic tumor cell line MIAPaCa-2.  The present study demonstrates that fluvastatin inhibits proliferation, induces apoptosis in pancreatic cancer cells harboring a p21ras mutation at codon 12 and synergistically potentiates the cytotoxic effect of gemcitabine.  The pharmacol. activities of fluvastatin are prevented by administration of mevalonic acid, suggesting that the shown inhibition of geranyl-geranylation and farnesylation of cellular proteins, including p21rhoA and p21ras, plays a major role in its anticancer effect.  Fluvastatin treatment also indirectly inhibits the phosphorylation of p42ERK2/mitogen-activated protein kinase, the cellular effector of ras and other signal transduction peptides.  Moreover, fluvastatin administration significantly increases the expression of the deoxycytidine kinase, the enzyme required for the activation of gemcitabine, and simultaneously reduces the 5'-nucleotidase, responsible for deactivation of gemcitabine, suggesting a possible addnl. role of these enzymes in the enhanced cytotoxic activity of gemcitabine.  Finally, a significant in vivo antitumor effect on MIAPaCa-2 xenografts was obsd. with the simultaneous combination of fluvastatin and gemcitabine, resulting in an almost complete suppression and a marked delay in relapse of tumor growth.  In conclusion, the combination of fluvastatin and gemcitabine is an effective cytotoxic, proapoptotic treatment in vitro and in vivo against MIAPaCa-2 cells by a mechanism of action mediated, at least in part, by the inhibition of p21ras and rhoA prenylation.  The obtained exptl. findings might constitute the basis for a novel translational research in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl8pbWZepbKrVg90H21EOLACvtfcHk0lggPvybroyfFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFensb0%253D&md5=ddf12edf69898780a2368031c96f609b</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6602720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6602720%26sid%3Dliteratum%253Aachs%26aulast%3DBocci%26aufirst%3DG.%26aulast%3DFioravanti%26aufirst%3DA.%26aulast%3DOrlandi%26aufirst%3DP.%26aulast%3DBernardini%26aufirst%3DN.%26aulast%3DCollecchi%26aufirst%3DP.%26aulast%3DDel%2BTacca%26aufirst%3DM.%26aulast%3DDanesi%26aufirst%3DR.%26atitle%3DFluvastatin%2520synergistically%2520enhances%2520the%2520antiproliferative%2520effect%2520of%2520gemcitabine%2520in%2520human%2520pancreatic%2520cancer%2520MIAPaCa-2%2520cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D93%26spage%3D319%26epage%3D330%26doi%3D10.1038%2Fsj.bjc.6602720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tassone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagliaferri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viscomi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caraglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAlessandro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galea, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbruzzese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boland, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venuta, S.</span></span> <span> </span><span class="NLM_article-title">Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">1971</span>â <span class="NLM_lpage">1978</span>, <span class="refDoi">Â DOI: 10.1038/sj.bjc.6600986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fsj.bjc.6600986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=12799645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksVKjtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2003&pages=1971-1978&author=P.+Tassoneauthor=P.+Tagliaferriauthor=C.+Viscomiauthor=C.+Palmieriauthor=M.+Caragliaauthor=A.+D%E2%80%99Alessandroauthor=E.+Galeaauthor=A.+Goelauthor=A.+Abbruzzeseauthor=C.+R.+Bolandauthor=S.+Venuta&title=Zoledronic+acid+induces+antiproliferative+and+apoptotic+effects+in+human+pancreatic+cancer+cells+in+vitro&doi=10.1038%2Fsj.bjc.6600986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro</span></div><div class="casAuthors">Tassone, P.; Tagliaferri, P.; Viscomi, C.; Palmieri, C.; Caraglia, M.; D'Alessandro, A.; Galea, E.; Goel, A.; Abbruzzese, A.; Boland, C. R.; Venuta, S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1971-1978</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bisphosphonates (BPs) are an emerging class of drugs mostly used in the palliative care of cancer patients.  The authors investigated the in vitro activity of the most potent antiresorptive BP, zoledronic acid (ZOL), on the growth and survival of three human pancreatic cancer (PC) cell lines (BxPC-3, CFPAC-1 and PANC-1).  Pancreatic cancer frequently has a dysregulated p21ras pathway and therefore appears to be a suitable target for BPs that interfere with the prenylation of small GTP-binding proteins such as p21ras.  The authors found that ZOL induces growth inhibition (IC50:10-50 Î¼M) and apoptotic death of PC cells.  The proapoptotic effect was correlated to cleavage/activation of caspase-9 and poly(ADP)-ribose polymerase, but not of caspase-3.  Moreover, the authors studied the p21ras signaling in cells exposed to ZOL and detected a redn. of p21ras and Raf-1 content and functional downregulation of the terminal enzyme ERK/MAPkinase and of the pKB/Akt survival pathway.  Finally, the authors obsd. that ZOL induces significant cytoskeletal rearrangements.  In conclusion, the authors demonstrated that ZOL induces growth inhibition and apoptosis on PC cells and interferes with growth and survival pathways downstream to p21ras.  These findings might be relevant for expanding application of BPs in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW9UukUWEf4rVg90H21EOLACvtfcHk0lguIUF5SdDQZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksVKjtb8%253D&md5=7329ecc3946ae9bbe132b8827529a1dd</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600986%26sid%3Dliteratum%253Aachs%26aulast%3DTassone%26aufirst%3DP.%26aulast%3DTagliaferri%26aufirst%3DP.%26aulast%3DViscomi%26aufirst%3DC.%26aulast%3DPalmieri%26aufirst%3DC.%26aulast%3DCaraglia%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Alessandro%26aufirst%3DA.%26aulast%3DGalea%26aufirst%3DE.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DAbbruzzese%26aufirst%3DA.%26aulast%3DBoland%26aufirst%3DC.%2BR.%26aulast%3DVenuta%26aufirst%3DS.%26atitle%3DZoledronic%2520acid%2520induces%2520antiproliferative%2520and%2520apoptotic%2520effects%2520in%2520human%2520pancreatic%2520cancer%2520cells%2520in%2520vitro%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D88%26spage%3D1971%26epage%3D1978%26doi%3D10.1038%2Fsj.bjc.6600986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haney, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varney, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chhonker, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murry, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holstein, S. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">5308</span>â <span class="NLM_lpage">5320</span>, <span class="refDoi">Â DOI: 10.1038/s41388-019-0794-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fs41388-019-0794-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=30918331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1Kisbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=5308-5320&author=S.+L.+Haneyauthor=M.+L.+Varneyauthor=Y.+S.+Chhonkerauthor=S.+Shinauthor=K.+Mehlaauthor=A.+J.+Crawfordauthor=H.+J.+Smithauthor=L.+M.+Smithauthor=D.+J.+Murryauthor=M.+A.+Hollingsworthauthor=S.+A.+Holstein&title=Inhibition+of+geranylgeranyl+diphosphate+synthase+is+a+novel+therapeutic+strategy+for+pancreatic+ductal+adenocarcinoma&doi=10.1038%2Fs41388-019-0794-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Haney, Staci L.; Varney, Michelle L.; Chhonker, Yashpal S.; Shin, Simon; Mehla, Kamiya; Crawford, Ayrianne J.; Smith, Heather Jensen; Smith, Lynette M.; Murry, Daryl J.; Hollingsworth, Michael A.; Holstein, Sarah A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">5308-5320</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Rab proteins play an essential role in regulating intracellular membrane trafficking processes.  Rab activity is dependent upon geranylgeranylation, a post-translational modification that involves the addn. of 20-carbon isoprenoid chains via the enzyme geranylgeranyl transferase (GGTase) II.  We have focused on the development of inhibitors against geranylgeranyl diphosphate synthase (GGDPS), which generates the isoprenoid donor (GGPP), as anti-Rab agents.  Pancreatic ductal adenocarcinoma (PDAC) is characterized by abnormal mucin prodn. and these mucins play important roles in tumor development, metastasis and chemo-resistance.  We hypothesized that GGDPS inhibitor (GGDPSi) treatment would induce PDAC cell death by disrupting mucin trafficking, thereby inducing the unfolded protein response pathway (UPR) and apoptosis.  To this end, we evaluated the effects of RAM2061, a potent GGDPSi, against PDAC.  Our studies revealed that GGDPSi treatment activates the UPR and triggers apoptosis in a variety of human and mouse PDAC cell lines.  Furthermore, GGDPSi treatment was found to disrupt the intracellular trafficking of key mucins such as MUC1.  These effects could be recapitulated by incubation with a specific GGTase II inhibitor, but not a GGTase I inhibitor, consistent with the effect being dependent on disruption of Rab-mediated activities.  In addn., siRNA-mediated knockdown of GGDPS induces upregulation of UPR markers and disrupts MUC1 trafficking in PDAC cells.  Expts. in two mouse models of PDAC demonstrated that GGDPSi treatment significantly slows tumor growth.  Collectively, these data support further development of GGDPSi therapy as a novel strategy for the treatment of PDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEnq8v0pZgI7Vg90H21EOLACvtfcHk0lguIUF5SdDQZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1Kisbo%253D&md5=511c7c9357df4755ab435f84d33930d7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fs41388-019-0794-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-019-0794-6%26sid%3Dliteratum%253Aachs%26aulast%3DHaney%26aufirst%3DS.%2BL.%26aulast%3DVarney%26aufirst%3DM.%2BL.%26aulast%3DChhonker%26aufirst%3DY.%2BS.%26aulast%3DShin%26aufirst%3DS.%26aulast%3DMehla%26aufirst%3DK.%26aulast%3DCrawford%26aufirst%3DA.%2BJ.%26aulast%3DSmith%26aufirst%3DH.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BM.%26aulast%3DMurry%26aufirst%3DD.%2BJ.%26aulast%3DHollingsworth%26aufirst%3DM.%2BA.%26aulast%3DHolstein%26aufirst%3DS.%2BA.%26atitle%3DInhibition%2520of%2520geranylgeranyl%2520diphosphate%2520synthase%2520is%2520a%2520novel%2520therapeutic%2520strategy%2520for%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26spage%3D5308%26epage%3D5320%26doi%3D10.1038%2Fs41388-019-0794-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiezewska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallner, G.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">191</span>â <span class="NLM_lpage">198</span>, <span class="refDoi">Â DOI: 10.1006/abbi.1998.0611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1006%2Fabbi.1998.0611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=9606952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADyaK1cXjt1Kgsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=1998&pages=191-198&author=M.+Bentingerauthor=J.+Grunlerauthor=E.+Petersonauthor=E.+Swiezewskaauthor=G.+Dallner&title=Phosphorylation+of+farnesol+in+rat+liver+microsomes%3A+properties+of+farnesol+kinase+and+farnesyl+phosphate+kinase&doi=10.1006%2Fabbi.1998.0611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase</span></div><div class="casAuthors">Bentinger, Magnus; Gruenler, Jacob; Peterson, Elisabeth; Swiezewska, Ewa; Dallner, Gustav</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-198</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">As farnesol may serve as a nonsterol endogenous regulator of the mevalonate pathway, the possibility that a kinase specific for its phosphorylation is present in the rat liver was investigated.  In the 10,000g supernatant of rat liver, farnesyl monophosphate was synthesized in the presence of ATP.  The Km value for farnesol was 2.3 Î¼M.  Various detergents inhibited the activity of the enzyme.  The farnesol kinase was present in rough and in smooth I microsomes, but not in smooth II microsomes, mitochondria, peroxisomes, Golgi, or plasma membranes.  The enzyme was assocd. with the inner, luminal surface of the vesicles.  Further analyses have demonstrated that an enzymic mechanism exists which catalyzes the phosphorylation of farnesyl-P to farnesyl-PP.  Activity of the farnesyl phosphate kinase resulted in the phosphorylation of the monophosphate by CTP but not by ATP, GTP, or UTP.  This enzyme is activated by low concns. of detergents.  Treatment with proteases and chem. probes indicate that this second phosphorylation reaction probably takes place on the outer, cytoplasmic surface of microsomal vesicles.  These results demonstrate that rat liver microsomes contain two enzymes for the consecutive phosphorylation of farnesol to farnesyl-PP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO0_Na3H33OLVg90H21EOLACvtfcHk0lguIUF5SdDQZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjt1Kgsbg%253D&md5=d0141328747a9563fbe389c7a50c6d7e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1006%2Fabbi.1998.0611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabbi.1998.0611%26sid%3Dliteratum%253Aachs%26aulast%3DBentinger%26aufirst%3DM.%26aulast%3DGrunler%26aufirst%3DJ.%26aulast%3DPeterson%26aufirst%3DE.%26aulast%3DSwiezewska%26aufirst%3DE.%26aulast%3DDallner%26aufirst%3DG.%26atitle%3DPhosphorylation%2520of%2520farnesol%2520in%2520rat%2520liver%2520microsomes%253A%2520properties%2520of%2520farnesol%2520kinase%2520and%2520farnesyl%2520phosphate%2520kinase%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D1998%26volume%3D353%26spage%3D191%26epage%3D198%26doi%3D10.1006%2Fabbi.1998.0611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matise, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diers, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largaespada, D. A.</span></span> <span> </span><span class="NLM_article-title">RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1086</span>â <span class="NLM_lpage">1096</span>, <span class="refDoi">Â DOI: 10.1182/blood-2008-01-132316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1182%2Fblood-2008-01-132316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=18952898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A280%3ADC%252BD1M7gtlOmsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=1086-1096&author=W.+I.+Kimauthor=I.+Matiseauthor=M.+D.+Diersauthor=D.+A.+Largaespada&title=RAS+oncogene+suppression+induces+apoptosis+followed+by+more+differentiated+and+less+myelosuppressive+disease+upon+relapse+of+acute+myeloid+leukemia&doi=10.1182%2Fblood-2008-01-132316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia</span></div><div class="casAuthors">Kim Won-Il; Matise Ilze; Diers Miechaleen D; Largaespada David A</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1086-96</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To study the oncogenic role of the NRAS oncogene (NRAS(G12V)) in the context of acute myeloid leukemia (AML), we used a Vav promoter-tetracycline transactivator (Vav-tTA)-driven repressible TRE-NRAS(G12V) transgene system in Mll-AF9 knock-in mice developing AML.  Conditional repression of NRAS(G12V) expression greatly reduced peripheral white blood cell (WBC) counts in leukemia recipient mice and induced apoptosis in the transplanted AML cells correlated with reduced Ras/Erk signaling.  After marked decrease of AML blast cells, myeloproliferative disease (MPD)-like AML relapsed characterized by cells that did not express NRAS(G12V).  In comparison with primary AML, the MPD-like AML showed significantly reduced aggressiveness, reduced myelosuppression, and a more differentiated phenotype.  We conclude that, in AML induced by an Mll-AF9 transgene, NRAS(G12V) expression contributes to acute leukemia maintenance by suppressing apoptosis and reducing differentiation of leukemia cells.  Moreover, NRAS(G12V) oncogene has a cell nonautonomous role in suppressing erythropoiesis that results in the MPD-like AML show significantly reduced ability to induce anemia.  Our results imply that targeting NRAS or RAS oncogene-activated pathways is a good therapeutic strategy for AML and attenuating aggressiveness of relapsed AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaPf2e-GZBYJagfuraLLzSfW6udTcc2ebmJ9Vtu3rdeLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7gtlOmsQ%253D%253D&md5=963673a542ef53f9309ad591c5cfc3ea</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-01-132316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-01-132316%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%2BI.%26aulast%3DMatise%26aufirst%3DI.%26aulast%3DDiers%26aufirst%3DM.%2BD.%26aulast%3DLargaespada%26aufirst%3DD.%2BA.%26atitle%3DRAS%2520oncogene%2520suppression%2520induces%2520apoptosis%2520followed%2520by%2520more%2520differentiated%2520and%2520less%2520myelosuppressive%2520disease%2520upon%2520relapse%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D1086%26epage%3D1096%26doi%3D10.1182%2Fblood-2008-01-132316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">The dark side of Ras: regulation of apoptosis</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">8999</span>â <span class="NLM_lpage">9006</span>, <span class="refDoi">Â DOI: 10.1038/sj.onc.1207111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1038%2Fsj.onc.1207111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=14663478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsFOmsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=8999-9006&author=A.+D.+Coxauthor=C.+J.+Der&title=The+dark+side+of+Ras%3A+regulation+of+apoptosis&doi=10.1038%2Fsj.onc.1207111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The dark side of Ras: regulation of apoptosis</span></div><div class="casAuthors">Cox, Adrienne D.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">56</span>),
    <span class="NLM_cas:pages">8999-9006</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mutational activation of Ras promotes oncogenesis by disrupting a multitude of normal cellular processes.  Perhaps, best characterized and understood are the mechanisms by which oncogenic Ras promotes deregulated cell cycle progression and uncontrolled cellular proliferation.  However, it is now clear that oncogenic Ras can also deregulate processes that control apoptosis.  In light of the diversity of downstream effector targets known to facilitate Ras function, it is perhaps not surprising that Ras regulation of cell survival is complex, involving the balance and interplay of multiple signaling networks.  While our understanding of these events is still far from complete, and is complicated by cell type and signaling context differences, several important mechanisms have begun to emerge.  We review the role and mechanism of specific effectors in regulating the antiapoptotic (Raf, phosphatidylinositol 3-kinase and Tiam1) and apoptotic (Nore1 and RASSF1) actions of oncogenic Ras, and discuss the possibility that the effector actions of p120RasGAP make a significant contribution to Ras regulation of apoptotic events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVFAJRj7yjhbVg90H21EOLACvtfcHk0lg8Sg18w4x0QQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsFOmsro%253D&md5=9b1b257ddc3638c187ea260c4817ca98</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207111%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520dark%2520side%2520of%2520Ras%253A%2520regulation%2520of%2520apoptosis%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D8999%26epage%3D9006%26doi%3D10.1038%2Fsj.onc.1207111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scagliotti, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmidis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreurs, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel-Riedel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schallier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manegold, C.</span></span> <span> </span><span class="NLM_article-title">Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2082</span>â <span class="NLM_lpage">2087</span>, <span class="refDoi">Â DOI: 10.1093/annonc/mds128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1093%2Fannonc%2Fmds128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=22730101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A280%3ADC%252BC38jksFGntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=2082-2087&author=G.+V.+Scagliottiauthor=P.+Kosmidisauthor=F.+de+Marinisauthor=A.+J.+Schreursauthor=I.+Albertauthor=W.+Engel-Riedelauthor=D.+Schallierauthor=S.+Barberaauthor=H.+P.+Kuoauthor=V.+Salloauthor=J.+R.+Perezauthor=C.+Manegold&title=Zoledronic+acid+in+patients+with+stage+IIIA%2FB+NSCLC%3A+results+of+a+randomized%2C+phase+III+study&doi=10.1093%2Fannonc%2Fmds128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study</span></div><div class="casAuthors">Scagliotti G V; Kosmidis P; de Marinis F; Schreurs A J M; Albert I; Engel-Riedel W; Schallier D; Barbera S; Kuo H-P; Sallo V; Perez J R; Manegold C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2082-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Bone metastases are common in patients with advanced non-small-cell lung cancer (NSCLC) and can have devastating consequences.  Preventing or delaying bone metastases may improve outcomes.  PATIENTS AND METHODS:  This study evaluated whether zoledronic acid (ZOL) delayed disease progression or recurrence in patients with controlled stage IIIA/B NSCLC after first-line therapy.  Patients received vitamin D and calcium supplementation and were randomized to i.v.  ZOL (every 3-4 weeks) or no treatment (control).  The primary end point was progression-free survival (PFS).  RESULTS:  No significant intergroup differences were observed in PFS or overall survival (OS).  Median PFS was 9.0 months with ZOL versus 11.3 months for control.  Fifteen ZOL-treated (6.6%) and 19 control patients (9.0%) developed bone metastases.  Estimated 1-year OS was 81.8% for each group.  ZOL safety profile was consistent with previous clinical data, but with higher discontinuations versus control.  Fifteen ZOL-treated (6.6%) and five control patients (2.3%) had renal adverse events.  Two cases of osteonecrosis of the jaw were reported.  CONCLUSIONS:  ZOL did not significantly affect PFS or OS in stage IIIA/B NSCLC patients with controlled disease, with a trend toward worsening PFS in the longer-term follow-up.  Few patients experienced bone metastases, possibly limiting the potential ZOL impact on disease course.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6N1RIViUs1kmhnSqMnvzDfW6udTcc2ebmJ9Vtu3rdeLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jksFGntA%253D%253D&md5=5d6f2d638e91d946bbc16d3a83d7953e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds128%26sid%3Dliteratum%253Aachs%26aulast%3DScagliotti%26aufirst%3DG.%2BV.%26aulast%3DKosmidis%26aufirst%3DP.%26aulast%3Dde%2BMarinis%26aufirst%3DF.%26aulast%3DSchreurs%26aufirst%3DA.%2BJ.%26aulast%3DAlbert%26aufirst%3DI.%26aulast%3DEngel-Riedel%26aufirst%3DW.%26aulast%3DSchallier%26aufirst%3DD.%26aulast%3DBarbera%26aufirst%3DS.%26aulast%3DKuo%26aufirst%3DH.%2BP.%26aulast%3DSallo%26aufirst%3DV.%26aulast%3DPerez%26aufirst%3DJ.%2BR.%26aulast%3DManegold%26aufirst%3DC.%26atitle%3DZoledronic%2520acid%2520in%2520patients%2520with%2520stage%2520IIIA%252FB%2520NSCLC%253A%2520results%2520of%2520a%2520randomized%252C%2520phase%2520III%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3D2082%26epage%3D2087%26doi%3D10.1093%2Fannonc%2Fmds128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janni, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedl, T. W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenegger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blohmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forstbauer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juckstock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneeweiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brucker, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rack, B.</span></span> <span> </span><span class="NLM_article-title">Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: phase III data from the SUCCESS A study</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">GS1-06</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.SABCS17-GS1-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1158%2F1538-7445.SABCS17-GS1-06" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=GS1-06&issue=4&author=W.+Janniauthor=T.+W.+P.+Friedlauthor=T.+Fehmauthor=V.+Mullerauthor=W.+Lichteneggerauthor=J.+Blohmerauthor=R.+Lorenzauthor=H.+Forstbauerauthor=E.+Bauerauthor=V.+Finkauthor=I.+Bekesauthor=J.+Juckstockauthor=A.+Schneeweissauthor=H.+Teschauthor=S.+Mahnerauthor=S.+Y.+Bruckerauthor=G.+Heinrichauthor=M.+W.+Beckmannauthor=R.+Colemanauthor=B.+Rack&title=Extended+adjuvant+bisphosphonate+treatment+over+five+years+in+early+breast+cancer+does+not+improve+disease-free+and+overall+survival+compared+to+two+years+of+treatment%3A+phase+III+data+from+the+SUCCESS+A+study&doi=10.1158%2F1538-7445.SABCS17-GS1-06"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.SABCS17-GS1-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.SABCS17-GS1-06%26sid%3Dliteratum%253Aachs%26aulast%3DJanni%26aufirst%3DW.%26aulast%3DFriedl%26aufirst%3DT.%2BW.%2BP.%26aulast%3DFehm%26aufirst%3DT.%26aulast%3DMuller%26aufirst%3DV.%26aulast%3DLichtenegger%26aufirst%3DW.%26aulast%3DBlohmer%26aufirst%3DJ.%26aulast%3DLorenz%26aufirst%3DR.%26aulast%3DForstbauer%26aufirst%3DH.%26aulast%3DBauer%26aufirst%3DE.%26aulast%3DFink%26aufirst%3DV.%26aulast%3DBekes%26aufirst%3DI.%26aulast%3DJuckstock%26aufirst%3DJ.%26aulast%3DSchneeweiss%26aufirst%3DA.%26aulast%3DTesch%26aufirst%3DH.%26aulast%3DMahner%26aufirst%3DS.%26aulast%3DBrucker%26aufirst%3DS.%2BY.%26aulast%3DHeinrich%26aufirst%3DG.%26aulast%3DBeckmann%26aufirst%3DM.%2BW.%26aulast%3DColeman%26aufirst%3DR.%26aulast%3DRack%26aufirst%3DB.%26atitle%3DExtended%2520adjuvant%2520bisphosphonate%2520treatment%2520over%2520five%2520years%2520in%2520early%2520breast%2520cancer%2520does%2520not%2520improve%2520disease-free%2520and%2520overall%2520survival%2520compared%2520to%2520two%2520years%2520of%2520treatment%253A%2520phase%2520III%2520data%2520from%2520the%2520SUCCESS%2520A%2520study%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D4%26spage%3DGS1-06%26doi%3D10.1158%2F1538-7445.SABCS17-GS1-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodwell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkinshaw, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grieve, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett-Lee, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaunt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiley, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R.</span></span> <span> </span><span class="NLM_article-title">Breast-cancer adjuvant therapy with zoledronic acid</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">1396</span>â <span class="NLM_lpage">1405</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1105195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1056%2FNEJMoa1105195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=21995387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlals7jP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1396-1405&author=R.+E.+Colemanauthor=H.+Marshallauthor=D.+Cameronauthor=D.+Dodwellauthor=R.+Burkinshawauthor=M.+Keaneauthor=M.+Gilauthor=S.+J.+Houstonauthor=R.+J.+Grieveauthor=P.+J.+Barrett-Leeauthor=D.+Ritchieauthor=J.+Pughauthor=C.+Gauntauthor=U.+Reaauthor=J.+Petersonauthor=C.+Daviesauthor=V.+Hileyauthor=W.+Gregoryauthor=R.+Bell&title=Breast-cancer+adjuvant+therapy+with+zoledronic+acid&doi=10.1056%2FNEJMoa1105195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Breast-cancer adjuvant therapy with zoledronic acid</span></div><div class="casAuthors">Coleman, Robert E.; Marshall, Helen; Cameron, David; Dodwell, David; Burkinshaw, Roger; Keane, Maccon; Gil, Miguel; Houston, Stephen.; Grieve, Robert J.; Barrett-Lee, Peter J.; Ritchie, Diana; Pugh, Julia; Gaunt, Claire; Rea, Una; Peterson, Jennifer; Davies, Claire; Hiley, Victoria; Gregory, Walter; Bell, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1396-1405</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in patients with early-stage breast cancer.  We conducted a study to det. whether treatment with zoledronic acid, in addn. to std. adjuvant therapy, would improve disease outcomes in such patients.  METHODS: In this open-label phase 3 study, we randomly assigned 3360 patients to receive std. adjuvant systemic therapy either with or without zoledronic acid.  The zoledronic acid was administered every 3 to 4 wk for 6 doses and then every 3 to 6 mo to complete 5 years of treatment.  The primary end point of the study was disease-free survival.  A second interim anal. revealed that a prespecified boundary for lack of benefit had been crossed.  RESULTS: At a median follow-up of 59 mo, there was no significant between-group difference in the primary end point, with a rate of disease-free survival of 77% in each group (adjusted hazard ratio in the zoledronic acid group, 0.98; 95% confidence interval [CI], 0.85 to 1.13; P = 0.79). Disease recurrence or death occurred in 377 patients in the zoledronic acid group and 375 of those in the control group.  The nos. of deaths - 243 in the zoledronic acid group and 276 in the control group - were also similar, resulting in rates of overall survival of 85.4% in the zoledronic acid group and 83.1% in the control group (adjusted hazard ratio, 0.85; 95% CI, 0.72 to 1.01; P = 0.07).  In the zoledronic acid group, there were 17 confirmed cases of osteonecrosis of the jaw (cumulative incidence, 1.1%; 95% CI, 0.6 to 1.7; P < 0.001) and 9 suspected cases; there were no cases in the control group.  Rates of other adverse effects were similar in the two study groups.  CONCLUSIONS: These findings do not support the routine use of zoledronic acid in the adjuvant management of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpISmlJLPnAebVg90H21EOLACvtfcHk0lgeaGi6x2KePQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlals7jP&md5=3c61150ab39db154b5370ea59896c73f</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105195%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%2BE.%26aulast%3DMarshall%26aufirst%3DH.%26aulast%3DCameron%26aufirst%3DD.%26aulast%3DDodwell%26aufirst%3DD.%26aulast%3DBurkinshaw%26aufirst%3DR.%26aulast%3DKeane%26aufirst%3DM.%26aulast%3DGil%26aufirst%3DM.%26aulast%3DHouston%26aufirst%3DS.%2BJ.%26aulast%3DGrieve%26aufirst%3DR.%2BJ.%26aulast%3DBarrett-Lee%26aufirst%3DP.%2BJ.%26aulast%3DRitchie%26aufirst%3DD.%26aulast%3DPugh%26aufirst%3DJ.%26aulast%3DGaunt%26aufirst%3DC.%26aulast%3DRea%26aufirst%3DU.%26aulast%3DPeterson%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DHiley%26aufirst%3DV.%26aulast%3DGregory%26aufirst%3DW.%26aulast%3DBell%26aufirst%3DR.%26atitle%3DBreast-cancer%2520adjuvant%2520therapy%2520with%2520zoledronic%2520acid%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1396%26epage%3D1405%26doi%3D10.1056%2FNEJMoa1105195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudock, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cass, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Beek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papapoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukkamala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, E.</span></span> <span> </span><span class="NLM_article-title">Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">5153</span>â <span class="NLM_lpage">5162</span>, <span class="refDoi">Â DOI: 10.1021/ja808285e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja808285e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFKnsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=5153-5162&author=Y.+H.+Zhangauthor=R.+Caoauthor=F.+Yinauthor=M.+P.+Hudockauthor=R.+T.+Guoauthor=K.+Krysiakauthor=S.+Mukherjeeauthor=Y.+G.+Gaoauthor=H.+Robinsonauthor=Y.+Songauthor=J.+H.+Noauthor=K.+Berganauthor=A.+Leonauthor=L.+Cassauthor=A.+Goddardauthor=T.+K.+Changauthor=F.+Y.+Linauthor=E.+Van+Beekauthor=S.+Papapoulosauthor=A.+H.+J.+Wangauthor=T.+Kuboauthor=M.+Ochiauthor=D.+Mukkamalaauthor=E.+Oldfield&title=Lipophilic+bisphosphonates+as+dual+farnesyl%2Fgeranylgeranyl+diphosphate+synthase+inhibitors%3A+an+X-ray+and+NMR+investigation&doi=10.1021%2Fja808285e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR Investigation</span></div><div class="casAuthors">Zhang, Yonghui; Cao, Rong; Yin, Fenglin; Hudock, Michael P.; Guo, Rey-Ting; Krysiak, Kilannin; Mukherjee, Sujoy; Gao, Yi-Gui; Robinson, Howard; Song, Yongcheng; No, Joo Hwan; Bergan, Kyle; Leon, Annette; Cass, Lauren; Goddard, Amanda; Chang, Ting-Kai; Lin, Fu-Yang; Van Beek, Ermond; Papapoulos, Socrates; Wang, Andrew H.-J.; Kubo, Tadahiko; Ochi, Mitsuo; Mukkamala, Dushyant; Oldfield, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5153-5162</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Considerable effort has focused on the development of selective protein farnesyl transferase (FTase) and protein geranylgeranyl transferase (GGTase) inhibitors as cancer chemotherapeutics.  Here, we report a new strategy for anticancer therapeutic agents involving inhibition of farnesyl diphosphate synthase (FPPS) and geranylgeranyl diphosphate synthase (GGPPS), the two enzymes upstream of FTase and GGTase, by lipophilic bisphosphonates.  Due to dual site targeting and decreased polarity, the compds. have activities far greater than do current bisphosphonate drugs in inhibiting tumor cell growth and invasiveness, both in vitro and in vivo.  We explore how these compds. inhibit cell growth and how cell activity can be predicted based on enzyme inhibition data, and using X-ray diffraction, solid state NMR, and isothermal titrn. calorimetry, we show how these compds. bind to FPPS and/or GGPPS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHhFMAMouc-rVg90H21EOLACvtfcHk0ljBeHQ35h259w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFKnsLw%253D&md5=373a71c889ed9f0ae6510d2503127e94</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fja808285e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja808285e%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DYin%26aufirst%3DF.%26aulast%3DHudock%26aufirst%3DM.%2BP.%26aulast%3DGuo%26aufirst%3DR.%2BT.%26aulast%3DKrysiak%26aufirst%3DK.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.%2BG.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DNo%26aufirst%3DJ.%2BH.%26aulast%3DBergan%26aufirst%3DK.%26aulast%3DLeon%26aufirst%3DA.%26aulast%3DCass%26aufirst%3DL.%26aulast%3DGoddard%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DT.%2BK.%26aulast%3DLin%26aufirst%3DF.%2BY.%26aulast%3DVan%2BBeek%26aufirst%3DE.%26aulast%3DPapapoulos%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DA.%2BH.%2BJ.%26aulast%3DKubo%26aufirst%3DT.%26aulast%3DOchi%26aufirst%3DM.%26aulast%3DMukkamala%26aufirst%3DD.%26aulast%3DOldfield%26aufirst%3DE.%26atitle%3DLipophilic%2520bisphosphonates%2520as%2520dual%2520farnesyl%252Fgeranylgeranyl%2520diphosphate%2520synthase%2520inhibitors%253A%2520an%2520X-ray%2520and%2520NMR%2520investigation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D5153%26epage%3D5162%26doi%3D10.1021%2Fja808285e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sastry, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adzhigirey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annabhimoju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span> <span> </span><span class="NLM_article-title">Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">221</span>â <span class="NLM_lpage">234</span>, <span class="refDoi">Â DOI: 10.1007/s10822-013-9644-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1007%2Fs10822-013-9644-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=23579614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A280%3ADC%252BC3srksFekug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=221-234&author=G.+M.+Sastryauthor=M.+Adzhigireyauthor=T.+Dayauthor=R.+Annabhimojuauthor=W.+Sherman&title=Protein+and+ligand+preparation%3A+parameters%2C+protocols%2C+and+influence+on+virtual+screening+enrichments&doi=10.1007%2Fs10822-013-9644-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments</span></div><div class="casAuthors">Sastry G Madhavi; Adzhigirey Matvey; Day Tyler; Annabhimoju Ramakrishna; Sherman Woody</div><div class="citationInfo"><span class="NLM_cas:title">Journal of computer-aided molecular design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Structure-based virtual screening plays an important role in drug discovery and complements other screening approaches.  In general, protein crystal structures are prepared prior to docking in order to add hydrogen atoms, optimize hydrogen bonds, remove atomic clashes, and perform other operations that are not part of the x-ray crystal structure refinement process.  In addition, ligands must be prepared to create 3-dimensional geometries, assign proper bond orders, and generate accessible tautomer and ionization states prior to virtual screening.  While the prerequisite for proper system preparation is generally accepted in the field, an extensive study of the preparation steps and their effect on virtual screening enrichments has not been performed.  In this work, we systematically explore each of the steps involved in preparing a system for virtual screening.  We first explore a large number of parameters using the Glide validation set of 36 crystal structures and 1,000 decoys.  We then apply a subset of protocols to the DUD database.  We show that database enrichment is improved with proper preparation and that neglecting certain steps of the preparation process produces a systematic degradation in enrichments, which can be large for some targets.  We provide examples illustrating the structural changes introduced by the preparation that impact database enrichment.  While the work presented here was performed with the Protein Preparation Wizard and Glide, the insights and guidance are expected to be generalizable to structure-based virtual screening with other docking methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQd2Qiai-OqeXqj_yg7twvpfW6udTcc2ea1aRRhOC9dCLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srksFekug%253D%253D&md5=9eb1a820e121aca2742ed53f24481ace</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1007%2Fs10822-013-9644-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-013-9644-8%26sid%3Dliteratum%253Aachs%26aulast%3DSastry%26aufirst%3DG.%2BM.%26aulast%3DAdzhigirey%26aufirst%3DM.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DAnnabhimoju%26aufirst%3DR.%26aulast%3DSherman%26aufirst%3DW.%26atitle%3DProtein%2520and%2520ligand%2520preparation%253A%2520parameters%252C%2520protocols%252C%2520and%2520influence%2520on%2520virtual%2520screening%2520enrichments%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2013%26volume%3D27%26spage%3D221%26epage%3D234%26doi%3D10.1007%2Fs10822-013-9644-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viegas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobrega, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrita, E. J.</span></span> <span> </span><span class="NLM_article-title">Saturation-transfer difference (STD) NMR: a simple and fast method for ligand screening and characterization of protein binding</span>. <i>J. Chem. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">990</span>â <span class="NLM_lpage">994</span>, <span class="refDoi">Â DOI: 10.1021/ed101169t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ed101169t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVant7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2011&pages=990-994&author=A.+Viegasauthor=J.+Mansoauthor=F.+L.+Nobregaauthor=E.+J.+Cabrita&title=Saturation-transfer+difference+%28STD%29+NMR%3A+a+simple+and+fast+method+for+ligand+screening+and+characterization+of+protein+binding&doi=10.1021%2Fed101169t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Saturation-Transfer Difference (STD) NMR: A Simple and Fast Method for Ligand Screening and Characterization of Protein Binding</span></div><div class="casAuthors">Viegas, Aldino; Manso, Joao; Nobrega, Franklin L.; Cabrita, Eurico J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Education</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">990-994</span>CODEN:
                <span class="NLM_cas:coden">JCEDA8</span>;
        ISSN:<span class="NLM_cas:issn">0021-9584</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society and Division of Chemical Education, Inc.</span>)
        </div><div class="casAbstract">Satn. transfer difference (STD) NMR has emerged as one of the most popular ligand-based NMR techniques for the study of protein-ligand interactions.  The success of this technique is a consequence of its robustness and the fact that it is focused on the signals of the ligand, without any need of processing NMR information about the receptor and only using small quantities of nonlabeled macromol.  Moreover, the attractiveness of this expt. is also extendable to the classroom.  In the context of a practical NMR class, this expt. is ideal to illustrate some fundamental NMR concepts, such as the nuclear Overhauser effect and relaxation in a multidisciplinary context, bridging chem. and biochem. with a taste of medicinal chem.  We use the readily available human serum albumin (HSA), 6-D,L-methyl-tryptophan (6-CH3-Trp), and 7- D,L-methyl-tryptophan (7-CH3-Trp) to introduce the STD-NMR expt. and to illustrate its applicability for ligand screening, mapping of binding moieties, and detn. of the dissocn. const., in a context that can be explored or adapted to the student's course level and topic (chem. or biochem.).  We also cover the most important theor. aspects of the STD expt., calling attention to some of its limitations and drawbacks without a complex theor. approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo29sluoDoJ87Vg90H21EOLACvtfcHk0lhZLFvWf-EYJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVant7c%253D&md5=807194fdb33d075121408463767cbf74</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fed101169t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fed101169t%26sid%3Dliteratum%253Aachs%26aulast%3DViegas%26aufirst%3DA.%26aulast%3DManso%26aufirst%3DJ.%26aulast%3DNobrega%26aufirst%3DF.%2BL.%26aulast%3DCabrita%26aufirst%3DE.%2BJ.%26atitle%3DSaturation-transfer%2520difference%2520%2528STD%2529%2520NMR%253A%2520a%2520simple%2520and%2520fast%2520method%2520for%2520ligand%2520screening%2520and%2520characterization%2520of%2520protein%2520binding%26jtitle%3DJ.%2520Chem.%2520Educ.%26date%3D2011%26volume%3D88%26spage%3D990%26epage%3D994%26doi%3D10.1021%2Fed101169t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shelley, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholleti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timlin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchimaya, M.</span></span> <span> </span><span class="NLM_article-title">Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">681</span>â <span class="NLM_lpage">691</span>, <span class="refDoi">Â DOI: 10.1007/s10822-007-9133-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=10.1007%2Fs10822-007-9133-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=17899391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKrtbzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=681-691&author=J.+C.+Shelleyauthor=A.+Cholletiauthor=L.+L.+Fryeauthor=J.+R.+Greenwoodauthor=M.+R.+Timlinauthor=M.+Uchimaya&title=Epik%3A+a+software+program+for+pK%28a%29+prediction+and+protonation+state+generation+for+drug-like+molecules&doi=10.1007%2Fs10822-007-9133-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Epik: a software program for pKa prediction and protonation state generation for drug-like molecules</span></div><div class="casAuthors">Shelley, John C.; Cholleti, Anuradha; Frye, Leah L.; Greenwood, Jeremy R.; Timlin, Mathew R.; Uchimaya, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">681-691</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Epik is a computer program for predicting pKa values for drug-like mols.  Epik can use this capability in combination with technol. for tautomerization to adjust the protonation state of small drug-like mols. to automatically generate one or more of the most probable forms for use in further mol. modeling studies.  Many medicinal chems. can exchange protons with their environment, resulting in various ionization and tautomeric states, collectively known as protonation states.  The protonation state of a drug can affect its soly. and membrane permeability.  In modeling, the protonation state of a ligand will also affect which conformations are predicted for the mol., as well as predictions for binding modes and ligand affinities based upon protein-ligand interactions.  Despite the importance of the protonation state, many databases of candidate mols. used in drug development do not store reliable information on the most probable protonation states.  Epik is sufficiently rapid and accurate to process large databases of drug-like mols. to provide this information.  Several new technologies are employed.  Extensions to the well-established Hammett and Taft approaches are used for pKa prediction, namely, mesomer standardization, charge cancellation, and charge spreading to make the predicted results reflect the nature of the mol. itself rather just for the particular Lewis structure used on input.  In addn., a new iterative technol. for generating, ranking and culling the generated protonation states is employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC6PRLT1xT8LVg90H21EOLACvtfcHk0lhZLFvWf-EYJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKrtbzP&md5=f4f429ea3894e1ad2519cdf3333a5645</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs10822-007-9133-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-007-9133-z%26sid%3Dliteratum%253Aachs%26aulast%3DShelley%26aufirst%3DJ.%2BC.%26aulast%3DCholleti%26aufirst%3DA.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DTimlin%26aufirst%3DM.%2BR.%26aulast%3DUchimaya%26aufirst%3DM.%26atitle%3DEpik%253A%2520a%2520software%2520program%2520for%2520pK%2528a%2529%2520prediction%2520and%2520protonation%2520state%2520generation%2520for%2520drug-like%2520molecules%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2007%26volume%3D21%26spage%3D681%26epage%3D691%26doi%3D10.1007%2Fs10822-007-9133-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span> <i>PyMOL Molecular
Graphics System</i>, version <span class="NLM_edition">2.0</span>; <span class="NLM_publisher-name">SchrÃ¶dinger, LLC</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PyMOL+Molecular%0AGraphics+System%2C+version+2.0%3B+Schr%C3%B6dinger%2C+LLC."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPyMOL%2520Molecular%250AGraphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4N1Z" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4N1Z','PDB','4N1Z'); return false;">PDB: 4N1Z</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N6K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N6K','PDB','3N6K'); return false;">PDB: 3N6K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RXA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RXA','PDB','4RXA'); return false;">PDB: 4RXA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0W','PDB','4P0W'); return false;">PDB: 4P0W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JA0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JA0','PDB','5JA0'); return false;">PDB: 5JA0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV2','PDB','5JV2'); return false;">PDB: 5JV2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2F8Z" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2F8Z','PDB','2F8Z'); return false;">PDB: 2F8Z</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0X" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0X','PDB','4P0X'); return false;">PDB: 4P0X</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JV1','PDB','5JV1'); return false;">PDB: 5JV1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0V','PDB','4P0V'); return false;">PDB: 4P0V</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i105"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01405">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_18174"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01405?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01405</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Binding mode of various inhibitors to <i>Hs</i>FPPS, mechanism involved in the formation of bridged compounds, catalase-addition experiment results, IC<sub>50</sub> values of zoledronate (<b>6</b>) and <b>CA28a</b> after different incubation times, WaterLOGSY result of <b>CA5d</b>, LCâMS detection results of <b>CA28a</b> plus <i>Hs</i>FPPS, <b>CA28a</b>âs docking pose in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4P0X">4P0X</a> with the location of S1âS4 sites, correlation analysis between clogP and clogD<sub>7.4</sub> with EC<sub>50</sub>, HPLC analysis of key compounds, and NMR spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and associated biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_002.csv">CSV</a>)</p></li><li><p class="inline">Docking files (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_003.zip">ZIP</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_001.pdf">jm9b01405_si_001.pdf (5.87 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_002.csv">jm9b01405_si_002.csv (12.7 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01405/suppl_file/jm9b01405_si_003.zip">jm9b01405_si_003.zip (585.34 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01405&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-23%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01405" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01405" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                12MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677abfc638503cee","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
